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Abstract 
Malaria, a parasitic disease caused by five species of the protozoan parasite 
Plasmodium, still kills an estimated 0.6 million people each year, almost all in 
the third world African countries. With renewed emphasis on global eradication 
of malaria, genome-based discovery of novel anti-transmission candidates has 
been identified as one of the priority research areas for the immediate future. 
The aim of this study was to exploit the benefits of a combination of classical 
forward/reverse genetics approaches, flow cytometry and high throughput whole 
genome sequencing to examine the molecular basis of gametocytogenesis in the 
rodent malaria parasite, P. berghei. Plasmodium is known to spontaneously 
generate gametocyte non-producing (GNP) mutants if asexually maintained for a 
long time. Using a sex-specific fluorescently labelled P. berghei parental line, 
ten parallel isogenic lineages were asexually maintained in mice by repeated 
mechanical passage for a year. Three, out of the potential ten lines, developed 
the GNP phenotype at the end of the study. 
The three GNP and their isogenic parental lines were sequenced using the 
Illumina platform and the sequence variations analysed. It was discovered that 
one single gene, a transcription factor with an AP2 domain (PBANKA_143750), 
was uniquely mutated in all the three de novo GNP mutants and also in the two 
pre-existing GNP mutants. The gene, called AP2-G, was thus implicated in 
regulating a switch associated with commitment to gametocytogenesis. 
Further conclusive evidence was generated using targeted AP2-G knockout 
studies (producing the GNP phenotype) and complementation studies in the AP2-
G mutants (restoring the WT phenotype). AP2-G was also shown to recognize and 
bind to a conserved DNA motif in the selected gene promoters in a sequence-
specific manner. Inhibition of this interaction by a synthetic customized 
polyamide compound, ISS-15, was also demonstrated in vitro.   
Collectively, the work done in the thesis (together with simultaneous 
independent evidence of involvement of the P. falciparum orthologue of AP2-G 
in gametocytogenesis) established AP2-G as the critical regulator of the 
commitment to gametocytogenesis in the form of a molecular switch. 
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1.1   Global burden of Malaria 
It has been more than four thousand five hundred years since the first ever 
recorded historical note of the symptomatology akin to that of Malaria was 
described in the Nei Ching (The Canon of Medicine, ancient Chinese medical 
writings) back around 2,700 BC (History of Malaria, Centers for Disease Control 
and Prevention, CDC, Atlanta). Indeed, Malaria is almost certainly one of the ten 
most ancient diseases of mankind but unfortunately is also the most prevalent 
parasitic infection (Figure 1-1) and one of the most important infections in 
humans (Haldar et al., 2007; Clements et al., 2013).  
 
Figure 1-1. Global malaria (P. falciparum) endemicity map showing the regions around the 
globe with varying degree of age-standardized P. falciparum parasite rate (PfPR2-10) which 
describes the estimated proportion of 2-10 year olds in the general population that are infected with 
P. falciparum at any one time, averaged over the 12 months of 2010. Blue and red regions show 
the extremes of PfPR2-10 (with dark blue signifying 0% and red signifying 70% PfPR). Clearly visible 
are the parts of Africa which still include reddish areas on the map. Source: Gething et al., 2011 – 
reproduced with permission.  
The start of coordinated efforts to fight this disease in the form of health 
programs is relatively new, dating back to the 1940s (Yekutiel, 1980). Despite 
our frantic efforts to conquer this scourge, malaria is still annoyingly one of the 
major killers in the third world – with an estimated 207 million cases globally 
and 0.62 million or more deaths worldwide in 2012 of which 80% of cases and 
90% of deaths were in Sub-Saharan Africa region (Murray et al., 2012; World 
Malaria Report, 2013). The vast majority (77%) of deaths due to malaria involve 
children under-five years of age (World Malaria Report, 2013). Not only does it 
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kill but malaria is responsible for over 219 million “attacks” leading to 800 
million days of illness annually in Africa alone (Breman et al., 2004). Out of the 
estimated 207 million malaria cases in 2012, ~80% were in the African region 
alone, followed by 13% in South-East Asia and 6% in the Eastern Mediterranean 
region (World Malaria Report, 2013). A total of 104 countries of the globe are 
affected by Malaria putting 3.4 billion people at risk and contributing to 35.4 
million DALYs in Sub-Saharan Africa (Global Malaria Action Plan, 2008; World 
Malaria Report, 2013). 
1.2   Clinical features of Malaria 
Human malaria is caused by five species of Plasmodium parasites – 
Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium 
malariae, and most recently included Plasmodium knowlesi (Cox-Singh et al., 
2008), particularly in  South-East Asia (Antinori et al., 2013). P. falciparum is 
responsible for almost all cases of malaria (99%) in African Region (Figure 1-2) 
whereas it contributes to only 53% cases in South-East Asian region (World 
Malaria Report, 2013). P. vivax causes ~50% of the global malaria burden outside 
Africa, particularly in the Americas (65%) and South East Asia (47%) (Price et al., 
2007; Guerra et al., 2010; World Malaria Report, 2013).  
 
Figure 1-2. Global malaria endemicity map showing the distribution of the Plasmodium spp. 
(P. falciparum and P. vivax) across various regions around the globe. Dark brown regions 
show a high proportion (>90%) of P. falciparum cases whereas the violet areas show 
predominantly P. vivax malaria. Light brown regions have mixed infections with Plasmodium 
species. Source: Feachem, et al., 2010 – reproduced with permission. 
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The pathogenesis of P. falciparum malaria is complex and the clinical 
spectrum ranges from an asymptomatic infection to mild disease to a rapidly 
evolving life-threatening disease, severe malaria, involving multiple organ 
systems and ultimately death. Severe malaria is a clinico-pathological syndrome 
which may comprise hyperparasitemia (>100,000 per mm3), cerebral malaria, 
severe anemia and respiratory distress syndrome (WHO, 2000; Weatherall et al., 
2002). Although rarely fatal, P. vivax malaria in contrast contributes to a 
debilitating illness which potentially ends up causing reduced learning and 
hampered economic growth and development (Wellems et al., 2009). Also, P. 
vivax can remain latent in the liver as hypnozoites which may get activated and 
result in relapses of malaria later. However, frequent under-reporting of P. vivax 
associated disease and mortality is not uncommon, particularly in children 
(Poespoprodjo et al., 2009).  
1.3   Challenges in Malaria control 
Despite an estimated 1.1 million malaria deaths averted during the last 
decade, primarily due to a scale-up of malaria interventions, malaria – an 
entirely preventable and treatable disease – still, on an average, takes the life of 
an African child every minute (World Malaria Report, 2012). The problems of 
severity (especially with Plasmodium falciparum infections) and the complex 
nature of the disease are further exacerbated by a continuing and evolving 
parasite and vector resistance to antimalarial drugs and insecticides, 
respectively, which remains one of the most formidable challenges (Tanner and 
de Savigny, 2008; Campbell, 2009; Mendis et al., 2009; Breman, 2012; 
Cheeseman et al., 2012; Mideo et al., 2013; Rosenthal, 2013).  
A plateauing of the scaled increase in getting access to the most crucial 
anti-malaria interventions like insecticidal nets, indoor residual spraying, 
diagnostic testing, and artemisinin-based combination therapies was observed 
for the very first time in 2010-11. Resistance to artemisinins, the key compounds 
in artemisinin-based combination therapies or ACTs, has been detected in four 
countries of South-East Asia (Greater Mekong sub-region: Cambodia, Myanmar, 
Thailand and Viet Nam), while mosquito resistance to insecticides has been 
found in 64 countries around the world. Despite the observed changes in parasite 
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sensitivity to artemisinins, ACTs continue to cure patients provided that the 
partner drug is still efficacious (World Malaria Report, 2012; Miotto et al., 2013). 
1.3.1 Artemisinin resistance 
Artemisinin, the wonder drug discovered by Youyou Tu and colleagues in 
1981, has been the mainstay for malaria treatment since late 1990’s (Miller and 
Su, 2011). A resistant polymorphic locus conferring slow parasite clearance rates 
on Artemisinin Combination Therapy (ACT) and subsequently found associated 
with ACT resistance has been located on P. falciparum chromosome 13 thus 
providing a genetic basis for the phenotype (Cheeseman et al., 2012). These 
findings have recently been substantiated with the discovery of a molecular 
marker of artemisinin resistance, a mutant kelch propeller domain protein 
(termed K13-propeller; PF3D7_1343700), which was associated with artemisinin 
resistance, both in vivo and in vitro (Ariey et al., 2014). Early identification of 
emerging or low level resistance to artemisinin will be a key target in the 
immediate future to restrict the resistant parasites and thus controlling the 
spread of resistance (World Malaria Report, 2013). High throughput methods 
including deep sequencing data have already been exploited to predict the early 
development of resistant parasites using differential phenotypic “signatures” of 
the resistant parasites in a mixed population within a patient (Mideo et al., 
2013). 
1.3.2 Malaria Vaccines 
Malaria candidate vaccines have started to move from laboratories to the 
field but an effective vaccine still remains a distant dream. With no licensed 
malaria vaccine yet, the scientific community is eagerly awaiting the results of 
the Phase 3 Clinical Trial of the candidate vaccine – RTS,S/AS01 to expand its 
armamentarium against malaria. Although there are approximately 20 other 
candidates in the pipeline (Clinical Trials), they all are at least 5-10 years behind 
RTS,S/AS01 (World Malaria Report, 2013). The RTS,S/AS01 consists of a fusion 
protein involving the carboxy terminus (aa 207-395) of the P. falciparum 
circumsporozoite (CS) antigen (Stoute et al., 1997) and hepatitis B surface 
antigen virus-like particle (VLP) lyophilized with GlaxoSmithKline’s AS01 
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adjuvant (Reed et al., 2009). Recent Phase 3 clinical trial results estimate 
statistically significant vaccine efficacy after dose 3 for the age group of 5-17 
months (46%) and 6-14 weeks (27%) against clinical malaria (Agnandji et al., 
2011; Agnandji et al., 2012; Moorthy et al., 2013a; Otiene C, 2013). With the 
much needed “second generation” malaria vaccine, probably a transmission 
blocking one, already on the roadmap, high quality and multi-disciplinary 
research centered on gametocytogenesis is the need of the hour (Moorthy et al., 
2013a & b; WHO “Immunization, Vaccines and Biologicals, 2013). 
1.4   Malaria eradication – a distant possibility? 
Although in 2007, the Bill and Melinda Gates Foundation, one of the major 
funders of all global Malaria related activities, reiterated and revived the 
malaria fraternity to embrace the audacious goal of malaria eradication 
(Sherrer, 2012), it stands out as a challenge (and perhaps a debate) to the 
malaria research community worldwide to reconsider the feasibility of malaria 
eradication in the future (Greenwood, 2009). Visualizing and realizing global 
malaria eradication as a distant possibility, a tri-tiered strategy towards 
eradication (Figure 1-3) was developed and endorsed to move on the road to 
eradication – aggressive malaria control in countries with highest disease burden 
and death, progressive elimination from endemic margins inwards thus shrinking 
the malaria map, and intensive research into development of novel interventions 
and technologies that could be utilized to achieve eradication (Roll back 
malaria, 2008; Feachem and Sabot, 2008; Feachem et al., 2009).  
 
Scrutinizing the malaria eradication efforts in the past along with 
currently available interventions and in-depth analysis of parasite biology, it can 
be easily inferred that approaches directed towards blockage of malaria 
transmission are potentially the need of the hour (Sinden, 2009) and at the very 
least a promising approach. 
 
1.5   Future priority areas for Malaria research 
It’s been a decade since the Plasmodium and Anopheles genomes were 
sequenced (Holt et al., 2002; Gardner et al., 2003) but nothing substantial, in 
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terms of the immediate utility, has yet been translated out of the genome 
projects (Greenwood and Owusu-Agyeyi, 2012). A huge ray of renewed hope has 
been levied on the application of the genomic database to find a possible 
working solution to malaria transmission in the post-genomic period – unless 
there is a new major technological (probably genomics-based) breakthrough 
addressing malaria transmission, eradication will always be a distant theoretical 
goal (The malERA Consultative Group on Basic Science and Enabling 
Technologies, 2011; Greenwood and Owusu-Agyeyi, 2012; World Malaria Report, 
2012). Realisation of immediate insufficiency of the existing tools necessary to 
achieve the renewed and rejuvenated goal of global malaria eradication in the 
near future, opens a whole new arena of discovering novel anti-malaria 
measures but at the same time, puts an enormous pressure on the research 
community and stake-holders to provide the rays of hope to achieve this 
mammoth task (Alonso et al., 2011). 
 
Figure 1-3. Global malaria map showing the distribution of countries categorized as being 
malaria free (green), countries eliminating malaria (blue) and countries controlling malaria 
(red). It is quite apparent that most of the countries where the endemicity is high together with 
predominant P. falciparum infection are still in the malaria control phase. Source: Feachem, et al., 
(2010) – reproduced with permission. 
 
Considering the limitations of vector control and vaccines, appropriate 
use of antimalarial drugs remains a cornerstone of malaria control with no solid 
substitute for ACTs in the near future. Other priority research areas are 
mechanisms of action of artemisinins, development of new partner drugs with 
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different modes of actions, and identification of new classes of antimalarial 
drugs. The best way to stop drug resistance in P. falciparum malaria is to 
eliminate transmission. The biggest challenge in malaria eradication today, 
along with vaccine development, is how best to marshal an assault on 
gametocytes with existing measures. In view of the stakes in the fight against 
emerging ACT resistance, and the goal of worldwide eradication of malaria, 
gametocytocidal drugs should be used as an additional measure in areas at risk, 
and development of newer and better drugs, and even vaccines against 
gametocytes, should be emphasised (Breman, 2012).  
 
With the constant loss of standard anti-malarials to ongoing resistance 
and no available vaccine for public use in sight, a multi-pronged approach to 
research, including better understanding of the pathogenesis of the disease and 
control of severity of the disease is imperative.  
1.6   Life cycle of Plasmodium 
Malaria parasites have accompanied us throughout the Darwinian descent 
and our understanding of the biology of Plasmodium is relatively naïve. Any 
attempt to eliminate (or even control) the disease will necessitate delving 
deeper into the life cycle and biology of transmission of Plasmodium and 
understand the bottlenecks thereof. There are many missing links that need to 
be comprehended and sensibly interpreted to solve this puzzling problem and it 
is this deficiency in understanding of parasite biology that is one of the major 
obstacles in finding a permanent solution for Malaria (Balu and Adams, 2007). 
Although ultimately the disease must be understood in humans, much of our 
current understanding of the pathogenesis of malaria comes from animal models 
and in vitro cultures of P. falciparum.  
Plasmodium has a complex life cycle that switches between an asexual 
phase in the vertebrate host and a sexual phase followed by asexual phase in the 
mosquito (Figure 1-4). 
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1.6.1 Asexual development in the vertebrate host 
The asexual developmental phase inside the vertebrate host can be 
divided into a pre-erythrocytic phase (including the development of malaria 
parasites from the point of entry into the host and development inside the liver 
up to the entry of parasites into the RBCs of the vertebrate host), an intra-
erythrocytic phase (including the development inside the RBCs), and a post-
erythrocytic development (between exit from the infected RBCs either to 
become gametocytes or to re-invade the naïve RBCs) (Figure 1-4). 
1.6.1.1 Pre-erythrocytic development 
 Haploid sporozoites are inoculated into the skin of a vertebrate host with 
the bite of an infected female anopheline mosquito. An average inoculum size of 
100-125 sporozoites has been shown in studies on rodent malaria parasites in 
laboratories (Medica and Sinnis, 2005) and the field (Rosenberg et al., 1990; 
Beier et al., 1991). Recent studies in rodent malaria have demonstrated that 
there exists a skin sub-cutaneous stage in the course of malaria infection (Ejigiri 
and Sinnis, 2009) wherein the sporozoites are mostly inoculated in the dermis 
(Sidjanski and Vanderberg, 1997; Matsuoka et al., 2002). Once injected, 
sporozoites move along random paths and take between one and three hours to 
leave the injection site (Yamauchi et al., 2007) and eventually invade blood or 
lymph vessels (Amino et al., 2006). Not all sporozoites end up in blood vessels – 
some are destroyed in the skin while some (0.5-5%) may remain at the 
inoculation site and develop as exoerythrocytic stages (Gueirard et al, 2010; 
Voza et al, 2012). About 20% migrate to the draining lymph node (Amino et al., 
2006; Yamauchi et al., 2007) where the dendritic cells prime CD8(+) T 
lymphocytes, the first immune response to the parasite (Chakravarty et al., 
2007). However, the skin exoerythrocytic stage has only been demonstrated in 
the rodent malaria parasites and it is an important area to explore whether such 
stages also occur in primate or human malaria species (Sinnis and Zavala, 2012).  
Sporozoites that enter blood vessels move along the endothelium of blood 
vessels and travel to the liver and cross several hepatocytes before infecting a 
final one and settling there (Frevert et al., 2005) in a process called productive 
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invasion (Prudencio et al.,2011). Productive hepatocyte invasion is mediated by 
invagination of the host cell plasma membrane to form a parasitophorous 
vacuole which surrounds the invading sporozoites and in which they develop into 
the next infective stage (Mota et al., 2001). Within the hepatocyte, the 
sporozoite develops within 47-52 hours via the trophozoite stage into the mature 
schizont that can contain 1,500-8,000 merozoites (exo-erythrocytic schizogony). 
 
 
 
Figure 1-4. The life cycle of Plasmodium showing the different growth stages of the parasite 
in a vertebrate host and in mosquito vector. The mosquito life stages, particularly, the 
development of ookinete and midgut invasion, constitute a major population bottleneck in the 
parasite life cycle. Source: Sauerwein et al., (2011) – reproduced with permission from Nature. 
 
These merozoites bud off from the infected hepatocyte in membrane bound 
vesicles termed merosomes after inducing death and detachment of the host 
hepatocyte. The merosomes squeeze out of the liver through the endothelial cell 
layer and are thus released into the neighbouring sinusoids (Sturm et al., 2006; 
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Falae et al., 2010). The merosomes ultimately break off releasing the 
merozoites into the blood stream where they invade red blood cells and start 
the blood stage development (Vaughan et al., 2008). The merozoites are 
invasive and within a period of 30 minutes of their release, they invade a fresh 
RBC to initiate the erythrocytic cycle. 
 
The liver stage, despite being asymptomatic, is again an important phase 
of the parasite life wherein the parasite could be attacked to interrupt the cycle 
at the initial stages of establishment of infection (Prudencio et al., 2011; March 
et al., 2013). Many of the intriguing immunological cross-talks and other host-
parasite interactions (Silvie et al., 2008; Tarun et al., 2008) have been shown to 
occur during this relatively under-explored stage of the parasite life cycle 
including the promotion of liver infection in P. berghei by host heme-oxygenase 
1 (Epiphanio et al., 2008). The host cell liver stage transcriptome analyses in P. 
berghei revealed that the host cell transcriptome is modified by the parasitic 
infection in a timely fashion to best fit the parasites’ changing developmental 
needs (Albuquerque et al., 2009).  
 
1.6.1.2 Intra-erythrocytic development 
An intracellular life style has been adopted by apicomplexans to, in part, 
evade the host immune attacks (Dowse and Soldati, 2004; Foller et al., 2009). 
Intra-erythrocytic development ensures initial rapid expansion and sustained 
maintenance of the parasite population in the vertebrate host. Mature red cells 
which are terminally differentiated cells that lack standard biosynthetic 
pathways and intracellular organelles, offer certain advantages for the parasite.  
Since RBCs do not display antigens related to the major histocompatibility 
complexes on their surfaces, they are a preferred site for immunological escape 
(Silvie et al., 2008). Also, the abundance of a rich source of nutrients readily 
available to the parasite, rapid turnover of the red cells, and easy access to the 
mosquito vector are among other factors behind the specific predilection of 
Plasmodium to red blood cells (Pasvol and Wilson, 1982). However, the absence 
of standard endocytic and secretory pathways presents a potential hurdle for the 
fast-growing obligate intracellular parasite. This is partly compensated by a 
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considerable export of a range of remodeling proteins and virulence factors into 
the red cell cytoplasm.  
This export is mediated through a recently identified specific targeting 
sequence, termed Plasmodium export element (PEXEL) or host targeting (HT) 
signal (Chang et al., 2008) or vacuolar transport signal (VTS) and a newly 
discovered protein export machine, Plasmodium translocon of exported proteins 
or PTEX (de Koning-Ward et al., 2009). This specific targeting sequence for 
translocation is a short consensus sequence RxLxE/Q/D (Hiller et al., 2004; Marti 
et al., 2004).However, PEXEL/VTS-negative exported proteins (PNEP) have also 
been identified which suggests a redundancy in the protein export machinery 
(Grüring et al., 2012; Heiber et al., 2013). Once secreted into the 
parasitophorous vacuole lumen, the exported proteins are shown to be 
associated with a putative Plasmodium translocon of exported protein or PTEX 
(de Koning-Ward et al., 2009), which resides at the PVM as an interface between 
the parasite and host environment and is supposed to play a role in unfolding 
and translocating the parasite proteins (Haase and de Koning-Ward, 2010; Bullen 
et al., 2012). The PTEX translocon is shown to consist of at least 5 components 
(de Koning-Ward et al., 2009), – EXP2 (a small PVM-associated protein which 
probably forms a membrane spanning pore, HSP101 (belongs to the ClpA/B 
chaperone family which probably helps in unfolding the exported proteins), 
PTEX150 (unknown function; Bullen et al., 2012), PTEX88 (unknown function) 
and TRX2 (thioredoxin-2). A recent study involving the direct growth competition 
assay using fluorescently-labelled P. berghei lines identified PTEX88 to be 
associated with blood stage development of the parasite as ptex88- mutants had 
a strongly reduced blood stage multiplication rates as compared to the WT 
parasite line (Matz et al., 2013). 
In general, four distinct life forms of malaria parasite, namely the rings, 
the trophozoites and the schizonts, have been described to be involved in an 
erythrocytic developmental cycle, with a very transient fourth one, the most 
distinct merozoites. The parasite enters into a red blood cell in the form of 
merozoites, about 8-24 of which are released from a mature schizont (Lee and 
Fidock, 2008). A recent study has generated evidence to link the role of an 
epigenetic mechanism, PfSir2a (the P. falciparum histone deacetylase) in 
controlling parasite proliferation and the number of merozoites produced in a 
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schizont. PfSir2a, which is an epigenetic silencer, was found to negatively 
regulate the rDNA transcription and number of merozoites per schizont (Mancio-
Silva et al., 2013).  
 
The development of the merozoites (via the ring form) into a mature 
trophozoite, just before nuclear division starts, takes around 16 hours. The 
trophozoite then matures into a schizont containing merozoites. After rupture of 
the mature schizonts, the free merozoites invade new red blood cells, resulting 
in a new erythrocytic cycle and a corresponding increase in the parasitemia 
(Figure 1-5). 
 
In P. falciparum, one complete cycle of development of the parasite 
inside the RBCs takes approximately 48 hours and progresses from rings (0-24 
hours) to trophozoites (24-36 hours) to schizonts (36-48 hours) finally ending in 
the formation and subsequent release of many merozoites from a mature 
schizont (Reilly et al., 2007). The total duration of the asexual blood stage 
development in P. berghei is 22-24 hours. The in vivo blood stage development 
of P. berghei is asynchronous as compared to a tightly synchronized in vivo intra-
erythrocytic cycle in P. falciparum (Trager and Jensen, 1976). Also, P. berghei, 
P. chabaudi (McNally et al., 1992) and to a lesser extent, P. falciparum (Pasvol 
et al., 1980) have a preference for reticulocytes but can also invade mature red 
blood cells. Gross and molecular details of the invasion mechanism have now 
been described as a stepwise process involving initial attachment, reorientation, 
and invasion (Cowman et al., 2012). 
  
The attachment of merozoites to the red blood cells is believed to be 
mediated by the low affinity interactions between parasite plasma membrane-
anchored surface proteins and host cell receptors. The attachment is followed 
by a passive reorientation process mediated by a gradient of adhesive proteins 
(including apical membrane antigen 1 or AMA1) towards the anterior end of the 
merozoite (Mitchell et al., 2004, Sanders et al., 2005). A moving junction or MJ 
is believed to be formed before invasion which actually forms an aperture 
through which the parasite tries to enter the host cell (Aikawa, 1978). Through 
the MJ, the parasite transfers important rhoptry proteins like RON2, 4, and 5 
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from the rhoptry neck into the host cell to form a solid connection with the host 
cell cytoskeleton.  
 
 
Figure 1-5. Intra-erythrocytic development of P. falciparum. 1-3: Identification, attachment, 
orientation and invasion of RBC by merozoite; 4: Merozoite invasion accompanied by simultaneous 
formation of parasitophorous vacuole membrane; 5: Ring form of the parasite characterized by 
large digestive vacuole; 6: Actively growing form of the parasite, the trophozoite, characterized by 
hemoglobin digestion and increasing accumulation of hemozoin in the digestive vacuole; 7: 
Schizogony, characterized by DNA replication into the syncytium; 8: Merozoites secrete axonemes 
in  preparation to egress; 9: Rupture of membranes (PVM and RBC membrane) accompanied by 
release of merozoites into the extracellular space to identify fresh RBCs for initiating the next 
erythrocytic cycle. Source: Silvie et al., (2008) - reproduced with permission. 
 
 The established belief that actual invasion in apicomplexan parasites 
essentially involves an active process requiring the actin-myosin motor 
machinery called glideosome (Matuschewski and Schuler, 2008; Soldati-Favre, 
2008; Daher and Soldati-Favre, 2009), including actin, MyoA, TRAP family 
proteins including MIC2 (Huynh and Carruthers, 2006) and AMA1 has recently 
been challenged (Meissner et al., 2013). Reverse genetics studies have shown 
that the invasion machinery is not essential for host cell penetration in 
Toxoplasma gondii (Andenmatten et al., 2013). These evidence leave the 
current understanding of the invasion process in apicomplexa intriguing as they 
suggest that there might be redundancies in the mechanism of invasion and/or 
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the possible existence of species-specific invasion machinery within the 
apicomplexans.  
 
Whatever the machinery involved, it takes only seconds for a merozoite to 
invade a new red cell but this includes many steps involving multiple receptor-
ligand interactions (Cowman and Crabb, 2006; Silvie et al., 2008). The merozoite 
has many special features related to invasion of red blood cells, such as the 
apical organelles, i.e. the rhoptries, micronemes and dense granules. Rhoptries 
contain proteins necessary for recognition and subsequent invasion of the RBCs. 
They also contain lipid stocks which are helpful in the formation of the PVM 
(Kats et al., 2006). The adhesins used to identify and attach the merozoite to 
the host RBC and also to link to actomyosin filaments for gliding and invasion are 
supplied by micronemes (Dowse and Soldati, 2004), whereas dense granules 
contain proteins for establishing communication between PVM and RBC 
membrane and beyond (Mercier et al., 2005).  
 
During invasion, the contents of rhoptry bulb are secreted into the host 
cell thus forming the parasitophorous vacuole membrane (PVM) which enables 
the parasite to reside inside the host cell within its own parasitophorous vacuole 
(Riglar et al., 2011). Time lapse imaging has identified two clear and distinct 
phases of the very fast invasion process. The first or the pre-invasive phase 
includes the initial contact of merozoite with the RBC membrane, apical 
orientation of the merozoite and RBC deformation and recovery. The ensuing 
second or the invasion phase involves the beginning of the entry of merozoite 
into the red cell and its subsequent internalization. A third or post-invasive 
phase has also been described which includes the alterations in the shape of the 
RBC (echinocytosis) after the complete entry of the merozoite into the cell 
(Gilson and Crabb, 2009). 
 
A number of (surface) proteins of merozoites, which are likely to play a 
role in invasion, appear to be conserved between rodent and human malaria 
parasites (Chitnis and Blackman, 2000; Cowman et al., 2000). Examples include 
MSP1, MSP4/5, AMA1, MAEBL, RhopH3 and SUB2.  
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Merozoite invasion of RBCs is central to the maintenance of parasite life 
cycle and malaria pathogenesis thus making it an attractive process in terms of 
identification of potential vaccine and drug candidates (Boyle et al., 2013). One 
of the recent successes in identifying such a candidate is the discovery of a 
single receptor-ligand pair: Basigin (BSG), an erythrocyte receptor for the 
parasite invasin reticulocyte binding protein 5 or Rh5 (PfRH5) which is believed 
to be required by all tested P. falciparum strains for entering into  host red 
blood cells (Crosnier et al., 2011; van Ooij, 2011). 
  
The biological complexity of P. falciparum is reflected in the constantly 
changing structure of the parasite during the repeated red blood cell cycles 
which are always approximately of 48 hours duration each (Bannister and 
Mitchell, 2003). Inside the RBC, the parasite development progresses through the 
following stages, based merely on the morphology of the parasite, as observed 
by light microscopy after nuclear staining (Arnot and Gull, 1998): 
 
The ring stage: The name is derived from the typical shape of a signet 
ring, the parasite appears like in the Giemsa-stained blood smears after the 
invasion of the red cell (Bannister et al., 2000). The parasite lies in the 
parasitophorous vacuole (formed during the invasion process) and feeds on the 
hemoglobin through its cytosome. As the ring grows further, it synthesizes 
molecules specific to this stage and exports them to the RBC, thus modifying the 
red cell membrane and making it more adhesive to the non-infected RBCs 
(rosetting) and to the endothelium of the blood vessels (Bannister and Mitchell, 
2003).  
 
The trophozoite: For the next 12 hours or so, the parasite is most active 
in feeding and growth and becomes more rounded. New molecules are 
continuously synthesized and exported into the RBC – some of them assemble as 
membranous sacs and are seen as Maurer’s clefts in stained smears. Export of 
new parasite proteins leads to knob formation on the RBC surface. Active 
feeding on hemoglobin leads to accumulation of products of hemoglobin 
digestion as hemozoin crystals, visible as dark pigment scattered within the food 
vacuole (Bannister and Mitchell, 2003). The appearance of this pigment marks 
the onset of the trophozoite stage (Arnot and Gull, 1998).  
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The schizont: This stage is marked by the nuclear divisions and synthesis 
and assembly of molecules essential for RBC invasion (Bannister and Mitchell, 
2003). Schizonts are defined on the basis of the presence of more than one 
nucleus (Arnot and Gull, 1998). Nuclear divisions result in the formation of about 
16 nuclei which move into merozoite buds around the periphery of maturing 
schizonts. Merozoites bud off from the residual body of cytoplasm and move into 
the buds. After multiple rounds of asynchronous divisions, about 8-24 mature 
merozoites breech the PVM and RBC membranes to escape the old red cell, for a 
brief extracellular phase till they eventually invade a new red cell (Bannister 
and Mitchell, 1998; Lee and Fidock, 2008). 
 
The merozoite: Just after the release from schizont, the free merozoite 
is very small, ~1.2μm long and is fully armoured with the essentials of the 
invasion machinery – the rhoptries, the micronemes, and the dense granules 
(Bannister and Mitchell, 1998). This stage is immunologically important as the 
parasite remains in the extracellular compartment, although for a very short 
period of time, and thus is exposed to the host antibodies (Bannister et al., 
2000). The two phases in the life of the parasite that have received an 
overwhelming attention of researchers are the mechanisms of release of 
merozoites and their subsequent invasion of the new red cell. 
 
1.6.1.3 Post-erythrocytic development 
Release of merozoites / egress of parasites from RBCs: P. falciparum 
infection is infamous for its synchronous release of merozoites from infected 
RBCs. The process and the molecular mechanisms involved in the infected red 
cell rupture and subsequent release of merozoites are still not fully unraveled 
(Lee and Fidock, 2008). However, recent studies reveal certain key molecular 
determinants involved in the parasite’s egress. The whole process is understood 
as a highly regulated proteolytic cascade culminating in the loss of host cell 
integrity that preludes the release of merozoites from the RBCs. A secreted 
subtilisin-like protease, PfSUB1, is thought to play a central role in this cascade 
(Yeoh et al., 2007; Arastu-Kapur et al., 2008). The protease is one of the three 
subtilisin-like proteases expressed by P. falciparum and is secreted by the newly 
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discovered organelle – the exoneme – into the parasitophorous vacuole space 
shortly preceding the RBC rupture.  
 
After its release, PfSUB1 targets and activates another family of 
proteases, one of the serine repeat antigens also known as SERA5 (Miller et al., 
2002) and SERA6 (Ruecker et al., 2012), proteolytic activation of which is 
implicated in the breakdown of both, the parasitophorous vacuole membrane 
and the RBC membrane. In addition to its role in egress, PfSUB1 is also believed 
to be involved in re-invasion of fresh RBCs (Yeoh et al., 2007). A cGMP 
dependent protein kinase, PfPKG has recently been shown to be required for the 
discharge of PfSUB1 into the PV and also for the release of the proteins from 
micronemes (Collins et al., 2013). A similar role of PbPKG is established in 
mediating the egress of merosomes during liver stage P. berghei infection (Falae 
et al., 2010).   
 
All these events are highly regulated and coordinated to ensure that all 
the merozoites contained in a schizont are fully matured prior to the release 
otherwise one or two of the merozoites racing ahead to maturity than others 
might trigger the rupturing cascade. This coordination prevents the premature 
rupture of PVM and RBC membrane and subsequent release of a sub-optimal 
number of infective merozoites (Janse and Waters, 2007). However, there are 
other proposed models of merozoite egress from the RBC briefly proposing that 
the rupture of the host RBC occurs without immediate hemolysis and that 
merozoites are released packaged within a thin membrane (Clavijo et al., 1998; 
Winograd et al., 1999; Lew, 2001).  
 
Time lapse imaging of mature schizont stage of P. falciparum has 
revealed many details of the schizont rupture and merozoite release process 
(Gilson and Crabb, 2009).  Just before rupture, the schizont attains full 
“maturity” including an increase in size, merozoites becoming increasingly 
distinct as they begin separating clearly and the mature schizont takes a 
“flower-like” appearance (Glushakova et al., 2005). As the schizont matures 
fully and approaches imminent rupture, the merozoites disaggregate further, 
presumably due to the breakdown of the PVM, and fill the RBC (Gilson and 
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Crabb, 2005). Thus, a fully matured pre-rupture schizont has clearly separated 
merozoites with no distinction of the PVM separate from the RBC membrane.  
 
Invasion of RBCs: A fresh erythrocytic cycle is initiated with the invasion 
of the target red cells by merozoites released from a ruptured RBC. Generally, 
merozoites are able to recognize new target RBCs within 1 minute of their 
release from their host RBCs under in vitro conditions. RBC invasion ensues and 
the entry into new host cell is complete on average 27.6 seconds after primary 
contact with the new target RBC (Gilson and Crabb, 2009).  
1.6.2 Sexual development  
1.6.2.1 Gametocytogenesis 
In each asexual cycle of P. berghei, a small and variable proportion of 
parasites (5-25%) stops asexual multiplication and differentiate into sexual cells, 
the so-called gametocytes (Mons, 1986). It has been observed that as low as 0.2% 
to 1% of asexual parasites of the intra-erythrocytic phase may generate 
gametocytes during each cycle (Sinden, 1983). These haploid macrogametocytes 
(females) and microgametocytes (males) are the precursor cells of the female 
and male gametes, respectively. The time required for gametocytes to attain 
full maturity varies strikingly between rodent and human malaria parasites.  
 
Whereas P. berghei (Mons et al., 1985) and P. yoelii (Garnham, 1966) 
gametocytes require 24-26 hours to reach maturity, the gametocyte of P. 
falciparum require further 8-10 days of maturation (Field and Shute, 1956) into 5 
morphologically recognizable stages (I-V), following RBC invasion by a sexually 
committed merozoite (Hawking et al., 1971). The sex ratio in Plasmodium is 
consistently female-biased which could be explained on the basis of local mate 
competition theory as males in Plasmodium can each fertilize more than one 
female and an equal sex ratio would result in overabundance of male gametes 
(Hamilton, 1967; Reece et al.,2008). It is also suggested that sex ratios in P. 
falciparum are clone-specific and thus might have a genetic component (Burkot 
et al., 1984).  
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The genes encoding proteins secreted early from the gametocytes (up to 
stage II of gametocyte development), grouped into a cluster designated Pfge or 
P. falciparum gametocytogenesis early (Eksi et al., 2012), include Pfg27 (an 
RNA-binding cytoplasmic phosphoprotein and maintains cellular integrity of 
gametocytes; Carter et al., 1989; Olivieri et al., 2009), Pfs16 (secreted within 
24-hours post-invasion; Bruce et al., 1994), Pfpeg3 or Pfmdv1 and Pfpeg4 
(proteins of early gametocytes; Silvestrini et al., 2005), Pfg14.744 and Pfg14.748 
(proteins exported in early gametocytes; Eksi et al., 2005; Silvestrini et al., 
2010), Pfs47 (mediates immune evasion of the mosquito’s immune response and 
is critical for transmission from a mammalian host to a mosquito; Molina-cruz et 
al., 2013), and Pfgeco (gametocyte erythrocyte cytosolic protein – a gametocyte 
exported protein; Morahan et al., 2011) among others. Among these, Pfs16, 
Pfpeg3/Pfpeg4 and Pfg14.744 and Pfg14.748 have been shown to be located in 
the parasitophorous vacuole membrane (PVM) and this commonality of origin of 
these proteins indicate a distinct remodelling of the PVM in gametocytes as 
compared to the asexual stages of the parasite (Alano, 2007). It is interesting 
here to note that Pfg27 has no known orthologue in other Plasmodium spp. other 
than P. reichenowi (a primate malaria species) thus suggesting its role in the 
longer developmental period of gametocytes in these species (Baker, 2010). 
 
Sex-specific morphological features appear in the gametocytes only at 22 
hours in the 26 hour of maturation of P. berghei (Janse and Waters, 2004) and 
around day 6 in the 10-day maturation of P. falciparum gametocytes (Alano and 
Billker, 2005). However, molecular differentiation of male and female 
gametocytes is thought to occur much earlier than the appearance of sexual 
dimorphism. It has been shown that Pfs16 and then Pfg27/25 are the first 
molecular markers for gametocytes and are expressed 24-hours into their 
development (Silvestrini et al., 2005). Pfnek-4 expression, in P. falciparum, 
might help in identifying the sexually committed parasites, as early as, at the 
schizont stage (Reininger et al., 2012) as it is known that commitment to sexual 
differentiation occurs at least one developmental cycle before the actual 
appearance of sexual-stage parasites such that all the merozoites derived from a 
particular “committed” schizont generate gametocytes (Bruce et al., 1990) in 
the following cycle and will produce all male or female gametocytes (Silvestrini, 
Alano and Williams, 2000). 
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There is a basic purpose-directed difference in mature male and female 
gametocytes, both at the cellular and molecular level. Males have very minimal 
cellular structure – reduced ribosome and endoplasmic reticulum. In comparison, 
the females have well developed endoplasmic reticulum, mitochondrion and 
apicoplast – all in preparation for the next stage of the life cycle, the rapidly 
developing zygote. A comparison of stage-specific proteome of P. berghei also 
identified sex-specific divergence of proteins with only 69 proteins shared 
between the male and female gametocytes (Khan et al., 2005). They also 
possess DOZI-mediated translationally repressed/silent transcripts whose rapid 
activation, when needed, is a key to the rapid development at the zygote stage 
(Paton et al., 1993; Mair et al., 2006). Osmiophilic bodies (more abundant in 
females) are the secretory organelles which help the gametocytes emerge from 
RBCs (Lal et al., 2009; Ponzi et al., 2009). Pfg377 is implicated to have a role in 
formation of osmiophilic bodies and gamete egress (de Koning-Ward et al., 
2008). Sex-specific proteome data shows that the male proteome contains 36% 
of proteins unique to the sex whereas the female proteome has 19% of unique 
proteins (Khan et al., 2005).  
 
Transcriptome data from several microarray experiments in P. falciparum 
suggest that about 200-300 gametocyte-specific transcripts are significantly up-
regulated in the first 40-48 hours of sexual development (Eksi et al., 2005; 
Silvestrini et al., 2005; Young et al., 2005) including those of P25 and P28 which 
are however kept translationally repressed in gametocytes (Paton et al., 1993; 
Hall et al., 2005). Thus, the gametocytes appear to be arrested at the G0 phase 
of the cell cycle in the mammalian host (Sinden, 1996). Plasmodium parasites 
are unique in the developmentally regulated expression of small subunit 
ribosomal RNA (SSU rRNA). There are seven of these in P. falciparum and four in 
P. berghei. The A-type rRNA is expressed in asexual stages whereas the S-type 
rRNA (previously called C-type) is expressed in gametocytes in a precursor form 
and processed in later mosquito stages. The switching of transcriptional activity 
to differential expression of the two rRNA types in P. berghei is associated with 
species-specific developmental transition from mammalian host to the mosquito. 
No S-type precursor forms are seen in P. falciparum (Waters et al., 1989; Waters 
et al., 1997). 
 
Chapter 1 General Introduction 42 
 
There is currently no evidence suggesting the occurrence of DNA 
replication in male gametocytes as suggested by the absence of tritiated 
hypoxanthine uptake (Raabe et al., 2009) and rapid DNA replication only occurs 
after activation of male gametocytes in the mosquito midgut.  
 
Experimens on detailing the timing of sexual commitment are difficult 
with P. falciparum as induction of gametocytogenesis by overgrowing asexual 
parasite cultures produces wide biological variations in microarray experiments 
and large-scale purification of gametocytes younger than 48 hours is difficult 
(Alano, 2007). Although different in many aspects from P. falciparum 
gametocytes, it is here that P. berghei is considered to be a desirable model to 
study gametocyte biology. This is further favoured by a high degree of 
conservation of sex-specific transcripts and proteins between the two species. 
 
1.6.2.2 Gametogenesis, Fertilization and Ookinete formation 
 in the mosquito 
When a mosquito feeds on an infected host, only the mature gametocytes 
can undergo further development in the mosquito midgut. This involves an 
active escape of the gametocytes from the red blood cell and the formation of 
gametes (the process of gametogenesis). The female gametocyte differentiates 
into a single, spherical female gamete (macrogamete) whereas the male 
gametocyte produces 8 'sperm-like' microgametes which is a rapid process called 
exflagellation and is completed within 10-20 minutes (Figure 1-6). Male 
gametogenesis is associated with three rounds of DNA replication and axoneme 
assembly (Toyé et al., 1977; Raabe, et al., 2009) whereas female gametogenesis 
involves a release of the “silent” transcripts from the DOZI-mediated 
translational repression (Mair et al., 2006).  
 
Three environmental triggers have been described that induce the 
differentiation of the gametocytes into the gametes: a drop in temperature of 
the infected blood to at least 5°C below that of the vertebrate host (Sinden et 
al., 1996), a rise in pH from 7.3 to 7.8-8.0 (Nijhout and Carter, 1978) and the 
presence of a gametocyte activating factors (GAF) (Billker et al., 1997; Garcia et 
al., 1997). This mosquito-derived GAF was shown to be Xanthurenic acid (XA) in 
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P. berghei (Billker et al., 1998) and P. falciparum/P.gallenaceum (Garcia et al., 
1998). The signalling mechanisms that regulate this rapid development in the 
mosquito remain largely unknown. However, studies have shown a stimulation of 
Guanylyl cyclase (GC) by xanthiurenic acid (Muhia et al, 2001) which stimulates 
cGMP (Kawamoto et al., 1990) to promote exflagellation in male gametocytes in 
P. berghei and P. falciparum. 
 
Figure 1-6. Development of malaria parasite inside the mosquito vector. The male and female 
gametocytes are ingested by the female Anopheles mosquito which activate and fertilize within the 
stomach to form the zygote. The zygote transforms into a motile ookinete which penetrates the 
midgut epithelial cells and rests under the basal lamina as oocyst. Oocyst undergoes extensive 
growth to generate sporozoites which when released from the oocyst travel to the mosquito 
salivary gland and wait for their chance of getting transmitted back to the vertebrate host. Source: 
Aly et al., (2009) – reproduced with permission. 
 
 It is also established that the action of cGMP in P. falciparum 
gametogenesis is mediated via a cGMP-dependent protein kinase, PfPKG 
(McRobert et al., 2008). A very delicate threshold-based regulation of cGMP via 
GC (which increases cGMP) and phosphodiesterases (PDE, which decrease cGMP) 
has been shown to be crucial for sexual development in Plasmodium (Taylor et 
al., 2008).  
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These events are also believed to activate the phosphoinositol pathway 
leading to a release of calcium from the cytoplasmic stores which, in turn, 
activates CDPK and MAP kinase, organize DNA replication, axoneme assembly, 
nuclear division and expulsion of gametes (Sinden, 2009; Tewari et al., 2010). A 
recent transcriptomic study in P. falciparum comparing the transcriptomes of 
mature non-activated gametocytes with gametocytes at 30 minutes post-
activation by Suppressive Subtractive Hybridization (SSH) identified 126 genes 
with differential expression and 17.5% out of them were implicated to have a 
role in signalling mechanisms (Ngwa et al., 2013). 
After approximately 10 minutes of induction to undergo gametogenesis, 
the gametocytes round up and emerge out of the RBCs (Billker et al., 1998). It 
has been demonstrated in P. berghei that an atypical mitogen-activated protein 
kinase-2 (Pbmap-2) has a role in initiating cytokinesis and axoneme motility in 
male gametes after the cell cycle checkpoint for completion of DNA replication 
and/or mitosis has been reached (Tewrai et al., 2005). Between 10 minutes and 
1 hour after gametogenesis, fertilization takes place in the midgut of the 
mosquito by penetration/fusion of the haploid male gamete to the haploid 
female gamete, resulting in the diploid zygote (Janse et al., 1986). It has been 
demonstrated that a number of gamete surface proteins are conserved between 
rodent and human parasites (Thompson et al., 2001; van Dijk et al., 2001). The 
gametes contact each other through cell-cell adhesion probably mediated by 
Pfs48/45 and P230. The male gamete specific P48/45, one of the 10 identified  
members of a protein family containing domains with 6 positionally conserved 
cysteine residues (the 6-cys protein family) has been shown to be responsible for 
recognition/attachment with the female gamete (van Dijk et al., 2001). Two 
other members of the 6-cys family, P47 (on female gametes) and P230 (on male 
gametes) have recently been identified to play a role in gamete fertilization. 
Pfs230 negative mutants show that the protein is essential for the characteristic 
agglutination of extracellular gametes with uninfected RBCs during 
exflagellation (Eksi et al., 2006).  P47 and P230 knockout gametes have been 
shown to be responsible for gamete recognition and/or attachment and produce 
very few ookinetes with 20-50 fold reduced transmissibility to mosquitoes (van 
Dijk et al., 2010).  
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Currently, 24 proteins have been identified which have the potential to 
induce transmission blocking antibodies. These include P48/45, P230, P25, and 
P28 (Sinden et al., 2012). Pfs48/45 and Pfs230 are located in the form of a 
complex on the plasma membrane of the gametocyte. Upon activation, these 
proteins become directly exposed to the blood meal on the extracellular surface 
of the male and female gametes. It has been observed that monoclonal 
antibodies raised against these proteins blocked Plasmodium transmission when 
fed to the mosquitoes artificially (Targett et al., 1990). 
Another group of six adhesive proteins called the PfCCp in P. falciparum 
(Simon et al., 2009) and lap in P. berghei (Trueman et al., 2004) which are 
expressed in gametocytes but later secreted and are supposed to play a 
signalling mediated role in cell-cell interactions between the female gametes 
during fertilization, as one of the PfCCPs, PfCCp4, has been demonstrated to 
associate with Pfs230 (Scholz et al., 2008). 
The success of transmission of Plasmodium through Anopheles is a crucial 
rate-limiting step and is potentially determined by a variety of factors derived 
from the vertebrate host, the parasite and the mosquito (Sinden et al., 1996). 
One of the parasite-derived factors is a conserved male-specific sterility gene, 
HAP2, expressed exclusively in gametocytes and localized in the male 
gametocyte and the microgamete. Reverse genetics studies in P. berghei and 
complementary studies on Chlamydomonas have shown that HAP2 is essential 
not for the attachment but for the fusion of the male and female gametes (Liu 
et al., 2008) and thus could be considered as a potential transmission-blocking 
vaccine candidate (Blagborough and Sinden, 2009). 
Meiotic division occurs in the zygote after about 2-3 hours of fertilization 
of male and female gametes (Sinden and Hartley, 1985; Janse et al., 1986). 
Meiosis is not directly followed by nuclear division, resulting in single nucleated 
zygote/ookinete with 2-4 times the haploid amount of DNA (Janse et al., 1986). 
The spherical zygote develops into a banana-shaped, motile ookinete within a 
period of 18-24 hours. The small pigment granules that are scattered throughout 
the cytoplasm of the gametocytes/zygotes become 'packaged' into a few clusters 
in the mature ookinete. It has been shown that a NIMA (never in mitosis / 
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Aspergillus)-related protein kinase (NIMA-related kinase or Nek-4) is critical for 
development of ookinete from the zygote (Reininger et al., 2005).  
 Ookinetes are one of the motile stages of Plasmodium and are known to 
exhibit actin-myosin-based gliding motility. Gliding locomotion and its associated 
machinery is shared by all members of Apicomplexa as a means of life-cycle 
progression as it allows them to move actively and is fast (Matuschewski and 
Schüler, 2008). The actin-myosin motor is typically based on scaffolds of actin 
and myosin polymers or myosin monomers working against F-actin tracks. The 
myosin involved is myosinA (MyoA) (Meissner et al.,2002), a class XIV tail-less 
myosin restricted to Apicomplexa and ciliates (Heintzelman and Schwartzman, 
1997; Foth et al., 2006). The other components of the motility machinery 
includes the unique double membrane layer, the inner membrane complex (IMC) 
(Morrissette and Sibley, 2002), two accessory proteins, the gliding-associated 
proteins 45 and 50 (GAP45/GAP50) that link MyoA to the IMC through the 
glycoprotein GAP50 (Gaskins et al., 2004). The GAP45/ GAP50 pair likely acts in 
concert with MyoA-tail interacting protein (MTIP), a MyoA-associated protein 
that is reminiscent of the regulatory light chain (Bergman et al., 2003). Recent 
experiments with P. berghei ookinetes have strongly suggested that the Myosin A 
(MyoA) is vital for the motility of the ookinetes (Siden-Kiamos et al., 2011). A 
tight control of cGMP mediated signalling mechanisms regulated by guanylyl 
cyclase β (PbGCβ; Hirai et al., 2006; Moon et al., 2009) and phosphodiesterase δ 
(PbPDEδ; Moon et al., 2009) has been shown to be responsible for gliding 
motility and midgut invasion by the ookinetes. 
1.6.2.3 Ookinete to Oocyst Transformation 
The ookinete contains an apical complex (Sinden, 1985a) that has 
secretory organelles called micronemes for penetration and traversing of cells of 
the midgut epithelium. Several (surface) proteins of ookinetes that are involved 
in interaction of the ookinete with the mosquito midgut such as the peritrophic 
matrix (a proteoglycan matrix that separates the food from the midgut of 
insects), midgut epithelium and basal lamina, are conserved in structure 
between rodent and human parasites. Examples are Chitinase, Circumsporozite 
and TRAP-Related Protein (CTRAP), P25 and P28 proteins (Yuda et al., 1999; 
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Dessens et al., 2001; Tomas et al., 2001). Of particular interest is the 
micronemal protein, MAOP (membrane attack ookinete protein) which is 
implicated in disruption of the host cell membrane and ookinete penetration 
(Kadota et al., 2004).  
 
Other proteins that probably assist in ookinete to oocyst transformation 
include glycosylphosphatidylinositol (GPI)-anchored ookinete surface proteins 
P25 and P28 (Tomas et al., 2001), and two proteins with adhesive domains, SOAP 
(secreted ookinete adhesive protein) (Dessens et al., 2003) and the 
aforementioned CTRP (Limviroj et al., 2002; Mahairaki et al., 2005). Recently, 
potassium channels, particularly, have been shown to be involved in oocyst 
development as a knockout of such channels in P. berghei (pfkch1) was shown to 
have 98% reduction in mosquito infectivity as compared to the WT (Ellekvist et 
al., 2008).   
 
Mature, motile ookinetes traverse the midgut epithelium by invasion of 
cells of the epithelium (cell traversal) and settles between the basement cell 
membrane and the basal lamina of the midgut wall (Han et al., 2000; Sinden and 
Billingsley, 2001). The invaded cells undergo apoptosis (Han et al., 2000; 
Vlachou et al., 2004). The ookinete invasion of the mosquito midgut is a complex 
process – the ookinete surface is covered by enolase which mediates the binding 
of plasminogen from the mammalian blood meal to the ookinete surface and this 
interaction, coupled with conversion of plasminogen into active plasmin, has 
been shown to be essential for midgut invasion and subsequent oocyst 
development (Ghosh et al., 2011). It is important here to note that the ookinete 
is the only invasive stage that is not preceded by a multiplication step, resulting 
in severe reduction of ookinete numbers due to activation of host protective 
mechanisms ignited by the invasion process (Han et al., 2000; Aly et al., 2009).  
 
1.6.2.4 Oocyst development and sporozoite differentiation  
Upon emerging from the epithelial cell, the ookinete makes contact with, 
but appears to be unable to penetrate the basal lamina. The cell traversal 
appears to trigger the change from penetrating mode to sessile mode (Aly et al., 
2009). Here the parasites rapidly round up and develop into the oocyst stage. 
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After a growth phase of the oocyst asexual, mitotic replication results in the 
formation of a mature oocyst that contains thousands of daughter cells 
(sporozoites). A distinguishing feature of all Plasmodium spp. is the occurrence 
of a time gap between karyokinesis and cytokinesis (Aly et al., 2009). 
LCCL/lectin adhesive-like proteins are thought to play a key decisive role in 
sporozoite formation (Trueman et al., 2004).  
 
The oocysts increase in size from 2-3 μm in diameter to about 40 μm (and 
even up to 50-60 μm) within 10-13 days, stretching the basal lamina overlying 
the oocyst (Meis et al., 1992; Aly et al., 2009). Consequently, oocysts rupture 
and the haploid sporozoites are released into the hemocoele that will invade the 
salivary glands (Sinden, 1978; Meis et al., 1989). The subsequent migration of 
the sporozoites to the salivary glands is poorly understood (Baton and Ranford-
Cartwright, 2005). The first sporozoites reach the salivary gland at day 13-14 
after the infectious blood meal. The invasion of the salivary glands by 
sporozoites is an active process and involves parasitophorous vacuole formation 
(Pimenta et al., 1994; Kappe et al., 2003). Sporozoites migrate through cells of 
the gland and exit into the extracellular secretory space where the sporozoites 
can persist for many weeks before being injected into a new host, thus 
completing the lifecycle (Sterling et al., 1973; Pimenta et al., 1994; 
Frischknecht et al., 2004). 
  
Recent researches into the sporozoite stages of the rodent malaria 
parasite, P. berghei, have identified a family of 4 proteins, the Plasmodium 
cysteine repeat modular proteins (PCRMP1-4). The pcrmp1 and 2 knockout 
parasites have been shown to be infective when injected intravenously into the 
host mouse but are unable to target and invade mosquito’s salivary glands 
(Thompson et al., 2007). In contrast, the pcrmp3 and 4 knockouts were unable 
to egress from the oocyst and could not enter the mosquito salivary glands. In 
addition, although infective to liver, the pcrmp3-4 null mutants were unable to 
develop in the liver (Douradinha et al., 2011).   
 
Several other micronemal proteins are also hypothesized to be associated 
with the sporozoite invasion of the mosquito salivary glands including the 
circumsporozoite protein (CSP), the apical membrane antigen/erythrocyte 
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binding-like protein (MAEBL), the thrombospondin-related anonymous protein 
(TRAP), and the up-regulated-in-oocysts sporozoites protein 3 (UOS3) 
(Mikolajczak et al., 2008), also called S6/TREP (Combe et al., 2009; 
Steinbuechel and Matuschewski, 2009). One of the salivary gland proteins 
secreted by the distal lobes of the female salivary glands and whose expression 
is induced by blood feeding, Saglin, is believed to act as one of the sporozoite 
receptors (Brennan et al., 2000; Korochkina et al., 2006; Okulate et al., 2007; 
Ghosh et al., 2009).  
 
An intriguing set of proteins recently identified to have a role in P. 
berghei sporozoite development includes the Plasmodium Puf family of proteins 
which are evolutionary conserved in eukaryotes. Puf proteins typically contain a 
Puf domain which binds to 3’UTR of the target mRNA and leads to its 
translational repression and/or degradation (Wickens et al., 2002; Quenault et 
al., 2011). The nomenclature Puf is derived from D. melanogaster protein 
Pumilio and C. elegans protein fem3 binding factor (FBF) (Zamore et al, 1997; 
Zhang et al., 1997). Two proteins have been identified to contain the Puf 
domains in Plasmodium to date – Puf1 and Puf2. Both Puf1 and Puf2 in P. 
falciparum have been shown to be differentially expressed in gametocytes (Cui 
et al., 2002; Fan et al., 2004) where PfPuf2 (which is intriguingly found to be 
most highly expressed in sporozoites (Le Roch et al., 2003)) is believed to play a 
role in supressing gametocytogenesis and differentiation of male gametocytes 
(Miao et al., 2010). However, in P. berghei, both Puf proteins have been shown 
to be expressed in sporozoites (Hall et al., 2005). PbPuf2 has been shown to 
control the sporozoite latency in mosquito salivary glands which prevents 
premature transformation of sporozoites before transmission to mammalian host 
and thus maintains infectivity to mammalian host (Muller et al., 2011). It has 
been recently shown that the eukaryotic translation initiation factor 2α (eIF2α) 
kinase and a phosphatase play a regulatory role in converting salivary gland 
sporozoites into liver stage sporozoites (Molloy, 2010; Zhang et al., 2010).  
 
Thus, ookinete and sporozoites are the bottleneck stages in malaria 
parasite life cycle and are hence critical for exploiting potential candidates for 
drug and/or vaccines (Aly et al., 2009). However, a paucity of ex vivo or in vitro 
experimental systems to study the molecular details of the events happening at 
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the sporozoite-salivary gland interface is a key deterrent in advancing the 
understanding of these mechanisms to allow the identification of drug and/or 
vaccine targets (Mueller et al., 2010).  
 
1.7   Gametocytogenesis – a sexual    
  developmental switch 
1.7.1 Commitment to gametocytogenesis 
Since the identification and description of gametocytes which led to the 
discovery of Plasmodium parasites by Laveran in 1880 and up to the recent 
advances in attributing genes involved in the process of gametocytogenesis, 
surprisingly many aspects of gametocyte biology are still under cover (Babiker, 
Schneider and Reece, 2008; Dixon et al., 2008). If we take proper cues from the 
life cycle of the parasite, we could conveniently infer that there are certain 
checkpoints or bottlenecks which need to be explored further in order to have 
some control over interrupting the parasite life cycle. Commitment to the sexual 
phase of the life cycle in the form of generation of viable gametocytes 
(gametocytogenesis) in the vertebrate is one such essential step for 
establishment of infection in the mosquito vector. These processes are critical 
for life cycle completion and represent a major population bottleneck or 
checkpoint in the parasite’s life (Sinden and Billingsley, 2001; Ecker et al., 
2008).  
 
Sexual differentiation in Plasmodium is not dependent upon segregation 
of sex-specific chromosomes but instead is derived from the haploid genome of 
the preceding asexual parasite (Cornelissen, 1988; Smith et al., 2002). In 
addition to the innate genetic factors, the switch from asexual to sexual stage is 
also probably regulated by environmental cues from the host blood (Smith et al., 
2002). 
 
Differentiation and development of sexual stages in Plasmodium spp. can 
be divided into steps of induction, commitment and maturation but the 
molecular basis underlying these processes are barely known (Baker, 2010). It is 
however known that in P. falciparum commitment to sexual stage occurs one 
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cycle before gametocytes appear in blood such that all merozoites released from 
a single schizont are already committed for following either a sexual cycle or an 
asexual one (Bruce et al., 1990; Talman et al., 2004). This implies that the 
trophozoites of the preceding asexual cycle were already committed to follow 
either a sexual or an asexual cycle (Talman et al., 2004). Also, all merozoites 
from a “sexually committed” schizont become either male or females 
(Silvestrini, Alano and Williams, 2000; Smith et al., 2000). That would indicate 
that commitment to male or female gametocytes either happens concomitantly 
or follows the asexual-to-sexual switching (Smith et al., 2002). 
  
1.7.2 Factors associated with the commitment switch 
It is not known, however, when the commitment to sexual differentiation 
takes place in P. berghei parasites. The molecular mechanisms that induce and 
regulate the switch from asexual multiplication to sexual differentiation are still 
unknown. It is difficult in P. falciparum to study the triggers and timing of 
gametocytogenesis in vivo in humans as many inter-related factors potentially 
influence the switching mechanism and also because of sequestration of early 
gametocyte stages to spleen and bone marrow (Carter, 1988). Both in P. 
falciparum and in P. berghei there is evidence that the switching mechanism is 
highly flexible and is responsive to primary signals which include certain 
environmental factors which are believed to switch on the gene(s) that 
determine the commitment to the sexual phase (Dyer and Day, 2000; Alano, 
2007). The role of environment as a modulator of the switching mechanism first 
became clear when it was demonstrated that addition of fresh blood and a lower 
parasitemia significantly reduced commitment of gametocytogenesis (Carter and 
Miller, 1979). Subsequent studies have added onto these factors which could now 
be grouped as those contributed by the host or the parasite, or could simply 
include a drug treatment or a signalling mechanism (Talman et al., 2004).  
 
Various host factors contributing to increased commitment to 
gametocytogenesis include increased immune pressure (Smalley and Brown, 
1981; Ono et al., 1986; Buckling and Read, 2001), increased steroids and 
corticosteroids (Lingnau et al., 1993), increased proportion of reticulocytes in 
blood (Trager and Gill, 1992; Trager et al., 1999) and anemia (Drakeley et al., 
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1999; Price et al., 1999). Chloroquine was also found to induce 
gametocytogenesis (Buckling et al., 1999; Talman et al., 2004a). 
  
Many parasite borne factors have been demonstrated which affect 
gametocytogenesis. These include the presence of mixed-genotype infections 
(Taylor et al., 1997; Williams, 1999), levels of asexual parasitemia (Dyer and 
Day, 2000) and presence of lysed parasitized erythrocytes (Schneweis et al., 
1991). These environmental triggers strongly suggest a signal transduction 
mechanism through which the parasite receives a cue to sexual commitment. G-
proteins have been implicated as a signalling mechanism to mediate the 
switching to sexual development in response to environmental stimulus (Dyer 
and Day, 2000). As there are no parasite heterotrimeric G-proteins that are 
homologous to mammalian G–proteins, it is possible that the parasite recruits 
host erythrocyte derived G-proteins for signalling (Harrison et al., 2003).  The 
involvement of cAMP-dependent and protein kinase C-dependant signalling 
pathways have been shown to induce gametocytogenesis (Kaushal et al., 1980; 
Inselburg, 1983; Trager and Gill, 1989; Li et al., 2001; Muhia et al., 2003) 
however no protein kinase C have been identified in malaria parasies (Hall et 
al., 1997). Expression of such switch-on genes may also dictate sex specificity of 
gametocytes. Sexual differentiation, thus, must be dependent upon an 
orchestrated mechanism of gene expression and their regulation, involving 
sexual stage-specific gene(s) and their protein products (Lobo and Kumar, 1998).   
 
Despite some evidence that this differentiation could also be triggered by 
some “secreted” factors, these have not been defined and experimentally 
proven until recently where it was shown that small extracellular vesicles, called 
exosome-like vesicles or ELVs, secreted by infected RBCs act as the mediators 
for transfer of DNA/signals between infected cells. These ELVs were found to be 
composed of both red blood cells and parasite-derived proteins. It was 
comprehensively shown using complementary approaches that the ELVs are 
internalized by other neighbouring Plasmodium-infected cells in the culture 
leading to gametocyte differentiation of the recipient asexual parasitized cells 
(Mantel et al., 2013; Regev-Rudzki et al., 2013). It has also been shown that ELV 
formation is dependent upon a protein, PfPTP2. In the context of ELV carrying 
sexual differentiation signals to other infected cells triggering them to commit 
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to gametocytogenesis, it would be intriguing to know whether deletion of PfPTP2 
has any effect on the ability to generate gametocytes and what exactly is the 
signal carried by these ELVs (del Portillo and Chitnis, 2013; Tilley and 
McConville, 2013).   
1.7.3 Timing of commitment – when does the 
 commitment occur? 
  Despite the demonstration of fluorescent schizonts through expression of 
GFP labelled SET genes under a gametocyte-specific promoter in P. berghei 
(Pace et al., 2006), further experimentation with isolating such fluorescent 
schizonts and determining their gametocyte generating capabilities might prove 
confirmatory of the earliest molecular identification of “sexual schizonts” 
(Alano, 2007).  An understanding of the timing of irreversible commitment to 
gametocytogenesis is extremely relevant to pin down the mechanisms of sexual 
dimorphism in Plasmodium. 
 
Molecular differentiation of male and female gametocytes is thought to 
occur much earlier than the appearance of sexual dimorphism. It has been 
shown that Pfs16 and then Pfg27/25 are the first molecular markers for 
gametocytes and are expressed 24-hours into their development (Silvestrini et 
al., 2005). Pfnek-4 expression might help in identifying the sexually committed 
gametocytes (Reininger et al., 2012). Pfg27 knockout gametocytes were shown 
to be developmentally impaired with a variety of morphological forms (Olivieri 
et al., 2009), suggesting its role in gametocyte maturation rather than 
commitment. Transcriptome data from several microarray experiments suggest 
that about 200-300 gametocyte-specific transcripts are significantly up regulated 
in the first 40-48 hours of sexual development (Eksi et al., 2005; Silvestrini et 
al., 2005; Young et al., 2005). Experiments detailing the timing of sexual 
commitment are difficult with P. falciparum as induction of gametocytogenesis 
by overgrowing asexual parasite cultures produces wide biological variations in 
microarray experiments and large-scale purification of gametocytes younger 
than 48 hours is difficult (Alano, 2007). 
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The basic key question that is still unanswered is how the decision to 
switch to sexual mode from asexual cycle is induced and regulated. Further 
switching models describing whether the switch is constitutive and/or subjected 
to environmental sensing and regulation still remain debated (Sinden et al., 
2012).    
 
1.7.4 Spontaneous loss of gametocytogenesis and 
 genomic changes 
A progressive decrease in the production of sexual stages of the parasite 
has been observed following continuous maintenance in blood culture in P. 
falciparum (Bhasin and Trager, 1984) and during repeated mechanical passage 
(from one vertebrate host to another without an opportunity for vector 
transmission) in P. berghei (Mons, 1986; Dearsly et al., 1990; Janse et al., 
1992b). P. falciparum clone 3D7 and its parental isolate NF54 are widely used 
gametocyte producer which during continuous in vitro passage lose their ability 
to generate gametocytes and the non-producers get positively selected 
(Ponnudurai et al., 1982). However, particularly in P. falciparum, because of the 
longer development of gametocytes, it happens frequently that the suggested 
GNP line does not reveal any gametocyte on Giemsa-staining but IFA or other 
high throughput techniques such as flow cytometry can detect early gametocytes 
suggesting that the block in gametocytogenesis occurred during the development 
rather than at the commitment stage (Baker, 2010).  
 
The time taken by the parasite to lose the ability to produce gametocytes 
varies from a few weeks (Brockelman, 1982; Graves et al., 1984) to more than a 
year, both in P. falciparum (Carter and Miller, 1979; Trager, 1979; Ponnudurai et 
al., 1982) and in P. berghei (Janse et al., 1992b). Genetic variations have been 
identified within isolates of P. falciparum that alter the capacity to produce 
gametocytes (Bhasin and Trager, 1984; Burkot et al., 1984; Graves et al., 1984; 
Janse et al., 1989). Based on these experiments, it could be inferred that 
certain, possibly multiple genetic loci may control various steps in the process of 
gametocytogenesis and these loci become mutated and positively selected 
during repeated asexual multiplication and in the absence of vector transmission 
(Janse et al., 1992b; Lobo and Kumar, 1998). Positive selection is possible 
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because of the selective growth advantage offered by the non-gametocyte 
producer mutants. These mutations responsible for the loss in the ability to 
generate gametocytes might develop at several steps involved in the production 
of viable gametocytes (Birago et al., 1994).  
 
The inability to produce gametocytes has been related to genomic 
changes in P. berghei including loss of repetitive DNA sequences (Birago et al., 
1982; Casaglia et al., 1985) and karyotype variations (Janse et al., 1989). Large 
chromosomal rearrangements including a deletion on chromosome 5 in P. 
berghei (Janse et al., 1992a) and a 0.3 Mb subtelomeric deletion on chromosome 
9 (Day et al., 1993; Alano et al., 1995) and a defect in chromosome 12 (Vaidya 
et al., 1995; Guinet et al., 1996) in P. falciparum have been detected and found 
to be correlated to the inability to produce gametocytes. The deleted region on 
chromosome 9 consists of 15 annotated genes - including Pfgig which has been 
characterized by gene silencing and complementation studies to be associated 
with reduction in gametocyte production and restoration of gametocyte-specific 
transcripts, respectively (Gardiner et al., 2005). Gametocyte-specific transcripts 
have been detected by comparing gametocyte-producing and non-producing 
lines (Hall et al., 2005a; Kooij and Matuschewski, 2007) and sex specific markers 
including pfg377 (for females), α–tubulin II (Kooij et al., 2005b) and pfmdv-1 (for 
males; Furuya et al., 2005) have been identified and characterized (Silvestrini, 
Alano and Williams, 2000).  
 
Recently, a forward genetics approach using PiggyBac insertional 
mutagenesis in P. falciparum identified 29 clones, called IGM (Insertional 
Gametocyte-deficient Mutants), which did not form mature gametocytes. Out of 
them, 16 were identified to be putatively responsible for gametocytogenesis. 
These included LCCL domain-containing (PfCCP2), Putative Hsp70-interacting 
protein (PfHip), Repressor of RNA polymerase III (MAF1), AP2 transcription factor 
(PF13_0097), and Small PEXEL-containing hypothetical protein. The 
identification of an AP2 family protein is interesting as AP2’s are already 
implicated in Plasmodium gametocytogenesis (Ikadai et al., 2013). 
 
Although the characterization of a potential gene located on chromosome 
5 which is implicated in gametocytogenesis has been attempted in P. berghei 
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(Birago et al., 1994), smaller mutations like indels and SNPs still remain 
undetected or unaddressed. Clones of gametocyte non-producer (GNP) lines 
have been developed from their parental high gametocyte producers (HP), for 
example, 233 (GNP) from 234 (HP) of ANKA strain of P. berghei (Dearsly et al., 
1990) and clone HPE (GNP) from clone 8417 (HP) (Janse et al., 1992b). Molecular 
studies involving such mutant lines defective in the ability to produce 
gametocytes have thrown some light in understanding the genetic control of the 
process of gametocytogenesis but there is still a lot to be learned and 
deciphered towards complete understanding of the molecular events behind 
these intricate processes. Comparisons of whole genomic sequences and 
epigenetic information between normal gametocyte producers and non-producer 
mutant lines could be crucial as they would help pinpoint the genetic loci 
controlling gametocytogenesis and identify suitable interventions.  
 
Coupled with techniques based on molecular amplification, which are 
more sensitive to detect and quantify gametocytes at very low parasitemias 
(e.g. 0.02-10 gametocytes per microliter) (Schneider, 2006; Babiker, Schneider, 
and Reece, 2008), further analysis of gametocyte-specific transcripts in 
reference to the gametocyte non-producer lines may help refining the 
approximate time when the parasites have lost their ability for 
gametocytogenesis. However, transcript analysis is beset with the problem that 
the absence of any given transcript is not a reliable indicator of a causal effect, 
i.e. the expression of which gene or set of genes is truly responsible for the 
commitment to gametocytogenesis. Therefore direct whole genome sequencing 
methods which are unbiased representations of the differences between 
producer and non-producer genomes may more unambiguously lead to 
identification of the gene(s) responsible for commitment to sexual development. 
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1.8   Recent technological advances in Whole  
  Genome Analysis 
1.8.1 Sequencing methods  
The last 4-5 years have witnessed a major shift away from the so-called 
“first generation” sequencing method or the automated Sanger sequencing for 
genome analysis. This is partly because of the ceiling of throughput being 
reached with automated Sanger technology and partly due to the flurry of new 
or advanced sequencing techniques, known as the Next Generation Sequencing 
(NGS). The limitations of any further improvements in cost and throughput with 
Sanger sequencing generated the need to develop and improve novel sequencing 
technologies (Metzker, 2010). The most important achievements of the NGS are 
the ability to generate tremendous amount of reliable data cheaply and rapidly.  
1.8.2 Next-generation sequencing 
These latest and improved technologies dramatically increase the 
sequencing throughput by laying millions of fragmented/sheared DNA molecule 
on a single solid support and sequencing all these fragments in parallel, the so 
called Massively Parallel Sequencing (Pop and Salzberg, 2008; Tucker et 
al.,2009). NGS includes the commercially available technologies from 
Roche/454, Illumina/Solexa, Life/APG and Helicos BioSciences. Although the 
basic platform for NGS is similar in all these techniques, these differ with 
respect to the various individual processes for the analysis of a genome, such as, 
template preparation, sequencing and imaging, and genome alignment and 
assembly. Whereas 454 and Applied Biosystems platforms first attach the DNA 
fragments to coated beads, Solexa and Helicos attach them directly to the 
support (Pop and Saltzberg, 2008). Therefore, the type of data produced through 
each of these platforms is unique to that platform and presents specific 
computational challenges in the downstream processes like alignment and 
genome assembly. As of now, the most widely applied platform for genome 
sequencing is the Illumina/Solexa platform which seems to have an edge over 
the other currently available sequencing platforms (Metzker, 2010).  
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The Illumina/Solexa platform: The Illumina platform is based on a clonal 
bridge amplification of single DNA molecules on a flow cell surface which 
generates 10 million single-molecule clusters per square centimetre of flow 
surface (Pettersson et al., 2009). Once the DNA is sheared, adapters are ligated 
at both ends of the fragments of DNA. These sample DNA fragments are then 
passed over a solid support surface which has a dense lawn of adapter 
complementary sequences attached to it. When the adapter-linked DNA 
molecules pass over this surface, each of these molecules becomes annealed to 
its nearby adapter-complementary sequence (primer). Bridge amplification 
(characteristic of this technique) is then performed which generates a double-
stranded bridge after elongation (Illumina; Adessi et al., 2000). A denaturation 
step then frees the two strands which now remain attached to the flow cell 
surface by means of the adapter-complementary oligonucleotides. Repeated 
amplification cycles generate colony-like local clusters, each containing 
approximately 1000 copies and with a diameter of about 1 μm. Sequencing is 
then carried out with fluorescently labeled reversible terminator nucleotides 
(Pettersson et al., 2009). Only one base is interrogated and incorporated at a 
time as further chain elongation is prevented by reversible terminators (Bentley, 
2006). Once all colonies on the flow cell surface are interrogated for bases and 
the appropriate base attached, the fluorophores are removed and terminating 
bases are inactivated permitting the next cycle of base-interrogation and 
incorporation. The chances of mis-incorporation (errors) are claimed to be 
minimized by the presence of all four nucleotides during each cycle and the 
competition generated thereof. The relatively short read length generated by 
this technique may be due to incomplete incorporation of nucleotides and/or 
ineffective removal of reverse terminators or fluorophores (Pettersson et al., 
2009).  
 
Although the length of reads generated by Illumina/Solexa platform is 
relatively shorter (45, 75 or 130 bases) than the average read length from 
Roche/454 (330 bases), the throughput is much higher (than Roche/454) in terms 
of base-pairs generated in each run by almost 35 and 75 fold (fragment run and 
mate-pair run, respectively) (Metzker, 2010). The raw accuracy is claimed to be 
98.5% and the cost per base is only 1% of the cost of Sanger sequencing (Illumina 
website, http://www.illumina.com). The error rates and shorter read lengths 
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are compensated, at least in part, by the use of paired-end libraries (paired-end 
sequencing) which generate double the volume of data in each run (Pettersson 
et al., 2009).  
 
All NGS platforms have this strategy for paired-end sequencing but the 
sequencing method from the opposite end of a DNA strand differs between 
various NGS platforms. Illumina uses a different hardware module and a 
modified paired-end enabled flow cell to re-synthesize the template using bridge 
amplification PCR (Figure 1-7). Sequence from one end is obtained by 
amplification, linearization and de-hybridization of DNA template resulting in a 
single strand molecule covalently attached to the flow cell which is subjected to 
sequencing by synthesis. A subsequent step of amplification regenerates the 
double-stranded template and the opposite strand is de-hybridized this time and 
sequenced (Holt and Jones, 2008). 
 
1.8.3 Genome assembly 
In order to create a new genome map (de novo) or to analyse differences 
between two genomic sequences (resquencing), the reads (short DNA sequences 
produced by NGS platforms) need to be combined and the original genome has to 
be reconstructed.  This is accomplished by computer programs called genome 
assemblers using various input-specific algorithms. Major genome assembly 
challenges include the presence of large sections of repetitive DNA sequences 
(genomic repeats) distributed throughout the genome and the length of reads 
generated by NGS with large genomes (insufficient coverage) and/or short read 
lengths presenting specific computational problems (insufficiently unique 
sequence reads) (Mardis, 2008; Pop, 2009). The assembly of NGS data is further 
complicated by the bulk of the data to be assembled and moreover, by the 
nature of the data being generated with short(er) read lengths incorporating 
new(er) types of sequencing errors (Mardis, 2008).  
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Figure 1-7. The technique of bridge-amplification used by Illumina-Solexa for generating the 
paired-end sequencing. This method of sequencing the opposite end of DNA strand is unique to 
the Illumina platform. Source: Illumina website – open access. 
The quality of genome assembly is found to be directly related to the read 
length (Chaisson et al., 2004; Whiteford et al., 2005). It has been observed that 
read-lengths of 200 bp or longer are necessary for good quality de novo genome 
assembly (Pop and Saltzberg, 2008). Short read lengths makes it particularly 
difficult to assemble specifically the repeat regions of genomes (particularly if 
the repetitive segments are longer than the read length) contributing to 
ambiguity in genome assembly and resultant fragmented assemblies (Figure 1-8). 
This limitation of the NGS is partly compensated by deep coverage of the 
genome (Krause et al., 2006) and the availability of paired-end reads and mate-
pair sequencing with Illumina/Solexa. Combining data generated from mate pair 
library sequencing with that from short-insert paired-end reads provides a 
powerful combination of read lengths for maximal genomic sequencing coverage 
across the genome and detection of structural variants (Illumina website).  
 
Figure 1-8. The effect of length of repeats on genomic assembly using Sanger and SRS 
sequencing data. Blue: repeats longer than 800 bp. Red: repeats shorter than 800 bp. Sanger 
sequencing data generating read lengths greater than red repeats would result in a longer contig 
Sanger 
Genomic repeats 
SRS 
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represented at the top (only breaking at repeated longer than read lengths) whereas SRS (short 
read sequences) data would result in a much more fragmented assembly breaking at both repeat 
lengths. Paired-end reads (thin curved lines) tend to provide long range connectivity across 
repeats. Source: Pop and Salzberg, (2008) – reproduced with permission. 
 
The length of the reads coupled with specific sequencing steps for 
different platforms is driving the bioinformatics community to develop new 
bioinformatic software and keep pace with the advancements in short read 
sequence (SRS) technology (Pop and Salzberg, 2008). Thus, the SRS data cannot 
be effectively analyzed using the software developed for the Sanger sequencing 
data (Nickerson et al., 1997; Moore et al., 2006; Chen et al., 2007; Huse et al., 
2007) due to specific algorithmic requirements that are based on long read 
lengths and also to specific types of sequencing errors incorporated by SRS 
platforms (Pop and Salzberg, 2008). 
 
Recently developed de novo genome assemblers like SSAKE (Warren et al., 
2007), VCAKE (Jeck et al., 2007) and SHARCGS (Dohm et al., 2007), all use the 
“greedy” overlap-layout-consensus logarithmic approach to tackle genome 
assemblies using very short sequences. Greedy algorithms join individual reads 
together into contigs iteratively, starting with the reads that overlap best and 
finishing when no more reads can be joined (Pop, 2009). The term “greedy” 
implies that the decisions made by the algorithm are locally optimized between 
any two reads and may not result in globally optimal assembly thus generating 
problems in assembling repeats (Pop, 2009). An alternative recent approach 
towards genome assembly uses the deBruijn graph paradigm (Eulerian strategy) 
which is less affected by the short read lengths (Chaisson and Pevzner, 2008) and 
thus is typically better suited for SRS data (Pop, 2009). Two recently developed 
assemblers incorporating the Eulerian strategy are Velvet (Zerbino and Birney, 
2008) and Allpaths (Butler et al., 2008). Velvet algorithms are claimed to solve 
the major challenges posed by the SRS data – can remove sequencing errors and 
in the presence of read-pair information can resolve large repeats (Zerbino and 
Berney, 2008). 
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1.8.4 Structural variants 
Variations in pathogenicity in P. falciparum could be attributed to the 
underlying genome sequence variations as detected by DNA re-sequencing 
methods. Such genome structural variations include single nucleotide 
polymorphisms (SNPs), insertion and deletion of short sequences (indels), large 
scale deletions, amplifications, inversions and translocations (Cheeseman et al., 
2009). All variations arising out of alterations involving 2 or more base-pairs are 
termed as structural variations in contrast to the sequence variations which 
typically involve a single nucleotide (Scherer et al., 2007). Gene copy number 
variations or CNVs (structural variants extending more than 1 kb in length) have 
been associated with various aspects of adaptive biology and several important 
phenotypes of P. falciparum including drug resistance (Cowman et al., 1994). 
Current sequence-based approaches to identify structural variants are based on 
paired-end read mapping (PEM) which compares the distance between paired-
mate reads to the average insert size of the genomic library (Tuzun et al., 2005; 
Korbel et al., 2007). However, PEM based approaches have poor sensitivity to 
detect structural variants (SVs) in highly duplicated genomic regions and 
duplications larger than the insert size of the library. To rescue these 
limitations, newer more sensitive and accurate approaches use read depth of 
coverage generated by NGS methods (typically 30x) to identify CNVs (Yoon et 
al., 2009). 
 
1.9   Transcription and its regulation 
1.9.1 General introduction 
Transcription, the cellular process of converting a particular region of 
dsDNA into ssRNA, is a very complex phenomenon regulated mainly by 
transcription factors (TFs) which either promote (as activators) or block (as 
repressors) the recruitment of RNA Polymerase II complex (Levine and Tjian, 
2003). The transcriptional machinery has been the focus of extensive research 
since many years but still the finer details of how this molecular circuitry is so 
precisely operated and controlled are yet to be confirmed. Synthetic biology 
through engineering of the molecular circuitry has helped to understand how 
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organisms behave and how the complex eukaryotic transcriptional machinery is 
recruited and regulated (van Driel et al., 2003; Muller and Stelling, 2009; Khalil 
et al., 2012).  
 
Gene expression is regulated at multiple levels, often called as the 
combinatorial regulation of gene expression. Besides regulation at 
transcriptional level, epigenetic and post-transcriptional regulation offer further 
levels of control over gene expression. Whereas epigenetics mainly involves DNA 
methylation and histone modifications, post-transcriptional gene regulation 
includes mRNA transport out of the nucleus, mRNA modifications such as 
5’capping, splicing and poly-adenylation (which tends to increase the half-life of 
mRNA), translational repression, regulation through micro-RNAs (miRNAs), small 
interfering-RNAs (siRNAs) and non-coding RNAs (ncRNAs) (Chakrabarty et al., 
2007; Chen and Rajewsky, 2007; Mourier et al., 2008; Zhou et al., 2010).  
 
1.9.2 Transcription Factors (TFs) 
Eukaryotic transcription factors (TFs) are intermediate protein molecules 
that recognize their regulatory cognate DNA sequences and then recruit the 
assembly of other protein complexes that control gene expression. Eukaryotic 
transcriptional regulation apparatus mainly includes the following: (a) RNA 
polymerase complex for the initiation and elongation of the transcripts, (b) the 
basal TFs which recruit the RNA polymerase complex and bind to the core 
promoter region (TSS) of the genes to be transcribed and are thus responsible for 
the baseline expression of the regulated gene (Ptashne and Gann, 2002), and (c) 
the specific TFs whose DNA binding domains (DBD) bind to the regulatory 
elements (cognate DNA sequence/s or the TF binding sites) in a sequence-
specific fashion in the promoter region other than the core promoter to fine 
tune the gene expression by activating or repressing the transcription (Lodish et 
al., 1999). 
 
The interactions of TFs with the polymerase complex may be direct or 
indirect. The indirect interaction may be mediated by chromatin remodelers or 
modifiers that increase access or protein-protein attractions via histone 
modifications (Fry and Peterson, 2001; Cosma, 2002). The interaction between 
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the DBD of the TF and its cognate DNA sequence is primarily dependent upon the 
structure of the DBD, with other protein regions of the TF trying to stabilize the 
complex (Kurokawa et al., 2009). Studies have shown that the DNA-binding 
domains of most of the TFs are highly conserved within a given phylum as 
compared to the rest of the protein sequence of the TF. Whereas the DBD is the 
principal trans-element involved in transcription initiation, the rest of the 
sequence might be useful in mediating protein-protein interactions and provide 
the activation domains (Ptashne and Gann, 1997; Setty et al., 2003; Fondon and 
Garner, 2004).  
 
The sequence specificity of the interaction is largely determined by 
hydrogen bridges and van der Waals forces. The binding specificity of any TF can 
now be experimentally shown using the high-throughput Protein Binding 
Microarrays or PBMs which usually contain 60-mer probes in which 8-mers occur 
several times in different sequence context (Berger et al., 2006). Prior methods 
of in vitro detection of DNA-binding specificity of TFs included Electrophoretic 
Mobility Shift Assay or EMSA (Fried and Crothers, 1981; Garner and Revzin, 
1981), DNase I footprinting (Galas and Schmitz, 1978), Southwestern blotting 
(Bowen et al., 1980) and surface plasmon resonance (Jost et al., 1991). All of 
these are predominantly low-throughput approaches and the level of precision 
for detection of a specific binding site also varies between the methods (Berger 
and Bulyk, 2009). The genome wide distribution of these TF binding sites can 
now be examined with ChIP-chip (chromatin immunoprecipitation coupled with a 
microarray) or ChIP-seq (chromatin immunoprecipitation coupled with next 
generation sequencing methods) (Johnson et al., 2007; Wold and Myres, 2008). 
 
Sometimes, the number of identified TF binding sites far exceeds the 
number of expected gene targets suggesting that the binding of TFs to the TF 
binding sites might have roles other than direct target gene regulation 
(MacQuarrie et al., 2011). One possible explanation of the disproportionally and 
comparatively increased TF binding sites is the presence of some “non-
functional” binding sites (Li et al., 2008). Presuming these are functional sites, 
there remains a possibility that some of these additional sites are low-affinity TF 
binding sites – wherein, a contact with the TF’s allows baseline low level 
transcription of the gene sufficient enough only to allow for evolutionary 
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conservation purposes (Tanay, 2006). Other possibilities determining the 
functionality of these sites include a dependence on the concentration of the 
TFs, induction of chromatin looping, changes in chromatin and nuclear structure, 
or involvement of a novel yet undiscovered regulatory pathway/s (MacQuarrie et 
al., 2011).  
 
Studies have demonstrated that the excess TF binding sites present in the 
intergenic regions or in repetitive elements but outside the regulatory region/s 
(promoters) serve as a low-affinity buffer reservoir, thus helping in fine tuning 
gene expression and reducing the molecular noise by limiting the concentration 
of the unbound/free TF (Lin and Riggs, 1975; Robertson et al., 2007; Li et al., 
2008; MacArthur et al., 2009; Cao et al., 2010). In the light of the above 
possibilities, and many more, it would be intriguing to find out the predominant 
role/s played by a particular transcription factor – whether the concerned TF 
produces a direct transcriptional activation and/or a dominant change in 
chromatin landscape to regulate the transcription process. 
    
1.9.3 Epigenetic control of gene expression 
 
Epigenetics simply implies inheritance which is not attributable to 
changes in the DNA sequence or difference in external conditions (Kouzarides, 
2007; Ptashne, 2007; Bonasio et al., 2010). In other words, epigenetics involves 
changes in gene expression without any underlying alteration in the DNA 
sequences (Scherf et al., 2008). The relevance of epigenetic influence through 
gene expression lies in the fact that comparative genome sequence analysis of 
mutant phenotypes alone may not reveal differences that can be causally 
associated to the phenotype as it may result from alterations in epigenetic 
marker profile or nucleosome phasing. Thus the profile of epigenetic markers 
and nucleosome phasing might be expected to provide useful information on 
genetic determinants of a particular phenotype should the genome sequence 
prove to be uninformative. 
 
With the advent of so-called “sequence census” methods for measuring 
the whole genome “profile” including the chromatin structure, the use of 
hybridization assays such as microarrays for identification of protein-DNA 
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interactions (ChIP-chip) is not the method of choice these days (Wold and Myres, 
2008). Genome-wide mapping of DNA-protein interactions are now possible with 
seq-based approaches such as ChIP-seq. They have an edge over ChIP-chip 
methods due to absence of false positive signals, more accurate quantification 
and a greater more dynamic resolution of signal range (Johnson et al., 2007; 
Wold and Myres, 2008).  
 
Chromatin remodelling and histone tail enzymatic modifications are the 
two epigenetic mechanisms involved in transcriptional control. Chromatin 
condensation patterns determine the access of the DNA sequence to the 
transcriptional machinery. The densely packed chromatin or the 
heterochromatin is transcriptionally silent whereas the loosely packed 
euchromatin remains transcriptionally active. 
 
Eukaryotic DNA is wrapped around an octamer of 4 core histones to create 
the nucleosome (Kornberg, 1977). Core histone proteins (H2A, H2B, H3 and H4) 
together with the linker histone H1 are the building blocks of chromatin. About 
145–147 bp of DNA are wrapped around a histone octamer protein core to form a 
nucleosome chain with 10–50 bp linker DNA spacing (Teif and Rippe, 2011). 
Because of this tight packaging, a substantial surface area of the DNA faces the 
histone octamers or is spatially occluded by the neighbouring nucleosomes in 
chromatin fibres. In both cases, DNA is not accessible and hence not available 
for the TFs to bind (Luger et al., 1997; Schalch et al., 2005). The nucleosome 
phasing relative to the TSS has a direct effect on the transcription through the 
alteration of the RNA-polymerase II binding (Schones et al., 2008). Nucleosome 
phasing can be mapped out by using relatively straightforward digestion of 
chromatin with varying concentration of micrococcal nuclease (MNAse) which 
makes double-stranded cuts on the linker DNA between nucleosome particles. 
This concentration dependent digestion of chromatin provides flexibility to the 
approach with higher concentrations of MNAse producing mononucleosome-
length DNA (Zaret, 2005). Variations in nucleosome spacing are likely to reflect  
differences in the assembly of chromatin and also the functional state of the 
underlying gene sequences in terms of their accessibility to the transcriptional 
apparatus (Blank and Becker, 1996) leading to an active transcriptional locus. 
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Studies have documented that all known TFs (to date) physically occupy 
less than a few percent of their potential cognate binding sites the remaining 
being not accessible. It has been further substantiated in Drosophila and yeast 
that it is the chromatin landscape which basically dictates where an individual 
TF must bind by controlling the accessibility of the other potential target sites 
(Carr and Biggin 1999; Iyer et al., 2001; Yang et al., 2006; Joseph et al., 2010; 
Kaplan et al. 2011). The TFs must find a way to expose these hidden DNA fronts 
for transcription to start (Zaret and Carroll, 2011).   
 
Chromatin looping is another chromatin-mediated phenomenon which 
basically provides transcriptional control by bringing the distant regulatory 
elements into functional proximity of the target genes (Ragoczy et al., 2006; 
Schoenfelfer et al., 2010; Yochum et al., 2010). Studies in yeast have shown that 
TFs binding to the genome-wide recognition sites might not help in regulating 
the gene expression directly but may alter the chromatin and/or nuclear 
structure so that the accessibility of these regions is sufficiently enhanced to 
allow the direct interaction of downstream TFs expressed later in development 
(Badis et al., 2008; Hartley and Madhani, 2009; Ganapathi et al., 2011).  
 
The mechanism underlying this epigenetic control through histone tail 
enzymatic modification includes covalent post-translational modifications on 
over 30 residues of histone tails generally of histones H3 and H4 (Strahl and Allis, 
2000; Grant, 2001). These modifications predominantly include acetylation, 
phosphorylation, and methylation but also deimination, ubiquitylation and 
sumoylation, ADP ribosylation, histone tail clipping, etc. (Bannister and 
Kouzarides, 2011). In general, whereas histone acetylations (mediated by 
histone acetyltransferases or HATs) have been found to be associated with 
transcriptional activation (by relaxing the chromatin thus promoting 
transcription) and DNA repair (Masumoto et al., 2005); methylations (mediated 
by histone methyltransferases or HMTs) control the formation of transcriptionally 
active and inactive regions of chromatin and usually establish a silent chromatin 
domain blocking transcription (Grant, 2001; Hakimi and Deitsch, 2007).  
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1.9.4 The promoter region of the gene 
 
The promoter is the region upstream of the coding sequence wherein the 
TF-RNA polymerase complex binds and initiates transcription. The TFs are 
assembled in the pre-initiation complex (PIC) by the transcription adapter 
molecules. The PIC then places the RNA-polymerase II complex at the 
transcription start site (TSS) in the basal or core promoter located normally 
within 50 bp upstream to the TSS (Kornberg, 2007). The rest of the promoter 
might offer TF binding sites (TFBS) which provide fine tuning of the transcription 
process. This is typical of classical bi-partite eukaryotic promoters comprising a 
basal promoter region and an upstream regulatory region. In eukaryotes, the 
presence of TFs is critical for transcription to start and hence the transcription is 
switched off in eukaryotes by default (Wray et al., 2003). The TFs are believed 
to control transcription through a combination of actions at the control regions 
including promoters, enhancers, silencers and insulators, which might be located 
on either side of the TSS. Enhancers and silencers respectively promote and 
prevent transcription directly whereas insulators tend to prevent the action of 
enhancers on the promoter.  
 
The effect of the distance between the binding sites of repressor and 
activator proteins on gene expression was highlighted recently (Fakhouri et al., 
2010) wherein it was shown that the repressor efficiency was higher at smaller 
distances between the repressor and activator binding sites present on the gene 
promoter region. Novel gene expression within an organism may arise through a 
combination of changes in upstream regulators (the trans factors) and mutations 
in noncoding regulatory DNA sequences of a gene (the cis factors) (Rabeiz et al., 
2011). Further, the long stretches of “junk” genomic DNA might contain 
recognition sequence for certain TFs (Berman et al., 2004). Any random point 
mutations and/or indels in these regions might also produce a functional 
regulatory region (Stone and Wray, 2001), further complicating the regulation of 
gene expression in eukaryotes.   
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1.9.5 Regulation of gene expression in Plasmodium 
1.9.5.1 Introduction 
Plasmodium’s complex life cycle between two hosts involves well defined 
morphological stages accompanied by a masterly orchestrated stage-specific 
gene expression profile, the mechanisms regulating which are broadly unknown 
(Coleman and Duraisingh, 2008). The parasite’s gene expression follows a typical 
eukaryotic expression pattern but with an exclusive stage-specific well-
coordinated expression profile   in a highly, almost 90%, AT-rich genome 
(Gardner et al., 2002; Balaji et al., 2005; Hall and Carlton, 2005). The whole 48-
hour parasite transcriptome looks sigmoid, signifying successive expression of 
genes, also called the “just in time” expression profile (Bozdech et al., 2003a; 
Llinas et al., 2006). The following may be  factors contributing to this, including, 
but not limited to – high levels of anti-sense transcription (transcription 
complementary to other RNA transcripts), unique patterns of mRNA storage and 
decay, stage-specific and well-orchestrated gene expression cascades, relative 
paucity of established TFs and regulatory elements and poorly defined gene 
promoter regions (Aravind et al., 2003). Genome analyses however revealed a 
relative paucity of both cis- and trans-regulatory elements for transcription in 
Plasmodium which reflected/suggested a minor role of regulation in 
transcription by the TFs (Coleman and Duraisingh, 2008; Llinas et al., 2008). 
 
1.9.5.2 Transcription factors in Plasmodium 
 
Evolutionarily speaking, the expansion of TFs across the eukaryotes shows 
a lineage specific pattern wherein the core TFs are mostly conserved throughout 
the eukaryotes but the distribution of specific TFs across eukaryotes is more or 
less unique for each lineage (Chervitz et al., 1998; Riechmann et al., 2000; 
Lespinet et al., 2002). Despite this lineage-specific expansion of the specific 
TFs, the apicomplexa showed an intriguing apparent deficiency of known, 
conserved TFs as evident by the significantly (10-25 fold) higher ratio of the 
total number of genes to the total number of TFs as compared to free-living 
yeasts (Templeton et al., 2004).  
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This could be explained partially by the parasitic life of the apicomplexa 
but then the explanation is overruled by the facts that the phylum possesses an 
extensive network of structural and regulatory chromosomal and signalling 
proteins (Aravind et al., 2003; Templeton et al., 2004), has a very complex 
alternating two-host life-cycle and demonstrates an intricate but well-
orchestrated stage-specific gene expression profile (Bozdech et al., 2003; Le 
Roch et al., 2003). From this paradox, it was inferred that either the phylum 
apicomplexa had an undetected machinery of specific TFs which are unrelated 
or distantly related to the known families of DNA-binding domains and/or 
possessed an alternate regulatory mechanism/s, other than the TFs, including 
epigenetic and post-translational regulation (Balaji et al., 2005). 
 
The debate was answered (in part) by the discovery of a specific clan of 
lineage specific TFs in apicomplexa through sensitive sequence profile analyses 
methods. This new family of TFs possessed one or more copies of the DNA-
binding domains related to plants’ Ethylene Response Factors (ERF) or Apetala-2 
domain or more popularly, the AP2 domain. The striking stage-specific 
differential expression profile of ApiAP2 genes suggested their potential role in 
regulating transcription in apicomplexans (Balaji et al., 2005). Even with the 
discovery of ApiAP2 as specific TFs in Plasmodium, the ratio of genes to specific 
TF for Plasmodium would not be any closer to that for eukaryotes which would 
imply that either there might be more specific TFs yet undiscovered in 
Plasmodium or the regulation of gene expression is even more complex and 
involves a variety of post-transcriptional regulators. 
 
Certain other DBD-containing proteins have been documented to be 
involved in regulation of key genes related to cell cycle regulation and 
progression; however their definitive DNA binding has not yet been shown by 
Chromatin Immunoprecipitation (ChIP). These include PfMyb1 which is known to 
bind to the promoters of phosphoglycerate kinase, calcium-dependent kinase, 
TATA-binding protein, proliferating cell nuclear antigen, histones, and cyclin-
dependent kinase (Doerig et al., 1995; Doerig et al., 1996; Boschet et al., 2004; 
Gissot et al., 2005) and high-mobility-group (HMG) box proteins which are 
effective inducers of pro-inflammatory cytokines like TNFα and inducible Nitric 
oxide synthase (iNOS) and thus are thought to be useful in producing host 
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inflammatory immune response in malaria (Briquet et al., 2006; Kumar et al., 
2008). Studies involving P. falciparum in culture and P. berghei in mice suggest 
that the Plasmodium-infected red blood cells stimulate the host mononuclear 
cells to release HMGB which induces the secretion of host TNFα (Higgins et al., 
2013). HMG box proteins have also been shown to be involved in controlling 
genes important for oocyst development in mosquito (Gissot et al., 2008).  
 
Certain TFs have also been shown to bind to intergenic regions. This could 
be partly explained by the extreme (>80%) AT-richness of the Plasmodium 
genome (Gardner et al., 2002) which renders certain physical properties to the 
DNA such as increased curvature, more stable hydrogen bonding patterns (Nelson 
et al., 1987) and less efficient packaging into nucleosomes (Balaji et al., 2005; 
Polson and Blackman, 2005). In short, apart from Myb and HMG box proteins, the 
recent discovery of ApiAP2 family of TFs as evolutionary conserved proteins that 
bind to at least one cognate DNA motif (Eckert et al., 2005; Painter et al., 
2011), have provided a deeper insight into the regulation of stage-specific gene 
expression in Plasmodium (Yuda et al, 2009; Yuda et al., 2010; Iwanaga et al., 
2012).  
 
1.9.5.3 Epigenetic regulation of gene expression in 
 Plasmodium 
Gene expression and coordination in Plasmodium spp. as in so many 
eukaryotes is believed to involve multiple layers of regulation including 
epigenetic control (Hakimi and Deitsch, 2007; Dzikowski and Deitsch, 2009). The 
existence of the phenomenon of epigenetic control of gene expression is 
indirectly supported by the apparent lack of families of recognizable 
transcription factors in Plasmodium spp. (Hakimi and Deitsch, 2007; Scherf et 
al., 2008). These parasites possess the full machinery of chromatin-remodelling 
proteins which strongly suggests that epigenetics has a role to play in gene 
expression (Miao et al., 2006; Navadgi et al., 2006; Cui et al., 2007; Cui et al., 
2008; Iyer, et al., 2008). Research has shown that epigenetics in Plasmodium is 
majorly involved in regulation of transcription, delimitation of functional 
genomic elements and antigenic variation (Cortes et al., 2012).   
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In Plasmodium, tri-methylation of histone 3 lysine 9 (H3K9me3) has been 
shown to be responsible for gene silencing and di- or tri-methylation of histone 3 
lysine 4 (H3K4me2/me3) and acetylation of histone 3 lysine 9 (H3K9ac) 
responsible for activating transcription (Scherf et al., 2008; Fischer et al., 2008; 
Lopez-Rubio et al., 2009). DNA sequence elements that encode epigenetic 
modifiers such as histone acetyltransferases (HATs), deacetylases (HDACs) and 
methyltransferases (HMTs) have also been identified in Plasmodium spp. 
(Aravind et al., 2003; Horrocks et al., 2009). This epigenetic marking is dynamic 
and changes throughout the parasite asexual cycle (Salcedo-Amaya et al., 2009).  
 
Direct assessment of chromatin activity at or near var genes TSS has 
shown enrichment of typical epigenetic marks (Lopez-Rubio et al., 2007; Fischer 
et al., 2008; Scherf et al., 2008; Salcedo-Amaya et al., 2009; Cui and Miao, 
2010) associated with gene silencing (histone 3 lysine 9 tri-methylation or 
H3K9me3) (Duraisingh et al., 2005; Flueck et al., 2009; Perez-Toledo et al., 
2009) and activation (di- or tri-methylation of histone 3 lysine 4 or 
H3K4me2/me3 and acetylation of histone 3 lysine 9 or H3K9ac) (Freitas-Junior et 
al., 2005). In this regard, the regulation of var gene expression has been studied 
in detail and the major var gene regulon was found to be composed of a var 
gene promoter and its intron (Deitsch et al., 2001; Duraisingh et al., 2005; 
Freitas-Junior et al., 2005; Voss et al., 2006; Perez-Toledo et al., 2009), the 
ApiAP2 TF PfSIP2 (Flueck et al., 2010), the histone deacetylase duo PfSIR2A and 
PfSIR2B (Tonkin et al., 2009), the H3K4 methyltransferase PfSET10 (Volz et al., 
2012), heterochromatin protein 1 (PfHP1) and the histone variant H2A.Z (Petter 
et al., 2011). 
 
A very recent study with P. falciparum has convincingly established the 
role of one of the SET-domain bearing histone lysine methyltransferases, PfSET2 
in regulating the H3K36me3. PfSET2 was shown to be responsible for keeping the 
remaining 59 odd var genes silenced (hence it is also called PfSETvs; for var gene 
silencing) barring the one which is activated at any given time. Each of these var 
genes encode an individual PfEMP1 which has a role in P. falciparum virulence 
and it is this var gene switching that is the possible immune evasion mechanism 
adopted by the parasite inside the host. When PfSETvs was deleted, all the var 
genes were expressed together corroborating its role in var gene silencing. 
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Further, RNA- Fluorescent in-situ hybridization (FISH) experiments confirmed 
that all the var transcripts studied could be colocalized at a particular locus of 
the nuclear periphery - a specific transcriptionally active site (also shown by 
Lopez-Rubio et al., 2009). The study also showed that H3K36me3 occupancy at a 
silent var gene was considerably higher compared to the active one (Jiang et al., 
2013). Table 1-1 shows a composite summary of various histone modifications 
and proposed functions as observed in Plasmodium. 
 
1.9.5.4 Nuclear structure and gene regulation 
 FISH studies in P. falciparum have revealed a specific perinuclear 
arrangement of 60 var genes (of subtelomeric and more centromerically located 
clusters) in the nucleus instead of random distribution and the presence of a 
particular sub-nuclear var gene expression site. Although precise mechanisms of 
gene expression control in relation to the spatial occupation of active 
transcription sites within nucleus are not known, further studies have shown that 
there exists multiple active transcription sites both at the nuclear periphery 
(Ralph et al., 2005; Voss et al., 2006; Lopez-Rubio et al., 2009) and at the 
centre (Freitas-Junior et al., 2000; Moraes et al., 2013). A recent study showed 
the difference in spatial organization of transcription sites in P. falciparum rings 
& trophozoite stages – the transcription foci were found to be located in the 
outermost nuclear region in rings as compared to an even distribution in 
trophozoites (Moraes et al., 2013).  
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Table 1-1. Histone modifications in Plasmodium 
 
Histone Position 
Amino 
acid 
Modification Notation Enzyme 
Proposed 
Functions 
H2A 
N-
terminal 
-- Acetylation 
H2A-N-
term-ac 
  
3 
Lysine 
Acetylation H2AK3ac   
5 Acetylation H2AK5ac   
H2B 112 Lysine Ubiquitination H2BK112ub   
H3 
4 
Lysine 
Methylation H3K4me  Permissive 
euchromatin 
(di-& tri-Me), 
transcription 
activation 
Methylation-di H3K4me2  
Methylation-tri H3K4me3 PfSET1 
Methylation-
tetra 
H3K4me4  
9 
Acetylation H3K9ac PfSET3 
Transcription 
activation 
Methylation H3K9me   
Methylation-tri H3K9me3 PfGCN5 
Transcription 
silencing (tri) 
14 
Acetylation H3K14ac   
Methylation H3K14me   
Arginine 
Acetylation H3R14ac PfGCN5  
Methylation H3R14me PfGCN5  
17 
Lysine Methylation H3K17me PfCARM1  
Arginine 
Methylation H3R17me   
Methylation-di H3R17me2   
18 
Lysine 
 
Acetylation H3K18ac   
20 Methylation-tri H3K20me3   
23 Acetylation H3K23ac   
27 Acetylation H3K27ac   
36 
Methylation-di H3K36me2 PfSET2 Transcription 
silencing (tri) Methylation-tri H3K36me3 PfSET2 
56 Acetylation H3K56ac   
79 Methylation-tri H3K79me3   
H4 
N-
terminal 
-- Acetylation 
H4-N-term-
ac 
  
3 Arginine 
Methylation H4R3me PfPRMT1  
Methylation-di H4R3me2   
5 
Lysine 
 
Acetylation H4K5ac PfMYST  
Methylation H4K5me PfMYST  
8 Acetylation H4K8ac PfMYST  
12 
Acetylation H4K12ac PfMYST  
Methylation H4K12me   
16 Acetylation H4K16ac PfMYST  
17 Arginine Methylation H4R17me   
20 Lysine 
Methylation H4K20me PfSET8 Transcriptional 
silencing, 
heterochrom-
atin (tri) 
Methylation-di H4K20me2  
Methylation-tri H4K20me3 PfSET8 
 
Table 1-1. Summary of some of the known histone modifications in Plasmodium. Source: 
The table is modified, adapted and reconstructed to suit the needs from Trelle et al., 2009; Cui and 
Miao, 2010 and from the company Epigentek® and is used with permission.   
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1.9.5.5 Post-transcriptional regulation of gene expression  
 The regulation of gene expression after transcription is believed to play a 
major role in controlling transcription in Plasmodium (Le Roch et al., 2004; 
Shock et al., 2007; Foth et al., 2008; Agarwal et al., 2011). Based upon the 
transcriptomic studies in Plasmodium, it was established that almost 80% of the 
total genome remains transcriptionally active during various life stages signifying 
successive expression of genes, again following the “just in time” expression 
profile (Bozdech et al., 2003; Llinas et al., 2006). This supports the hypothesis 
that the protein expression is also controlled post-transcriptionally (Bozdech et 
al., 2003), that is, specific regions in the transcripts themselves regulate the 
stage-specific translation of the mRNA (Arbeitman et al., 2002), for example,  U-
rich regions in the UTRs act as translational repressors in P. berghei and are 
important for zygote development (Braks et al., 2008). Certain transcripts in 
female gametocytes have been shown to be kept in the repressed state 
mediated by a DEAD-box RNA helicase or DOZI until the translation of the 
repressed transcripts is needed (Mair et al., 2006; Braks et al., 2008; Mair et al., 
2010).  
 
Other examples of post-transcriptional gene regulation includes mRNA 
modification through 5’capping (Shuman, 2002), splicing (Zhang et al., 2011) and 
poly-adenylation (Shock et al., 2007; Narayan et al., 2009). The mRNAs are 
known to acquire a 7-methyl guanosine (m7G) cap in the nucleus which is 
important in nuclear export and translational initiation (Shuman, 2001; Gu and 
Lima, 2005; Sonenberg and Hinnebusch, 2009). Detection of uncapped mRNA 
species in Plasmodium strongly suggests that it might be a strategy in the 
parasite for mRNAs to remain translationally repressed until needed (Mair et al., 
2006; Shaw et al., 2007). Polyadenylation at the 3’UTR of the mRNA also exerts 
a regulatory role in gene expression (Oguariri et al., 2006; Shock et al., 2007). 
Post-transcriptional regulation of gene expression in Plasmodium is also 
mediated by splicing – the process of joining two exons by removal of intervening 
intron/s through small nuclear RNAs or snRNAs (Francoeur et al., 1985; Upadhyay 
et al., 2005) and alternative splicing by generating premature stop codons in the 
spliced variants (Otto et al., 2010; Sorber et al.,2011). 
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1.9.6 ApiAP2 Transcription factor family in 
 Plasmodium 
1.9.6.1 Introduction 
ApiAP2 family of TFs are a relatively newly discovered family of trans-
acting proteins in Plasmodium with a proven role in stage specific gene 
expression during the ookinete, sporozoite and liver stages of the parasite. Since 
there is no known eukaryotic lineage-specific expansion of the AP2 family other 
than that in apicomplexa, this specific lineage of AP2 proteins in apicomplexa is 
termed as apicomplexa AP2 or the ApiAP2 family (Balaji et al., 2005; Iyer et al., 
2008; Painter and Llinas, 2012). Currently, the ApiAP2 family is the only lineage-
specific TF family identified in Plasmodium spp. (Iyer et al., 2008).  
 
1.9.6.2 Conservation and functional significance 
ApiAP2 TFs have been found throughout apicomplexa including Theileria, 
Cryptosporidium and Toxoplasma (Balaji et al., 2005; Altschul et al., 2010; Iyer 
et al., 2010). Although well conserved across the Plasmodium spp., two of the 
ApiAP2 proteins tend to be species-specific; PFL1075w in primate malarias and 
PVX_080355 in P. vivax and P. knowlsei. This species-specific conservation might 
indicate important specific role played by these TFs in controlling functions 
restricted to the involved species such as hypnozoite formation (Painter et al., 
2011). And because of the lack of similarity of the ApiAP2 family of proteins to 
the human proteins, these are priority candidates for drugs and vaccines (van 
Ooij, 2008).  
 
Microarray experiments and RNA-seq analyses have found that the 
majority of the 27 ApiAP2 proteins were found to be temporally transcribed 
during the asexual intraerythrocytic development cycle (IDC) of the parasite 
(Bozdech et al., 2003; Le Roch et al., 2003; Otto et al., 2010) and some are 
transcribed during the sexual stages of the parasite thus it can be inferred that 
ApiAP2 TFs are important regulators of gene expression throughout the 
Plasmodium life cycle stages (Silvestrini et al., 2005; Young et al., 2005; Tarun 
et al., 2008; Yuda et al., 2009). 
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1.9.6.3 Structure of ApiAP2 proteins 
The family contains 27 AP2 DBD containing proteins in P. falciparum 
andthese are highly conserved throughout apicomplexa (Bischoff and Vaquero, 
2010). The AP2 domains in apicomplexans are found both as single domain as 
well as tandem domain arrangement i.e., two tandem AP2 domains separated by 
a short linker amino acid sequence (Balaji et al., 2005).  However, some 
members of the ApiAP2 family contain three DNA binding domains (PFF0670w, 
PF10_0075, PF11_0404 and PF13_0235) (Balaji et al., 2005). 
  
All the members are known to be expressed throughout the 
intraerythrocytic developmental cycle of the parasite (Balaji et al., 2005; 
Painter et al., 2011). Protein binding microarrays (PBM) and EMSA’s have 
established that the DBDs recognize a specific stretch of DNA sequence/s (target 
motif/s) in the promoter region of the gene whose transcription is to be 
controlled and bind to it/them in a sequence-specific manner. The motifs for 
AP2 domain in Plasmodium are more AT-rich as compared to the classical plant 
AP2 domains. The binding domain architecture and its sequence-specificity for 
binding to the target motif are also shown to be highly conserved between 
orthologous pairs of AP2 domains of even phylogenetically distant apicomplexans 
such as Plasmodium falciparum and Cryptosporidium parvum despite sequence 
variations in the rest of the pairs of ApiAP2 proteins. This specificity is possibly 
mediated through the conserved predicted β-strand residues. Although the DNA-
binding specificity is conserved, the putative target genes are not conserved 
between distant apicomplexa (DeSilva et al., 2008).  
 
Apart from the presence of DNA-binding domains, the rest of the protein 
family is unremarkable in terms of the presence of other domains and/or motifs 
for targeting the protein to specific sub-cellular localizations except for the 
presence of classical lysine- and arginine-rich nuclear localization signals 
supporting their role as TFs (DeSilva et al., 2008). Studies have also suggested 
that AP2 proteins interact with each other and also with other molecules 
including the chromatin remodelling factor, Plasmodium histone 
acetyltransferase, GCN5 (PF08_0034), at least in vitro (LaCount et al., 2005), a 
high mobility group (HMG) protein, fork head domain protein, and a plant 
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homeodomain (PHD) containing protein in Plasmodium (Bougdour et al., 2010). A 
part of PfSIP2 (PFF0200c; Meissner et al., 2005) and ApiAP2-O (PBANKA_090590; 
Pino et al., 2012) has been shown to act as a transactivation domain in yeast 
system and has been assayed in tetracycline transactivator-based inducible 
conditional knockout vectors for P. berghei (Krizec and Sulli, 2006). 
 
1.9.6.4 Structural determinants of ApiAP2-DNA binding 
The crystal structure of one of the DNA-bound dimers of PfAP2s DBD, 
PF14_0633, shows that the β-sheet fold binds the major groove of the DNA via 
base-specific contacts with support from the α-helix. Based on the requirement 
of two copies of the recognition motif for high affinity binding of the AP2-O with 
its cognate DNA, it was hypothesised and later shown that the ApiAP2 proteins 
hetero-dimerize when bound to their target DNA (Lindner et al., 2010). 
Dimerization may be important as it has been shown to influence gene 
regulation (Amoutzias et al., 2008). No additional Pfam domains have been 
predicted  for any of the AP2 proteins although they have been hypothesised to 
contain activation domains and/or domains involved in protein-protein 
interactions which have not yet been identified (Finn et al., 2008; Lindner et al., 
2010).  
The domain dimerizes via a 3D domain-swapping mechanism in which the 
α-helix of one protein is packed against the β-sheet of its dimer counterpart. 
This dimerization allows the Cys76 residues of each monomer to interact with 
one another permitting disulphide bond formation between the two (Lindner et 
al., 2010). This binding induced dimerization may also bring two distant DNA loci 
close together (a conformational rearrangement) in the nucleus and/or may 
induce functional rearrangements conducive to transcriptional regulation. It is 
also established that during the base-specific contact of the domain with the 
cognate DNA, certain bases such as Asn72, Arg74, Arg88, and Ser90, which make 
base-specific contacts with the motif, are conserved throughout Apicomplexa 
and hence appear critical for the contact (Lindner et al., 2010).  
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1.9.6.5 DNA-binding specificities 
Exhaustive biochemical and computational characterization of the entire 
P. falciparum AP2 family proteins revealed that multiple DBDs within the same 
protein bind to distinct DNA motifs for many AP2 proteins. Even proteins with a 
single DBD have secondary recognition motifs in addition to the primary ones 
which might be associated with reducing expression noise and fine-tuning of 
gene expression together with a widening of the choices of target genes that 
could be regulated by a particular TF (Campbell et al., 2010).  
 
1.9.6.6 ApiAP2 target genes 
Bioinformatic detection of 5’ upstream promoter regions of Plasmodium 
genes enriched for the specific DBD motif have been used to identify potential 
downstream target genes for certain ApiAP2. For PFF0200c (PfSIP2), apart from 
the individual ApiAP2 specific target genes, intriguingly, the target motif array 
(consisting of a direct (T/G)GTGC(A/G) repeat spaced by four nucleotides) was 
found to be enriched in the promoter regions of var gene families (Flueck et al., 
2010), other ApiAP2 genes and even on the same ApiAP2 gene indicating the 
many different ways in which these TFs regulate the expression of other genes 
including other TFs and also themselves i.e., auto-regulation (De Silva et al., 
2008). PfSIP2 is highly conserved although the var gene family is species-specific 
and not present in all Plasmodium species – the reasons for this are currently not 
known. 
 
However, it should be noted that the mere presence of a recognition 
motif does not guarantee an active interaction which has to be proven through 
competent techniques for detecting protein-DNA interactions including, but not 
limited to, chromatin immunoprecipitation or ChIP (Collas, 2010; Cai and Huang, 
2012; Furey, 2012).     
 
1.9.6.7 Role of ApiAP2 family in Plasmodium gene regulation 
The AP2 family of TFs have been shown to be the only class of sequence-
specific transcription factors with an established role during various life cycle 
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stages of Plasmodium spp. (Balaji et al., 2005; Iwanaga et al., 2012). What is 
common about the three AP2 TFs characterised recently (see below) is that 
these are involved in regulating the stage-specific gene transcription at various 
parasite progression points, for example, AP2-O (PBANKA_090590) at the 
ookinete stage (Yuda et al, 2009), AP2-Sp (PBANKA_132980) at the mosquito 
sporozoite stage (Yuda et al., 2010) and most recently, AP2-L (PBANKA_021440) 
at the liver sporozoite stage (Iwanaga et al., 2012). It is important to note here 
that these TFs were identified in P. berghei as the rodent malaria system allows 
the characterization of these genes at the respective life stages providing a 
significant advantage as compared to the P. falciparum system. Also, because 
these genes are not essential to blood stages which cannot be studied in all 
models, they could be characterised.  
 
1.9.6.7.1  ApiAP2-O 
A systemic examination of the AP2 genes not expressed in the asexual 
parasite life stages of the rodent malaria parasite, P. berghei, revealed the AP2 
protein called AP2-O (PBANKA_090590; orthologue of PF11_0442) which later 
proved to be essential for the formation of the invasive ookinete stage of the 
parasite life cycle, thus providing the first direct evidence of the role of AP2 TFs 
in regulating stage-specific gene expression in Plasmodium (Yuda et al., 2009). 
The AP2-O has orthologs in other Plasmodium spp. as well and encodes a protein 
containing 1258 amino acids which has a single highly conserved AP2 domain. It 
has been shown that AP2-O is highly expressed in the ookinete stage and is 
subjected to DOZI (Development of Zygote Inhibited) mediated translational 
repression (Mair et al., 2006; Yuda et al., 2009). AP2-O(-) parasites showed an 
inability to infect mosquitoes and when grown in culture showed an abnormal 
morphology of the ookinetes (pear-shaped as compared to banana-shaped in 
WT). AP2-O(-) ookinetes also demonstrated a 5-fold decrease in expression of 15 
genes, of which 4 were ookinete stage-specific genes. EMSA’s clearly 
documented that the AP2-O DBD recognizes and preferentially binds to the 6 bp 
sequence (TAGCTA) in the promoter region of the genes in addition to binding 
with similar sequences, although with a weaker affinity. In vivo experiments 
confirmed that TAGCTA sequence worked as a cis-acting element which was 
conserved across the Plasmodium spp. (Yuda et al., 2009; Campbell et al., 
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2010). AP2-O is also shown to be expressed during the intraerythrocytic 
developmental cycle thus suggesting that it might have additional (non-
essential) roles to play other than in ookinete development (Bozdech et al., 
2003; Le Roch et al., 2003; Otto et al., 2010). 
 
1.9.6.7.2   ApiAP2-Sp 
A similar ESTs search for the AP2’s in the P. berghei mosquito sporozoite-
stage AP2 database in PlasmoDB resulted in identification of PBANKA_132980 or 
AP2-Sp (PF14_0633). The expression of AP2-Sp starts from the late oocyst stage 
and continues up to the salivary gland sporozoite stage in the mosquito. AP2-Sp 
(-) parasites grew well up to the oocyst stage in the mosquito but did not 
generate the invagination of the plasma membrane necessary for the formation 
of the sporoblasts. Electromobility shift assays or EMSA’s clearly documented 
that the AP2-Sp DBD recognizes and binds to the 8 bp sequence (TGCATGCA) in 
the promoter region of the genes in a sequence-specific manner. Further 
refinement of the recognition motif identified that the minimum sequence 
essential for binding is TGCATG. Furthermore, when the AP2 DBD of endogenous 
AP2-O was swapped with that of AP2-Sp, the ookinete stage demonstrated 
induction of AP2-Sp target genes (Yuda et al., 2010). This would mean that the 
specificity of downstream gene activation depends purely upon the specific 
DBD/recognition sequence pair and once activated the subsequent effects are 
mediated by general/shared co-factors that are ubiquitously expressed (at least 
in sporozoites and ookinetes). AP2-Sp is documented to be expressed throughout 
the intraerythrocytic developmental cycle of P. falciparum and at least during 
the trophozoite stage of P. berghei (Bozdech et al., 2003; Le Roch et al., 2003; 
Hall et al., 2005).  
 
1.9.6.7.3  ApiAP2-L 
A survey of expressed sequence tags (ESTs) coding for the AP2’s in the P. 
berghei liver-stage AP2 database in PlasmoDB resulted in identification of 
multiple ESTs for PBANKA_021440 or AP2-L. The AP2-L has orthologs in other 
Plasmodium spp. and encodes a protein containing 1272 amino acids which has 2 
highly conserved AP2 domains. AP2-L(-) parasites showed 10,000-fold reduced 
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liver infectivity as compared to the WT. AP2-L(-) sporozoites were cultured in 
HepG2 cells and stained with anti-CSP antibody to show that the nuclear division 
of the AP2-L(-) liver stage parasites was arrested at 36 hours post-infection. This 
mid-schizont arrest caused the observed decrease in the liver cell infectivity of 
the AP2-L(-) parasites (Iwanaga et al., 2012).       
 
1.9.6.7.4  PfSIP2 
Recently, it was discovered that one of the ApiAP2 members, PfSIP2 
(SPE2-interacting protein; PFF0200c), binds to the SPE2 DNA motif array 
(consisting of a direct (T/G)GTGC(A/G) repeat spaced by four nucleotides) 
present in the sub-telomeric regions located upstream to certain var genes (Voss 
et al., 2003; Flueck et al., 2010). Other than the DNA mediated actions of these 
TFs, it has also been shown that the ApiAP2 proteins do interact with each other 
and also with the chromatin machinery, including the Plasmodium histone 
acetyltransferase GCN5 (LaCount et al., 2005). When PfSIP2 was overexpressed, 
it had no effects on the global transcriptional profile suggesting that it might not 
be involved in transcriptional regulation directly but instead has a role in 
formation and maintenance of heterochromatin (Flueck et al., 2010). The 
reasons why PfSIP2 is highly conserved across Plasmodium spp. which do not 
have var genes are not known currently. 
 
1.9.6.8 Combinatorial gene regulation and ApiAP2 TFs 
Evidence has now been made available regarding the role of ApiAP2 TFs 
in regulating gene expression in combination with epigenetic machinery. 
Chemical perturbation of class I and II histone deacetylase inhibitors in blood 
stage P. falciparum parasites by apicidin was found to be associated with 
increased expression of some of the ApiAP2 genes (which would normally be 
down-regulated otherwise) (Chaal et al., 2010). This is supported by evidence of 
enrichment of H3K9me3 marks at the pfl1085w ApiAP2 gene locus which is 
associated with silencing of pfl1085w (Lopez-Rubio et al, 2009; Salcedo-Amaya 
et al., 2009). These findings suggest a considerable overlap in the mechanisms 
involved in regulation of gene expression in Plasmodium spp. including the 
ApiAP2 TFs, epigenetic control and post-transcriptional control through 
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translational repression. These combinatorial and overlapping gene regulation 
mechanisms in Plasmodium are completely understandable in the light of its 
complex yet well-orchestrated stage-specific gene expression profile. 
1.9.6.9 Summary and future perspectives 
All the current research evidence on ApiAP2 TFs have established them as 
the prime regulators of stage-specific gene expression at all developmental 
stages in Plasmodium parasites (Balaji et al., 2005) with some evidence 
gathering from other Apicomplexans as well including Theileria spp. (Marta 
Pieszko and Brian Shiels, personal communication). Further studies are definitely 
needed to detail the molecular mechanism by which so few TFs (predominantly 
ApiAP2 family) act to tightly orchestrate complex gene expression pattern of 
Plasmodium spp. (Tuteja et al., 2011). Another intriguing area of research is the 
need for multiple DBDs within a TF together with the functional significance of 
unremarkable (other than presence of nuclear localisation signals) regions 
outside the DBD’s which might underpin the complexity and/or redundancy in 
transcriptional regulation by this family of TFs (De Silva et al., 2008).  
 
 Further, research is also needed to exploit these TFs as candidates for 
drugs as they carry huge potential towards becoming the next line anti-malarial 
agents of the future, keeping in view the ongoing spread of resistance against 
the current front line anti-malarials, the ACT. Also, becauseAP2s affect multiple 
downstream genes it could be more difficult for the parasites to develop 
resistance against them (Tuteja et al., 2011). If ApiAP2s can be developed and 
used as drug targets, they will surely be among the best candidates to achieve 
the daunting goal of global malaria eradication in the coming decades, unless 
some new transmission blocking drug candidate is discovered. 
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1.10 Plasmodium berghei – the rodent malaria  
  parasite 
1.10.1 Model malaria parasites 
Model malaria parasites provide unique insights into the developmental 
biology of Plasmodium and its interactions with host and vector. The African 
(thicket) rat parasites including Plasmodium berghei, are popular models for the 
study of human malaria (Carlton et al., 2005). The combination of in vitro 
cultivation of P. berghei (particularly cultures of liver and mosquito stages) and 
in vivo infections permit the detailed analysis of the phenotype of the parasites 
including gamete fertilization, zygote development, synchronous blood stage 
development, and gametocyte formation (Leiden Malaria Research Group 
website – http://www.lumc.nl/con/). Also, their usefulness in reverse genetic 
studies is well established (de Koning-Ward et al., 2000) as the most 
straightforward and efficient approach in any Plasmodium species (Janse et al., 
2011).  
 
An inherent and recognized limitation of malaria observational studies in 
humans is that studies of association cannot prove causality with the result that 
human studies on malaria are sometimes considered inconclusive. Even with 
such recognized limitations, human studies on malaria are needed but lack of 
access to human organ/tissue samples make it necessary to include animal 
malaria models (Langhorne et al., 2011).  Thus, rodent malaria models, 
particularly, P. berghei have been extremely valuable for understanding parasite 
biology and studying host-parasite interactions in malaria. Considering the 
limitations of each approach, human malaria studies and rodent model malaria 
studies, it has been found useful that the two approaches should be attempted 
not in competition to each other but rather in complementation so that they 
each inform the other (Langhorne et al., 2011). 
 
The availability and suitability of a wide range of efficient reverse genetic 
technologies for P. berghei with the possibility of analysing parasites throughout 
their complete life cycle, both in vitro and in vivo, have made P. berghei the 
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most frequently used malaria models for gene function analysis (Carvalho and 
Menard, 2005; Janse et al., 2006). The ease of completing the entire life cycle 
of the parasite under laboratory conditions, including both the vertebrate stages 
and the mosquito stages, further offers a great opportunity to study the complex 
parasite biology in many aspects (Balu and Adams, 2007; Kooij et al., 2012). 
 
With almost 80% of the 5300 or so genes in the Plasmodium genomes being 
orthologous, the relevance and significance of studies involving P. berghei 
becomes compelling (Janse et al., 2011). Comparative genomic studies of P. 
falciparum and P. berghei have revealed a core set of ~4,500 Plasmodium 
orthologues located in the highly syntenic regions of chromosomes (Kooij et al., 
2005a) which implies a high degree of conservation of genome organization, 
content and possibly gene regulation between P. falciparum and P. berghei 
(Janse et al., 1994; Rich and Ayala, 2003). 
  
Although favourite research models for human malaria, rodent malaria 
models have been criticized for some of their limitations. These include 
bypassing the liver stage of the parasite life cycle during infection of the mouse 
which is usually achieved by intravenous or intraperitoneal routes. However, the 
liver stage infections are achievable through the infected mosquito feeding on 
anesthetized mice which has now become a routine procedure for establishing 
evidence for studies involving sexual stages of the rodent malaria parasites.  
 
 Also, the lab mouse is now gradually being supplemented with the natural 
host, the African thicket rat. Secondly, as the laboratory mouse is the not the 
natural host of the rodent malaria in the wild, intricate differences in the host-
pathogen interactions may not be ideal or representative of the wild type 
scenario. This is particularly relevant in immunological studies related to vaccine 
development as deciphering the protective immune response to blood-stage P. 
falciparum infections in humans has been difficult (Doolan et al., 2009).There is 
then the third way to link evidences between rodent malaria and human malaria 
experiments by generating transgenic rodent malaria parasites containing an 
orthologue of the endogenous gene of interest from the human malaria parasites 
(Sinden et al., 2012). 
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1.10.2 Genetic engineering techniques in P. berghei 
1.10.2.1 Transfections in P. berghei 
 Stable transfection and gene targeting with a drug selectable marker was 
reported first in P. berghei (van Dijk et al.,1995; van Dijk et al.,96) followed by 
P. falciparum (Wu et al., 1996) and much later in another rodent malaria 
parasite, P. yoelii (Mota et al., 2001). P. berghei  is considered to be the best 
malaria model for successful stable transfection due to the long and tedious 
procedure to transfect P. falciparum combined with a low transfection 
efficiency of the order of ~10-6 (O’Donnell et al., 2002).  
  
 The exogenous DNA used for transfection has to cross at least three 
different membranes in P. falciparum in order to be able to reach the parasite 
nucleus (the RBC membrane, the parasitophorous vacuole membrane and 
parasite cell membrane) which makes transfections less efficient in P. 
falciparum.  P. berghei, on the other hand offers the advantage of using 
merozoites for transfection thus providing easier access for the exogenous DNA. 
 A distinct advantage in P. berghei is the ability to transfect a linearized 
DNA construct which drastically reduces the chances of development and 
maintenance of circular plasmids as episomes as observed in obligatory 
transfections with circular DNA constructs in P. falciparum (Kadekoppala et al., 
2001; O’Donnell et al., 2001; Thathy and Menard, 2002). The negative selectable 
marker available for use in P. falciparum (HSV/tk; herpes simplex virus 
thymidine kinase) is also not very specific in selection, thus killing non-hsv/tk 
expressing parasites as well (Duraisingh et al., 2002). The ease of completing the 
entire life-cycle of P. berghei under lab conditions is a big advantage in terms of 
studying the complex biology of the parasite.  
 
 High efficiency transfection: The use of non-viral nucleofector® 
transfection technology (Amaxa GmbH) increases the transfection efficiency to 
the order of 10-2-10-3 (Sakamoto et al., 2005; Janse et al., 2006). Such high 
transfection efficiency would mean lesser time to select the transfectants and 
easier selection (sorting) of fluorescently-labelled transfectants using FACS even 
in the absence of drug selection. Recent developments in P. berghei transfection 
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experiments like the small-scale in vitro culture protocol (Somsak et al., 2011) 
using as little as 20 µl of mouse tail blood has been shown to be equally efficient 
for a single transfection and at the same time offering multiple advantages over 
the conventional large-scale culture and purification protocol in terms of 
reduced requirement of time, parasite sample, consumables and most 
importantly, animals. 
 
 Positive-Negative drug selection: The use of a single positive-negative 
drug selectable marker cassette in the P. berghei transfection construct has 
significantly improved the flexibility in reverse genetics approaches. Use of a 
positive selection marker, such as hDHFR (offering resistance to the drug 
pyrimethamine) and a negative selection marker such as the fusion protein from 
yeast cytosine deaminase and uridyl phosphoribosyl transferase fusion protein 
(yFCU; offering sensitivity to the drug 5-FC) technically allows the possibility of 
achieving phenotypic rescue in single crossover mediated gene disruption (Braks 
et al., 2006), and selectable marker recycling or vector recycling for subsequent 
genetic manipulation of the same line. An improved negative selection method 
which replaces the need of i.p. injection of 5-FC with providing 5-FC dissolved in 
drinking water reduces the number of animals required for the procedure and 
other indirect costs while maintaining the consistency and reliability of the 
method (Orr et al.,2012).  
 
1.10.2.2 Studying essential genes in P. berghei 
 With the inability to use gene knockdown or silencing approaches, such as 
RNAi, in Plasmodium due to the absence of the necessary machinery (Baum et 
al., 2009), the following developments have opened a new area for studying the 
functions of genes which are essential for the parasite and hence cannot be 
knocked out. 
 
(a) Conditional knockout system: A conditional mutagenesis system using the 
Flp/FRT site-specific recombinases from yeast (Branda and Dymecki, 
2004) has been developed in P. berghei (Carvalho et al., 2004) and 
successfully applied (Lacroix et al., 2011). A modified cre/loxp based 
conditional mutagenesis system, called the DiCre system has recently 
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been successfully used in P. falciparum for site-specific recombinase 
mediated gene deletion. The DiCre system has a great potential for use in 
P. berghei which will further expand the P. berghei reverse genetics 
toolkit (Collins et al., 2013).  
 
(b) Transport shuttle mutagenesis: using a Tn5 transposon derivative in 
Escherichia coli (Sakamoto et al., 2005), it provides an indirect way to 
identify essential genes in blood stages by screening for genes that cannot 
be disrupted as the genes already disrupted using transposons are directly 
transformed into P. berghei. 
 
1.10.2.3 Gene complementation in P. berghei 
The process of genetic complementation (functional restoration of null 
mutant to wild type phenotype by introducing a fully functional WT copy of the 
disrupted gene) opens opportunities to establish a causal association between an 
implicated gene and its hypothesized function. Particularly, as in Apicomplexa, 
where an estimated ~47% of the gene pool comprises of hypothetical genes 
and/or genes with unknown functions (Florent et al., 2010), complementation 
experiments may serve as powerful tools in understanding the molecular basis of 
a variety of basic and applied phenomena in Apicomplexan biology (Striepen et 
al., 2001; Sultan et al., 2001; Florent et al., 2010). Despite the use of 
appropriate controls, it may be difficult to refute that the resulting phenotype 
from gene targeting experiments is not due to accumulation of independent 
genomic alterations during the recombination events or due to the presence of 
the altered recombinant / genomic locus per se (Janse et al., 2011). Looking at 
the vital role of complementation in establishing the causal inference, it is 
highly recommended that complementation experiments should become a part 
of standard procedure to causally associate genes with their functions (Goldberg 
et al., 2011).  
However, in Plasmodium species, complementation of gene knockouts is 
not widely attempted due in part to the inherent difficulty in cloning of large 
coding regions of such AT-rich genomes in order to be able to complement the 
full length of the knocked out gene, particularly when the gene to be 
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complemented is large. Also, low transfection efficiency in P. falciparum is 
another deterrent for successful complementation in the human malaria 
parasite. Although highly recommended, complementation can be substituted by 
the isolation of two independent mutant clones exhibiting the same phenotype 
in view of the above difficulties in complementing the gene. The role of a 
second independent mutant is said to be indispensable in difficult to 
complement genes (Goldberg et al., 2011).  
1.10.2.3.1 Complementation techniques  
 Basically, all complementation techniques are aimed at introducing the 
wild type copy of the disrupted gene back into the Plasmodium genome. 
Depending upon the method used to disrupt the gene (single/double crossover 
homologous recombination, or a natural/induced mutation(s) involving 
SNP(s)/indel(s)) and the extent of gene disruption (complete or partial), the DNA 
complementation construct and thus the method used for selecting the 
complemented parasites would vary.  
Because the single/double crossover-based gene disruption will ideally 
have the drug selectable marker cassette (SMC) already integrated into the 
genome at the endogenous gene locus, it is mandatory to use the positive-
negative SMC which is not recyclable (that is, must not contain two copies of the 
homologous 3’UTR in the SMC which could potentially mediate vector recycling 
either spontaneously or under negative selection drug pressure) for gene 
disruption. A double crossover-based complementation of the WT copy of the 
gene at the endogenous locus (using appropriate length of the gene based on the 
extent of gene disruption) could then be attempted using negative selection to 
select the complemented parasites from the transfectants.   
In cases where the disruption was mediated by SNPs or indels, the 
endogenous locus will not have a SMC integrated (until otherwise shown) and the 
complementation could be attempted with a construct bearing the full length 
WT copy of the gene flanked by sufficiently large homology arms to enable 
double crossover-based integration of the construct into the genome. One of the 
homology arms, preferably the downstream or the 3’ homology arm, should bear 
the SCM in order to be able to select transfectants with the complemented copy 
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of the gene using positive selection. The 5’ homology arm should be sparred for 
genetic manipulation as the presence of any extra (exogenous) DNA here might 
interrupt the promoter of the gene of interest thus interfering with the 
functional restoration of the gene to be complemented. This is particularly 
important in Plasmodium wherein the precise length of the promoters is largely 
unknown.  
It is important here to keep in mind that any attempt to complement the 
gene would be extremely difficult if the mutant to be restored has acquired a 
phenotypic growth advantage (as in the case of gametocyte non-producer 
mutants generated in the current study) as a result of the disruption. Even if 
strong negative selection based approach is used, there remains a biased 
likelihood that the natural selection pressure of the mutant parasites will 
overcome the drug selection pressure thus jeopardizing the complementation 
efforts.  
Recent application of complementation has shown the successful use of 
negative selection based approach (the Gene-In Marker-Out or the GIMO 
approach) to introduce the WT copy of the gene (complete or partial) thus 
replacing the disrupted endogenous locus. The complementation construct can 
simply be a PCR product of appropriate length amplified using a proof reading 
polymerase. The GIMO approach claims to offer multiple advantages over 
conventional complementation approaches in terms of being faster, less 
laborious and requires fewer animals (Lin and Annoura et al., 2011). 
Additionally, GIMO method could be clubbed with the recently developed 
“recombineering” based high-throughput gene targeting approach (Pfander et 
al., 2011). 
Apart from introducing the WT copy at the disrupted endogenous locus, 
complementation could also be achieved by introducing and expressing the WT 
copy of the gene (transgene) at another dispensable locus in the genome, such 
as the p230 paralog locus in P. berghei (Janse et al., 2006). Ideally the gene at 
the exogenous locus should be expressed under its own endogenous promoter 
and the 3’UTR.  
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1.10.2.4 Recent advances in P. berghei genetic engineering 
 techniques 
Some of the recent advances in P. berghei genetic engineering techniques 
include: 
 pBAT plasmids: Recently, highly optimized and versatile gene targeting 
vectors were developed for P. berghei genetic manipulations (Kooij et al., 
2012). Collectively called as pBAT (Berghei Adaptable Transfection) plasmids, 
these are claimed to be suitable for vector recycling, robust GFP labelling of 
recombinant parasites, C-terminal mCherry epitope tagging, and heterologous 
gene expression. With small size and versatile restriction endonuclease 
recognition sites, these plasmids promise a high throughput approach to 
Plasmodium reverse genetics. 
 
 PCR-generated knockout constructs: A two-step PCR-based method for 
generating the linearized transfection construct for double crossover 
recombination in P. berghei has been now devised (Ecker et al., 2006). The 
technique offers significant improvements over the conventional E. coli based 
generation of constructs in terms of bypassing the difficulties of cloning AT-rich 
DNA into E. coli, time saved over the lengthy and cumbersome conventional 
method and improving the yield of the construct. The PCR-based approach could 
have limitations in generating larger constructs due to the inherent difficulties 
in error-proof PCR-based amplification of larger DNA.  
 
 PiggyBac insertional mutagenesis: Forward genetic approaches have not 
been widely applied in Plasmodium research because of the lack of adequate 
tools for whole genome analysis. However, recently insertional mutagenesis 
using PiggyBac transposable elements (widely used functional genomics tool in 
many species) was applied to P. berghei. The piggyBac system has been 
successfully adapted and applied for P. falciparum forward genetics (Balu et al., 
2009). Such transposon-mediated random mutagenesis which widens the genetic 
manipulation armamentarium in P. berghei can be used as forward genetic 
screens for analysing gene function, particularly, for the many ‘hypothetical’ 
Plasmodium proteins (Fonager et al., 2011).  
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1.10.2.5 Recombineering based constructs for genetic 
 manipulation of P. berghei 
Larger than conventional (0.4-1.0 kb) homology arms (Janse et al., 2006) 
may be required for homologous recombination-based targeted genetic 
interventions at certain times to improve the recombination efficiency and to 
minimize the chances of random integration into the genome, particularly when 
the gene of interest is sufficiently large and when the complementation is to be 
attempted against a selection pressure favoring the disrupted genotype. Long 
homology arms, of up to 10 kb, have been shown to increase the recombination 
frequency substantially in other model systems (Hasty et al., 1991). However, 
cloning of such larger pieces of highly AT-rich DNA sequences (Gardner et al., 
2002; Hall et al., 2005) has been shown to be difficult in the traditional E. coli 
system as larger AT-rich inserts become unstable in E.coli and hard to 
manipulate using restriction-ligation based molecular cloning. To circumvent 
such difficulties, the recombineering strategy (Pfander et al., 2011) has been 
developed for P. berghei to generate gene targeting constructs bearing larger 
than conventional homology arms thus avoiding the creation of large circular 
plasmids for the purpose.  
A P. berghei gDNA library for large scale genetic manipulations is not 
available, for reasons stated above, in bacterial artificial chromosomes (BAC) 
and hence such a library was developed in low copy number plasmid based on 
bacteriophage N15, which replicates in E.coli as a linear, double stranded DNA 
molecule (Ravin and Ravin, 1999; Ravin et al., 2003) which is able to stably carry 
AT-rich Plasmodium sequences (Godiska et al., 2010). Such large AT-rich 
genomic DNA inserts in the N15 bacteriophage are amenable to homologous 
recombination in E. coli that transiently express the recombinase complex and 
proofreading activity encoded by the bacteriophage lambda redγβα operon and 
bacterial recA under the control of the arabinose-inducible pBAD promoter 
(Zhang et al., 1998; Wang et al., 2006). This approach, called lambda red 
recombineering or simply recombineering is robust and independent of 
restriction sites and is thus the method of choice to scale up targeted gene 
disruption in the mouse (Skarnes et al., 2011).  
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The recombineering strategy has been successfully applied to convert the 
gDNA library inserts into gene deletion, tagging and complementation vectors for 
the genome-wide functional analysis of P. berghei genes. Basically, a bacterial 
drug SMC was first introduced into the gDNA insert, either deleting the target 
gene thus making the construct useful for targeted gene knockout; or placing the 
SMC within either of the UTRs of the gene making the construct suitable for 
complementation studies; or preparing for 3′-end tagging. To complement a gene 
disrupted locus already bearing the SMC (see above), the large genomic inserts 
in the N15 bacteriophage could directly be used after linearization with 
appropriate unique restriction endonuclease. The bacterial marker was later 
replaced with a P. berghei positive-negative selection cassette in a Gateway LR 
Clonase reaction in vitro. NotI unique restriction sites placed at either end of 
the modified library insert could be used to release the construct from the 
plasmid backbone making it ready for transfection (Pfander et al., 2011). 
 
1.10.3 The genome of P. berghei:  
 
Comparative genomic information and sequencing of additional 
Plasmodium genomes will provide in the understanding of the inter- and intra-
species diversity in malaria parasites, the biology of the parasite and its 
interactions with mammalian host and mosquito vector (Pain and Hertz-Fowler, 
2009). It is evident that the recent technological advances in DNA sequencing 
together with falling costs of the techniques have rendered relatively facile the 
complete sequencing of the small genomes that are typical of apicomplexan 
parasites (~25Mb) (Carlton et al., 2005; Pain et al.,2005).  Similarly, advances in 
computing power and algorithm design mean that such genomes can be 
assembled accurately on desk top computers. The same technologies can also be 
harnessed to perform global epigenetic analyses, examining the genome-wide 
distribution of histone modifications.  The small size of a Plasmodium genome 
means that such characterisation can be achieved on a dynamic basis and the 
changing patterns of histone modification can be assessed and compared across 
distinct developmental stages.  
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1.10.4 Challenges in assembly of P. berghei genome  
P. berghei has an estimated genome size of 25-27Mb with 14 chromosomes 
(Kooij et al., 2006; Wellcome Trust Sanger Institute website - 
http://www.sanger.ac.uk/Projects/P_berghei/). The assembly of rodent 
malaria parasite genomes has lagged behind that of the human parasites but the 
genome of P. chabaudi (strain AS) is now 97% complete and that of the closely-
related P. berghei (clone ANKA and line 233 believed to be derived from ANKA) 
is advanced towards completion. As of February 2010, the P. berghei genome 
comprises 4881 predicted proteins (5124 in P.chabaudi), 22 pseudogenes (3 in P. 
chabaudi), 121 gaps with 68 gaps in core regions (3 gaps in P. chabaudi), and 43 
unassigned contigs (23 in P. chabaudi). Fifty eight genes have been annotated in 
the unassigned contigs, all of them belong to subtelomeric gene families. The 
genome is expected to be completed shortly (Chris Newbold, Sanger Institute, 
Personal communication). 
 
The sub-telomeric regions are presenting particular problems in 
completing the P. berghei genome assembly. In the Plasmodium genome, the 
sub-telomeric regions (extending 10-40 kb towards the internal part of the 
chromosomes) consist of species-specific repeats (Carlton et al., 2005). 
Extensive chromosome size polymorphism, exclusively involving differences in 
copy number of a largely universal 2.3 kb sub-telomeric repeat unit, has been 
observed during in vivo multiplication in P. berghei (Pace et al., 1987; Dore at 
al., 1990; Ponzi et al., 1990; Janse and Mons, 1992a). The complex and variable 
number of repetitive DNA in the sub-telomeric regions of the chromosomes still 
presents a remarkable challenge towards P. berghei genome assembly closure. 
The sub-telomeric regions are known to be particularly unstable (Pace et al., 
1995) and they also share extreme similarity between chromosomes (Carlton et 
al., 2002; Gardner et al., 2002) which makes it  difficult to map the scaffolds of 
contigs to the respective chromosomes.  
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1.11 Aims and objectives 
This research was started with the aim of exploring the hypothesis that 
the loss of ability to produce gametocytes is reflected in the organisation of the 
parasite genome at the level of the genome sequence and/or organisation as 
reflected by changes in the genome-wide epigenetic profile and/or nucleosome 
phasing.  The hypothesis was investigated using deep sequencing technology 
however, despite the indication and necessity of performing the epigenetic and 
nucleosome profiling; they could not be employed due to shortage of time. 
Broad aims of the thesis: 
1. To assess the global changes in a Plasmodium genome that are 
associated with the loss of the ability to commit to sexual 
development (produce gametocytes). 
2. To provide a causal link between the observed genomic changes 
and gametocytogenesis. 
  
 
 
 
 
 
 
 
 
 
 
 
 
2 Materials and Methods  
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2.1   General Parasitological methods 
The rodent malaria parasite P. berghei completes its natural life cycle in 
the wild in two hosts (Chaterjee et al., 2001) – asexual cycle in mammalian host, 
the thicket rat (Grammomys surdaster) and sexual cycle in mosquitoes 
(Anopheles dureni). Under laboratory conditions, the complete life cycle of the 
parasite was maintained either completely in vivo between Theilers Original 
(TO) mice and mosquito (Anopheles stephensi) or in a combination of in vivo and 
in vitro conditions. Completion of the full P. berghei life cycle is currently not 
possible in vitro probably because of the very low rates of spontaneous release 
of the merozoites from mature schizonts and subsequent re-invasion in vitro 
(Jambou et al., 2011).  
 
2.1.1 Parasite growth in vivo 
2.1.1.1 Animal handling and maintenance 
 
All animal experimentations were performed in strict accordance with the 
Home Office regulations and UK Animals (Scientific Procedures) Act 1986. The 
animal experimentation protocols were approved by the University of Glasgow 
Ethics Committee. A personal license (PIL 60/12380) was obtained from the 
Home Office to carry out regulated procedures on mice. Adult female outbred 
Theiler’s Original (TO) mice weighing 20-30g and aged approximately 6 weeks 
were procured from Harlan Laboratories (Shardlow, England, UK) and maintained 
in animal house for experiments. 
 
2.1.1.2 Infecting the mice with parasites 
 Desired inoculum of the parasites was introduced to the mice either 
through: 
(a) Intra-peritoneal (i.p.) injections on one or either side of the 
flanks of unanesthesized or Isoflurane (3-5% in Oxygen) anesthetized 
mice. This route of infection was used when infecting the mouse with 
blood stage parasites from cryopreserved stabilates or when mechanically 
passaging the parasites from an infected mouse to a naïve mouse. Briefly, 
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a cryotube containing ~0.5 ml of blood in equal volume of Glycerol/PBS 
solution (30% Glycerol v/v containing 50 µl Heparin stock (200 IU/ml in 
RPMI1640) solution) was taken out of the liquid Nitrogen storage tank and 
thawed at room temperature. A total of 0.1 to 0.5 ml of the suspension 
was then injected i.p. into the flanks of the mice with a sterile 
hypodermic 1 ml syringe. For mechanical passage, a drop of tail blood (~5 
µl) from an infected mouse (parasitemia between 5% and 15%) was 
collected into 1 ml of PBS in a microcentrifuge tube and 0.1 to 0.5 ml of 
the diluted blood was then injected i.p. into the flanks of the mouse, 
  
(b) Intra-venous (i.v.) injections in the tail vein of 
unanesthesized or Isoflurane (3-5% in Oxygen) anesthetized mice. 
Intravenous route was used for infecting the mice with the blood stage 
parasites for cloning the parasites, or synchronizing the infection or for 
transfection (see details below). Prior to the i.v. injections, the mice 
were put into a warm box at 30 °C for a period of ~30 minutes so that the 
tail veins were dilated. Once sufficiently dilated, approximately 0.2 ml of 
the infected blood suspension was injected into the tail vein with a sterile 
hypodermic 0.5 ml insulin syringe. During the i.v. injections, the mice 
were either kept steady with the help of a restrainer or isoflurane-
anesthetized (3-5% in Oxygen),   
 
 
(c) The bites of infected female anopheline mosquitoes (A. 
stephensi) under anaesthesia. This route was used to assess the infecting 
capacity or transmissibility of the parasites from infected female 
anopheline mosquitoes to the uninfected mouse. For such transmission 
bite-back experiments (TBB), naive mice were injected with Hypnorm® 
(Fentanyl-fluanisone; Crown Chemicals) / Hypnovel® (Midazolam; Roche 
Diagnostics) anesthetic combination approximately 30 minutes prior to 
the mosquito feed. The Hypnorm®/Hypnovel® mix was prepared by 
adding 1 part (0.15 ml) each of the two drugs to 2 parts (0.3 ml) of sterile 
water. The recovery dose of the mix was 0.11-0.13 ml whereas the non-
recovery dose was 0.02 ml over and above the recovery dose. The mice 
were then shaved from the flanks and abdomen so that the mosquitoes 
could have direct access to the skin. Once the sedation was confirmed, 
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the mice were then placed on top of the mosquito netted cage containing 
between 200 and 500 twentyfour-hour starved female mosquitoes. The 
mosquitoes were then allowed to feed from below onto the abdominal 
skin of the sedated and secured mice for a period of approximately 20-30 
minutes. Once fed on by the infected mosquitoes, the mice were allowed 
to recover from sedation slowly over a period of 4-6 hours. Blood smears 
were made from day 3 or 4 post-transmission to ascertain the parasitemia 
and thus the success of transmission.  
 
 
Once inside the mouse, the parasite count was continuously monitored 
through Giemsa-stained smears made from a drop of blood from a tail prick. The 
parasitemia was allowed to progress up to the desired level as determined by 
the need of the experiment or until the mouse showed any of the earliest signs 
of cerebral malaria, whichever was earlier. The infected mouse was then 
sacrificed through a cardiac puncture (regulated procedure under act) with a 
sterile 2 ml syringe containing heparin (200 IU/ml in RPMI1640). The animal was 
then killed by breaking the neck as a part of the regulated procedure under the 
Act. 
 
2.1.1.3 Maintaining infection between mice (weekly 
mechanical passage) 
Infected mice were serially monitored for parasitemia by Giemsa-stained 
smear starting from day 5 or 6 of infection, depending on the inoculum. After 
determining the parasitemia, each week on a fixed day (usually Wednesday), 
which was day 7 of the infection, the parasites from each of the ten lines were 
passaged to 10 naïve mice (thus creating 10 new infections each week) after 
making appropriate dilutions in enriched PBS. For parasitemia of less than 1%, 1 
tail-drop of blood was mixed with 1 ml of rich PBS at 4 °C. For parasitemias 
between 1 and 5% and more than 5%, a 1:10 and 1:100 dilution was done with 
enriched PBS is done, respectively. Once diluted, 30 µl of the suspension was 
added to 250 µl of enriched PBS to make up the injection volume and the 
complete volume (about 280 µl) was injected intra-peritoneally, half on each 
side of a naïve mouse. The target was to achieve parasitemia between 5 and 10 
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% on day 7 of weekly passage. When the parasitemia reached this level, the 
blood from the infected mice was examined under FACS for the presence of 
gametocytes. Once the presence (or absence) of gametocytes was ascertained 
by FACS, the mouse was culled by cardiac puncture under general anaesthesia 
and the blood was cryopreserved for downstream applications. From each 
mouse, about 1 ml of blood was collected into a 2 ml heparinised syringe (with 
26 gauge needle). Half of the blood was mixed with an equal volume of 
Glycerol/PBS solution (30% Glycerol v/v containing 50 µl Heparin stock (200 
IU/ml in RPMI1640) solution), the volume divided into two and immediately 
cryopreserved in two separate cryotubes in liquid nitrogen. The remaining blood 
(about 500 µl) was collected in a 1.5 ml microcentrifuge tube at 4ºC and 
centrifuged at 20,238 x g for short duration (8-10 seconds) to separate plasma 
from the red blood cells. The plasma (usually about 100 µl) was aspirated into a 
sterile cryotube and immediately cryopreserved in liquid nitrogen.  
 
If a mouse did not show parasites on Giemsa-stained smears even on day 
8, a new mouse was infected with one of the cryopreserved stabilates of its 
immediate predecessor. Each time, one cryotube was withdrawn from the liquid 
nitrogen store and thawed before injecting the whole volume intra-peritoneally, 
half on each side of a naïve mouse. This was usually done on a Friday so that the 
parasites were expected on the next Wednesday, along with the other mice from 
that week. 
  
The parasites from each of the ten lines were weekly passaged between 
naïve mice until approximately 52 such passages for each isogenic line were 
done or when the gametocytes were no longer detected by FACS for a 
continuous period of 4 weeks, whichever happened earlier. 
 
2.1.1.4 Mosquito handling and maintenance 
All stages of Anopheles stephensi mosquitoes, vectors for human and 
rodent malaria, were reared and maintained in the insectary under the optimum 
growth conditions of 28 °C temperature and 80% relative humidity. Adult 
mosquitoes were maintained in netted cages with a holding capacity of 
approximately 2000 mosquitoes per cage. They were fed through an impregnated 
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filter paper absorbing 5% fructose from a glass universal bottle placed inside the 
cage. Once every week, the mosquitoes were blood-fed from 4-week old mice 
for approximately 10-15 minutes.  
Following a blood meal (48-hours post-feed), eggs were collected onto a 
moistened filter paper placed into an egg bowl. Eggs from adult female 
mosquitoes were collected and then reared for 48 hours in a hatching tray (filled 
with low level of water to which 6-8 small fish food pellets were added) until 
they hatched. Upon hatching, the young larvae were transferred to hatchling 
trays and were again fed on fish food pellets. After about 10 days, the pupae 
were manually removed from the larval tray by vacuum pump or Pasteur 
pipette. The pupae were collected into a fresh bowl and kept within a net 
covered mosquito cage where they metamorphosed to adult mosquitoes.  
2.1.2 Parasite growth in vitro 
For experiments requiring the growth of the parasite under specific 
conditions or drugs or for exclusively growing a specific developmental stage of 
the parasite, the parasites were maintained out of the mice and or mosquitoes 
for some period of their life cycle. As in vitro maintenance of the full life cycle 
is currently not possible for P. berghei, parasites were ultimately passaged to 
mice and/or mosquitoes to complete their full life cycle. Freshly harvested 
asexual stages of the parasites from the mice can be maintained in vitro up to 
the schizont stage (schizont culture) of the parasite, thereinafter an intravenous 
injection of the matured schizonts to the mice is absolutely needed for the 
continuation of the life cycle as the mature schizonts of P. berghei either do not 
rupture and release merozoites spontaneously or there is very poor re-invasion 
potential of merozoites in culture (Jambou et al., 2011). Sexual stages of the 
parasite, i.e., the gametocytes, can be cultured in vitro to observe the 
activation and exflagellation of male gametocytes (exflagellation assay) and the 
development of ookinetes (ookinete culture) beyond which, the parasite cannot 
be maintained in vitro. 
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2.1.2.1 Schizont culture 
For experiments where the pure schizont stage of the parasites was 
needed, for example, for transfection or for synchronization of infections, 
approximately 1 ml of infected blood from a phenylhydrazine-treated mouse (at 
parasitemia between 3% and 4%) was collected through cardiac puncture into a 2 
ml heparinized sterile syringe and subsequently transferred into 10 ml of 
schizont media (RPMI 1640 with L-glutamine and 25 mM HEPES and NaHCO3 at 
pH7.3 containing 25% Fetal Calf Serum). The suspension was filtered through 
CF11 powder (Whatman™) columns (domestically made) equilibrated with 
schizont media to remove host leukocytes and the filtrate was added to 30 ml of 
schizont media in a 75 mm2 tissue culture flask. If the initial parasitemia was 
around 10% before bleeding, the CF11 filtrate was added to 60 ml of schizont 
media in a larger tissue culture flask (150 mm2). The culture was gassed with a 
mixture containing 5% CO2, 5% O2 and 90% N2 for 30 seconds to 1 minute and 
then incubated in a shaker at 37 °C and 25 rpm overnight. The development of 
schizonts was assessed next morning (around 9 am) by making a Giemsa-stained 
blood smear from the schizont culture and examining under a light microscope. 
When the maturity of schizonts was ascertained by observing the number of 
merozoites per schizonts, the schizonts were harvested and treated according to   
desired downstream applications.  
2.1.2.2 Ookinete culture and count 
For assessment of functional maturity of gametocytes, efficiency of 
fertilization of gametocytes and phenotypic analysis of zygote development, 
morphology and movement of the ookinetes, ookinete cultures were established 
from infected blood from mice with asynchronous infections. One or two drops 
of infected blood were collected from the tail of a phenylhydrazine-treated 
mouse in approximately 5 ml of ookinete culture medium (RPMI1640, pH 8.00) at 
21-22 °C and immediately incubated at 21 °C overnight. Smears were made the 
next day morning, fixed with methanol and stained with Giemsa to be viewed 
under 400 x magnifications. Normal ookinetes appear as banana shaped bodies 
and any deviation from normal appearance indicate an abnormal morphology. 
Apart from the shape, the number of ookinetes on a slide is an indication of 
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their adequacy for progression to the next developmental stage, the oocyst. To 
quantitate the functionality of the ookinetes, another estimate called the 
ookinete conversion rate was calculated. The ookinete conversion rate reflects 
the number of female gametocytes/gametes which got converted into ookinetes 
and is calculated by dividing the total number of ookinetes with the number of 
female gametocytes/gametes. The number of female gametocytes was 
determined by counting 30-50 female gametocytes from the Giemsa stained thin 
blood smears.        
2.1.2.3 Exflagellation assay 
The process of conversion of male gametocytes into male gametes, called 
exflagellation, is an important measure of functional maturity of the 
gametocytes. One or two drops of infected blood were collected from the tail of 
a phenylhydrazine-treated mouse in approximately 1 ml of the ookinete culture 
medium. The number of exflagellating male gametocytes in a culture is counted 
after 10-12 minutes by placing ~10 µl of culture into a Burker cell counter under 
a light microscope (400 x magnification). The rate of exflagellation was 
calculated by expressing the total number of exflagellation events per 105 
erythrocytes.   
2.1.2.4 Cryopreservation and reactivation 
 Labelling and storage of the stabilate: Each week, a unique alpha-
numeric code was assigned for each of the 10 mice showing successful parasite 
passage. The same code was applied to the stabilate. The code consisted of a 
mouse number (m1 to m10; serially denoting the ten isogenic passage lines) 
followed by a week number (denoting the chronological week of passage, as w1, 
w2, w3……). On occasions when the mouse was infected from a predecessor’s 
stabilate (see above), the week number is also followed serially by a lower case 
letter (for example, a, b, c, d,…..). The letter denoted the number of times a 
particular line did not come up with parasites and thus had been reactivated in a 
naïve mouse with infection from a cryopreserved stabilate (for example, “a” 
means once, “b” means twice, and so on). All the stabilates were stored 
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together in one rack of a liquid nitrogen tank in a chronological and easily 
identifiable fashion. 
 
2.1.3  Giemsa staining 
The course of parasitemia (=percentage of infected cells) was determined 
in Giemsa stained blood films made from tail blood. Briefly, thin blood films 
from tail blood on a standard microscope slide were made. The smears were air-
dried and fixed for 1 second in methanol. Fresh Giemsa solution in 'Giemsa-
staining buffer' (10%, v/v) was prepared each time and the smears were dipped 
in the Giemsa solution to stain for 10 minutes (Fluka Analytical, Sigma). The 
smears were then rinsed carefully with tap water and the slides were left in an 
upright position to air-dry. The stained blood films were examined under a 
standard light microscope with immersion oil and objective at 100 x. Parasites 
were identified as bodies in stained red blood cells and were counted in fields of 
uniformly spread out RBCs to avoid overlapping and duplication. At least 10 
fields each containing 300-500 red blood cells were examined for parasitemia 
and the final parasitemia was noted as the percent of red blood cells infected. 
The life-cycle stage of the parasites was identified by the distinctive 
morphological features of each stage.    
 
2.1.4  Collection of blood from the infected mouse 
 
The blood from infected mice was collected by cardiac puncture under 
Isoflurane anaesthesia (see above) and the animal was sacrificed as per the 
regulations mentioned in the Animal Licence. A 2 ml heparinised sterile syringe 
was used to draw approximately at least 0.5 ml of infected blood at the desired 
parasitemia into an equal volume of glycerol/PBS solution (30% glycerol; v/v), 
containing 0.05 ml of Heparin stock-solution (200 IU/ml in RPMI1640). The 
suspension was then transferred to two 2 ml cryotubes, 0.5 ml per cryotube, 
which were immediately transferred to an appropriate allotted slot in the liquid 
nitrogen storage tank. When required, the blood suspension from one stabilate 
(0.5 ml) was used to infect 1-2 mice through an intraperitoneal injection.   
Chapter 2 Materials and Methods 105 
 
2.1.5  Drugs used during parasite growth and 
 maintenance 
The following drugs were used during parasite growth in mice: 
(1) Phenylhydrazine: As P. berghei has a strong preference for 
reticulocytes as compared to mature red blood cells, mice were often treated 
with phenylhydrazine-HCl (Merck) to induce reticulocytosis. One single dose of 
0.1 ml of the (12.5 mg/ml) stock (125 mg/kg body weight) was injected i.p. with 
a sterile 1 ml syringe 2-5 days prior to the infection of the mice. 
Phenylhydrazine was administered to increase the number of asexual blood 
stages and gametocytes and also for establishment of synchronized parasite 
infections in mice.  
(2) Sulfadiazine: For purification of gametocytes from asynchronous 
infections, Sulfadiazine (Sigma-Aldrich; 30 mg/L) was dissolved in ddH2O and 
was administered as drinking water to the mice. Sulfadiazine selectively kills the 
asexual parasite stages while the mature gametocytes remain unaffected. This 
method yields relatively pure preparations of fully mature (and degenerated) 
gametocytes. Infected mice were put on the drug when the parasitemia reached 
~5% and were subsequently bled after 48 hours of Sulfadiazine treatment. 
(3) Pyrimethamine: Stock solution of Pyrimethamine (Sigma-Aldrich; 7 
mg/ml) was prepared in DMSO and then diluted 100 times with tap water and 
the pH adjusted between 3 and 5 using 1M HCl. The drug was administered in 
drinking water. Pyrimethamine was used a drug-selectable marker in presence of 
the P. berghei or T. gondii dhfr gene which confers resistance to the drug 
pyrimethamine and hence is useful to positively select for genetically modified 
parasites bearing the dhfr cassette. 
(4) 5-FC: 5-fluorocytocine or 5-FC (Sigma-Aldrich) was used as a 
selection screen for eliminating the transgenic parasites possessing the negative 
drug-selectable marker yFCU that combines yeast cytosine deaminase and uridyl 
phosphoribosyl transferase (UPRT). Parasites containing the yfcu gene in their 
genome develop sensitivity to a lethal metabolite of 5-FC, 5’fluorocytocine 
triphosphate (5FCTP) and get killed. The drug was administered either orally in 
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drinking water (1.5 mg/ml) or as i.p injection of up to 10 mg per day per mouse 
(from 10 mg/ml stock in 0.9% NaCl), or both.  
(5) Hypnovel®/Hypnorm® combination anesthetic: Hypnorm® 
(Fentanyl-fluanisone; Crown Chemicals) / Hypnovel® (Midazolam; Roche 
Diagnostics) anesthetic combination approximately 30 minutes prior to mosquito 
feed. The Hypnorm®/Hypnovel® mix was prepared by adding 1 part (0.15 ml) 
each of the two drugs to 2 parts (0.3 ml) of sterile water. The recovery dose of 
the mix was 0.11-0.13 ml whereas the non-recovery dose was 0.02 ml over and 
above the recovery dose. The cocktail was administered about 30 minutes before 
the desired procedure, usually a mosquito-bite experiment on the mouse.  
(6) Isoflurane: Isoflurane (3-5% in Oxygen) was used as a inhalant 
general anesthetic for knocking mice down before any surgical procedure. 
2.2  General molecular biology methods 
2.2.1 Isolation of genomic DNA 
In order to analyse the genotype of the transfected or cloned parasites or 
for performing broader downstream applications including PCR based analyses, 
restriction digest, molecular cloning, etc, parasite genomic DNA had to be 
extracted from the infected mouse blood. For this, infected blood, usually 
through a cardiac puncture, was collected in 10 ml of PBS. The suspension was 
filtered through the CF11 cellulose powder columns or Plasmodipur Filters 
(EuroProxima B.V., The Netherlands) to remove host leukocytes. The filtrate was 
spun to obtain the pellet which was dissolved in 40 ml of chilled 1x RBC lysis 
buffer. Lysis was allowed to happen over the next 10-20 minutes on ice or until 
the suspension became semi-transparent. The suspension was spun again to 
obtain the parasite pellet which was washed twice with PBS to remove the 
supernatant. The final PBS washed parasite pellet was then used to extract the 
DNA. 
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The pellet in a microcentrifuge tube was resuspended in 700 µl TNE buffer 
and the following supplements were added - 200 µg RNase A (Invitrogen), 1% 
(v/v) SDS, and demineralised water up to 1 ml. The lysate was incubated for 10 
minutes at 37 °C after which 200 µg of Proteinase K was added, with incubation 
for 1 hour at 37 °C. Buffered phenol was then added up to 1.5 ml and the tube 
inverted several times and centrifuged for 5 minutes at 20,238 x g. The aqueous 
upper phase was transferred to a new tube and buffered 
phenol:chloroform:isoamylalcohol (25:24:1) was added up to 1.5 ml. The tube 
was again inverted several times and centrifuged for 5 minutes at 20,238 x g. 
The aqueous upper phase was again transferred to a new tube and this time 
chloroform:isoamylalcohol (24:1) was added up to 1.5 ml. The tube was again 
inverted several times and centrifuged for 5 minutes at 20,238 x g. The aqueous 
upper phase was again transferred to a new tube and 0.1 volume of 3 M NaAc, 
pH 5.2, and 2 volumes of 96% ethanol were added. The reactions were gently 
mixed and the DNA was allowed to precipitate at –20 °C overnight. The next 
morning, the precipitate was centrifuged for 10 minutes at 20,238 x g at 4 °C 
and the DNA pellet washed by adding 500 µl 70% ethanol and centrifuged 5 
minutes at 20,238 x g at 4 °C. The supernatant was discarded and the pellet air-
dried. The DNA was re-suspended in 50 µl of demineralised water.  
 
2.2.2  Polymerase Chain Reaction (PCR) 
PCR was used to amplify specific regions of genomic and complementary 
DNA that would be a template for the following downstream applications: Sanger 
sequencing, molecular cloning, to confirm integration in transfected cell lines, 
PCR-based complementation attempts, insertion of a restriction site, etc. All 
oligonucleotides were synthesised by Eurofins MWG Operon (Ebersberg, 
Germany). The standard PCR reaction used was as follows; 1x PCR reaction 
buffer without MgCl2 (Invitrogen, Paisley, UK), 1.5 mM MgCl2 (Invitrogen, Paisley, 
UK), 0.4 μM of each primer (Eurofins MWG Operon, Ebersberg, Germany), 0.2 mM 
dNTPs (Invitrogen, Paisley, Scotland), 1.0 U Taq Polymerase (Invitrogen, Paisley, 
UK), and between 1 and 5 ng of plasmid DNA, or between 50 and 100 ng of gDNA 
template. The amplification was performed using a thermal cycler (PTC-200 DNA 
Engine Thermal Cycler, BioRad). The PCR program usually included an initial 
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denaturation step at 94 °C for 3 minutes was followed by between 25 and 35 
cycles of 94 °C for 30 seconds, an annealing temperature (Tm) specific for each 
set of primers for 30 seconds, and an extension step of 1 minute per kb of the 
expected length of the amplified DNA. A final extension step at 68 °C (or 72 °C 
for amplicons less than a kb) for 10 minutes was followed by a holding 
temperature of 4 °C.  
For the amplification of DNA for sequencing, an error-proof DNA 
polymerase system, Expand High Fidelity PCR system (Roche Diagnostics, 
Mannheim, Germany) was used. The reaction components used was as follows; 
1x Reaction Buffer including 1.5 mM MgCl2, 200 µM of each dNTP, 300 nM of each 
primer, 50-100 ng of template gDNA, 2.6 U of High Fidelity enzyme mix for each 
25 µl reaction volume. The cycling conditions were as follows; an initial 
denaturation step at 94 °C for 2 minutes was followed by 10 cycles of 94 °C for 
15 seconds, an annealing temperature depending upon the Tm of the primers for 
15 seconds, and an extension temperature of 68/72 °C for time depending on 
the fragment length (45 seconds for up to 0.75 kb, 1 minute for 1.5 kb, 2 
minutes for 3 kb, 4 minutes for 6 kb, 8 minutes for 10 kb). A final extension step 
at 68/72 °C for 7 minutes was followed by a holding temperature of 4 °C.  
 
2.2.3  Oligonucleotides 
All oligonucleotides were designed using Vector NTI (Invitrogen, Paisley, 
Scotland) and CLC Genomics Workbench 5.0 software and ordered from Eurofins 
MWG Operon (Ebersberg, Germany). A tabulated description of all the 
oligonucleotides used in the study is mentioned in Table A-13 (Appendices). 
 
2.2.4  Southern analysis 
Approximately 10 µg of purified genomic DNA was digested with 
appropriate restriction enzymes (New England BioLabs, Masachussets). A typical 
double digest consisted of 150 µl of reaction mix with not more than 10% of the 
total reaction volume as both the restriction enzymes (a total of 15 µl of both 
enzymes) in presence of BSA (if recommended) and appropriate NEB reaction 
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buffer. The reaction was incubated for ~4 hours at 37 °C (usually or as 
recommended) after which additional 2% of the total reaction volume of each 
enzyme (that is 3 µl of each enzyme) was supplemented to the reaction and 
digestion was continued at 37 °C for another 1 hour. The reaction mix was 
vacuum concentrated (SpeedVac; Thermo Scientific) to ~35 µl. The  
concentrated samples (together with 5x loading dye) were loaded on a 0.7% 
agarose gel (for fragments of 0.8 kb to 10 kb) in water (added SYBR®Safe DNA 
gel stain, Life Technologies TM) and fractionated at 20 Volts/cm overnight with 
circulating 1x TBE buffer. When the gel has run more than 3/4th of its length – a 
UV picture of the gel with a ruler was taken and ladder sizes marked on the 
picture. The DNA was then depurinated with 0.25 M HCl and incubated on a slow 
shaker for 15 minutes at room temperature (RT). Denaturation of the DNA was 
done by rinsing the gel with ddH2O and covering with denaturing buffer (see 
appendix A14) and incubated on a slow shaker for 20-30 minutes at RT. The DNA 
was neutralized by soaking the gel in 20x SSC for 30 minutes with constant 
shaking at RT.  
 
Rest of the steps including the transfer of the DNA from the gel, pre 
hybridization and hybridization steps, washing and visualization of bands were 
the same as that for RNA/northern analyses (see below).  
 
2.2.5  Isolation of  total RNA 
High quality total RNA was usually obtained from “fresh” parasite pellets 
obtained directly from the animal or from overnight in vitro culture. The 
procedure for parasite RNA extraction is same as for extraction of DNA up to the 
stage of obtaining the parasite pellet. Thereafter, the parasite pellet was 
resuspended in 1 ml of TRIzol® reagent (Invitrogen, Life Technologies) and 
vigorously vortexed until a homogenous solution was obtained. The solution was 
pelleted and the supernatant was transferred to a new microcentrifuge tube. 
Two hundred µl of chloroform was added and the sample vortexed for 30 
seconds and then incubated for 10 minutes at room temperature. The sample 
was then centrifuged at 20,238 x g , at 4 °C for 10 minutes in order to obtain 
phase separation. The upper aqueous phase was transferred to a fresh 
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microcentrifuge tube and 500 µl of isopropanol added. Precipitation was 
performed at -20 °C overnight. On occasion 20 µg of glycogen was added as a co-
precipitant in order to enhance precipitation. The RNA was pelleted by 
centrifugation at 20,238 x g for 15 minutes at 4 °C, and the supernatant 
decanted. The pellet was washed with 1 ml of 70% ethanol and spun again for 10 
minutes, at 20,238 x g at 4ºC. The supernatant was removed and the pellet dried 
for up to 10 minutes at room temperature. The dry pellet was then resuspended 
in 30-50 µl RNase-free demineralised water (depending on the pellet size). The 
RNA concentration was measured using a NanoDrop 2000 spectrophotometer 
(Thermo Scientific). RNA samples were stored at – 80 °C.  
 
2.2.6  Preparation of cDNA and RT-PCR 
 All RNA processing was done in an RNAse free environment by profound 
use of Ambion® RNaseZap® (Life Technologies™). Purified total RNA (~ 4 µg) was 
mixed with 10x DNAse I reaction buffer (Invitrogen) and 2 U DNAse I 
amplification grade (Invitrogen) in DEPC treated demineralized water in RNase 
free microcentrifuge tubes. The reaction was incubated at room temperature for 
15 minutes after which the DNAse I was inactivated by adding 1 µl of 25 mM 
EDTA and heating for 10 minutes at 65 °C. First strand cDNA synthesis was done 
using SuperScript III RT (Invitrogen). The reaction mix consisted of the following 
in a final volume of 20 µl- ~5 µg of total RNA (from above), 50 µM oligo (dT) 20, 
and 10 mM each of the dNTPs plus sterile distilled water. The reaction was 
incubated at 65 °C for 5 minutes followed by on ice for a minute. The reaction 
was centrifuged at 20,238 x g and the following added – 5x first strand buffer, 
0.1 M DTT, 40 U RNaseOUT (Invitrogen) and 400 U of SuperScript III RT 
(Invitrogen). The reaction was mixed gently and incubated at 65 °C for 30-60 
minutes. The reaction was terminated by incubating at 70 °C for another 15 
minutes. To remove RNA complementary to the cDNA, 1 µl (2 units) of E. coli 
RNAse H (Invitrogen) was added and samples incubated at 37 °C for 20 minutes. 
The first strand cDNA thus synthesised was used as a template for PCR, with a 
positive gDNA control and negative water and minus-RT controls. 
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2.2.7  Northern analysis 
 Freshly prepared and purified total RNA from the schizont preparation of 
Plasmodium parasites was used for northern analyses. Purified total RNA and an 
RNA ladder (Life TechnologiesTM; 1 µg/µl) were diluted in DEPC treated water to 
obtain ~5 µg of RNA sample and 7 µg of the RNA ladder each in 12 µl total 
volume. RNA was then denatured by adding 12 µl of 2X RNA loading dye (Thermo 
Scientific) to each 12 µl of RNA sample and heating at 70°C for 10 minutes 
followed by chilling on ice for 5 minutes. The samples were loaded on a 1.2% 
agarose gel (with added SYBR®Safe gel stain, Life Technologies TM) in DEPC water 
(containing 10x MOPS and 37% Formaldehyde). The RNA was fractionated at 20 
Volts/cm overnight in 1x MOPS running buffer.  
 
Next morning, the gel was soaked in DEPC water to remove formaldehyde 
(fluoresce under UV) and then photographed under UV light alongside a ruler to 
mark the ladder, wells and detect the 4 distinct bands of parasite rRNA. The RNA 
was then transferred from the gel onto a nylon membrane (Hybond-N+TM nylon 
transfer membrane, GE Healthcare) pre-wetted in 2x SSC using a TurboBlotterTM 
device (WhatmanTM, GE Healthcare). Briefly, the gel (as is) was placed on the 
pre-wetted nylon membrane with a stack of SSC-soaked filter papers on the gel 
as weights. The stack further supported a pre-wetted filter paper wick on top 
which was immersed in the 10x SSC transfer buffer. A light cover plate was just 
placed on the wick but not pressed. The gravity-aided capillary transfer of RNA 
from gel to the membrane was allowed to occur overnight. 
 
 Next morning, transfer efficiency was assessed by inspecting the 
membrane under UV and subsequently crosslinking the RNA to the membrane 
using ultraviolet light. The membrane was first incubated with pre-hybridization 
buffer at 55 °C for an hour before hybridization with denatured -32P dATP 
labelled double stranded probe specific to the analysed sequence at 60 °C 
overnight with gentle shaking. After overnight hybridisation, the blot was 
washed three times with 3x SSC/0.5% (v/v) SDS and once with 1x SSC/0.5% (v/v) 
SDS at 60 °C (each washing step for 15 minutes). The signal was detected using a 
storage phosphor screen (Kodak). 
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2.2.8  Generation of gene knockout constructs 
The plasmid pL0034 (Figure 2-1) was used to generate all of the three 
length variants of the gene knockout constructs. The plasmid pL0034 was 
selected because of the presence of only one copy of the 3’Pbdhfr UTR which 
would favour negative selection-based complementation of the knocked out 
gene. Conventional double crossover gene targeting constructs were developed 
by amplifying approximately 1 kb upstream and downstream homology arms 
flanking the region of the gene to be knocked out. The oligonucleotides used for 
amplifying each of these regions were synthesised by Eurofins MWG operon 
(Ebersberg, Germany) and were so designed to incorporate the desired 
restriction sites necessary to clone the homology arms into the pL0034 vectors. 
The homology arms (inserts) and the vector were digested with compatible 
restriction enzymes and the inserts sequentially cloned into the vector to 
generate the complete gene targeting vector bearing the homology arms 
flanking the drug selectable marker cassette. The recombineering-based gene 
targeting vector was kindly supplied by Oliver Billker, Sanger Institute, 
Cambridge, UK.   
 
2.2.9  Generating gene complementation constructs 
Two types of complementation constructs were used to restore the 
function of the knocked out gene – PCR-based constructs and recombineering 
based constructs. PCR based constructs were synthesised by conventional PCRs 
encompassing the region of the gene to be complemented using a 
“proofreading” polymerase system, the Expand High Fidelity PCR system (Roche 
Diagnostics, Mannheim, Germany). Recombineering-based complementation 
constructs were kindly supplied by Oliver Billker, Sanger Institute, Cambridge, 
UK.  
 
Chapter 2 Materials and Methods 113 
 
2.2.10 Parasite transfection 
2.2.10.1 Preparation of DNA for transfection 
DNA constructs for transfection were prepared according to standard 
molecular biology techniques. The homology arms for all generated constructs 
were obtained by PCR on wild type gDNA with standard PCR program conditions 
(see above). The amplified DNA was quantified using a spectrophotometer and 
an aliquot (usually 50-100 ng) of the obtained PCR products fractionated on 1% 
agarose gel to confirm the desired size of the homology arm/s. The remaining 
PCR product was purified using QIAquick PCR purification kit (Qiagen) as per the 
manufacturer’s instructions. The purified DNA was again quantitated as above. 
 
 
Figure 2-1. A cartoon of the pL0034 plasmid (size 5.4 kb) used for generating the vectors for 
targeting the AP2-G gene. Note that the plasmid has only one copy of the 3’pbdhfr/ts which 
prevents the usage of this particular vector for selectable marker recycling. Also, for the same 
reason, the vector is ideal for any negative selection based enrichment experiment, as in the case 
here, the complementation of the gene at the endogenous locus. The restriction sites at the 
multiple cloning sites are also depicted. 
  
 
For direct cloning into the desired plasmid vector, each PCR product or 
homology arm (the insert) was digested with appropriate restriction enzymes for 
approximately 1 hour at 37°C (or as specified for the target restriction enzymes) 
and again purified with QIAquick PCR purification kit (Qiagen, Manchester, UK). 
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The target plasmid was also simultaneously digested with corresponding 
appropriate restriction enzymes (double digestion) and purified as above (the 
vector). The concentration of both the insert and the vector was determined by 
use of the spectrophotometer.  
 
Vector and the insert DNA were ligated in a molar ratios ranging from 1:1, 
1:3 and 1:6. The ligation reaction was performed for 10 minutes at room 
temperature using Rapid DNA ligation kit (Roche Applied Science, Mannheim, 
Germany). A typical 15 µl ligation reaction consisted of the vector and insert at 
chosen molar ratio, 1.5 µl of 10x ligation buffer (Roche Applied Science, 
Mannheim, Germany) and 1 U of T4 DNA ligase (Roche Applied Science, 
Mannheim, Germany). The ligation mix was then added to 50 µl of ice-thawed 
Fusion-Blue competent E.coli cells (Clonetech), and the mix incubated on ice for 
30 minutes. Heat-shock transformation was performed at 42 °C for 45 seconds, 
followed immediately by incubation on ice for 1 minute. About 400 µl of room 
temperature SOC or LB medium was then added to each transformation reaction 
and incubated with shaking at 37 °C for an hour. The transformed bacteria were 
then spread on pre-warmed LB agar plate with 100 μg/ml ampicillin and 
incubated overnight at 37 °C. The next day bacterial colonies were inoculated in 
4 ml LB medium with 100 μg/ml ampicillin. After overnight incubation, the 
cultures were spun down and the plasmid DNA extracted using the QIAprep Spin 
Miniprep kit (Qiagen, Manchester, UK) as per the manufacturer’s instructions. A 
sample of the obtained plasmids were analysed by appropriate restriction 
enzyme digestion to confirm the ligation.  
 
 Approximately 20 µg of the final plasmids with introduced homology arms 
were linearized with suitable restriction enzymes overnight at 2 g per reaction 
with 10U/reaction of each of the enzymes in the appropriate buffer, at the 
appropriate temperature to ensure complete digestion. For the double crossover 
constructs, the plasmid was linearized using restriction sites at the end of the 
desired sequence target construct to separate the plasmid backbone from the 
desired linear recombination construct. The plasmid was also digested 
simultaneously with another unique restriction enzyme to cut the backbone to 
generate an easily separable desired linearized target construct and ensure 
minimal contamination with the circular construct.  
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The reactions were pooled and the digested plasmid (along with the 
undigested plasmid as a control) fractionated usually on an 0.8% agarose gel 
containing a minimal amount of SYBR®safe (Invitrogen, Paisley, UK)  to 
differentiate  uncut and the linearized plasmid. The band corresponding to the 
linearized plasmid was cut out the gel (with standard precautions to prevent 
contamination) as quickly as possible to minimize exposure to UV rays. DNA was 
extracted from the gel using QIAquick Gel Extraction kit (Qiagen, Manchester, 
UK) and precipitated with 0.1 volume of 3M NaAc, pH 5.2, and 2.5 volumes of 
96% ethanol overnight at -20 °C. Next morning, the DNA was spun down at 
20,238 x g for 15 minutes in a centrifuge at 4 °C, washed with 200 l of 70% 
ethanol and spun down again at 20,238 x g for 10 minutes at 4 °C. The DNA was 
air-dried and resuspended in 5-10 l of double-deionized water so as to make a 
final concentration of around 1 g/l. For transfection of P. berghei with the 
Amaxa® Human T-cell Nucleofector™ solution-buffer (Lonza, Germany), 5 g of 
DNA was used for each transfection. 
 
TOPO® TA cloning® (Invitrogen, Life Technologies) was done as an easy 
and fast way to ligate PCR products directly into the TOPO vector, thus avoiding 
the step of enzymatically making the insert compatible with the vector. The 
technology is based on the property of the Taq polymerase to add extra 
adenosines at the 3’ end of the amplified products which remain compatible to 
the complementary T sequences in the TOPO® vector. The ligations were done 
using the TOPO® TA cloning® kit for sequencing (Invitrogen, Life Technologies) 
as per the manufacturer’s instructions. Basically, 0.5-2 µl of fresh PCR product 
was incubated for 5 minutes at room temperature with 0.5 µl of TOPO® vector 
and sterile water in a 3 µl total reaction volume. The reaction was incubated on 
ice while a vial with One Shot® Top 10 Chemically Competent E. Coli cells (Life 
Technologies, Paisley, UK) was thawed on ice. Two µl of the cloning reaction 
was added to the vial of competent cells and mixed gently. After incubation on 
ice for 5-30 minutes, the cells were heat-shocked for 30 seconds at 42 °C 
without shaking and were immediately transferred to ice. The cells were then 
incubated with 250 µl of room temperature SOC medium at 37 °C for 1 hour with 
shaking. Finally, 10-250 µl of the reaction was spread on a LB-ampicillin plate 
and incubated at 37 °C overnight. 
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2.2.10.2 Preparation of schizonts for transfection 
 Matured P. berghei schizonts were used to transfect the linearized 
plasmid targeted construct. A phenylhydrazine-treated mouse was infected with 
the cryo-preserved parasites of the line to be genetically manipulated to serve 
as a source of blood stage parasites for the culture and purification of schizonts. 
The parasites were harvested on day 4 or 5 and put into schizont culture (see 
above). Prior to the electroporation, the schizonts were separated from the 
uninfected erythrocytes using 55% Nycodenz (Life Technologies, Paisley, UK)/PBS 
density gradient solution (v/v). Briefly, the culture suspension containing the 
schizonts was transferred to four 50 ml tubes (35 ml per tube). Using a 10 ml 
pipette, 10 ml of the Nycodenz-solution was gently added in each tube under the 
culture suspension, so that a sharp contrasting division is visible between the 
two suspensions. The suspension was then centrifuged for 20-30 minutes at 1500 
rpm with no brake. The brown/grey layer (containing schizont infected cells) at 
the interface between the two suspensions was carefully collected. The 
schizonts were then pelleted and washed with culture medium obtained from 
the top of the gradients. The supernatant was discarded and 100 µl of the 
Amaxa® Human T-cell Nucleofector™ solution-buffer (Lonza, Germany) 
containing 5-10 µl of DNA (5-10 µg DNA construct in water or TE buffer) was 
added to resuspend the parasites. DNA transfection was then performed with 
theNucleofector™ 2b Device (Lonza, Germany) using protocol U33. Immediately 
after transfection, 50 µl of the culture medium was added and the transfected 
parasites were immediately injected (i.v.) into mice. Each transfection was 
allocated a unique alphanumeric serial number for identification like G418.  
     
2.2.11 Cloning of transgenic parasites by limiting dilution 
A transfected parasite population normally consists of both the 
transfected (transgenic) and the wild type parasites. Therefore cloning by 
limiting dilution is necessary for further analysis of a homogenous transgenic 
line. Usually, on day 0, a phenylhyndrazine-treated donor mouse was infected 
intraperitoneally with 100 µl of a blood-suspension from cryo-preserved 
transfected parasites of the line to be cloned. On day 3 or 4 parasitemia was 
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checked (usually the parasitemia ranged between 0.3 and 1%) and 5 μl of tail 
blood was collected by a heparin-treated capillary tube into a microcentrifuge 
tube. The blood was then diluted in 1 ml of enriched PBS and 10 μl was used for 
red blood cell counting using a Bürker cell counter. The number of uninfected 
and infected erythrocytes per μl of the cell suspension was calculated and the 
sample diluted to a final concentration of 0.5 parasites/µl of enriched PBS 
solution. This solution was further diluted 200 times and 200 µl of the final 
diluted suspension was injected per mouse intravenously such that less than 1 
parasite is injected per mouse (in total 10 mice were used per cloning). 
 
Thus, 10 mice were infected for obtaining a cloned parasite line. 
According to the calculations above, 0.5 parasites are injected intravenously 
(i.v.) into each mouse, resulting in an infection rate of 20-50% of the mice (due 
to statistical probability, not every mouse receives a parasite). At day 8 after 
infection the parasitemia was determined. From the mice with a parasitemia of 
0.3 – 1%, approximately 1 ml of blood was collected through cardiac puncture. 
Half of the collected blood volume was used for extraction of DNA (for PCR 
based confirmation of the success of cloning experiment) and the remaining half 
was used to make stabilates for cryopreservation of the anticipated cloned line.  
 
2.3  Recombinant protein production 
N-terminal glutathione S-transferase (GST) fused extended ApiAP2 DNA 
binding domains (cloned into pGEX-4T1) from P. falciparum AP2-G (PFL1085w) 
and P. berghei AP2-G (PBANKA_143750) were kindly gifted by Manuel Llinas 
(Princeton University, USA) as plasmid DNA. Rosetta™ (DE3)pLysS competent 
cells (Merck Millipore, Germany) were transformed with the provided plasmid 
DNA (as above) and plated on LB/ampicillin (amp)/Chloramphenicol (cam) 
plates.   
 
Starter cultures were prepared by picking one colony from an LB/amp-
cam-plate into 10 ml LB containing 10 µl ampicillin (100 mg/ml stock) & 10 µl 
chloramphenicol (35 mg/ml stock). The cultures were grown overnight at 37 °C 
with shaking. Next morning, 100 ml of fresh LB/amp/cam was inoculated with 2 
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ml of overnight culture. The main culture was grown again at 37 °C for ~1 hour 
(up to an OD600 of ~0.2). The cultures were then transferred to 25 °C and grown 
for ~2 hours (up to an OD600 of ~0.6). Expression of the GST-tagged protein was 
induced with 0.2 mM of fresh UltraPure™ IPTG (Invitrogen, Life Technologies) 
and the culture was further incubated at 25 °C for 4 more hours. After that, the 
culture was spun at 6000 x g for 10 minutes to pellet cells. LB medium was 
decanted and the pellet was stored at -80 °C. The successful induction of the 
desired protein expression was ascertained by fractionating the proteins in a 12% 
SDS PAGE gel to determine if there is any protein in the induced sample that is 
significantly more than that in the un-induced one.  
 
The protein pellet was re-suspended in freshly prepared GST buffer at pH 
8 and cell lysis achieved using a cocktail of the following - 1 mM PMSF (Sigma-
Aldrich), 0.5% Triton X-100 detergent (Thermo Scientific), 1 mg/ml Lysozyme 
(Sigma-Aldrich), 100 U/ml of DNAse (Invitrogen, Life Technologies) and 1 tablet 
of protease inhibitor (cOmplete, Mini, EDTA free protease inhibitor cocktail 
tablets, Roche). The suspension was incubated for 30 minutes at 4 °C on a 
nutator at 20 rpm. To ensure completeness of bacterial cell lysis, the suspension 
was freeze-thawed and sonicated (thrice) in ice bucket in short 10-second bursts 
alternated with 1 minute of resting on ice. The completeness of lysis was 
indicated when the cloudy cell suspension became translucent. The cell debris 
was spun down immediately at 20,238 x g for 10 minutes at 4 °C. The soluble 
proteins in the resulting supernatant were batch purified using Glutathione resin 
(Glutathione HiCap Matrix slurry; Qiagen). Briefly, Glutathione beads were 
equilibrated and prepared as per manufacturer’s instructions and the cell lysate 
(supernatant) added to the equilibrated Glutathione beads. The suspension was 
then incubated at 4°C on the nutator for 4 hours at 20 rpm. The resin was 
allowed to settle for 5 minutes and the supernatant was drawn off. The resin 
was then washed 3 times with cold GST buffer, allowed to settle for 5 minutes 
and the supernatant drawn off. Finally, the GST-tagged protein was eluted using 
freshly prepared elution buffer at pH ~8.0 (containing reduced L-Glutathione 
(Sigma-Aldrich), Tris-HCl, ddH2O and protease inhibitor tablets (cOmplete, Mini, 
EDTA-free protease inhibitor cocktail tablets, Roche)). Elution was repeated 
thrice, with increasing duration of incubation, using 500 µl of the elution buffer 
each time in a nutator at 20 rpm. Each time, the resin was allowed to settle by 
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gravity and supernatant (eluate) containing the pure protein drawn off carefully. 
The purified proteins (elutions) were stored at 4°C. To render the tagged 
proteins directly usable in EMSAs, buffer exchange was performed with 1X PBS 
and proteins concentrated at the same time using Amicon-Ultra 30kDa spin 
concentrators (Amicon Ultra-0.5 Centrifugal filter devices; 30K device; Milipore). 
For long term storage, purified proteins were stored as pellets at a 
concentration 1 mg/ml in -80°C in 25% glycerol, aliquoted into 100 µl PCR tubes. 
 
2.4   Electro-mobility Shift Assays (EMSA) 
Binding of purified N-terminal GST fusions of AP2 domains of AP2-G of P. 
falciparum (PF3D7_1222600) and P. berghei (PABNKA_143750) to their cognate 
DNA sequences was analysed using EMSAs. Single stranded oligonucleotides 
containing the DNA-binding Domain (DBD) recognition motif flanked both by 
random nucleotides (same for all flanking sequences) and by actual nucleotides 
(as they occur naturally in the 5’ upstream regions of potential AP2 target 
genes) and their corresponding complementary oligonulceotides were purchased 
from Eurofins MWG Operon (Ebersberg, Germany) as labelled (5’-biotinylated & 
HPLC purified) and unlabelled sequences. These single-stranded oligonucleotides 
were annealed to their complementary oligonucleotides to create double-
stranded probes by heating the oligonucleotides,  in equi-molar concentration, 
at 95°C for 3-5 minutes followed by slow cooling at room temperature for about 
an hour. 
 
These annealed oligonucleotides were used as labelled and unlabelled 
target probes for the DNA-binding domain of AP2-G in non-competitive and 
competitive EMSAs, respectively EMSAs were done using the LightShift 
Chemiluminescent EMSA kit (Pierce Protein Biology Products, Thermo Fisher 
Scientific, Northumberland, UK). For non-competitive EMSA, 2 µg of the purified 
GST fusion of PFL1085w and PBANKA_143750 (in separate reactions) was 
incubated with the labelled probe (0.02 pmol) in 20 µl of the binding reaction 
containing 10X binding buffer, 1 µg poly(dI-dC), 50% glycerol, 100 mM MgCl2, 1% 
NP40, and 60 µg BSA at room temperature for 20 minutes in 1.5 ml 
microcentrifuge tubes,  protected from light. For competitive EMSA, the same 
amount of respective fusion protein was first pre-incubated with the unlabelled 
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probe (4 pmol; 200-fold excess to the labelled probe) in 20 µl of the binding 
reaction as above. The labelled probe (0.02 pmol) was then added to the 
reaction and incubated for further 20 minutes at room temperature.  
 
In either case, the reaction was fractionated using 12% polyacrylamide gel 
(without SDS) in 0.5x TBE at 100 Volts until the dye had run 2/3rd - 3/4th of the 
gel length. The nucleic acid (bound and unbound) was then transferred from the 
gel to a nitrocellulose membrane (Amersham Hybond Nitrocellulose membrane, 
GE Healthcare, Buckinghamshire, UK) as per manufacturer’s instructions. Briefly, 
the transfer cassette was assembled by placing the gel on to the Nitrocellulose 
membrane such that the dye-front of the gel faced the membrane and the two 
were sandwiched between two pieces of wetted Whatman™ paper (GE 
Healthcare) and the transfer sponges (reserved specifically for EMSAs). The 
transfer was performed at 100 Volts for 30 minutes in chilled 0.5x TBE buffer 
under cold room conditions.  
 
The membrane was then UV-cross-linked. Specific binding of the AP2 
domain with the target motif was detected as an upward shift using the 
Chemiluminescence Nucleic Acid Detection Module (Pierce Protein Biology 
Products, Thermo Fisher Scientific, Northumberland, UK) as per the 
manufacturer’s instructions. The membrane was first blocked with a blocking 
buffer for 15 minutes shaking at RT and then conjugated with Stabilized 
Streptavidin-Horseradish Peroxidase Conjugate for another 15 minutes. The 
membrane was then washed four times with 1x wash buffer for 5 minutes each 
and subsequently equilibrated with Substrate Equilibration Buffer for 5 minutes 
with shaking. The membrane was placed on clean saran wrap and then incubated 
with Luminol/enhancer and stable peroxide solution for a further 5 minutes in 
the dark without shaking. Chemiluminescence was detected using a storage 
phosphor screen with exposure for 30 seconds to 5 minutes on Kodak™ BioMax® 
MS (maximum sensitivity) and MR (maximum resolution) films. 
 
2.5  Flow cytometry 
Each week, gametocytogenesis in each of the infected lines was inferred 
from their expression of green and red fluorescent proteins and DNA content (or 
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ploidy) determined by FACS measurement of fluorescence intensity of cells 
stained with the DNA-specific dye Hoechst-33258 (Sigma-Aldrich) using a 
MACSQuant® Analyzer (Flowcytometer; Miltenyi Biotec, Germany). GNP lines 
were detected by the absence of gametocytes which the FACS analyses 
confirmed.  
2.5.1  Hoechst staining of the samples  
In short, 2-3 drops of tail blood was collected in 1 ml of enriched PBS at 4 
°C in a dark-coloured microcentrifuge tube kept on ice. The suspension was spun 
at 20,238 x g for 2 minutes to pellet the blood cells. The pellet was washed 
twice with enriched PBS before being finally stained with 1 ml of 0.2 µM Hoechst 
stain (Sigma-Aldrich) in enriched PBS. The suspension was always kept on ice to 
prevent the activation of male gametocytes. Once Hoechst was added, the 
suspension was incubated for 1 hour at 37 °C. Following incubation, the cells 
were examined using the MACSQuant® Analyzer (Flowcytometer; Miltenyi Biotec, 
Germany).   
2.5.2  Instrument settings for MACSQuant® Analyzer 
Each sample was run on the flowcytometer with a sample volume of 1000 
µl, uptake volume of 200 µl, on a standard mode with customized settings. A 
total of 200,000 events were counted with an average flow rate of up to 15000 
events per second. 
 
Five optical parameters of cells were analysed – three fluorescence 
channels and two scatter channels (one forward scatter or FSC and one side 
scatter or SSC channel). The cells were excited with a wavelength of 405 nm for 
FL1 (VioBlue/Hoechst) channel and 488 nm for FL2 (fluorescein 
isothiocyanate/GFP or FITC), FL3 (Phycoerythrin/RFP or PE) and FSC/SSC 
channels. Cells expressing GFP have an emission maximum of 521 nm and were 
hence detected in the green fluorescent channel (FL2/FITC, 525 nm with a 
bandwidth of 50 nm). Cells expressing RFP have an emission maximum of 585 nm 
and were hence detected in the red fluorescent channel (FL3/PE, 585 nm with a 
bandwidth of 40 nm). Thus, the following filters were used – 450/50 for 
FL1/VioBlue, 525/50 for FL2/FITC, 485/40 for FL3/PE and 488/10 for FSC/SSC.  
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A linear scale was used for FSC and SSC data whereas a logistic scale was 
used to analyze fluorescence signals as a difference in fluorescence signal 
intensities extended over several orders of magnitude. Cells for Hoechst analysis 
were selected on size by gating on FSC and SSC.  A sample volume of 1000 µl of 
Hoechst-stained cells with an uptake volume of 200 µl was examined using 
200,000 cells per sample run. Data processing and analysis was performed using 
the MACSQuantify™ analysis software (www.miltenyibiotec.com). Dot plot, 
density plots and histograms were used to analyze the distribution of cells. 
 
Cells on FSC versus SSC dot plot are widely gated (P1) to include most of 
the red blood cells while eliminating larger (lymphocytes and monocytes) and 
granular (granulocytes) leukocytes and smaller cellular debris. The gated 
population of cells (P1) was analyzed further on FITC versus VioBlue density plot, 
PE versus VioBlue density plot and FITC versus PE density plots. The FITC versus 
VioBlue density plot differentiated red blood cells that were only Hoechst 
positive (infected red blood cells; asexuals) from red blood cells that were 
positive for both Hoechst and GFP signals (infected red blood cells; male 
gametocytes). A second gate (P2) captured the male gametocytes in this plot 
and estimated the absolute number and proportion (as %) of male gametocytes 
out of the total population of red blood cells gated (P1) in FSC versus SSC dot 
plot. 
Similarly, the PE versus VioBlue density plot differentiated red blood cells 
that were only Hoechst positive (infected red blood cells; asexuals) from red 
blood cells that were positive for both Hoechst and RFP signals (infected red 
blood cells; female gametocytes). A third gate (P3) captured the female 
gametocytes in this plot and estimated the absolute number and proportion (as 
%) of female gametocytes out of the total population of red blood cells gated 
(P1) in FSC versus SSC dot plot. A histogram of VioBlue positive cells from the P1 
gate estimated the proportion of red blood cells infected out of the total 
population of red blood cells gated as P1. This showed the parasitemia as 
percent of red cells infected. A red cell population that was multiply infected 
was apparent as a separate density in the VioBlue density plots. The FITC versus 
PE density plot revealed the comparative presence of male (P2 gated) and 
female (P3 gated) gametocytes, respectively. The activated male gametocytes 
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that had duplicated their DNA were apparent as a separate density in the FITC 
versus VioBlue density plots.  
Any green fluorescent signal (which was supposed to be captured by the 
FL2 channel) that was leaking into the FL3 channel or vice versa was 
compensated in the appropriate channels by adjusting the amount of leaking 
signal intensity after acquisition of data.  
 
Two negative controls, blood from an uninfected mouse and from a mouse 
infected with P. berghei HP ANKA line which is a known high producer of 
gametocytes (which were not fluorescently labelled), were used.  These were 
used to precisely position the P1 gate in the FSC versus SSC plot to 
predominantly focus the red blood cell population. The samples were treated in 
the same way as the test samples and were also stained with Hoechst stain 
similarly.  
 
2.6  Sequencing and bioinformatic methods 
 
A flow diagram highlighting the major procedures performed from 
preparation of the DNA for sequencing up to the analysis of identified mutations 
is shown below (Figure 2-2). The work done by Wellcome Trust Sanger Institute 
(WTSI) has been shaded. Whole genome re-sequencing was performed by the 
pathogen sequencing unit at the WTSI. Assembly of the genomes, mapping of the 
reads onto the reference genomes and variant calling was performed by Dr 
Thomas Dan Otto of WTSI. This part of the work is mentioned only briefly here 
and only the work performed by me is detailed. A summary of basic algorithms 
used in generating a reference assembly, mapping and variant calling is 
presented in Table 2-1. 
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Figure 2-2. A flow diagram representing the major pipeline for whole genome sequencing, 
assembly, variant calling and analysis of mutations. The area shaded was performed at the 
WTSI. 
 
2.6.1  Preparation of DNA for whole genome   
  sequencing 
Naïve phenylhydrazine-treated mice were infected with stabilates from 
WT parental line 820cl1m1cl1cl2 (820) and the three natural GNP lines, namely 
m9w21d (m9), m7w32d (m7), and m8w52d (m8). The mice were sacrificed once 
the parasitemia reached approximately 10% and blood from each of the infected 
mice was filtered with Plasmodipur filters (EuroProxima B.V., The Netherlands) 
and grown up to schizonts into gassed flasks at 37 °C overnight in a shaking 
incubator before being harvested for isolation of DNA. The DNA was quantified 
Illumina / Solexa platform 
Assembly algorithms 
Mapping & variant calling 
Filtering 
DNA from 820 (HP) and GNPs 
Whole genome sequencing 
Reference assembly (820) Paired-end reads (GNPs) 
All mutations 
Refined mutations 
Analysis 
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on NanoDrop spectrophotometer (Fisher Scientific) and about 10 µg of the 
purified DNA from each of these lines shipped to WTSI under appropriate 
conditions for whole genome sequencing at WTSI.  
 
2.6.2  Illumina/Solexa whole genome sequencing and   
  assembly of the GNP and their WT isogenic  
  parental  lines  
 
This section was entirely performed by Dr Thomas Dan Otto and his group 
at the WTSI. All the de novo GNP isogenic lines (lines m7, m8 and m9) along with 
their common parental line (820cl1m1cl1cl2) were sequenced by whole genome 
sequencing on the Illumina/Solexa sequencing platform using paired-end reads. 
In addition to this, the pre-existing GNP line K173cl1 and line 233 along with its 
gametocyte producer parent, line 234, were also sequenced similarly. A 
summary of basic algorithms used in generating a reference assembly, mapping 
and variant calling is presented in Table 2-1. 
  
To sequence the clones 233, 820, m7, m8, and m9, libraries of 76 bp 
paired-end reads with an insert size range of 300-500 bp fragment length were 
generated following a PCR-free protocol (Quail et al., 2012). The libraries were 
sequenced using an Illumina Genome Analyser II with V4 chemistry.  
A de novo assembly of reads was generated from the 820 parental clone 
using Velvet assembler (Zerbino and Birney, 2008) version 1.0.12 and the 
following parameters: -exp_cov auto -min_contig_lgth 500 -cov_cutoff 10 -
ins_length 350 -min_pair_count 20. Four hundred and seventeen supercontigs 
with an N50 of 240 kb were obtained. The assembly was processed as described 
in the post-assembly genome-improvement toolkit protocol (Swain et al., 2012). 
In short, scaffolds were ordered with ABACAS (Assefa et al., 2009) against the P. 
berghei ANKA reference genomes (GeneDB, version July 2010). This resulted in 
16 pseudomolecules (14 chromosomes and 2 plastids) and a ‘bin’ of 100 contigs 
that could not be associated with a chromosome. Next, using scaffolds of at 
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least 1 kb as a substrate, IMAGE (Tsai et al., 2010) was used to close 469 (61 %) 
of the 774 sequencing gaps. Single base and small insertion or deletion (indel) 
errors were corrected using iCORN (Otto et al., 2010). This corrected 1067 
single-base errors and 92 indels. Altogether, 1589 positions had heterozygous 
calls, which represented collapsed repeats, mostly in BIR genes.  
Lastly, the annotation of the P. berghei ANKA reference genome was 
transferred onto the improved P. berghei 820 assembly using RATT (Otto et al., 
2011) assembly option. In total, 4821 of the 4938 gene models were transferred 
correctly to the new genome, 35 were partially transferred and 82 gene models 
could not be transferred which were mostly in the sub-telomeric regions. Ninety 
seven percent (97%) of the bases in the P. berghei reference genome were 
finally covered by the completed 820cl1m1cl1cl2 assembly (available on:  
ftp://ftp.sanger.ac.uk/pub/pathogens/Plasmodium/berghei/820/).  
2.6.3  Mapping and variant calling 
To call the variants, the software called SMALT (version 5.3; 
http://www.sanger.ac.uk/resources/software/smalt/) was used to map reads 
against the P. berghei ANKA reference and the generated 820 assembly. 
Variation was called with pileup and the varfilter (varFilter –D 2000; Quality >= 
60) options from the SAMtools package (Li et al., 2009). For the reads mapped 
onto the 820 assembly, the variation of each clone, and concordance with other 
clones was analysed using a PERL script. For the reads mapped onto the ANKA 
reference genome, the script ignored variants that were called in all m7-m9 
clones as well as 820, assuming them to be erroneous.  
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Table 2-1  
 
Tools What do they mean? Purpose 
Velvet De novo sequence assembler 
Creates the starting 
contigs from the reads 
ABACAS 
Algorithm Based Automatic 
Contiguation of Assembled Sequences 
Orders contigs against a 
reference sequence 
IMAGE 
Iterative Mapping & Asembly for Gap 
Elimination 
Identifies & closes gaps 
after contigs are ordered 
iCORN 
Iterative Correction Of Reference 
Nucleotides 
Improves base-calling at 
specific positions, corrects 
actual sequence of the 
consensus genome that is 
being created 
RATT Rapid Annotation and Transfer Tool 
Transfer of annotations 
from a reference onto a 
new consensus 
SMALT Sequence Mapping & Alignment Tool 
Maps reads against a 
reference 
SAM 
Tools 
Sequence Alignment & Mapping Calls sequence variants 
 
 
Table 2-1. A summary of basic algorithms used in generating a reference assembly, 
mapping and variant calling 
 
 
2.7  Parasite lines used in the study 
2.7.1  Lines used for assessing gametocytogenesis 
Cloned P. berghei parasite line PBANKA cl15cy1 820cl1m1cl1 (RMgm-164), 
a high gametocyte producer, was used as the parental line (Ponzi et al, 2009; 
Mair et al., 2010) for all genetic manipulations pertaining to understanding the 
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molecular basis of commitment to gametocytogenesis in malaria parasites. The 
line is transgenic for the production of RFP (in female gametocytes) and GFP (in 
male gametocytes) (Figure 2-3) and contains eGFP under the male gametocyte-
specific promoter of putative dynein heavy chain gene (PBANKA_041610) and 
3’UTR of putative calmodulin gene (PBANKA_101060) and RFP under the female 
gametocyte-specific promoter of an LCCL domain containing protein 
(PBANKA_131950) and 3’UTR of the transmission blocking target antigen 
precursor P48/45 (PBANKA_135960) at the p230p (PBANKA_030600) replacement 
locus on chromosome 3. Thus, male gametocytes appear green and female 
gametocytes appear red under appropriate channels in flow cytometry and 
fluorescence microscopy. The line was re-cloned by the limiting dilution method 
to generate two pure parental line clones. One, the re-cloned line (PBANKA 
820cl1m1cl1cl2) was used to infect a naïve Theiler’s Original mouse as a 
common source parental line. At this stage the line was not checked for the 
presence of the selectable marker cassette as the line had been supplied on the 
understanding that negative selection had already been applied to this line. 
 
 
Figure 2-3. A cartoon of the parental WT line PBANKA 820cl1m1cl1 locus showing the drug 
selection marker (SM) cassette and GFP/RFP expression cassette positioned immediately 
adjacent at the 230p locus (light blue) on chromosome 3. The SM cassette has dhfr (light 
brown) and yfcu (yellow) under control of pbeef1αa promoter (mentioned as eef; violet) and a 
pbdhfr 3’UTR (light grey). An extra copy of the pbdhfr 3’UTR is placed immediate upstream of the 
pbeef1αa promoter for SM recycling, if needed using negative selection. The GFP/RFP expression 
cassette has egfp (bright green) under the male gametocyte-specific promoter (putative dynein 
heavy chain gene; PBANKA_041610; light green) and the 3’UTR of putative calmodulin gene 
(PBANKA_101060; light blue; mentioned as 3’cam) together with rfp (red) under the female 
gametocyte-specific promoter (LCCL domain containing protein; PBANKA_131950; orange) and 
the 3’UTR of the transmission blocking target antigen precursor P48/45 (PBANKA_135960; light 
pink). 
 
2.7.2 Lines used as negative control 
The high gametocyte producer (HP) line of P. berghei ANKA was used as a 
negative control for fluorescence during FACS analysis and other experiments. In 
this line, the parasites stages are not labelled with any reporter proteins. Thus, 
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any positive fluorescent signal detected on FACS using P. berghei HP ANKA 
represented a background noise and hence was discounted from the relevant 
readings.  
2.7.3  Lines used for reference sequencing 
DNA from a number of related high gametocyte producer and low or pre-
existing gametocyte non-producer P. berghei lines were used for either whole 
genome re-sequencing or direct Sanger sequencing to detect any lineage-specific 
mutations. Mutations associated with the GNP phenotype in the isogenic 
successors of the parental 820 line were compared with mutations (if any) 
discovered in these reference lines. These lines included the line 234 (high 
gametocyte producer), and lines 233 and K173 (pre-existing GNP lines). 
  
 
 
 
 
 
 
 
 
 
 
 
 
3 Generation of de novo gametocyte non-
producer mutants 
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3.1  Introduction 
In Plasmodium berghei, during each of the asexual multiplication cycles, 
roughly between 10% and 20% of the asexually dividing parasites differentiate to 
the sexual precursors – the gametocytes (Janse and Waters, 1995). It is also well 
documented that Plasmodium parasites, otherwise producing an optimum 
number of gametocytes during their asexual replicative cycle in mammalian 
hosts, are known to spontaneously and irreversibly lose the ability to produce 
gametocytes under conditions of repetitive mechanical passages between their 
natural mammalian hosts in the absence of a vector (Micks, 1947; Janse et al., 
1989; Dearsly et al., 1990; Janse et al., 1992). In P. berghei, these gametocyte 
non-producer (GNP) mutants (or low gametocyte producer variants) could 
spontaneously arise from their high gametocyte producer parent line as a result 
of either unintentional prolonged continuous maintenance of these gametocyte 
producer parasite lines in mice without being exposed to mosquitoes, for 
example clone 1 of the K173 lineage (Vincke and Lips, 1948; Janse et al., 1989; 
Janse et al., 1992) and clone 233L derived from the parental clone 234L of the 
ANKA lineage (Killick-Kendrick, 1974; Dearsly et al., 1990); or as a planned and 
intended experimental outcome generating de novo GNP parasite lines (Micks, 
1947; Janse et al, 1992). Gametocyteless clones have also been generated in P. 
falciparum including clone C10 from isolate 1776 (Shirley et al., 1990; Day et 
al., 1993) and clones F12 and E4 from isolate 3D7 (Alano et al., 1995). 
Isogenic de novo GNP mutant lines are critical for forward genetics studies 
aimed at identifying the molecular basis of the resultant GNP phenotype. The 
underlying reason is straightforward – because the pre-existing GNP mutant lines 
remain an unknown number of generations apart from their gametocyte 
producing parents, and hence have the likelihood of acquiring and accumulating 
mutations over time. Any comparative mutational analysis between pre-existing 
GNP lines and their high gametocyte producer parent lines is expected to have a 
much higher noise to signal ratio in contrast to a similar analysis involving the de 
novo GNP lines and its high gametocyte producer parent lines. Although the rate 
of accumulation of mutations over time is low in Plasmodium, (1.7 x 10-9 and 4.6 
x 10-9 mutations per base pair per generation in the absence of drug pressure 
and for Atovaquone (ATQ)-resistant clones, respectively in P. falciparum 3D7), 
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any single accumulated mutation would tend to confound the findings of the 
actual result (Bopp et al., 2013). Thus, in the present study, attempts were 
made to generate 10 independent isogenic de novo GNP mutant lines from a 
single cloned high gametocyte producer parent line to provide enough statistical 
power so that any differences in the mutational profiles between the parent and 
GNP lines could be truly attributed to the differences in their phenotypic profile.   
3.2    Flow-cytometry (FACS) to monitor    
   gametocytemia 
  
Weekly monitoring of total parasitemia and gametocytemia was done by 
flow-cytometry (FACS) using 1-2 drops of peripheral blood from each of the ten 
isogenic passage lines. Gametocytemia was demonstrated in the presence of 
appropriate controls (Figure 3-1). A negative control for infection (Hoechst-
stained uninfected mouse blood), negative control for green and red fluorescent 
signals in presence of infection (Hoechst-stained blood from a non-fluorescent 
high gametocyte producer line infected mouse) and a positive control for green 
and red fluorescent signals in the presence of infection (Hoechst-stained blood 
from parental 820cl1m1cl1cl2 line) were included in all the FACS analyses. 
3.3  Asexual maintenance of ten isogenic lines  
Briefly, ten independent but parallel isogenic lines (all derived from a 
single cloned high gametocyte producer line 820cl1m1cl1cl2) were maintained 
asexually by repeated mechanical passage between mice in the absence of 
mosquito bites for ~52 weeks or the development of a gametocyte non-producer 
phenotype, whichever was earlier (See Material and Methods; section 2.1.1.3). 
Based on earlier experiments, (Janse et al, 1992), it was reasonable to expect 
that eventually by the end of the one year passage period, most, if not all, lines 
would have lost their capacity to produce gametocytes. 
However, in the current study, out of the 10 potential lines, only 3 
stopped producing gametocytes (lines 9, 7 and 8 - in that order) at the end of 
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the study period. The remaining seven were still producing a sub-optimal 
number of gametocytes (although at varied and reduced levels). 
 
Figure 3-1. Flow-cytometry (FACS) plots showing gametocytemia in the experimental 
controls. On the horizontal axis are shown the cells positive for Hoechst-33258 signals as 
detected in the VioBlue channel signifying the parasite infected RBCs. The vertical axis shows the 
GFP positive cells (male gametocytes; upper panel) and the RFP positive cells (female 
gametocytes; lower panel) as detected in the FITC-A and PE-A channels, respectively. No 
Hoechst-positive and GFP/RFP positive cells were detected for blood drawn from uninfected 
mouse (a) whereas significant Hoechst positive cells were observed for the HP infected mouse with 
no GFP/RFP positive cells (b) demonstrating that negative controls for Hoechst and GFP/RFP. The 
positive control (blood from mouse infected with WT parental line 820cl1m1cl1cl2; c) shows both 
the Hoechst positive cells (signifying the presence of infection) and the GFP/RFP positive cells 
(signifying the presence of male and female gametocytes at 0.36% and 0.51% of the total 
parasitemia, respectively).    
 
Although the experiment was planned for 52 weeks from the start of the 
first passage, further passages of the low gametocyte producer lines could be 
attempted in future by reactivating the weekly cryopreserved stabilates of the 
relevant lines.  
3.4  Growth kinetics among ten isogenic lines 
For each of the 10 parasite lines, growth of the parasites for each week in 
terms of total parasitemia (percentage of infected RBCs out of total RBCs) and 
gametocytemia (percentage of gametocytes out of total infected RBCs) as 
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detected by FACS was plotted along the 52-weeks period of asexual 
multiplication (passages). The figures (numbered 3-2 to 3-11) below show the 
kinetics of growth in each of the ten lines.  The total parasitemia is represented 
on the secondary Y-axis by the bold dark blue smooth line and the 
gametocytemia is represented along the primary Y-axis by bold grey smooth line. 
The gametocytemia was further subdivided into male gametocytemia (light blue 
smooth line) and female gametocytemia (pink smooth line) and is represented 
on the primary Y-axis. The X-axis shows the period of asexual multiplication 
(passage) in weeks.  
Each of the smooth lines is the best-fit polynomial regression line (order 
6) to the corresponding individual weekly observations joined by straight lines. 
In order to be able to detect very low number of gametocytes (even between 0% 
and 1% of the total parasitemia), the total parasitemia of all passaged lines was 
allowed to rise anywhere between 5% and 10%. However, during the initial phase 
of the experiment (initial 4-8 weeks), due to optimization of the protocol, total 
parasitemia for some of the lines could not be strictly maintained between the 
desired level of 5%-10% at passage and was a little lower than 5%  thus resulting 
in some difficulty in interpreting the gametocytemia during that period of study. 
None of the 10 parasite lines lost the ability to produce gametocytes during this 
initial experimental phase.  But beyond that period, the total parasitemia was 
stably maintained as desired. The weekly data for total parasitemia and 
gametocytemia are shown in Appendices (Tables A1-A10). 
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3.4.1 Kinetics of growth in line 1 
On average, the total parasitemia in line 1 was maintained between 5% 
and 10% barring week number 9 to 18, where it dipped to just below 4%. The 
gametocytemia showed the initial fluctuating phase (from week 1 to week 24) 
where it ranged between 10% and 20% at passage. This was followed by a 
declining phase where the gametocytemia declined to ~3% (from week 25 to 
week 34). The third phase in gametocytemia kinetics (week 35 to week 52) 
showed a fluctuation between 1% and 3% (which is strikingly at a lower value and 
within a narrower range as compared to the initial fluctuating phase in the 
gametocytemia kinetics in this line). The experiment was terminated after the 
parasites were passaged for 52 weeks as this was the planned end point of the 
experiment, should there be no time point where the gametocytemia was not 
detected (Figure 3-2). 
 
Figure 3-2. Parasitemia of the serially passaged line 1 at passage. 
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3.4.2 Kinetics of growth in line 2 
Line 2 was passaged for a total of 42 weeks only as there were 4 occasions 
during the experiment when the passage was not successful as no parasites could 
be detected in the passaged naïve mice. Also, except for the initial 8 weeks in 
the passage period, the total parasitemia was maintained at the planned level 
ranging between 5% and 10% at passage. The gametocytemia followed a similar 
3-phased trend as observed in line 1 but this was less prominent and within a 
narrower range than line 1. The first phase (high fluctuating gametocytemia; 
between 10% and 15%) lasted for the initial 17 weeks followed by a declining 
phase (week 18 to week 29) and finally a low fluctuating phase (week 30 to week 
47) when the gametocytemia ranged between 2% and 3% (Figure 3-3).   
 
 
 
Figure 3-3. Parasitemia of the serially passaged line 2 at passage. 
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3.4.3 Kinetics of growth in line 3 
Line 3 was maintained in asexual multiplication in mice for up to 53 
weeks. It was only once during the total passage period of 53 weeks that it was 
not possible to mechanically passage the parasites. The total parasitemia was 
between 3% and 5% between weeks 3 and 23 otherwise the parasitemia at 
passage was maintained between 5% and 10%. The fluctuations in gametocytemia 
were clearly evident as three visually distinct phases and hence the 
gametocytemia kinetics observed in this line was used as a prototype to explain 
the trend of gametocytemia over the total period of asexually multiplying 
parasites in the rest of the seven lines that were still gametocytes producers at 
the end of the experiment. For the initial 25 weeks, the gametocytemia 
fluctuated between 10% and 15% which was followed by a steady decline to ~1% 
over the next 14 weeks. From week 39 to week 53, the gametocytemia 
fluctuated at a lower (than initial) level and ranged between 1% and 2%, thus 
demarcating the lower fluctuating phase (Figure 3-4). 
 
 
Figure 3-4. Parasitemia of the serially passaged line 3 at passage. 
 
0
2
4
6
8
10
12
14
16
18
20
0
5
10
15
20
25
30
35
40
1 4 7 10 13 16 19 22 25 28 31 34 37 40 43 46 49 52
P
ar
as
it
e
m
ia
 (
%
) 
G
am
e
to
cy
te
m
ia
  (
%
 o
f 
p
ar
as
it
e
m
ia
) 
Period of Asexual Multiplication (Weeks) 
Line 3 Gams Males Females Total
Chapter 3 Generation of gametocyte non-producer mutants 138 
 
3.4.4 Kinetics of growth in line 4 
This line was maintained in asexual multiplication for a total of 51 weeks 
only as it was necessary to reactivate the line 6 times during the course of the 
experiment. It is for this reason that the total parasitemia could not be 
maintained between the desired level of 5% and 10% at passage for the first 33 
weeks. The gametocytemia showed a clear high fluctuating phase (between 9% 
and 16%) spanning the initial 31 weeks, followed by a declining phase where the 
gametocytemia declined to ~2% by week 38. The last phase was marked by a 
low(er) fluctuating gametocytemia for the remaining 13 weeks where it ranged 
from less than 1% to 2% (Figure 3-5). 
 
 
 
Figure 3-5. Parasitemia of the serially passaged line 4 at passage. 
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3.4.5 Kinetics of growth in line 5 
Line 5 could be passaged asexually for up to week 51 with but was 
reactivated from stabilate 7 times during this period. Barring the initial 15 
weeks, the average total parasitemia was maintained within the desired range of 
5% to 10% at passage. The fluctuations in the early fluctuating gametocytemia 
phase (initial 25 weeks) were quite prominent (ranging from ~7% to ~15%). The 
declining phase (week 26 to week 31) was followed by a rather stable low 
gametocytemia phase (week 32 to week 51) where the average fluctuations in 
gametocytemia could be barely appreciated. This is in sharp contrast to other 
low gametocyte producing lines generated in this study where this phase had 
fluctuating gametocytemia (but at a lower level than the early fluctuating 
phase) (Figure 3-6).   
 
 
 
Figure 3-6. Parasitemia of the serially passaged line 5 at passage. 
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3.4.6 Kinetics of growth in line 6 
This line could be passaged for the desired period of 53 weeks in total but 
with 3 reactivations from stabilates during the period. Similar to the other lines, 
the total parasitemia could not be maintained in the desired range of 5% to 10% 
at passage during the initial 18 weeks. The early fluctuating gametocytemia 
phase (up to initial 30 weeks) was unremarkable and so was the declining phase 
(week 31 to week 39). However, the late fluctuating gametocytemia phase 
(week 40 to week 53) was similar to that observed in line 5 in terms of the range 
of fluctuations in gametocytemia (Figure 3-7).   
 
 
Figure 3-7. Parasitemia of the serially passaged line 6 at passage. 
 
3.4.7 Kinetics of growth in line 7 
Line 7, along with lines 8 and 9 (see below) ended up being a gametocyte 
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asexual multiplication only for 33 weeks as it first demonstrated absence of 
gametocytes at week 28 and hence was only continued for further 5 weeks in 
order to confirm the phenotype. As observed with the other lines, the total 
parasitemia was below the desired lower level of 5% at passage for the initial 10 
weeks. The total parasitemia was deliberately raised to beyond 10% during the 
last 2 weeks of passage to allow the detection, if any, of even the minimal 
proportion of gametocytes that could have been present. The early fluctuating 
gametocytemia phase (first 17 weeks) was unremarkable. However, the 
declining gametocytemia phase (week 18 to week 27) was remarkable in sharp 
contrast to the other lines which still showed gametocytes (although at a sub-
optimal level) at the end of the period of asexual passages – instead of 
terminating as a low fluctuating gametocytemia phase, the decline in 
gametocytes continued until a point (week 28) where no gametocytes could be 
detected. This marked the first evidence of a loss of gametocytogenesis and 
hence was monitored for a further period of 5 weeks. At the end of 32 weekly 
passages, this line was finally categorised as a GNP line (Figure 3-8). 
 
Figure 3-8. Parasitemia of the serially passaged line 7 at passage. The coloured transparent 
rectangles (pink, blue and green) indicate different phases of the gametocytemia kinetics in the 
line. The tails (pink and blue) observed for gametocytemia after passage week 31 is due to the 
smoothed polynomial being fitted for the kinetics and do not represent actual gametocytemia.  
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3.4.8 Kinetics of growth in line 8 
Other than the initial 14 weeks of passage, line 8 was maintained in 
asexual reproduction with a total parasitemia between 5% and 10% at passage. 
The line was passaged for 53 weeks with 5 intermediate reactivations from 
stabilates. In terms of gametocytemia kinetics, this line is unique to the other 
lines included in this experiment in terms of (a) it ultimately ended as being a 
gametocyte non-producer line and, more intriguingly, (b) was inconspicuous  for 
the distinct gametocytemia phases during the passage period. The polynomial 
trend of gametocytemia declined steadily from week 7 of the weekly passages 
and continued to decline to no gametocytemia level, without being interrupted 
by low gametocytemia  fluctuations (as observed in the other 9 lines) (Figure 2-
30) . This atypical trend observed could have implications for understanding the 
way the whole process of gametocytogenesis is controlled and regulated (see 
proposed models later) (Figure 3-9). 
 
 
Figure 3-9. Parasitemia of the serially passaged line 8 at passage. The tails (pink and blue) 
observed for gametocytemia after passage week 52 is due to the smoothed polynomial being fitted 
for the kinetics and do not represent actual gametocytemia.   
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3.4.9 Kinetics of growth in line 9 
Line 9 was the first line to lose the capacity to form gametocytes 
happening as early as week 18 of the continuous weekly passages. The total 
parasitemia in this line was never maintained within the desired range and was 
~4% at passage for the majority of the experiment. The gametocytemia kinetics 
were not much different to that observed in line 8 (other than the initial 
fluctuations up to week 10) in terms of both the final end result as well as the 
absence of the late fluctuations in the gametocytemia levels. The first evidence 
of loss of gametocytogenesis was observed at week 18 and hence the line was 
only followed for a further 4 weeks. Line 9 mouse-to-mouse passage was 
interrupted 5 times during its passage period where it involved reactivation of 
the line with the help of the cryopreserved stabilates of the most recent passage 
(Figure 3-10).   
 
Figure 3-10. Parasitemia of the serially passaged line 9 at passage. The tails (pink and blue) 
observed for gametocytemia after passage week 20 is due to the smoothed polynomial being fitted 
for the kinetics and do not represent actual gametocytemia. 
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3.4.10  Kinetics of growth in line 10 
Line 10 was passaged for a total of 53 weeks but was recovered 3 times 
from the stabilates during this passage period. The total parasitemia was 
maintained within the desired range – between 5% and 10% at passage for most 
of the passage period except the initial 13 weeks, as in most of the lines. The 
gametocytemia followed the typical trend of three visually distinct phases – 
optimal fluctuating gametocytes (between 5% and 10%; up to week 26), declining 
gametocytes (week 27 to 35) and sub-optimal fluctuating gametocytes (between 
1% and 3%; week 36 to 53) (Figure 3-11).  
 
Figure 3-11. Parasitemia of the serially passaged line 10 at passage. 
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3.5  Lines 9, 7 and 8 did not produce 
 gametocytes 
As evident from the parasitemias and gametocytemia of the serially 
passaged lines in figures 3-3 to 3-12 above, the gametocytemia declined in all 
the ten lines studied but reached to zero in only three lines (Figure 3-12).  
 
Figure 3-12. Gametocytemia of the ten serially passaged lines at passage. Each of the 
coloured smooth lines is the best-fit polynomial regression line (order 6) to the corresponding 
individual weekly observations (not shown here due to clarity of the figure). As evident, the 
gametocytemia declined in all the ten lines studied but reached to zero only in lines 9,7 and 8 in 
that chronological order. 
 
Thus, lines 9, 7 and 8 evolved a gametocyte non-producer phenotype (in 
that chronological order) on week 21, 32 and 52, respectively. The absence of 
gametocytes in these GNP lines was ascertained by:  
3.5.1 Giemsa-stained peripheral blood smears 
No gametocytes were detected on Giemsa-stained smears (out of the 1500 
parasites examined per line) from lines 7, 8 and 9 throughout the 4-week period 
starting from the point where absence of gametocytes was first detected by 
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FACS. This was in contrast to 142 gametocytes observed in the WT parental line 
820 (data not shown). 
3.5.2 Flow cytometry analyses 
Absence of gametocytogenesis was also established by flow cytometry 
(FACS) based on the absence of red and green fluorescent signals for female and 
male gametocytes, respectively for at least four consecutive weekly passages 
after the absence of fluorescent signals was first detected by FACS. The absence 
of gametocytes was demonstrated in the presence of appropriate controls 
(Figure 3-1). The first line to lose gametocytogenesis was line 9, stopping to 
produce gametocytes at week 21 of the repeated passages. The next in the 
chronology was line 7 which lost gametocytogenesis at week 32 and the last line 
to become a GNP was line 8 which was conclusively shown by FACS to stop 
gametocytogenesis at week 52 of the continuous asexual growth. The initial and 
final gametocytemia of the three GNP lines is shown in Figure 3-13. The FACS 
observations together with that from Giemsa-stained peripheral smears confirm 
the absence of any detectable gametocytes in all the three de novo GNP lines 
generated in this study. 
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Figure 3-13. FACS analysis of Hoechst-stained blood from each of the de novo GNP lines as 
they arose – line 9, line 7 and line 8. X-axis: Hoechst signals as detected in the VioBlue channel; 
Y-axis: GFP signals as detected in the FITC-A channel (upper) & RFP signals as detected in the 
PE-A channel (lower plots). The gametocytes are gated (red rectangle) in each plot. A comparative 
male and female gametocytemia (%), GFP and RFP signals, respectively, is shown between the 
values at the start of the experiment/passage (week 1; a) and at the confirmation of their GNP 
status (weeks 21, 34 and 53 for line 9, line 7 and line 8, respectively; b). As clearly seen, these 
FACS findings confirm the absence of any detectable gametocytemia in each of the GNP lines (as 
compared to the controls depicted in Figure 3-1).   
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3.5.3 Exflagellation assays 
The evidence for loss of gametocytogenesis was further supported by the 
exflagellation assays which detect the presence of exflagellation occurring in 
functional male gametocytes and is measured by the formation of exflagellation 
centres or EC’s. No ECs per 104 red blood cells were observed for the GNP lines 
in comparison to 34.85 ECs in the WT parental line 820 (gametocyte producer 
line) which served as controls (Figure 3-14).  
3.5.4 Ookinete cultures 
To further support the loss of gametocytogenesis in the three de novo 
GNP lines, overnight ookinete cultures (which assess the capacity of male and 
female gametocytes to fertilize and form zygotes which further develop to form 
ookinetes) were set up. The results show no observable ookinetes per 20 fields 
examined under Giemsa-stained smears from overnight ookinete cultures for 
each of the GNP lines studied in comparison to 19 ookinetes in the WT parental 
line 820 (gametocyte producer line) which served as positive control (Figure 3-
14).  
 
Figure 3-14. Multiple bar chart demonstrating the absence of any detectable Exflagellation 
Centres & ookinetes. ECs are expressed as number per 10
4
 RBCs examined under a light 
microscope and ookinetes as number of ookinetes per 20 fields examined in Giemsa-stained 
smears in all the de novo GNP lines generated in the study (n=3). This is in comparison to the WT 
line 820 for which an average 34.85 EC’s were observed per 10
4
 red blood cells examined and 19 
ookinetes per 20 fields examined. The error bars denote ± 2 standard error around the mean. 
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3.5.5 Transmission through mosquitoes 
As final conclusive evidence of the absence of any functional gametocytes 
in the GNP mutants, all the de novo GNP lines after negative selection and 
cloning (and the parental 820 line as a separate positive control) were passaged 
from the GNP-line infected mouse through mosquitoes and then back to a naïve 
mouse (mosquito transmission and bite-back experiments) to complete one 
parasite life-cycle. None of the mice from the bite-back experiment showed any 
parasites indicating that there were no gametocytes in the GNP lines when fed 
to the mosquitoes and hence no subsequent development of infection of the 
mosquitoes (Figure 3-15).  
 
 
Figure 3-15. Development of parasitemia from the mosquito bite-back (transmission) 
experiment in all the de novo GNP lines generated in the study in comparison to the WT line 
820 as a positive control. Clearly evident, the GNP parasites never grew in the mosquitoes as 
they totally lacked the sexual stages necessary to develop in the mosquito and maintain the life 
cycle of the parasite. 
     
3.6  Characterization of the de novo GNP 
 mutants 
3.6.1 Asexual growth advantage 
Asexual growth of the de novo generated GNP parasites appeared to be 
faster as compared to the parental gametocyte producer line and the 
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descendent “low” gametocyte producer lines. This was finally confirmed by 
mixing cloned and negatively selected GNP line 9 constitutively expressing CFP 
in a 1:1 ratio with wild type (PBANKA HP) producer line constitutively expressing 
RFP (Sinha et al., 2014; data not shown). Parasites were monitored daily by flow 
cytometry and after gating for infected cells the % of the population expressing 
either RFP (red), CFP (blue) or both (purple) reflecting mixed-multiply infected 
cells was calculated. The GNP parasites almost completely replaced the WT 
counterparts by day 11 post infection. These observations convincingly 
supported the hypothesis that the GNP phenotype offered a distinct growth 
advantage over their producer and “low” producer counterparts which helped 
the GNP population to eventually overgrow and replace the gametocyte 
producer parasites (see also the section 3.7 on mathematical modelling below). 
3.6.2 Sexual growth 
Further proof for loss of gametocytogenesis was established through 
examination of transcripts of the sexual-stage specific gene, P28, in the GNP 
lines using Reverse Transcriptase PCR (RT-PCR; Figure 3-16) and subsequently by 
northern analysis (Figure 3-17). The results showed no P28 transcripts in all the 
generated GNP lines as compared to their isogenic wild type ancestor line 820. 
These findings in all the de novo GNP lines strongly support the absence of 
gametocytogenesis in malaria parasites.   
3.6.2.1 Absence of P28 transcripts on RT-PCR 
Presence of any sexual stage-specific transcripts for P28 was ruled out 
using reverse-transcriptase PCR (RT-PCR). Briefly, ~4 µg of purified DNAse 
treated total RNA from the WT parental line 820 and the three isogenic de novo 
GNP lines was subjected to RT-PCR (Section 2.2.6 of Materials & Methods).  
The efficiency of the RT reaction (and hence contamination of the cDNA 
with the gDNA, if any) was tested by amplifying the constitutive ALBA3 from all 
lines tested using primer sets GU515/GU516. Since ALBA3 gDNA has an intron, its 
PCR amplification after RT reaction allowed the differentiation between 
amplicons from gDNA and cDNA on the basis of difference in expected sizes: 0.64 
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kb for gDNA and 0.32 kb for cDNA. The RT reaction yielded pure cDNA 
(uncontaminated with any gDNA) as evidenced by the presence of the smaller 
0.32 kb band and absence of the gDNA band in ALBA3 RT-PCR amplicons (cDNA). 
Absence of the sexual stage specific P28 cDNA band in the RT-PCR analyses from 
all  three isogenic de novo GNP lines (in presence of the P28 band in gDNA and 
cDNA from WT 820 line) further corroborated the findings of the northern 
analyses, strongly indicating an absence of sexual stages in the three de novo 
GNP lines. No bands in the –RT reactions ruled out the presence of any gDNA 
contamination in the samples (Figure 3-16). 
 
 
 
 
 
  
Figure 3-16. Agarose gel electrophoresis pictures showing the amplified bands from RT-
PCR reactions of P. berghei ALBA3 (constitutive) and P. berghei P28 (sexual stage-specific). 
(a) shows the ALBA3 gDNA and ALBA3 cDNA (RT-PCR products) from the WT parental line 820 
and the three isogenic de novo GNP lines to assess the efficiency of the reverse transcriptase 
reaction in terms of gDNA contamination of cDNA. Since the alba3 gene (0.6 kb) contains an intron 
(0.3 kb) which reflects in the length of the alba3 cDNA (0.3kb) thus providing a basis of detecting 
the gDNA (0.6 kb band) contamination of the cDNA. Absence of any 0.6 kb bands in all the 
samples rules out the possibility of the presence of any gDNA in the RT-PCR products. Sexual 
stage-specific P28 was reverse-transcribed and PCR-amplified from the WT line 820 and all the 
three isogenic de novo GNP lines (b). Presence of P28 gDNA bands in all the lines and P28 cDNA 
only in the parental WT 820 line together with the similar findings from the northern analyses 
strongly establishes the absence of any expression of sexual stage-specific prototype P28 from all 
the three isogenic de novo GNP lines thus documenting confirmed absence of sexual stages in the 
GNP lines – 7, 8 and 9.  
 
 
3.6.2.2 Absence of P28 transcripts on northern analysis 
After ruling out the presence of any sexual stage forms of the parasite in 
all the de novo GNP mutants, the formation of sexual stage specific transcript 
0.65kb 
 Marker 
820 
0.6kb 
0.3kb 
(a) (b) 
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(P28) was also examined using the northern blot technique. Briefly, 
approximately 5 µg of RNA sample for each of the WT parental line 820 and the 
three GNP mutants was used for the analysis (for details see Section 2.2.7 of 
Materials & Methods). The absence of P28 signals from all the de novo GNP 
mutants is consistent with the absence of mature sexual stages in these lines 
(Figure 3-17). 
 
Figure 3-17. Northern blot of total RNA from lines 820 (WT line) and the three naturally 
acquired de novo isogenic GNP lines – line 7, line 8 and line 9. The blot was probed for sexual 
stage specific transcripts with 
32
P labelled P28 dsDNA (~1.5 kb band in WT line 820 and no bands 
in the naturally acquired de novo GNP lines) and normalized with HSP70 probe (PBANKA_071190; 
~3 kb band in all lines). The absence of P28 signal from the all the de novo generated lines is 
highly suggestive of absence of sexual stages in the GNP lines. (Note: the original blot had three 
extra lanes for showing the absence of P28 signals in the three implicated gene knockout length 
variant lines after the lane for the GNP line 9; the same have been cropped out of the image (and 
shown elsewhere in Chapter 5, Figure 5-8) and the rest of the image merged to allow for the 
continuity of chapter and better understanding of the results discussed here). 
 
 
3.6.3 Confirmation of the presence of the GFP/RFP 
 expression cassette in the de novo GNP 
 mutants 
To rule out the possibility that the GFP/RFP expression cassette was 
neither deleted (in part or total) from the parasite genome, structurally re-
arranged in the genome or had become non-functional during the period of 
asexual multiplication thus giving rise to a false positive indication of loss of 
gametocytogenesis on FACS, the presence of full-length GFP and RFP expression 
HSP70 band 
P28 band 
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cassette in the original position (p230p locus of chromosome 3) was established 
by PCR in addition to the physical checks for the production of competent 
gametocytes that have already been detailed above. Evidence of the presence of 
GFP/RFP expression cassette was also sought from the whole genome re-
sequencing data which also suggested the retention of the expression cassette in 
the GNP mutants, thus confirming that the FACS findings and biological 
observations were, in fact, correct. 
3.6.3.1 PCR confirmation of the expression cassette 
PCRs were carried out to amplify and thus confirm the presence of full 
length GFP and RFP open reading frames along with amplification of the 3’ 
integration PCR product using appropriate oligonucleotide pairs (Table 3-1 and 
Figure 3-18a). The presence of appropriately sized bands for GFP and RFP 
(Figure 3-18b) indicates the presence of unaltered GFP/RFP expression cassette 
in the original genomic locus (p230p locus of chromosome 3). 
Table 3-1 
Oligo set Details 
Expected band size with DNA (kb) 
Ta 
(°C) 
Ext. 
Time 
(min) 
820 GNP7-9 Water HP 
1034/1032 GFP 0.66 0.66 -- NA 53 5 
1030/1031 RFP 0.68 0.68 -- NA 53 5 
1030/1029 3’ Integration Check 2.61 2.61 -- NA 53 5 
13/14 Control (HP) NA NA NA 0.6 53 5 
Table 3-1. Basic PCR reaction settings for amplifying various regions of and around the 
GFP/RFP expression cassette at the 230p genomic locus to identify the presence of the expression 
cassette in the genome of the GNP lines. 
 
 
(a) 
Figure 3-18 (a). Schematic (not to scale) showing the genomic 230p locus (blue thin bars) on 
P. berghei chromosome 3.  Also shown is the presence of a positive-negative drug selection 
marker cassette (aqua coloured thick bar) and GFP/RFP expression cassette containing e-GFP 
gene (green thick bar) driven by a 5’male-specific promoter of dynein heavy chain (olive green thick 
bar) and 3’ UTR of Pb calmodulin gene (purple thick bar). The RFP (red thick bar) is under a 5’ 
female-specific promoter of ccp2 (light red thick bar) and p48/45 3’UTR (light orange thick bar). The 
primer sets used for amplifying and the expected sizes of the amplicons for the regions “a” (forward 
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and reverse from eGFP), “b” (forward and reverse from RFP) and “c” (forward from RFP and 
reverse from outside the 230p locus) include GU1034/GU1032 (0.66 kb), GU1030/GU1031 (0.68 
kb) and GU1030/GU1029 (2.61 kb), respectively. 
 
(b) 
Figure 3-18 (b). PCR showing the amplification of appropriate sized bands for the WT line 820 and 
the GNP lines 7, 8 and 9 denoting that the GFP/RFP expression cassette is retained in place by all 
the natural GNP mutants generated de novo in this study. 
 
This further implies that the absence of GFP/RFP signals for the GNP lines 
7, 8 and 9 as reported by FACS was real and not simply due to alteration and/or 
absence of the expression cassette itself and thus indicates non-production of 
gametocytes. 
3.6.3.2 Evidence from whole genome re-sequencing data 
 
Re-sequencing the GNP lines and mapping on the gametocyte producer 
ancestor lines presented a specific problem. Line 820cl1m1cl1cl2 (cloned, parent 
line of the GNP mutants) was initially mapped onto the reference line ANKA 
which does not possess the GFP/RFP expression cassette and thus the cassette 
was assembled in fragments on chromosome 3 and places elsewhere 
(chromosomes 4, 7, 10, 11, 13 and bin) as expected due to mapping on to the 
promoters used to drive the GFP/RFP expression. So when the GNP lines were 
sequenced and mapped on to 820, the same observations regarding the presence 
of the cassette were made.  
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3.6.4  Selectable Marker Cassette and de novo GNP mutants 
After the experiment to de novo generate the isogenic gametocyte non-
producer mutants from the parental 820 line was mid-way through, in an 
independent experiment, the growth kinetics of the parental 820 line 
(820cl1m1cl1cl2) under pyrimethamine selection (see Section 2.1.5 of Materials 
and Methods) suggested that the parasites were in fact resistant to the drug 
(Figure 3-19). The WT parental line 820 and a non-fluorescent labelled and non-
drug selectable marker bearing line HP (as negative control) were grown under 
pyrimethamine drug pressure from day 0 of the infections. As evident from the 
figure, the parasites grew normally in the WT line 820 as these were supposed to 
be resistant to the drug in contrast to the HP infection which were controlled by 
the drug. This strongly suggested that the WT line 820 still possessed the dhfr 
gene in the drug selectable marker cassette (SMC; despite indication that a 
round of negative selection was previously applied to recycle the SMC).  
This was further confirmed when the drug 5-FC (1 mg per mouse per day; 
intra-peritoneally) was added to the WT line 820 regime from day 3 post-
infection. The retention of the drug SMC (a positive-negative SMC) would confer 
sensitivity to the lethal drug 5-FC through yfcu – the rapid decline in parasitemia 
following 5-FC administration supported the presence of the drug SMC in the WT 
parental line 820. The absence of sensitivity to 5-FC in the HP line (which does 
not possess the SMC) was also demonstrated by growing the new line HP in 
presence of the drug 5-FC – the parasites grew normally signifying the absence of 
the SMC.  
Thus the experiment implied that the WT parental line 820cl1m1cl1cl2 
still possessed the positive-negative SM cassette integrated into the genome 
suggesting that the SMC was not recycled after a round of negative selection. 
This was later confirmed by PCR analysis. Since the de novo GNP lines 9, 7, and 8 
were isogenically derived from the WT parental line 820, these GNP lines were 
also suspected to still possess the drug SMC. This  implied that any further 
genetic manipulation of these GNP lines would not be effective in the future as 
the SMC was not recycled, thus demanding a negative selection on these lines 
followed by cloning. 
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Figure 3-19. Drug assay showing the retention of the SMC. The assay involved growing the WT 
parental line 820 and non-fluorescent high gametocyte producer line HP under pyrimethamine 
selection in drinking water and 5-FC selection intraperitoneally to show the retention of the positive-
negative drug SMC in the 820 genome. Pyrimethamine (oral) was started from day0 to both WT 
parental line 820 and HP. 5-FC (i.p.) was added to the WT parental line 820 on day3. 
Independently, 5-FC was also administered to the HP line alone. The kinetics of all the lines 
strongly suggested the retention of the drug SMC by the WT parental line 820 and thus also by all 
three de novo GNP lines derived from 820. 
 
3.6.4.1 Removal of the drug selectable marker cassette (SMC) 
from the GNP lines 
 
In order to be able to perform any subsequent complementation 
experiments on the GNP lines, the SM cassette must be eliminated from the 
genome of the GNPs. Because of the relative paucity of sufficient number of 
drug selectable markers for Plasmodium genetic manipulations (Ganesan et al., 
2011; Lin et al., 2011), SM recycling provides an alternative way to reuse the 
same/limited drug selective markers for any number of successive experiments 
requiring these drugs to select the mutants (Braks et al., 2006; Maier et al., 
2006; Orr et al., 2012). This was  achieved by putting these lines on the drug 5-
FC (Negative selection; 1.5 mg/ml) added to drinking water and administered for 
a period of approximately 8-10 days, depending upon the experiments. A 
schematic showing the negative selection based removal of the drug SMC from 
the GNP mutants is shown in Figure 3-20. 
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Figure 3-20. A schematic (not-to-scale) of the P. berghei 230p locus before (a) and after (b) 
negative selection process using 1.5 mg/ml of the drug 5-FC in drinking water. Also shown is 
the position of the oligonucleotide pair (GU1028; GU0918) used for amplifying the full length of the 
SMC in the GNP mutants alongside the WT line 820. 
 
Negative selection of the GNP line 7 produced 4 negatively selected lines 
from GNP m7 and hence they are called m7m1 to m7m4. Similarly, GNP line 8 & 
GNP line 9 produced 2 negatively selected lines, namely m8m1-2 and m9m1-2.   
3.6.4.2 Cloning of the negatively selected GNP lines 
 
Having removed the SM cassette (SMC) from the GNP genomes through 
marker recycling under negative selection, these SM-minus GNP lines 
(particularly m7m4, m8m1 and m9m1 were cloned by the limiting dilution 
method. It was necessary to clone the negatively selected line before 
attempting any further genetic manipulations on the line. This is of paramount 
importance when the intended planned experiment is complementation to 
restore the gametocyte producer WT phenotype.  
 
The three independent cloning experiments resulted in two PCR-
confirmed clones each from GNP7 (m7m4cl1-2), GNP8 (m8m1cl1-2) and GNP9 
(m9m1cl1-2) as shown in Figure 3-21. Equal amount of purified DNA (~100 ng) 
from each line was used for the PCR conformation using the oligonucleotide pair 
(GU1028/GU0918; Figure 3-20) for amplifying through the full length of the SMC 
in the GNP mutants before and after negative selections (pre-NS and post-NS, 
Recombinogenic locus 
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respectively) alongside the WT line 820. The expected band-size for pre-NS lines 
was 4.1 kb and for the post-NS cloned lines was 1.3 kb.  
 
 
 
Figure 3-21. Agarose gel electrophoresis of the PCR-amplified DNA before and after 
negative selection. Pre-negative selection (pre-NS) and post-negative selection (post-NS; cloned 
and uncloned) for SMC recycling was applied on the WT line 820 and GNP lines 7, 8 and 9 using 
the oligos GU1028/GU0918. Expected band size of 4.1 kb was observed for all the pre-NS 
samples signifying the presence of the SM cassette. A desired band of 1.3 kb on the all the post-
NS samples suggests the elimination of the SM cassette from the GNP lines. 
 
 
3.7  Evidence from mathematical modelling of 
 the kinetics 
Mathematical modelling (interim analyses) of the kinetics of parasitemia 
and gametocytemia in all the ten isogenic lines was performed by Dr Mathew 
Denwood and Prof Dan Haydon, University of Glasgow. Although the dataset 
given was complex, the main parameter that was included was the change in 
gametocytemia (percent) over time as a function of repeated mechanical 
passages through mice. 
  
3.7.1 The distribution of the data for the controls 
The available data for the controls (representing the background noise) 
closely followed a normal distribution after logistic transformation of the data 
which was done in accordance with the exponential pattern of parasite growth. 
The mean background noise was estimated to be approximately 3 false positive 
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cells per 1000 cells examined with a standard deviation ranging between 0.8 and 
1.7 (Figure 3-22).   
 
Figure 3-22: Plotting of the raw data after a logistic transformation in the ten isogenic lines. 
The data also revealed a linear trend for most mouse lines, which is reassuring (see graph above – 
days are shown in different colours & the 'random noise' baseline is shown dashed). The overall 
picture strongly suggested overall decreasing gametocytemia kinetics in all the lines. In the 
eventual GNP lines, GNP lines 7, 8 & 9, the lines representing the gametocyte kinetics crosses and 
dips below the ‘random noise’ baseline. 
 
 
3.7.2 Sex Ratio  
It was found from the data that the proportion of female gametocytes was 
consistently lower than the male counterparts for all ten lines (Figure 3-23). In 
general, female biased sex ratios are seen in Plasmodium in nature (Read et al., 
1992, 2002; Robert et al., 1996; Sowumni et al; 2008; West et al, 2001), but 
nevertheless, neutral and male biased sex ratios have also been observed (Read 
et al., 1992 and 2002; Robert et al., 1996). Briefly, sex ratios in Plasmodium are 
very dynamic and may involve a range including female- and male-biased ratios 
(Teboh-Ewungkem and Wang, 2013). Although P. berghei follow the same 
principles of sex ratio as any other Plasmodium, a male biased sex ratio has been 
observed after phenylhydrazine treatment of the mouse (Chris Janse, 
Unpublished observations, Leiden University Medical Centre). Relatively lower 
females may also be due to weaker expression/detection of RFP in comparison 
to GFP. 
Line 1 Line 2 Line 3 Line 5 Line 4 
Line 6 Line 7 Line 8 Line 9 Line 10 
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Figure 3-23: Statistically modelled female (vertical axis) and male (horizontal axis) 
gametocyte kinetics of the ten isogenic lines. The proportion of female gametocytes (red 
straight line) almost always appeared to be lower than their male counterparts (black straight line). 
The variance around the proportion of female gametocyte (red dashed lines) was also always 
below the black line for males. 
 
3.7.3 Predicting post-mutational timescale changes 
 in parasite population within a mouse 
The available data was also be used to predict the time needed for the 
gametocytemia to drop to zero following the generation of a GNP mutation in a 
single parasite. For example, if such a GNP conferring mutation arose in an 
individual parasite reducing gametocyte (%) production from 11% (the average at 
week 1 of the study) to 0%, the time the mutated parasite would take to 
increase from one to 7000 (this number is based on the average parasitemia at 
week 1 corrected for the circulating blood volume of the mouse) would be 
approximately 150 days (Figure 3-24), assuming that: 
(1) An asexual parasite takes 24 hours to produce daughter cells 
(2) An average of 16 daughter cells per parent is produced 
(3) There is no competitive advantage incurred from the genetic mutation 
except that which is directly attributable to the reduction in gametocyte 
production (i.e. death rates and division time remain the same) 
 
Line 1 Line 2 Line 3 Line 4 Line 5 
Line 6 Line 7 Line 8 Line 9 Line 10 
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Figure 3-24. Change in gametocytemia kinetics due to the presence of even one parasite 
harbouring the GNP mutation. The upper graph displays the raw (untransformed) data whereas 
the bottom graph shows that the proportion of parasites with the mutation (red) increases linearly 
on the logistic scale, but this is manifest as a long lag period before an appreciable change 
(decrease) in the average gametocyte production of the overall parasite population (blue). Also 
shown are the approximate number of days for the total gametocytemia to reach the 0% level as 
the GNP-mutation bearing parasite population grows from 0% to 100%.   
 
In addition to the estimate for the time needed for a single GNP 
genetically coded parasite to overgrow and fully replace the gametocyte 
producing WT parasites, independent growth competition assays involving a mix 
of GNP and WT population demonstrated the growth advantage offered by the 
GNP parasites to overgrow and eventually replace their WT counterparts (Sinha 
et al., 2014; data not shown). 
 
3.7.4  Variance Partitioning 
Analysis of between sample variability was highly convincing not only in 
terms of the level of confidence that could be placed in a single observed 
gametocyte (%) observation but also for planning future similar studies with 
optimum efficiency. Conceptually, the variation in the study can be partitioned 
into the following (Figure 3-25): 
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-  Between mice variability: Variation between samples taken from different 
mice infected with the same parasite  
-  Between days variability: Variation between blood samples taken (over a 
short time period) from the same mouse [There was no evidence that these 
are anything other than random over a period of 5 days] 
-  Within days’ variability: Variation between 100μl sub-samples taken from 
the same blood sample 
-  Variation due to the Binomial distribution (counting error) and random 
'noise' of the lab process 
 
 
 
Figure 3-25. Boxplots showing the different possible sources of variability within the 
experimental setting. As seen, the variability between mice, although based on a single 
observation, is very low as compared to the variability within days of experiment (variation between 
sub-samples from the same blood) and variability between days but within mice (blood samples 
taken over few days from the same mouse) which was the greatest. 
 
 
The above analyses on variation suggested that the variation between 
days appeared to be greater than that within days but the variation between 
mice may not be more than that between samples from the same mouse 
(Denwood et al., 2012). Although it would not be statistically appropriate to 
place too much confidence in the single observation, it could be inferred that 
variation between mice did not contribute a substantial amount of variation. 
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3.8  Summary and discussion 
Generation of at least one de novo gametocyte non-producer (GNP) line 
(out of the potential ten passaged lines) from the cloned high gametocyte 
producer line 820 was the first major objective of the study. Within the period 
of approximately one year, ten parallel but independent lines (line 1 to 10) 
derived from a common ancestral line (PBANKA 820cl1m1cl1cl2) were serially 
passaged from one mouse to another until the end of the study period or 
development of a GNP phenotype, whichever was earlier. At the end of the 
study period, 3 out of 10 potential lines turned out to be GNP lines on flow 
cytometry and Giemsa-stained smear examination.  
These de novo GNP lines were later confirmed for absence of viable 
gametocytes directly by in vitro (exflagellation assay and ookinete counts) and 
in vivo (passaging through mosquitoes) experiments and indirectly by showing 
absence of sexual stage specific transcript of P28 (Northern and RT-PCR 
analyses). Upon confirmation, these de novo GNP lines were subsequently 
negatively selected, cloned and cryopreserved for further characterizations. A 
brief summary of details of passages involving each of the 10 lines is shown in 
the following table (Table 3-2). The rest of the passaged lines were 
characterised as low gametocyte producers at the end of the study period. 
These lines remain intriguing in terms of the revelations of genotypic changes 
associated with the phenotypic transition from high gametocyte production to no 
gametocyte production.   
In general and simply by visual inspection, the gametocytemia trend could 
be broadly categorised following a three phase pattern over the study period of 
~52 weeks in all the isogenic serially passaged lines, barring the GNP line 8 
which showed  somewhat different kinetics (exemplified by the kinetics in the 
GNP line 3; Figure 3-26a). For all the other lines, the gametocytemia fluctuated 
between 7% and 17% initially during the first half of the total weekly passage 
period (herein termed as the normal fluctuating phase). The second phase of 
gametocytemia trend could be inferred as the gradual declining phase where the 
percentage of gametocytes gradually declined over the next 10 week period to 
~3%. The first two phases were almost similar in all the lines (except line 8) but 
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the third phase differed for most lines between those that ultimately became 
GNP and those that remained (low) gametocyte producers after ~52 weeks of 
mechanical passage. 
Table 3-2 
Line 
Total number of 
weekly passages 
Number of times reactivated 
from stabilates 
End point 
End-point 
phenotype 
1 52 4 End of study Low producer 
2 47 5 End of study Low producer 
3 53 1 End of study Low producer 
4 51 6 End of study Low producer 
5 50 7 End of study Low producer 
6 53 3 End of study Low producer 
7 32 5 GNP GNP 
8 53 5 GNP GNP 
9 21 5 GNP GNP 
10 53 3 End of study Low producer 
 
Table 3-2. Summary of weekly passages of the ten isogenic lineages derived from the 
common WT ancestor line 820. Clearly evident is the generation of three GNP lines at the end of 
the study period (lines 7-9). These lines had phenotypically confirmed GNP status each at weeks 
32, 21 and 53 of the serial passages. Lines 1, 3, 6 and 10 were passaged for at least 52 weeks 
whereas lines 2, 4 and 5 could be passaged only for 47, 51 and 50 weeks due to the frequent 
failure of weekly infections (indicated by the number of times the lines had to be reactivated from 
the cryo-preserved corresponding stabilates. The lines which did not end up being GNP had a 
lower (than starting) parasitemia which could be intriguing to explore.  
 
In the lines which did eventually develop as GNP lines barring line 8, this 
third phase showed a continued decline (as an extension to the declining phase) 
in gametocytemia until eventually no gametocytes could be identified 
(exemplified by kinetics in the GNP line 7; Figure 3-26b). In the rest of the lines, 
the third phase again showed a fluctuation in low level gametocytemia (herein 
termed as the low fluctuating phase), but generally at levels lower than the 
initial gametocytemia being, between 1% and 3%.  
The kinetics of GNP line 8 exhibited a unique pattern (Figure 3-26c) 
wherein the gametocytemia fell gradually, at almost a steady rate, since the 
start of period of absolute asexual multiplication, maintains the same trend 
throughout till the line no longer produced gametocytes at the end of 52 weeks 
of asexual multiplication. The difference in the kinetics between line 8 and the 
rest of the lines opened an intriguing debate which might underpin a molecular 
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mechanism mediated by the necessity for a cascade of mutants before a line 
becomes a GNP line.  
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Figure 3-26: Representative growth kinetics from a gametocyte producer line (line 3, fig 3-
27b); GNP line (line 7, fig 3-27b), and another GNP line (line 8, fig 3-27c). X-axis shows the 
period of asexual multiplication (weekly passage number) in weeks. Total parasitemia (shown as 
navy blue trend line, as %age of infected red blood cells out of 1500 red blood cells examined) is 
represented along the secondary Y-axis whereas gametocytemia (shown as grey trend line, as 
%age of total gametocytes, males and females, out of the infected red blood cells) is represented 
on the primary Y-axis. Total percent of gametocytes were further sub-categorised into percent male 
(blue line) and percent female (pink line) gametocytes out of the total infected red blood cells. Each 
individual weekly observation is joined by a spiky line of representative colour whereas the 
smoothed line is the best-fit polynomial trend line that best explains the trend of fluctuations of 
individual weekly observations. The pink, blue and green semi-transparent rectangles represent the 
hypothesised phases 1 to 3, respectively of the observed gametocytemia kinetics. The tails (pink 
and blue) observed for gametocytemia in line 7 (Figure 3-26b) after passage week 31 is due to the 
smoothed polynomial being fitted for the kinetics and do not represent actual gametocytemia. 
 
 
The recent identification of many genes essential for gametocytogenesis 
in P. falciparum through transposon mediated mutagenesis also suggests that 
these are essential for gametocyte maturation (Ikadai et al., 2013). Although the 
systematic gene deletion (P. berghei) and transposon mutagenesis (P. 
falciparum) have identified genes essential for gametocytogenesis,  reverse 
genetics screens have not indicated an absolute GNP phenotype in any of these 
mutants to date.  
3.9   Future directions 
Is there a possibility of a reversal of GNP mutant phenotype to WT in 
nature or in vitro is an interesting question to be addressed in future. There 
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exists limited evidence of gametocytogenesis being induced in lines which 
naturally evolved to the GNP phenotype as a result of continuous maintenance in 
the absence of mosquito bites by adding chemicals such as ammonium 
compounds and Berenil (Ono and Nakabayashi, 1990; Ono et al., 1993) or by 
adding RBC lysate (Carter and Miller, 1979) or mammalian hormones (Maswoswe 
et al., 1985; Lingnau et al., 1993) to P. falciparum culture. In terms of 
evolutionary advantage, investment in sexual stages would be inefficient in the 
absence of uptake by the vector but some natural cues (like onset of 
transmission season and bites from uninfected mosquitoes) associated with 
increased gametocytogenesis have been mentioned (Ouedraogo et al., 2008; 
Paul et al.,2004; van der Kolk et al., 2003). 
   
It would also be worthwhile to statistically predict from a mathematical 
model, the approximate time (in terms of weekly passage number) when the 
currently cryopreserved low gametocyte producer lines might develop the GNP 
phenotype and which lines should be preferentially chosen on the basis of the 
least distance/time to become a GNP in terms of the number of passages 
needed. Such a model could also be fine-tuned to predict the period of latency 
from the time of precise occurrence of a causal mutation and the generation of 
the first detetctable GNP phenotype in such lines.  
 
Further, accumulating recent evidence in support of the involvement of 
cell-to-cell signalling in malaria parasites might be one of the possible triggers to 
commitment of the parasite to sexual development mediated by microvesicles 
and exosome-like vesicles (Mantel et al., 2013; Regev-Rudzki et al., 2013). In 
this regard, the comparative analyses of the metabolomes from the cryo-
preserved plasma of the de novo generated GNP line/s and its immediate 
gametocyte producing ancestor/s could help us identify if there are any 
molecular signatures of possible communication/s leading to the generation of 
the GNP phenotype and possibly decode the language used by parasites for such 
communication (del Portillo and Chitnis, 2013). 
  
 
 
 
 
 
 
 
 
 
 
 
 
4 Whole genome re-sequencing, assembly and 
genome-wide comparison of de novo GNP 
mutants and the isogenic parental line   
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4.1  Introduction 
One of the most significant achievements of  next generation sequencing 
technologies is the ability to generate a tremendous amount of reliable data 
cheaply and rapidly (Metzker 2010). These latest and improved technologies 
(including Roche/454, Illumina/Solexa, Life/APG and Helicos BioSciences) 
dramatically increase the sequencing throughput by laying millions of 
fragmented/sheared DNA molecule on a single solid support and sequencing all 
these fragments in parallel, the so called Massively Parallel Sequencing (Pop and 
Salzberg, 2008; Li et al., 2009; Tucker et al.,009;). 
Whole genome re-sequencing or sequencing the genomes for which there 
exists a reference genome has opened the ways to strongly establish associations 
between the documented phenotype and the genotype (Stratton, 2008). 
Application of whole genome re-sequencing approaches in Plasmodium has 
helped narrow the number of candidate mutations implicated for a particular 
phenotype. It has now been possible to precisely identify, locate and study the 
exact nature of the genetic mutation/s behind various important phenotypes 
generated by applying forward genetic screens in the isogenic lines of different 
Plasmodium species (Modrzynska et al., 2012). These include identification of 
specific genetic mutations responsible for generating resistance to common anti-
malarial drugs like Artemisinin (Hunt at al., 2007; Hunt et al., 2010), 
Sulphadoxine (Martinelli et al., 2011), or Mefloquine and Lumifantrine (Borges et 
al., 2011) and Chloroquine (Modrzynska et al., 2012) in the model (rodent) 
malaria parasite, P. chabaudi.  
Following the same principles, a whole genome re-sequencing approach 
was applied here by mapping the whole genome sequencing reads of the three 
independent naturally selected isogenic gametocyte non-producer (GNP) lines 
(generated by repeated in vivo passage; Chapter 3) on the de novo assembled 
reference genomic sequence of their parental wild type line (WT 820), and also 
on the already assembled reference genome of P. berghei ANKA, to understand 
the precise molecular basis of gametocytogenesis in malaria parasites. To obtain 
supporting evidence, the mapping was also performed from the reads of two 
independent pre-existing gametocyte non-producer lines: clone 1 of the K173 
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lineage (Vincke and Lips, 1948; Janse et al., 1989; Janse et al., 1992) and clone 
233L derived from the parental clone 234L of the ANKA lineage (Killick-Kendrick, 
1974; Dearsly et al., 1990).  
A flow diagram highlighting the major procedures performed from 
preparation of the DNA for sequencing up to the analysis of identified mutations 
is shown in Materials & Methods (Figure 2-2). A summary of the basic algorithms 
used in generating a reference assembly, mapping and variant calling is 
presented in Table 2-1 of Materials & Methods. 
4.2  Illumina/Solexa whole genome sequencing 
 and assembly of the GNP and  WT 
 isogenic parental lines 
 This section was entirely performed by Dr Thomas Dan Otto and Mandy 
Sanders and colleagues at the WTSI. All the de novo GNP isogenic lines (lines m7, 
m8 and m9) along with their common parental line (820cl1m1cl1cl2) were 
sequenced by whole genome sequencing on the Illumina/Solexa sequencing 
platform using paired-end reads. In addition to this, a pre-existing GNP line 
K173cl1 and line 233 along with its gametocyte producer parent, line 234, were 
also sequenced. A summary of reads for each project including accession codes 
are given in Table 4-1. Data are available at 
http://www.ebi.ac.uk/ena/data/view/ERP000253. 
Table 4-1  
Isolate / 
clone 
Number of 
reads 
Accession 
number 
% mapped reads on P. 
berghei ANKA 820 
approximate 
coverage x 
820 52,888,156 ERS012301 90.8 194 
m7 66,824,730 ERS016741 91.77 248 
m8 123,118,738 ERP000253 90.43 450 
m9 63,297,465 ERS012302 87.5 224 
233 29,330,944 ERS004442 89.23 106 
 
Table 4-1. Parameters of WGS of GNP P. berghei lines used in this study 
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4.3 Mutations identified in the study lines after  
mapping them on the reference assembly 
lines 
After mapping onto their corresponding reference genomes, the mutations 
(SNPs and indels) were called using SSAHA2 and SAMtools algorithms (see 
Materials & Methods section 2.6.3). Two separate lists of SNPs and indels were 
created (Tables 4-3 and 4-4) based upon (a) mapping of all lines onto 
820cl1m1cl1cl2 reference assembly; and (b) mapping of all lines onto ANKA 
reference assembly. A list was also generated for mutations in the un-translated 
regions (UTRs) of the genes - within 1 kb upstream (5’UTR) and 1 kb downstream 
(3’UTR) of the coding sequences, including those in the coding sequences (Table 
4-5). The WGS and SNP analytical pipeline is summarized in Figure 4-1. 
 
Figure 4-1. Whole genome sequencing and SNP calling analyses. A de novo assembly of the 
parental WT line 820 was created. All the three natural mutant lines were also sequenced and 
assembled using the 820 assembly as the reference. SNPs were called by mapping the GNP lines 
on to the 820 parental line for all the 13 chromosomes. Also, the WT parental line 820 was mapped 
on itself to identify any sequencing and/or base calling errors. The mutations for each line (inverted 
triangles) are denoted by green (for 820 line; possible errors), red (for GNP line 7; probably real), 
blue (for GNP line 8; probably real) and yellow (for GNP line 9; probably real). The inset shows the 
gene PBANKA_143750 on chromosome 14 with unique mutations in all the three natural GNP 
mutants. 
 
K173 
 
233 
 
820 
 
m7 
 
m8 
 
m9 
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4.3.1  Mutations identified within the open reading       
frames in the GNP study lines after mapping 
onto the 820 reference assembly 
 A total of 4352 SNPs and 184 indels were detected when all the lines 
(820cl1m1cl1cl2, ANKA, 233, 234, line 7, 8 and 9) were mapped onto the 820 
reference genome. All mutations were first filtered using two or three 
subsequent filtering steps to segregate the suspected erroneous and/or lineage 
specific mutations from the possibly real causative and thus analysable 
mutations. The general schema for mapping and filtering mutations is shown in 
Table 4-2. 
Candidates were first filtered for mutations arising out of obvious 
artefacts and possible errors in mutation calling programs. Those mutations were 
considered erroneous which were called by mapping the WT line 820 sequencing 
reads on its own de novo assembly and were identified in all the other lines. 
Such mutations were eliminated (as errors in mutation calling) not only from 
those detected in 820 but from those identified in other lines as well (FILTER 1). 
Table 4-2 
 
Table 4-2. A general schematic of how the total identified mutations were treated and classified for 
further analyses. Basically, possibly erroneous/suspicious and lineage specific mutations were eliminated 
from the mutation pool by looking at the number of mutations in the GNPs which are common to their 
respective isogenic parental lines. The rest of the mutations were carried over for analyses considering 
them to be probably real.  Mutations were initially NOT called in: regions flanking assembly gaps & mis-
assemblies (telomeres), regions of low depth of coverage, non-coding regions except UTRs. 
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Thus, more than half (54%) of the SNPs were eliminated this way leaving 
behind 2004 potential SNPs and 184 indels (Table 4-3). These were further 
filtered for those co-occurring with mutations in lines 820cl1m1cl1cl2, 234 
and/or ANKA as these indicate potential sequencing and/or assembly errors 
(false positive mutations) rather than real potentially causative SNPs and indels 
(FILTER 2).  
The total number of mutations remaining after these 2 filters comprised 
40 SNPs and 31 indels. A total of 6 synonymous SNPs were further filtered 
(FILTER 3) thus leaving 34 SNPs and 31 indels for further analyses. To this 
number were added 58 already filtered SNPs from the analysis of the GNP line 8, 
making the total number of SNPs 92. It is worth noting at this point that 
sequence comparisons between GNP lines and their isogenic cloned parent 
reveal a relatively small number of potential mutations. Considering the stability 
of these genomes, it is highly likely that these mutations have some potential 
consequences. The distribution of these across various lines studied (except 
K173) is shown in Table 4-3. 
 
Table 4-3 
 
COMPARISON AGAINST 820 REFERENCE 
LINES 
TOTALS 
FILTER 1 – 
Artefacts / 
errors 
Eligible after 
F1 
FILTER 2 – 
Common 
with 
234, ANKA 
AND/OR 820 
Eligible 
after F2 
FILT 
3 - 
Syn. 
SNP 
Eligible after 
F3 
SNP IND SNP IND SNP IND SNP IND SNP IND SNP IND 
233 1118 25 590 0 528 25 502 19 26 6 3 23 6 
234 540 23 249 0 291 23 291 23 0 0 0 0 0 
820 1008 40 521 0 487 40 487 40 0 0 0 0 0 
ANKA 595 32 313 0 282 32 282 32 0 0 0 0 0 
7 430 38 233 0 197 38 196 21 1 17 0 1 17 
8 -- -- -- -- -- -- -- -- -- -- -- 58 0 
9 661 26 442 0 219 26 206 18 13 8 3 10 8 
Total 4352 184 2348 0 2004 184 1964 153 40 31 6  92 31 
 
Table 4-3. Table showing total number of mutations within the coding sequences as 
identified by mapping lines 233, 234, 820cl1m1cl1cl2, ANKA, and lines 7, 8 and 9 on 820 
reference and filters used to refine them. SNPs for line 8 were added as already filtered from the 
variant calling program and no indels were reported.  
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4.3.2  Mutations identified within the open reading 
frames in the  GNP study lines after mapping  
onto the ANKA reference assembly 
In the same way as done for the mapping onto the 820 reference 
assembly, 1885 SNPs and 270 indels were identified in the predicted open 
reading frames (ORFs) when the lines were mapped onto the ANKA reference 
genome (Table 4-4). After eliminating the mutations which were also present 
(common mutations) in lines 820cl1m1cl1cl2 and/or 234 (FILTER 1), only 61 
potential SNPs and 34 indels remained. A final filter to eliminate all synonymous 
SNPs (FILTER 2) refined the total number of SNPs and indels to 55 and 34, 
respectively. To this number were added 132 already filtered SNPs from the 
analysis of the GNP line 8, making the total number of SNPs 187. It is important 
here to note that after filtering for potential errors, only a small number of 
mutations (9 and12, respectively) were finally observed in the de novo GNP lines 
7 and 9, except in GNP line 8 where it totalled to 132 SNPs.  Given the stability 
of the genomes, these mutations are likely to be significantly related to the 
observed phenotypic difference under study. The distribution of these remaining 
mutations across the studied lines (except K173) is shown in Table 4-4.   
Table 4-4 
COMPARISON AGAINST ANKA REFERENCE 
LINES 
TOTALS 
FILTER 1 – 
Common with 
234 AND/OR 
820 
Eligible after 
F1 
FILTER 2 – 
All 
synonymous 
SNPs  
Eligible after 
F2 
SNP IND SNP IND SNP IND SNP IND 
233 475 38 440 34 35 4 6 29 4 
234 472 50 467 50 5 0 0 5 0 
820 337 57 337 57 0 0 0 0 0 
7 333 66 324 50 9 16 0 9 16 
8 -- -- -- -- -- -- -- 132 0 
9 268 59 256 45 12 14 0 12 14 
Totals 1885 270 1824  236  61 34 6  187 34 
 
Table 4-4: Total number of mutations within the coding sequences as identified by mapping 
lines 233, 234, 820cl1m1cl1cl2, and lines 7 and 9 on ANKA reference and filters used to 
refine them. SNPs for line 8 were added as already filtered from the variant calling program and 
no indels were reported. 
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4.3.3 Mapping mutations within 1 kb upstream and 
 downstream of the open reading frames in the 
 study lines using the ANKA reference assembly 
When the lines 233, 234, 820cl1m1cl1cl2, m7 and m9 were mapped onto 
the ANKA reference and mutations were called within 1 kb upstream and 
downstream of the coding sequence of all annotated genes (including the coding 
sequence of the gene), a total of 4533 SNPs and 1006 indels were identified 
(analysis not done for GNP line 8 because the GNP line 8 was only mapped on to 
line 820 and the data from WTSI was obtained by using a different version of SAM 
tools that included filtered mutations). Filtering them for those which were also 
present (common mutations) in lines 820cl1m1cl1cl2 and/or 234, left 107 and 
147 potential SNPs and indels, respectively that are unique to the GNP lines 
(FILTER 1). A further filtering for synonymous SNPs (FILTER 2; as they do not 
result in an amino acid change) eliminated only 9 SNPs thus leaving 98 SNPs and 
147 indels as potential candidates for further analysis although the final SNP list 
included 5 synonymous SNPs anticipated being important for further analysis. 
Their distribution across the studied lines (except K173) is shown in Table 4-5. 
Table 4-5 
COMPARISONS OF THE UTRs AGAINST ANKA REFERENCE 
LINES 
  
TOTALS 
FILTER 1: Common with  
234 and/or 820 
Eligible 
after F1 
FILTER 2: Only 
Synonymous SNPs 
Eligible after 
F2 
SNP IND SNP IND SNP IND SNP SNP IND 
233 1198 175 1141 149 62 26 5 57 26 
234 1012 207 1009 202 3 5 0 3 5 
820 827 199 827 197 0 2 0 0 2 
7 739 199 724 150 17 49 2 15 49 
8 NA NA NA NA NA NA NA NA NA 
9 757 226 734 161 25 65 2 23 65 
Totals 4533 1006 4435 859 107 147 9 98 147 
 Note: The SNPs eligible after F2 include 5 important synonymous SNPS  
 
Table 4-5. Total number of mutations within the coding sequences & 1kb upstream and 
downstream in each of the coding sequences as identified by mapping lines 233, 234, 
820cl1m1cl1cl2, and GNP lines 7 and 9 on ANKA reference and filters used to refine them. 
Analysis was not performed for GNP line 8 because the GNP line 8 was only mapped on to line 
820 and the data from WTSI was obtained by using a different version of SAM tools that included 
filtered mutations. 
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4.3.4  Summary of filtered mutations 
Table 4-6 includes all the filtered mutations from tables 4-3 to 4-5. A 
grand total of 377 SNPs and 212 indels were carried forward for further detailed 
analysis. As Table 4-5 also includes mutations within the coding sequences 
(together with their 1 kb upstream and downstream UTRs), the common 
mutations between list 3 and lists 1 and 2 were thus eliminated (FILTER 1; but 
reserved for in depth analysis) leaving behind a total of 348 SNPs and 211 indels 
as shown in Table 4-7. A total of 277 SNPs and 184 indels were temporarily 
eliminated (FILTER 2) as being not known to be directly involved in 
gametocytogenesis and are thus pooled as reduced ranking priority mutations. 
These reduced ranking priority mutations mostly included those affecting 
conserved Plasmodium proteins with unknown functions (42%) and BIR genes 
(14%) and other miscellaneous gene products (Figure 4-2). Full details of these 
and their co-occurrence in the GNP lines are shown in Table A-11 in the 
Appendices.  
Table 4-6 
TOTAL FROM 3 LISTS 
LINES 
TOTAL SNPs TOTAL INDELS GRAND TOTAL  
 LIST 1 - 
ON 
820 
LIST 2 - ON 
ANKA 
LIST 3 - WITH 
UTRs ON 
ANKA 
LIST 1 - 
ON 820 
LIST 2 - 
ON 
ANKA 
LIST 3 - 
WITH UTRs 
ON ANKA 
SNPs INDELS 
 
 233 23 29 57 6 4 26 109 36  
 234 0 5 3 0 0 5 8 5  
 820 0 0 0 0 0 2 0 2  
 ANKA 0 0 0 0 0 0 0 0  
 7 1 9 15 17 16 49 25 82  
 8 58 132 NA NA NA NA 190 NA   
9 10 12 23 8 14 65 45 87  
 Totals 92 187 98 31 34 147 377 212  
  
Table 4-6.  A summary of filtered mutations from lists 1, 2 and 3; tables 4-2, 4-3 and 4-5, 
respectively. 
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Table 4-7 
FINAL MERGED LIST 
LI
N
ES
 
TOTALS 
FILTER 1 
– 
Common 
in 
UTRs & 
cds 
Eligible 
after F1 
FILTER 2 – 
reduced 
ranking 
priority 
mutations 
Eligible 
after 
F2 
FINAL PRIORITISED 
MUTATIONS 
SN
P
s 
IN
D
EL
S 
SN
P
s 
IN
D
EL
S 
SN
P
s 
IN
D
EL
S 
SN
P
s 
IN
D
EL
S 
SN
P
s 
IN
D
EL
S 
SNP INDEL 
IN
 C
D
S 
IN
 U
TR
 
TO
TA
L 
IN
 C
D
S 
IN
 U
TR
 
TO
TA
L 
233 109 36 9 2 100 34 92 28 8 6 7 1 8 3 3 6 
234 8 5 2 1 6 4 1 2 5 2 4 1 5 0 2 2 
820 0 2 0 0 0 2 0 1 0 1 0 0 0 0 1 1 
7 25 82 8 0 17 82 17 72 0 10 0 0 0 7 3 10 
8 190 -- -- -- 190 -- 134 -- 56 -- 56 -- 56 -- -- -- 
9 45 87 10 0 35 89* 33 81 2 8 2 0 2 2 6 8 
Tot 377 212 29 3 348 211 277 184 71 27 69 2 71 12 15 27 
PS 
The total number of SNPs includes 4 synonymous SNP and 1 SNP in the inter-exonic region 
*ADDITIONAL MUTATIONS DISCOVERED 
 
Table 4-7. Final merged list of the number of mutations after filtering for reduced ranking 
priority mutations 
 
 
 
 
Figure 4-2. Breakdown of mutated gene products temporarily considered as reduced 
ranking priority and hence not included in the analysis. The majority (44%) of these genes are 
conserved Plasmodium proteins (unknown functions), followed by BIR proteins (16%) and 
Plasmodium exported proteins (unknown functions; 12%). 
16% 
44% 
12% 
Plasmodium exported 
proteins, unknown function 
BIR (berghei interspersed repeats) 
proteins 
Conserved Plasmodium 
proteins, unknown function 
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The final merged list of number of refined mutations included a total of 
71 potential SNPs (69 in coding sequences and 2 in the UTRs) and 27 potential 
indels (12 in coding sequences and 15 in the UTRs). A breakdown of these across 
the studied lines is shown in Table A-12 in Appendices. These 71 SNPs and 27 
indels were further characterized in detail and were grouped according to their 
co-occurrence (whether these mutations were present in isolated GNP lines or 
similar mutations in other GNP lines included in the present study) across other 
studied GNP lines as shown in Table A-12 in Appendices. 
 
4.4  One gene uniquely mutated in all the 
 GNPs 
Out of the total number of genes (and their UTRs) found mutated, it is 
clearly evident that there is a single gene (PBANKA_143750; a transcription 
factor with an AP2 domain) that has non-synonymous SNPs and/or indels 
resulting in premature insertion of a stop codon or transcriptional frame shift, 
respectively (Figures 4-1 and 4-3) in all GNP lines included in this study 
compared with the isogenic gametocyte producer parental genomes. The only 
other gene (PBANKA_093910; another transcription factor with AP2 domain) that 
was found to be related to all the GNP under study had upstream alterations 
therefore PBANKA_143750 was the overwhelmingly favourite candidate. 
However, there were other interesting candidates including RNA binding 
proteins, an RNA helicase, cdc2 related protein kinases, a histone demethylase, 
a translation initiation factor and a histone deacetylase among others but these 
occurred in isolation in one or the other gametocyte non-producer lines. 
Interestingly, none of these genes were found in common with the list of 15 
genes that were found to be putatively responsible for gametocytogenesis in P. 
falciparum using transposon mutagenesis (Ikadai et al., 2013) except 
PBANKA_040300 (ortholog of PFC0200w; 60S ribosomal protein; mutated in GNP 
m7) and PBANKA_082360 (ortholog of PFI1215w; splicing factor 3a; mutated in 
GNP m7 and m9) – both the genes having mutations in 5’ UTR of the ORF. 
Whilst PBANKA_143750 (hereinafter also referred to as PbAP2-G or AP2-G) 
stood out as the number one priority gene implicated in gametocytogenesis, 
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later confirmed by targeted gene deletion and successful gene 
complementation, others are certainly worth consideration in future as it can be 
hypothesised that it could be a cascade of genes/transcription factors rather 
than a single key determinant for commitment to gametocytogenesis. Also, 
considering the important role of epigenetics in non-transcriptional regulation of 
commitment (Brancucci et al., 2014; Coleman et al., 2014) together with a more 
contextual background in which the process of commitment occurs (Flueck and 
Baker, 2014), the implication and thus the importance of additional commonly 
associated genes cannot be completely ruled out. 
 
Figure 4-3. A schematic of the AP2-G (PBANKA_143750) open reading frame. The orf (yellow) 
is showing the location of the three naturally acquired de novo GNP mutations (m9, m8 and m7; 
maroon coloured vertical bars) and two pre-existing GNP mutations (K173cl1 and 233; green 
vertical bars) relative to the translation start site (position 1) of the AP2-Ggene and the DNA 
binding domain (blue rectangle). These mutations were identified by mapping the reads from whole 
genome sequencing of the de novo and pre-existing GNP lines on the 820 reference assembly 
(see text). The details of the independent mutations are also shown as “reference base/s – altered 
base/s” pattern followed by the expected outcome of the mutation. 
 
PBANKA_093910 is another Api-AP2 family member gene, the 5’UTR of 
which is mutated in all the GNP lines characterised. The gene had a cluster of 4 
different indels at various positions within 1 kb of the 5’ UTR of the gene in all 
the gametocyte non-producer lines studied and compared to ANKA. Indels were 
also detected in parental lines 234 and 820cl1m1cl1cl2 when mapped on the 
ANKA reference assembly, however the indels differed between the GNP lines 
and their isogenic parental WT lines both in terms of their location and the bases 
involved (except in the 234/233 lines). When the gene and its UTRs were 
examined for any mutations in the available data from line K173cl1, 2 indels 
were detected within 1 kb 5’ UTR. Mutations exclusive to the GNP involved the 2 
indels in K173cl1 and one in line m9 (at -442 relative to the AUG). The rest of 
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the 3 indels, one each in line 233, m7 and m9 at position 1446814 (-132 relative 
to AUG), are same as the indel in line 234 whereas line 820 has an indel 1 base 
upstream at position 1446813. The functional significance, if any, of these is yet 
to be explored.  
The mutations detected at the PBANKA_093910 locus in K173cl1 are 
strikingly at different locations as compared to the mutations in other GNP lines 
and this could be explained on the basis of the lineage difference between K173 
and ANKA. For the rest of the GNP lines, one possible explanation of how 
mutations upstream of the ApiAP2 proteins might regulate gene expression is by 
interrupting the sequence of a DNA binding motif so that the DNA binding 
domain is prevented from binding to its cognate DNA sequence. Although, no 
motif consensus sequence (GTAC) was identified around the position/s where 
indels were reported, the identification of the target sequence GTAC at position 
-300 relative to AUG, poses intriguing possibilities that could attribute the indel 
at position -442 relative to AUG in GNP line m9 to the GNP phenotype in that 
line possibly due to altered ability of PBANKA_143750 DBD to bind here. It has 
been shown that the P. falciparum homologue to PBANKA_093910 (PF11_0091) 
recognizes a specific motif (aGcATAC) to bind DNA (Painter et al., 2011). A 
simple motif search with GCATAC found no such sequence within 1 kb upstream 
to the AUG suggesting that this ApiAP2 might not  influence its own expression 
and hence the indels detected above might not affect  transcription in an 
autoregulatory manner. 
4.4.1 Evidence from pre-existing GNP lines 
 
Apart from the identification of a single gene (PBANKA_143750) uniquely 
mutated in all the GNP lines under study, whole genome resequencing of the 
pre-existing GNP lines, 233 and K173, identified another two ApiAP2 
transcription factors (PBANKA_011210 and PBANKA_141570) mutated in both pre-
existing GNP lines.  
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4.4.1.1 Mutations in PBANKA_011210 
Whole genome resequencing of the two pre-existing GNP lines, 233 and 
K173, that were included in the study revealed that another ApiAP2 transcription 
factor (PBANKA_011210)   was mutated in both of these lines. The translated 
protein product of PBANKA_011210 has a DNA binding domain ranging from 1813 
to 1866 amino acids of the 2578 aa protein. The GNP line 233 has a thymine to 
cytosine non-synonymous SNP at position 453650 bp resulting in an amino acid 
change from phenylalanine to serine at position 1823. The gene, when examined 
for mutation in line K173cl1 revealed the same mutation. The same mutation 
was however also detected in the 234, the gametocyte producer parental line 
for 233. It is important to note, however, that the mutation is present within the 
DNA binding domain of the protein and hence might be a candidate for further 
exploration.  
4.4.1.2 Mutations in PBANKA_141570 
PBANKA_141570 was yet another transcription factor with AP2 domains 
with mutations detected in both the pre-existing GNP lines – 233 and K173cl1 
together with mutation in the parental line 234. The gene had a G to A SNP at 
position 591556 bp in the two GNP lines, along with the same mutation in line 
234. The mutation was just upstream to the stop codon for the gene and 
involved the last amino acid, changing it from methionine to isoleucine. The DNA 
binding domain of the protein spans amino acids 1156 to 1209 of the 2487 aa 
long protein and was thus 3834 bp upstream to the locus of mutation. The 
functional interpretation of these mutations is similar, in principle, to that for 
the gene PBANKA_011210.  
4.5  Confirmation of PBANKA_143750   
 mutations by direct sequencing 
The mutations identified by whole-genome re-sequencing were confirmed 
by di-deoxy sequencing to eliminate any association with sequencing errors. The 
full open reading frame of PBANKA_143750 (7.02 kb) was amplified from the 
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purified genomic DNA of WT line 820, the three de novo GNP lines (m9, m8 and 
m7) and the pre-existing GNP lines (233 and K173cl1) using primers 
GU1070/GU1071 and a proof-reading polymerase (HiFi Long template Taq 
Polymerase; Roche) and sent for sequencing to Eurofins MWG operon, Germany. 
In case, if the full orf was not amplifiable, the gene was amplified in 4 different 
parts of ~2 kb each and all the fragments sequenced. The following primer pairs 
were used for fragment 1 (GU1070/GU1239), fragment 2 (GU1182/GU1240), 
fragment 3 (GU1241/GU1242) and fragment 4 (GU1237/GU1071). 
The DNA sequences were first converted to protein sequences and were 
subsequently aligned using CLC Genomics Workbench version 5.1 software 
(Figure 4-4). The sequence alignment confirmed the mutations in the various 
GNP lines studied and also ruled out the presence of any mutation/s other than 
those detected by the WGS and subsequent mapping.   
4.6 The ApiAP2 family of transcription factors 
and AP2-G 
Interest in  transcription factor-based gene regulation in Plasmodium has 
arisen from a recent discovery of a family of conserved proteins containing 
apicomplexan AP2 DNA-binding domains (known as the ApiAP2) (Balaji et al, 
2005; Yuda et al, 2009; Yuda et al, 2010). Three of the conserved P. berghei AP2 
genes have already been implicated in controlling stage specific development in 
Plasmodium (Yuda et al., 2009; Yuda et al, 2010; Iwanaga et al., 2012). Further 
attempts are continuing to pinpoint the functional roles of various ApiAP2 
proteins in transcriptional regulation during Plasmodium development and as 
these are strong candidates as potential regulators of gene expression in 
Plasmodium. 
PBANKA_143750 is a 7020 bp long gene and spans from genomic position 
1365549-1372568 bases on the forward strand on chromosome 14 of the most 
recent version of the P. berghei genome assembly (ftp://ftp.sanger.ac.uk/pub/ 
pathogens/P_berghei /February_2011/) and contains 2339 amino acids. The 
gene has a 55aa DNA binding domain (characteristic of the family of ApiAP2 
transcription factors) spanning from 2197-2252aa. 
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Figure 4-4. Portions of multiple amino-acid sequence alignment (CLC Genomic Workbench 
software version 5.1) converted from nucleotide sequences obtained from sequencing the 
PCR amplified copy of the WT full length PBANKA_143750 from the parental line 820 and 
GNP lines m9, m8, m7 and 233. The consensus sequence, conservation of the amino-acids and 
the sequence logo are shown below the alignment. Only the parts of the alignment which had the 
mutations in the GNP lines are shown but there were no mutations in the gene other than that 
depicted here corroborating the findings of the whole genome resequencing approach. The line m9 
had a stop codon (*) at position 880 whereas 233 had the same at position 2263. Lines m7 and m8 
had frameshifts at positions 1723 and 974, respectively.    
 
4.6.1 AP2-G DBDs are highly conserved across 
apicomplexa 
 The DNA binding domain (DBD) and target recognition motif of the PbAP2-
G are highly conserved across orthologues in even distantly related 
apicomplexans. A BLAST search for the AP2-G DBD query sequence resulted in a 
100% identity (top 2 hits) to the two rodent malaria parasites, P. berghei and P. 
yoelii (Figure 4-5). The next four similarity hits in decreasing order of identity 
were P. falciparum (86%), Theileria annulata (73%), Theileria parva (73%) and 
Babesia bovis (73%). This conservation suggests that the ApiAP2-G TF play 
important and critical roles during the life cycle of apicomplexans.  
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Figure 4-5. BLAST search hits when AP2-G DBD sequence of P. berghei was used as the 
query sequence. The top two hits showed 100% identity as they belonged to the rodent malaria 
parasites – P. berghei and P. yoelii. The next four hits in decreasing order of similarity were P. 
falciparum (86%), Theileria annulata (73%), Theileria parva (73%) and Babesia bovis (73%).  
 
Since PbAP2-G DBD sequence identity on BLAST is more with some of 
Theileria and Babesia sequences as compared to the identity with P. knowlesi 
and P. vivax, it appears that PbAP2-G DBD forms a phylogenetic cluster with 
orthologues from Plasmodium, Theileria and Babesia species and thus may be 
functionally associated with sexual differentiation in these species. The 
restriction of the orthologues to the ones with a clearly defined asexual stage 
implies that the AP2 transcription factor has a deterministic role during the 
sexual stages of these organisms.  
 
It has been shown that Plasmodium (P. falciparum, P.berghei and P. 
yoelii) and Theileria share a higher number of orthologous AP2 domains between 
them within apicomplexa supporting conclusion that these are phylogenetically 
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relatively closer (Leander et al., 2003; Balaji et al., 2005). It might be possible 
that certain AP2 domains regulating a particular stage in the life cycle of certain 
apicomplexans evolved prior to the diversification of their genera (Brian Shiels, 
University of Glasgow, personal communication). Recent research with Theileria 
has demonstrated that an ApiAP2 protein containing the clear orthologue of the 
DBD from PbAP2-G in Theileria annulata (TA13515) is up-regulated in piroplasms 
prior to the production of gametes (Brian Shiels and Marta Pieszko, University of 
Glasgow, personal communication). 
 
4.6.2  Expression profile of PbAP2-G 
The expression profile of PbAP2-G through various developmental stages 
of P. berghei including ~4-hour rings, 16-hour trophozoites, 22-hour schizonts, 
gametocytes and ookinetes was analysed from the RNA sequencing database 
available with the Waters lab (Hoeijmakers WAM, Religa A, Janse CJ, Waters AP, 
and Stunnenberg HG, unpublished data) generated from purified mRNA from 
each of these stages obtained from synchronized infections.  
Gene expression is shown either as the number of tags per gene (TPG) or 
number of tags per kilobase (TPK) of the genome. Although both measure the 
amount of gene expression, TPG shows a higher value because of the presence of 
intergenic areas which don’t contribute to gene expression and hence dilute the 
TPK value (Figure 4-6). Although the number of tags per gene is the highest for 
the ring stage, comparative expression ranking of PbAP2-G amongst all the genes 
expressed within the ring stage is very low at 21 percentile which means that 
only 20% of the genes expressed at ring stage rank below AP2-G expression. 
Similarly, the expression ranking of AP2-G within the 22-hour schizont stage is 
relatively better – 67 percentile. The corresponding ranking at 16-hour 
trophozoites and gametocytes is 50 percentile and 30 percentile, respectively.  
With such relatively low expression of PbAP2-G in all stages of the intra-
erythrocytic developmental cycle of the parasite, it was difficult to assess the 
expression and localisation of the gene, not even with a tagged transgene (Sinha 
et al., 2014)). The expression profile of the AP2-G transcription factor appeared 
to be comparatively better at the late schizont stage. With an implicated role of 
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AP2-G in commitment to sexual stage differentiation in malaria parasites, this 
relatively higher expression of the gene would suggest that the commitment 
might take place during or just following the late schizont stage in P. berghei.   
 
Figure 4-6. Expression profiling of PbAP2-G across different developmental stages of 
synchronised P. berghei parasite stages shown as the number of tags per gene (TPG) and tags 
per kilobase of the genome (TPK). From the data, it appears that PbAP2-G is most highly 
expressed in the ring stage followed by the gametocytes.  
 
4.6.3  Localization studies; GFP- and HA-tagged   
PbAP2-G 
Although efforts to epitope tag AP2-G with GFP and HA were made, 
success could not be achieved in tagging the gene. One of the group members 
(Anne Graham; data not shown) did eventually succeed in tagging allelic PbAP2-
G with both GFP and HA yet the protein could not be detected even with 
available peptide antisera or commercial antibodies against the tags, possibly 
because it is expressed at low levels. However, a truncated transgene was 
generated by yet another member of the group (Katie Hughes; data not shown) 
comprising the N-terminal 100aa and the entire C-terminal region (300 aa) 
including the DBD sandwiching CFP and driven by the PbAP2-G promoter (2 kb of 
upstream DNA). The transgene could be detected in nuclei of female 
gametocytes, consistent with a role for PbAP2-G in gametocyte development. 
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4.7 Summary and discussion 
4.7.1 Whole-genome sequencing and GNP mutations 
Whole-genome sequencing (WGS) based studies in Plasmodium have 
become increasingly popular in the last decade after the publication of the 
malaria genome in 2002 (Gardener et al., 2002; Bright and Winzeler, 2013). 
Although the majority of such studies emphasized the discovery of the molecular 
basis of drug resistance in Plasmodium (Miotto et al., 2013; Neafsey, 2013; 
Bright and Winzeler, 2013; Menegaon et al., 2007; and Eckland and Fiddock, 
2007), these high throughput technologies could be harvested for better 
understanding of  basic parasite biology and identification of novel drug and/or 
vaccine targets.  
WGS was thus applied in the current study towards understanding the 
molecular basis of commitment to gametocytogenesis in malaria parasites. Three 
natural GNP mutants were generated by serially passaging a WT fluorescent 
labelled gametocyte producer clone and their genomes were sequenced. The 
sequences from these lines and the two existing GNP lines, 233 and K173, were 
compared with the WT parental line 820 and line ANKA. Mapping of the 
sequencing reads from the WGS of the three GNP lines on to their parental 
reference assembly identified approximately 10,770 SNPs plus 1460 indels. These 
were then sequentially filtered (Figure 4-7) to a final list of 15 SNPs and 27 
indels. On the basis of commonality of occurrence in all the GNP lines, 
PBANKA_143750 (transcription factor with AP2 domain) emerged as the one and 
the only gene to be uniquely mutated in all three de novo GNP mutants plus the 
pre-existing GNP lines K173cl1 and 233.      
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Figure 4-7.  A flow diagram showing the scrrens applied to filter the detected mutations.  
The screens eliminated  false positive mutations (being detected due to lineage differences 
between the lines mapped and variant calling errors), synonymous SNPs (resulting in no amino 
acid change), duplication in mutation detection, and temporarily, the mutations in genes classified 
as reduced ranking priority  on the basis of bioinformatic prediction of gene function and  possible 
association with gametocytogenesis.   
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4.7.2  De novo GNP mutations and PBANKA_143750 
(AP2-G) 
 
Apart from the evidence generated in this study which establishes a 
possible role of PBANKA_143750 in commitment to gametocytogenesis, 
compelling evidence resulting from a parallel and independent approach using P. 
falciparum also identified the same ApiAP2 trabscription factor (PFL_1085w) as 
the critical regulator of commitment to gametocytogenesis in malaria parasites 
(Kafasack et al., 2014).  
 
Crucial evidence in the present study comes from the isogenic de novo 
GNP lines m7, m8 and m9 derived from the parental gametocyte producer line 
820cl1m1cl1cl2. GNP line m9 had a non-synonymous SNP at position 2640 causing 
the base change from thymine to adenine with the resulting amino acid change 
at position 880 from tyrosine to a stop codon. Whereas in the GNP lines m7 and 
m8, there are indels (AA to A) at position 5165 in m7 and (TAAAAA to TAAAA) at 
position 2888 (relative to the translation start site) which result in a 
transcriptional frame shift. In both of these situations, this is expected to 
produce an altered functional product – a truncated protein devoid of its DNA 
binding domain and thus probably ineffective as a transcriptional regulator. The 
predicted sizes of the truncated protein product of the naturally mutated 
PBANKA_143750 was 879aa in m9, and 1759aa in m7 (see Table 4-8), as 
compared to 2339aa in the WT gene. 
An important functional consideration while exploring these mutations is 
the position of the mutation on the gene relative to the DNA binding domain. 
With the exception of line 233, the mutations in the rest of the 3 GNP lines 
studied here occur upstream of the DNA binding domain. This relative location of 
the mutations has a functional implication – the nonsense/missense mutations 
occurring upstream to the DNA binding domain are expected to result in a 
truncated/altered protein product, respectively, without the DNA binding 
moiety. Such upstream mutations disrupting the function of AP2 domain would 
be manifest at the transcriptional level. In contrast, a nonsense mutation 
downstream to the DNA binding domain in a GNP (as in line 233 – R2263STOP) is 
expected to result in a fully functional DNA binding domain. This might indicate 
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yet another level of functional regulation which may involve protein-protein 
and/or protein-DNA interactions involving the region of the AP2 protein 
downstream of this mutation.  
 
Table 4-8 
 
Line 
Nucleotide 
Position* 
Type Nucleotide change 
Amino 
acid 
change 
Effect 
Predicted 
length of the 
protein (aa)# 
7 5165 Indel AA to A  Frameshift 1759 
8 2888 Indel TAAAAA to TAAAA  Frameshift 973 
9 2640 SNP TAT to TAA 
Y to 
STOP 
Termination 
codon 
879 
233 6787 SNP CGA to TGA 
R to 
STOP 
Termination 
codon 
2262 
K173 2880 Indel CATATA to CATA  Frameshift 959 
 
Table 4-8. Distribution of mutations across PBANKA_143750 orf.  The table shows the 
distribution with respect to the nucleotide position and nucleotide change involved in the 
mutation, the type of mutation, the resulting amino acid change, the predicted effect as a 
result of the mutation and the predicted length of the mutated protein. * With respect to 
ATG; # Predicted length of WT protein: 2339aa.  
 
 
Recent evidence from protein binding microarray experiments involving 
recombinant AP2 fragments of PFL1085w, the PBANKA_143750 orthologue in P. 
falciparum (Manuel Llinas, personal communication) suggest that extra 
sequences both at N- and C-terminal to the DNA binding domain (35aa upstream 
and 32aa downstream to the domain) in addition to the domain itself, are 
critical for DNA binding (Balaji et al., 2005; Campbell et al., 2010). In the 
context of the mutation in GNP line 233, it is important here to note that the 
mutated amino acid at position 2263 falls within this downstream critical zone 
(domain plus 32aa downstream) and thus might explain the GNP phenotype. 
Using such recombinant proteins as a guide, it can be speculated that a mutation 
in the AP2 protein downstream of its DNA binding domain might still affect its 
capacity to bind cognitive DNA sequence. Additional evidence from existing P. 
berghei GNP lines and/or their P. falciparum counterparts will certainly be 
crucial to explain the possible mechanisms involved in the expression of genes 
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likely to play a contributory role in commitment to gametocytogenesis in 
Plasmodium. 
 
4.7.3  Supplementary evidence from WGS of pre- 
  existing GNP lines 
The involvement of PBANKA_143750 as a critical regulator of commitment 
to gametocytogenesis in malaria parasites is further supported by analyses of the 
WGS data from the already available GNP line 233, wherein PBANKA_143750 has 
a non-synonymous SNP at position 6787 (relative to the translation start site) 
which causes a single nucleotide change from cytosine to thymine thus changing 
the amino acid at position 2263 from arginine to a stop codon thus potentially 
precociously terminating the transcription. Supplementary evidence comes from 
the available data of an independent already available unrelated non-
gametocyte producer line K173cl1, where the gene has an indel at position 963 
(relative to the translation start site) thus generating a transcriptional frame 
shift (CATATA-CATA) and thus an altered product. K173cl1 had a high number of 
WGS SNPs and indels when mapped to ANKA, but this is expected as K173cl1 has 
a lineage which is different from ANKA. 
One of the important considerations to be borne in mind while attributing 
differentially identified mutations in the pre-existing GNP lines to the GNP 
phenotype includes the fact that various mutations occur in the parasite genome 
over time due to continuous evolution of the parasite and there is thus a 
tendency of the parasite to accumulate the mutations that remain favourable to 
the parasite during their evolutionary development. Because the pre-existing 
GNP lines have an unknown number of generations apart from the isogenic 
parental clone, the precise time of evolution of the GNP phenotype remain 
unascertained, mutation/s may be spuriously associated with the phenotype and 
hence may not be real. Any phenotype associated with mutations in such a 
lineage should always be confirmed by reverse genetic experiments to causally 
link the ascribed mutation/s to the phenotype. Recent data, however, shows 
that the basal rate of accumulation of mutations in P. falciparum remains low 
(1.0–9.7 x 10-9 mutations per base pair per generation) and also that such 
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mutation/s mostly remain confined to  sub-telomeric multi-gene families with a 
relatively stable core genome (Bopp et al., 2013).    
This has three implications – either the mutation has no role towards 
commitment to gametocytogenesis in these two lines (at least) or it could also 
be possible that, since 234 is also derived from ANKA, although the line 234 
itself is a producer of gametocytes it is actually in a transitional phase in a 
continuum to develop gametocyte non-producer mutants from ANKA. If this 
might be the case, it will be intriguing to explore the point at which this 
mutation is acquired and the post-acquisition GNP kinetics of the line, especially 
when it is not known how many generations the lines 234 and 233 are apart. The 
third possibility could be that the process of commitment to gametocytogenesis 
is cascade dependent and GNP phenotype occurs through mutations in a series of 
genes involved, of which, PBANKA_011210 is a part, the master regulator being 
PBANKA_143750. This would then imply that PBANKA_011210 is positioned 
upstream to PBANKA_143750 AP2-G in the hypothesised cascade. This places 
more emphasis on the data derived from the de novo gametocyte non-producer 
mutants in the present study where we can explore the time point/s of 
acquisition of any particular mutation simply by retrospectively 
tracking/analysing the genome sequence of a particular GNP line. Efforts to 
knockout PBANKA_011210 were attempted but a successful knockout could not 
be generated. The efforts could not be continued / repeated due to paucity of 
time. 
Further, the Waters lab already possesses the following available pre-
existing GNP lines HPEcy1m50cl1, PbHpD25mcl17, PbHpD25mcl20, Pb 
LPjaune8409, Pb LPvert8458 (kind gift from Chris Janse, Leiden University) and 
KSP11, SP11 and LUKA (kind gift from Sarah Reece, University of Edinburgh). The 
gene of interest, PBANKA_143750 and other genomic areas of potential interest 
pertaining to gametocytogenesis regulation could be amplified for sequencing. 
Any mutations in AP2-G (PBANKA_143750) and/or other examined genomic 
regions in comparison to the ANKA reference could provide conclusive supporting 
and contextual evidence towards the implication of PBANKA_143750 and its 
precise functioning in commitment to gametocytogenesis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 Gene knockout studies to confirm the 
involvement of AP2-G in commitment to 
gametocytogenesis   
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5.1 Introduction 
Genetic manipulation, in terms of gene knockout, gene knock-in and gene 
disruption is one of the essential and fundamental molecular biology tools to 
investigate the role of the implicated gene/s  
As the gene under study was longer than the usual (~7 kb), a multitude of 
targeted gene knockout strategies were planned and carried out. These included 
conventional double- and single- crossover designs and also the newer 
recombineering-based knockout vector designs. Stable transfection of the 
Plasmodium schizont stage with genetic constructs that allow homologous 
recombination based targeted gene alterations are now standard procedures 
(van Dijk et al., 1995; Wu et al., 1996; Fidock et al., 2000; Crabb, 2002; Sidhu et 
al., 2002; Su etal., 2007). 
Gene knockout strategies in Plasmodium are based on the principles of 
homologous recombination between the targeted genomic sequence and its 
homolog present in the gene-targeting vector. Conventionally, this vector 
construct could, in turn, be circular (plasmids; as in P. falciparum) or a 
linearized piece of DNA (as in P. berghei) and carry a single copy of the 
homology arm upstream of the drug selectable marker (insertion type) or two 
copies of the homology arms, flanking a drug selectable marker (replacement 
type). The length of the homology arms is usually between 0.4-1.0 kb.  
In P. berghei targeted genetic manipulation, the insertion-type vector is 
prepared for transfection by linearizing it with a unique restriction enzyme and 
the linearized DNA construct inserts into the genome by single crossover (SCO) 
between homologous arms – the vector backbone being retained in the modified 
genome. In contrast, the replacement-type vector is prepared by linearizing the 
vector with two restriction enzymes which removes the intervening vector 
backbone and the linearized DNA construct inserts into the genome via a double 
crossover event (DCO) between the two homologous homology arms thereby 
replacing the target region with the drug selectable marker (Carvalho and 
Menard, 2004; Janse et al., 2006).  
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Alternatively, the DCO gene targeting vector could be a linear construct 
instead of a circular plasmid that is derived from bacteria (bacteriophage N15 
which can be efficiently modified using the lambda Red method of 
recombineering) and containing very long homology arms - up to 10 kb (Pfander 
et al., 2011). Since these newer recombineering-based approaches claim to 
improve the recombination frequency substantially (Hasty et al., 1991; Shulman 
et al., 1990), particularly in highly AT-rich genomes like Plasmodium (Pfander et 
al., 2011), these were included as strategies for gene knockout experiments with 
Pb AP2-G. 
5.2 The AP2-G knockout length variants 
As discussed in the previous section regarding the potential expected 
difficulties in knocking the whole open reading frame (ORF, 7.02 kb) out, the 
conventional double-crossover targeted knockout was attempted for various 
lengths of the ORF of AP2-G. The full length knockout of AP2-G involved the 
attempted knockout of the whole 7020 bp of the ORF with the help of ~1 kb 
upstream and downstream conventional short homology arms (all homology arms 
are indicated in blue in Figure 5-1) and also with longer homology arms (~1.8 kb 
and 2.7 kb; the recombineering-based approach) all situated respectively in the 
5’ and 3’ UTRs of the gene (Figures 5-1b and c). The partial gene knockout (also 
named part-knockout) involved the knockout of a region of the orf bearing the 
m7, m8 and m9 mutations (these mutations were situated between 2167 bp to 
5636 bp from the ATG; a total of 3470 bp of the ORF). The homology arms 
contributing to the partial gene knockout were derived from the regions of the 
AP2-G ORF flanking the mutations (Figure 5-1d). A third partial gene knockout 
was designed to delete the DNA binding domain (DBD) involving the full length 
DBD of AP2-G (from 6066 bp to 7020 bp from the ATG; total 954 bp including 168 
bp DBD) with the upstream homology arm coming from within the orf flanking 
the DBD and the downstream homology arm derived from the 3’UTR of the gene 
(Figure 5-1e). 
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Figure 5-1 (a-e). Schematic representation (not-to-scale) of the various length variants of 
AP2-G knockouts in Plasmodium berghei. The genomic location of the PbAP2-G 
(PBANKA_143750) is represented in (a). The black thicker bar represents the open reading frame 
(orf) of AP2-G and the green rectangle of the orf represents the DNA-binding domain (DBD). The 
different lengths of the AP2-G orf knocked out are shown in red bars placed upon various portions 
of the AP2-G orf including full-length orf ko (b and c), partial length orf ko (d) and DBD ko (e). Blue 
bars (b-e) represent different lengths of the homology arms used for homologous recombination: 
thin blue bars represent homology regions outside the AP2-G orf whereas blue thick bars represent 
homology regions within the orf. The relative length of the thin blue bars in (b) and (c) highlight the 
importance of recombineering based ko approach with 1.8 kb and 2.7 kb long homology arms in (c) 
as compared to conventional ~1 kb long homology arms in (b), (d) and (e). Yellow vertical bars in 
(d) represent the relative location of the three gametocyte non-producer (GNP) mutations which 
developed during the weekly passage of the WT line.  
 
 
5.3 The knockout genotype 
The success of the knockout transfectants attempted was initially 
assessed with the diagnostic PCRs and finally confirmed by PCRs and Southern 
analyses of the cloned mutants.  
m9 m8 m7 
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5.3.1 PCR analyses of the knockout mutants: 
 
5.3.1.1 The double-crossover (conventional) full length AP2-G 
orf knockout mutant 
HindIII and EcoRI double-digested (New England BioLabs), linearized and 
purified targeted vector DNA (pG0271) was transfected (~5 µg) to the purified 
schizonts of the WT line (820em1dcl2) in triplicate. The mutant lines (G401, 
G402 and G403) were selected by using pyrimethamine in drinking water. 
Diagnostic PCRs were performed using oligonucleotide pairs GU1076/GU52 (for 
5’ integration) and GU53/GU1077 (for 3’ integration) as shown in Figure 5-2. The 
expected approximate length of the amplicons for each of the integration events 
was 2.6 kb (Table 5-1). The transfectants were also screened by amplifying for 
the full length of the region knocked out by using oligonucleotide pairs 
GU1076/GU1077 (expected band size 5.4 kb in the ko mutants and 9.0 kb in the 
WT) and line G401 was taken further for cloning. A summary of PCR details is 
shown in Table 5-1. Presence of integration bands of expected size in all three 
transfected lines suggested a successful AP2-G knockout.   
 
 
Table 5-1 
 
Oligo set Details 
Expected band size with DNA 
(kb) 
Ta 
(°C) 
Ext. 
Time 
(min) 820 G401-3 Water HP 
1076/52 5’integration -- 2.6 -- NA 50 5 
53/1077 3’integration -- 2.6 -- NA 54 5 
1076/1077 
Across 
integration 
9 5.4 -- NA 54 10 
1233/1235 Control1 NA NA NA 5.9 54 10 
1233/1242 Control2 NA NA NA 2.9 50/54 5 
 
 
Table 5-1. Basic PCR reaction settings for amplifying various regions of the PbAP2-G 
genomic locus to identify the presence of 5’ and 3’ integration of the knockout constructs 
into the genome. Ta: annealing temperature for the primer pair 
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(a) 
 
 
 
 
(b) 
 
Figure 5-2 (a). Schematic of AP2-G (PBANKA_143750) conventional DXO knockout strategy 
(not-to-scale) showing endogenous & modified genetic locus together with the plasmid 
which was linearized with HindIII & EcoRI before transfection in triplicate into the WT 820 
line. The resulting transgenic mutants (G401-3) were positively selected using the drug 
pyrimethamine. Also shown are the positions of the oligonucleotide primers (GU1076/GU52) and 
(GU53/GU1077) used for examining the successful integration of the construct into the genomic 
locus. (b) Diagnostic PCR confirmed successful integration using the following primer pairs: (1; 5’ 
integration=2.6 kb) GU1076/GU52 (2; 3’ integration=2.6kb) GU53/GU1077 and (3; through the 
modified locus=5.4 kb in the ko and 9.0 kb in the WT) GU1076/GU1077. Strong positive bands of 
desired sizes were observed for all the three mutants indicating the integration of the construct into 
the PbAP2-G locus knocking it out. The bigger sized bands appear faint as Taq polymerase in the 
reaction might have exhausted during its amplification thus generating weaker bands (Selectable 
marker cassette: orange=3’UTR of Pbdhfr; dark blue=pbeef1aa; violet=hdhfr; green=yfcu).   
 
 
5.3.1.2 The double-crossover (recombineering) full length 
AP2-G orf knockout mutant 
 
NotI-digested (New England BioLabs) and purified targeted 
recombineering vector DNA (pG0277) was transfected (~2 µg) to the purified 
schizonts of the WT line (820em1dcl2) in triplicate. The mutant lines (G355, 
G356 and G357) were selected by using pyrimethamine in drinking water. 
5’ integration 3’ integration 
Across 
integration 
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Diagnostic PCRs were performed (except on G355 as the mouse unfortunately 
died on procedure) using oligonucleotide pairs GW2/GT (for 3’ integration) as 
shown in the Figure 5-3. The expected length of the amplicons for the 
integration event was 2.4 kb (Table 5-2). None of the lines were cloned, as a 
cloned line of the other knockout variant (conventional DXO full orf ko) was 
already generated and selected for characterization. Diagnostic PCRs (Figure 5-
3b) suggested successful integration of the drug selectable marker cassette at 
the AP2-G locus. 
Table 5-2 
 
Oligo set Details 
Expected band size with DNA (kb) 
Ta (°C) 
Ext. Time 
(min) 820 G356-7 Water 
GW2/GT Genotyping oligos -- 2.4 -- 47 5 
1237/1071 Within AP2-G orf 2.1 -- -- 54 5 
1233/1242 Control (HP) 2.9 -- -- 47 5 
 
Table 5-2. Basic PCR reaction settings for amplifying various regions of the PbAP2-G 
genomic locus to identify the presence of 3’ integration of the recombineering knockout 
construct into the genome and also to assess the presence of any wild type contamination 
in the knockouts. 
 
 
 
 
 
 
(a) 
 
 
Figure 5-3 (a). Schematic of AP2-G (PBANKA_143750) recombineering-based DXO knockout 
strategy (not-to-scale). The figure shows endogenous & modified genetic locus together with the 
plasmid which was linearized with NotI before transfection in duplicate into the WT 820 line. The 
resulting transgenic mutants (G356, G357) were positively selected using the drug pyrimethamine. 
(Selectable marker cassette: orange=3’UTR of Pbdhfr; dark blue=pbeef1aa; violet=hdhfr; 
green=yfcu), 
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(b) 
Figure 5-3 (b). Diagnostic PCR for integration. The PCR confirmed successful integration using 
the GW2/GT primers producing the 3’ integration bands of 2.4 kb in each knockout. WT orf (2.1 kb) 
was minimally amplified from the knockout lines – this might be expected as the knockout lines 
were still not cloned.  
 
5.3.1.3 The double-crossover (conventional) partial length 
AP2-G orf knockout mutant 
HindIII and EcoRI double-digested (New England BioLabs), linearized and 
purified targeted vector DNA (pG0274) was transfected (~5 µg) into the purified 
schizonts of the WT line (820em1dcl2) in duplicate. The mutant lines (G528 and 
G529) were selected by using pyrimethamine in drinking water. Equal amount of 
purified DNA (~100 ng) from each of these mutant lines was PCR-screened for 
successful integration of the knockout construct into the genome by using 
synthesised oligonucleotide pairs GU1407/GU414 (for 5’ integration) and 
GU392/GU1826 (for 3’ integration) as shown in Figure 5-4(a). The expected 
lengths of the amplicons for the integration events were 1.2 kb and 1.8 kb, 
respectively (Table 5-3). The transfectants were also screened by amplifying for 
the full length of the region knocked out by using oligonucleotide pairs 
GU1407/GU1826 (expected band size 5.3kb in the ko mutants and 5.9 kb in the 
WT). Amplified DNA (25 µl) was fractionated on 1% agarose gel electrophoresis at 
100V for 90 minutes to identify the bands of appropriate sizes (Figure 5-4(b)).  
The integration of the construct at the 5’ end could not be validated 
by the PCR screen as there were no bands seen. The presence of strong 
3’integration bands (in both G528 and G529) together with a weak, although 
appropriate sized, band (5.9 kb) in G529 suggests a successful knockout of the 
desired PbAP2-G segment in G529. The line G529 was preferentially selected for 
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cloning over G528 as the signal for WT contamination was reduced as evident 
from a weaker amplification of the orf to be knocked out.   
Table 5-3 
 
Oligo set Details 
Expected band size with DNA (kb) 
Ta (°C) 
Ext. Time 
(min) 820 G528 G529 Water HP 
1407/414 5’Integration NA 1.2 1.2 - NA 51 3 
392/1826 3’Integration NA 1.8 1.8 - NA 51 3 
1407/1826 Across integration 5.9 5.3 5.3 - NA 51 7 
1241/1242 Orf 1.9 -- -- - NA 51 3 
1241/1242 Control1 (HP) NA NA NA NA 1.9 51 3 
1233/1235 Control2 (HP) NA NA NA NA 5.9 51 7 
 
Table 5-3. Basic PCR reaction settings for amplifying various regions of the PbAP2-G 
genomic locus to identify the presence of 5’ and 3’ integration of the partial gene knockout 
constructs into the genome. Ta is annealing temperature. 
 
 
(a) 
 
 
Figure 5-4 (a). Schematic of partial AP2-G (PBANKA_143750) conventional DXO knockout 
strategy (not-to-scale) showing endogenous & modified genetic locus together with the plasmid 
which was linearized with HindIII and EcoRI before transfection in duplicate into the WT 820 line. 
The resulting transgenic mutants (G528, G529) were positively selected using the drug 
pyrimethamine. Also shown are the positions of the oligonucleotide primers (GU1407/GU414) and 
(GU392/GU1826) used for examining the successful integration of the construct into the genomic 
locus. (Selectable marker cassette: orange=3’UTR of Pbdhfr; dark blue=pbeef1aa; blue=hdhfr; 
green=yfcu).  
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(b) 
 
Figure 5-4 (b). Diagnostic PCR for integration. The PCR confirmed successful integration using 
the following primers: (3’ integration=1.8 kb GU392/GU1826) and (through the modified locus=5.3 
kb in ko and 5.9 kb in the WT GU1407/GU1826). Strong positive bands of desired sizes were 
observed for the two mutants indicating the 3’ integration of the construct into the PbAP2-G locus 
knocking a part of the PbAP2-G out.  
 
5.3.1.4 The double-crossover (conventional) AP2-G DNA 
binding domain (DBD) knockout mutant 
HindIII and EcoRI double-digested (New England BioLabs), linearized and 
purified targeted vector DNA (pG0273) was transfected (~5 µg) into the purified 
schizonts of the WT line (820em1dcl2) in duplicate. The mutant lines (G417, 
G418 and G419) were selected by using pyrimethamine in drinking water. 
Diagnostic PCRs (Table 5-4) using the oligonucleotide pairs GU1237/GU1132 (for 
5’ integration) and GU1133/GU1077 (for 3’ integration) showed a successful 
knockout genotype (Figure 5-5). G418 was subsequently cloned successfully. 
Table 5-4 
Oligo set Details 
Expected band size with DNA (kb) 
Ta 
(°C) 
Ext. 
Time 
(min) 
820 G417-19 Water HP 
1237/1132 5’Integration -- 2.2 -- NA 54 4 
1133/1077 3’Integration -- 2.5 -- NA 54 4 
1237/1077 Across integration 3.1 5.0 -- NA 54 7 
1238/1183 Orf 0.4 -- -- NA 54 4 
1182/1415 Control 1 (HP) NA NA NA 4.9 54 7 
1233/1242 Control 2 (HP) NA NA NA 2.9 54 4 
 
Table 5-4. Basic PCR reaction settings for amplifying various regions of the PbAP2-G 
genomic locus to identify the presence of 5’ and 3’ integration of the PbAP2-G DBD 
knockout constructs into the genome. Ta is the annealing temperature. 
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(a) 
 
 
 
 
(b) 
 
 
Figure 5-5 (a). Schematic of AP2-G (PBANKA_143750) DNA-binding domain (DBD) knockout 
strategy (not-to-scale). The schematic shows endogenous & modified genetic loci together with 
the plasmid which was linearized with HindIII & EcoRI before transfection in triplicate into the WT 
820 line. The resulting transgenic mutants (G417-9) were positively selected using the drug 
pyrimethamine. Also shown are the positions of the oligonucleotide primers GU1237/GU1132, and 
GU1133/GU1077 used for examining the successful integration of the construct into the genomic 
locus. (b) Diagnostic PCR which confirmed successful integration using the following primers: (1; 
5’ integration=2.2 kb) GU1237/GU1132 (2; 3’ integration=2.5 kb) GU1133/GU1077 and (3; through 
the modified locus=5.0 kb) GU1237/GU1077. (Selectable marker cassette: orange=3’UTR of 
Pbdhfr; dark blue=pbeef1aa; violet=hdhfr; green=yfcu) 
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5.3.2 Southern analyses of cloned knockout mutants 
5.3.2.1  Cloning of AP2-G knockout variants 
One of each of the AP2-G length variant knockout mutants which had the 
least WT contamination on PCR analyses was selected for cloning by limiting 
dilution method (Please see Section 2.2.11 of Materials & Methods). The clones 
were again analysed by PCRs for integration and WT contamination and the clone 
which showed no WT contamination on the PCRs for each of the knockout 
variants was selected for Southern analyses and subsequent experimentation. 
Thus, G401, G529 and G418 were selected for cloning from each of the 
full-length, partial-length and DBD knockouts of the AP2-G open reading frame, 
respectively. Three clones each were obtained for G401 and G529 cloning and 
G401cl1 and G529cl2 were selected as the best clones to carry forward for 
Southern Analyses based on PCR screening. G418 cloning resulted into 6 positive 
clones but the cloning had to be repeated on the basis of some WT 
contamination being identified throughout the clones. A second round of cloning 
was performed on G418cl6 yielding four clones, out of which G418cl6cl3 was 
selected for further analyses and experimentation. 
5.3.2.2    Southern analyses of clones 
Technical details of Southern analysis are given in Section 2.2.4 of 
Materials & Methods. Briefly, for comparison with the WT line (820), purified 
gDNA from WT and G401cl1, WT and G418cl6cl3 & WT and G529cl2 was double-
digested with the High-Fidelity (HF) versions of NcoI & SpeI, NcoI & BamHI and 
EcoRI & SpeI, respectively (Table 5-5 and Figure 5-6a). The membrane was then 
divided into three parts and then hybridized separately with P32 labelled single-
stranded DNA probes from specific regions from one of the homology arms used 
for generating the gene targeting vector. The probes were PCR-amplified and 
purified using the following oligonucleotides: GU1058/GU1059 for G401cl1, 
GU1416/GU1417 for G418cl6cl3 and GU1414/GU1415 for G529cl2. Each of the 
three membranes was washed and exposed for 35 hours (Figure 5-6b). 
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Table 5-5 
 
WT and G401cl1 WT and G418cl6cl3 WT and G529cl2 
WT G401cl1 Plasmid WT G418cl6cl3 Plasmid WT G529cl2 Plasmid 
RE NcoI & SpeI NcoI & BamHI EcoRI & SpeI 
Probe 
Downstream homology 
arm of full orf ko construct 
Upstream homology arm of 
the DBD ko construct 
Downstream homology arm 
of part orf ko construct 
Band 
size 
(kb) 
5.1 7.4 7.2 7.8 2.6 6.0 1.6 3.7 3.4 
 
Table 5-5. Restriction digest pattern and probes used for Southern analyses of the three 
PbAP2-G cloned knockout variants. Genomic DNA from WT & G401cl1, WT & G418cl6cl3 and WT 
& G529cl2 were double-digested with NcoI/SpeI, NcoI/BamHI and EcoRI/SpeI, respectively. The 
differential restriction digest pattern in each of the WT/knockout duo as evident by the difference in 
the size of the observed bands in each digest was clearly visible (Figure 5-6b).  
 
 
 
 
 
 
 
 
Figure 5-6 (a): Southern blot: Schematic (not to scale) showing the restriction digestion 
pattern of gDNA from AP2-G full orf knockout (ii), AP2-G DBD knockout (iii) and AP2-G part 
orf bearing the GNP mutations 7, 8,9 knockout (iv) double-digested with NcoI/SpeI, 
NcoI/BamHI and EcoRI/SpeI, respectively. The restriction pattern of WT 820 line being digested 
with all the 4 enzymes is shown in (i). The red arrowheads denote the site of action of the 
respective RE’s. The digested DNA was fractionated in 0.7% agarose and transferred to a nylon 
membrane. The membrane was UV-cross-linked and cut into three and subsequently probed 
separately with P
32
 labelled single-stranded PCR-amplified probes derived from the following 
homology arms: downstream homology arm for (ii) shown as blue bar immediately downstream to 
the AP2-G orf, upstream homology arm for (iii) shown as yellow bar within the AP2-G orf and 
downstream homology arm for (iv) shown as grey striped bar within the AP2-G orf. (Selectable 
marker cassette: orange=3’UTR of Pbdhfr; dark blue=pbeef1aa; violet=hdhfr; green=yfcu).  
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Figure 5-6 (b): Southern blots showing the restriction digestion pattern of NcoI/SpeI 
digested gDNA (a) from 820 WT (5.1 kb) and G401cl1 (7.4 kb); NcoI/BamHI  digested gDNA (b) 
from 820 WT (7.8 kb) and G418cl6cl3 (2.6 kb); and EcoRI/SpeI  digested gDNA (c) from 820 WT 
(1.6 kb) and G529cl2 (3.7 kb).  
 
5.4  The knockout phenotypes 
The effect of different length variant knockouts of the AP2-G gene was 
assessed on the basis of the resulting phenotypic changes on the sexual stage of 
development of Plasmodium.  The modalities to test this included Giemsa-
stained smears from peripheral blood, flow cytometric (FACS) analyses of the 
mutant lines, exflagellation assays, ookinete cultures, transmitting the mutant 
lines through mosquitoes, and northern and RT-PCR based analyses of the 
knockout mutants. 
5.4.1 Giemsa-stained peripheral smears 
Peripheral blood smears from the cloned knockout lines and WT line 820 
(as control) at total parasitaemia between 5% and 10% were stained with Giemsa 
stain and examined for gametocytes under a microscope (please see Section 
2.1.3 of Materials & Methods for details). Fifteen hundred parasites for each of 
the mutant and WT lines were examined and the number of gametocytes 
observed recorded as a percentage of total parasites. No gametocytes could be 
identified in all three knockout variants as compared to 11 % gametocytes in the 
WT line 820. These results strongly favoured absence of gametocytemia in all 
the AP2-G length variant knockout lines. 
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5.4.2 Flow cytometry-based evidence 
Hoechst-stained peripheral blood from the cloned knockout lines, along 
with WT line 820 (as positive control), non-fluorescent high gametocyte 
producer line HP (as negative control) and uninfected mouse (also as negative 
control) was examined using flow cytometry (please see Section 2.5 of Materials 
& Methods for details) as in Figure 5-7. Samples were examined when the total 
parasitemia in the infected lines reached between 5% and 10%. Convincingly, 
none of the mutant lines showed any gametocytemia, further indicating that 
these lines no longer produce any gametocytes. 
 
Figure 5-7 (a). FACS plots showing the Hoechst signals detected in the VioBlue channel in 
all six lines examined. VioBlue signals (the green peaks), as they come from the Hoechst-stained 
DNA, reflect the proportion of infected red blood cells detected in the gated population. The 
200,000 red blood cells/events that were examined on the Forward and Side Scatter plots from 
FACS (not shown here) were appropriately gated (selected) to select predominantly for the red 
blood cells to be included in further analyses (shown here). Thus, majority of the other potential 
sources of DNA have been excluded from the analyses. The reading (reflected from the green 
peaks) in these plots indicate the proportion of parasite-infected cells together with some 
background noise  as detected in the sample from the uninfected mouse (negative control). The 
population of cells showing the VioBlue signals in these plots were again gated (red horizontal 
bars) to select for the Hoechst-positive population that best reflects the infected red cells 
predominantly (shown as percentage over the red bars). The percentage of infected cells (1.62%) 
detected from the uninfected negative control line reflects the background false positive noise and 
hence should be discounted from the readings obtained from other infected lines. The 
undiscounted parasitemias in the HP, WT 820, G401cl1, G418cl6cl3 and G529cl2 lines was 6.45%, 
11.7%, 17%, 10.1% and 11.6%, respectively. The red gated population from these plots was 
included in further analyses of red and green fluorescence (see Figure 5-7b and 5-7c).  
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Figure 5-7 (b and c). FACS plots showing the GFP and RFP signals (Y-axis) detected in FITC 
and PEA channels, respectively in Figures 6-7 (b) and (c), in the Hoechst-positive population 
(X-axis) gated in Figure 5-7a among all the six lines examined. Each blue dot lying in the red 
rectangular gate represents a Hoechst-positive red blood cell which is positive for GFP/RFP signals 
as well, and thus is a male/female gametocyte, respectively, within the RBC. The proportion of 
such cells (shown as percentage above the red rectangular gate) represents the percentage of 
male/female gametocytes among the infected red blood cells. The male and female gametocytemia 
shown for the uninfected line (0.01% and 0.0%, respectively) and for the high gametocyte producer 
non-GFP/RFP fluorescent line HP (0.01% and 0.0%, respectively) thus reflects background 
fluorescence (false-positive error) and thus was discounted from the gametocytemia shown for the 
WT line 820 and the three cloned knockout lines. The undiscounted male gametocytemia in the WT 
820, G401cl1, G418cl6cl3 and G529cl2 lines was 0.23% and 0% each, respectively. The 
undiscounted female gametocytemia in the WT 820, G401cl1, G418cl6cl3 and G529cl2 lines was 
0.35% and 0% each, respectively. 
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5.4.3 Exflagellation assays 
In the absence of any visible gametocytes on Giemsa-stained smears and 
flow cytometry, the presence of any undetected functional male gametocytes in 
the knockout lines was investigated using the capacity of male gametocytes to 
exflagellate in vitro in ookinete culture media. The male gametocytes from 
peripheral blood, if any, in the WT line 820 and in each of the knockout variants 
were allowed to undergo the process of exflagellation reaction in the ookinete 
culture media. The number of exflagellation centres (ECs) formed in the WT line 
was then compared to in each of the knockout variants and expressed as ECs per 
104 red blood cells examined. No ECs were observed in any of the AP2-G 
knockout variants in comparison to 29 ECs in the parental WT line 820, further 
strengthening the evidence that none of these mutants is gametocytogenic 
(Table 5-6). 
5.4.4 Ookinete cultures 
Overnight ookinete cultures were set up with 1-2 drops of peripheral 
blood from the WT line 820 and each of the knockout variants being incubated 
with ~5 ml of ookinete culture media at 21 °C overnight to examine the 
presence of ookinetes under a microscope (expressed as the number of ookinetes 
per 20 fields), thus documenting the presence of functional male and female 
gametocytes, if any. No ookinetes were identified in all the AP2-G knockout 
variants as compared to 21 ookinetes in the WT parental line 820 (Table 5-6).   
 
 
 
 
 
Chapter 5 AP2-G knockout studies 210 
 
Table 5-6 
 820 
(WT) 
G401cl1 
(full orf ko) 
G529cl2 
(partial orf ko) 
G418cl6cl3 
(DBD ko) 
Flowcytometry (FACS) 
(percentage gametocytes out 
of the total infected RBCs) 
0.58 Zero Zero Zero 
Giemsa-stained smears 
(% of gametocytes per 1500 
parasites) 
11% Zero Zero Zero 
Exflagellation assay 
(number of Exflagellation 
Centres per 10
4 
 RBCs; n=3) 
29.6 Zero Zero Zero 
Ookinete counts 
(number of ookinetes per 20 
fields) 
21 Zero Zero Zero 
Mosquito passage 
(Transmission bite-back) 
Parasites 
seen 
No 
parasites 
No  
Parasites 
No 
Parasites 
 
Table 5-6. A composite table showing the examined phenotype of the three knockout 
variants of PbAP2-G as compared to the WT parental line 820. No evidence of gametocytes 
being produced by any of the three PbAP2-G knockout variants (G401cl1 – full orf ko; G529cl2 – 
partial orf ko; and G418cl6cl3 – DBD ko) as compared to the WT parental line 820 could be 
established by FACS (No observable gametocytes in the three ko’s compared to 11% in the WT), 
Giemsa-stained smears (No observable gametocytes per 1500 parasites in the three ko’s 
compared to 0.58% in the WT), Exflagellation assay (No observable exflagellation centres (EC’s) 
per 10
4 
 RBCs in the three ko’s compared to 29.6 EC’s in the WT), Ookinete cultures (No 
observable ookinete per 20 fields in the three ko’s compared to 21 in the WT), and finally mosquito 
passage (No parasites in the three ko’s transmission bite-back mice compared to 0.58% in the 
WT). All these evidences taken together convincingly demonstrate the absence of 
gametocytogenesis in all the knockout mutants. 
 
 
5.4.5 Northern analyses of the mutants 
After ruling out the presence of any sexual stage life forms of Plasmodium 
in all the AP2-G knockouts, the expression of the sexual stage specific transcript 
(P28) was examined using the northern blot technique. Briefly, approximately 5 
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µg of RNA sample for each of the WT parental line 820 and the three knockout 
variant lines (except G529cl2; which was ~2 µg) was used for the northern 
analyses. The RNA on the membrane was probed for the sexual stage transcript 
with P32 labelled P28 DNA probe (PBANKA_051490; 0.62 kb cds) and normalised 
using an HSP70 probe (PBANKA_071190; 2.08 kb cds). The absence of P28 signals 
from all the AP2-G knockouts is consistent with the absence of sexual stages in 
these lines (Figure 5-8).  Northern analyses of the three knockouts were 
performed together with the three de novo GNP mutants. The gel picture in 
Figure 5-8 has been cropped to remove the three lanes bearing the natural GNP 
mutants intervening between the WT 820 lane and the lanes bearing the three 
knockouts.  
Figure 5-8. Northern blot of total RNA from lines 820 (WT line) and AP2-G knockout length    
variant mutant lines G401cl1 (full orf knockout), G418cl6cl3 (DNA binding domain knockout) 
and G529cl2 (partial orf knockout eliminating the region of the orf with the three natural GNP 
mutations). The blot was probed for sexual stage specific transcripts with 
32
P labelled P28 dsDNA 
(~1.5 kb band in WT line 820 and no bands in the ko lines) and normalized with HSP70 probe 
(PBANKA_071190; ~3 kb band in all lines). The absence of P28 signal from all the ko lines is 
highly suggestive of absence of sexual stages in the GNP lines. (Note: the original blot had three 
extra lanes for showing the absence of P28 signals in the three naturally acquired GNP lines after 
the lane for the WT 820 line; the same have been cropped out of the image (and shown elsewhere 
in Chapter 3; Figure 3-17) and the rest of the image is shown here as two images but they come 
from the same gel). 
 
5.4.6 RT-PCR analyses 
The presence of any sexual stage-specific transcripts for P28 was again 
ruled out using reverse-transcriptase PCR (RT-PCR). Briefly ~4 µg of purified 
DNAse treated total RNA from the WT parental line 820 and the three AP2-G 
knockout variants was subjected to RT-PCR, as mentioned under Section 2.2.6 of 
P28 band 
HSP70 
bands 
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Materials & Methods. The efficiency of the RT reaction (and hence 
contamination of the cDNA with the gDNA, if any) was tested by amplifying the 
constitutive ALBA3 (PBANKA_120440) from all the lines tested using primer sets 
GU515/GU516. Since ALBA3 gDNA has an intron, its PCR amplification after the 
RT reaction allowed differentiation between amplicons from gDNA and cDNA on 
the basis of difference in expected sizes: 0.64 kb for gDNA and 0.32 kb for cDNA. 
 
                 
 
  
(a) 
 
 
 
 
                 
 
 
(b) 
 
Figure 5-9. Agarose gel electrophoresis pictures showing amplified bands from RT-PCR 
reactions of P. berghei ALBA3 (constitutive) and P. berghei P28 (sexual stage-specific). 
Figure 5-9 (a) shows the ALBA3 gDNA and ALBA3 cDNA (RT-PCR products) from the WT parental 
line 820 and the three PbAP2-G knockouts to assess the efficiency of the reverse transcriptase 
reaction in terms of gDNA contamination of cDNA. Since the alba3 gene (0.6 kb) contains an intron 
(0.3  kb)  provides a basis of detecting the gDNA (0.6 kb band) contamination of the cDNA. 
Absence of any 0.6 kb bands in all the samples rules out the possibility of the presence of any 
gDNA in the RT-PCR products. Sexual stage-specific P28 was reverse-transcribed and PCR-
amplified from the WT line 820 but not the three PbAP2-G knockout variants Figure 5-9 (b). 
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Presence of P28 gDNA bands in all the lines and P28 cDNA only in the parental WT 820 line 
together with similar findings from the northern analyses strongly establishes the absence of any 
expression of sexual stage-specific prototype P28 from all knockout lines, thus supporting an 
absence of sexual stages in the knockouts.  
 
 
The RT reaction yielded pure cDNA (uncontaminated with any gDNA) as 
evidenced by the presence of the smaller 0.32 kb band and absence of the gDNA 
band in the ALBA3 RT-PCR amplicons (cDNA). Absence of the sexual stage 
specific P28 cDNA band in the RT-PCR analyses from all  three AP2-G knockout 
lines (in presence of the P28 band in gDNA and cDNA from WT 820 line) further 
corroborated the findings of the northern analyses, strongly indicating an 
absence of sexual stages in the three AP2-G knockout variants. No bands in the –
RT reactions ruled out the presence of any gDNA contamination in the samples 
(Figure 5-9b). 
 
5.4.7 Transmission through mosquitoes 
As a final confirmation of the absence of any residual functional 
gametocytes in the three AP2-G knockout variants, the full length AP2-G 
knockout variant (G401cl1) was transmitted through the mosquitoes along with 
the WT parental line 820 in separate experiments. Briefly, a mouse infected 
independently with the WT line 820 was fed to approximately 200 adult 
mosquitoes (predominantly females) and a mouse infected with G401cl1 was fed 
to approximately 600 adult mosquitoes (predominantly females) in independent 
cages at a parasitemia between 2% and 4%. The mosquitoes were maintained at 
21°C for 21 days in the insectary after which they were fed on naïve mice 
(mosquito bite-back or transmission bite-back or TBB). Blood samples from the 
mice were smeared from day 0 of the bite-back and were examined for 
parasites/gametocytes by Giemsa stain and flow cytometry (FACS). The WT line 
820 bite-back mouse had detectable parasitemia in the peripheral blood on day 
0 post-bite back and the parasites followed normal growth kinetics. No 
parasitemia could be detected in G401cl1 TBB line up to day 6 post-TBB (Figure 
5-10) and even on day 10 and day 14 of the bite-back (data not shown), 
confirming that the cloned knockout line lacked viable gametocytes when 
initially fed by the mosquitoes.    
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Figure 5-10. Post-transmission parasitemia kinetics as percentage of infected red blood 
cells in lines WT 820 and G401cl1 (full orf ko line) on Y-axis and days post-biteback on X-
axis. WT 820 line showed detectable parasitemia straightaway from the day the infected 
mosquitoes were allowed to feed on the naïve mice. The knockout line G401cl1 did not show any 
parasites up to day 6 post-TBB and even by day14 post-TBB (not shown in the kinetics above). 
These findings show conclusive evidence that the knockout line, G401cl1, failed to transmit through 
the mosquitoes as they lacked functional gametocytes. 
 
 
5.5 Summary and discussion 
 
Gametocytogenesis in Plasmodium has been poorly understood in terms of 
the genetic regulation of the process in general and the molecular basis of 
commitment to gametocytogenesis in particular (Eksi et al., 2012; Ikadai et al., 
2013). Although microarray experiments in P. falciparum have identified many 
genes being associated with early and mature gametocytes as gametocyte-
specific genes (Young et al., 2005), targeted gene knockout of some of them 
including Pfs16 (Kongkasuriyachai et al., 2004), Pfg27 (Olivieri et al., 2009), 
Pfmdv1/peg3 (Furuya et al., 2005), Pf11.1, Pfs230 (Eksi et al., 2006) and Pfg377 
(de Koning-Ward et al., 2008) did not produce an absolute gametocyte non-
producer mutant.  
 
The role of ApiAP2 TF PBANKA_143750 (termed AP2-G) in commitment to 
gametocytogenesis (established earlier in Chapter 3 and 4) was tested by a 
reverse genetics approach, using conventional and recombineering—based 
homologous recombination, by knocking out the PbAP2-G. Because of the 
relatively large size of the gene, at least two different knock out strategies and 
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knock out involving three different regions of the AP2-G gene (including the 
complete open reading frame) were attempted. A variety of experiments 
targeted towards understanding the phenotype of the three length-variants of P. 
berghei AP2-G (full length, partial length and DNA-binding domain) knockout 
convincingly established a central role for the transcription factor in 
gametocytogenesis. 
Knockout of the implicated gene and correlation of the resulting 
phenotype with the expected role played by the gene are amongst the first steps 
towards establishing a causative association of the implicated gene with the 
phenotype. AP2-G was implicated to play a central role in commitment of the 
parasite towards sexual development on the basis of its uniqueness in being 
mutated in all three de novo GNP mutants generated in this study. Three 
independent Pb AP2-G targeted knockout constructs varying in the length of the 
gene region to be knocked out were made including: a full length AP2-G 
knockout, a partial length AP2-G knockout deleting the region which had the 
three GNP mutations and a DBD knockout. Each construct was transfected in 
triplicate to generate three mutant lines from each knockout variant. 
The PbAP2-G knockout length variants also established the criticality of 
different regions of the protein in terms of their functional requirement for 
gametocytogenesis. Whereas the full-length and DBD knockout associated GNP 
phenotype revealed the expected functional essentiality of the domain, the 
partial length knockout variants eliminating the portion of the orf bearing the 
three GNP mutations explained the contributory role of frameshift and 
premature stop codons upstream to the DBD in gene expression. However, it 
would still be interesting to examine the role of the region downstream to the 
DBD as it was involved in the GNP attributed to the mutation in line 233.     
Collective evidence from the genotypic and phenotypic analyses of the 
knockout variants unambiguously revealed that none of these mutants produced 
viable gametocytes thus confirming the central role of PbAP2-G in commitment 
to Plasmodium gametocytogenesis. Independent experiments with the P. 
falciparum ortholog of PBANKA_143750, PF11_1085w knockout also identified a 
GNP phenotype (Kafsack et al., 2014). This conservation of function of the AP2-G 
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gene in both the species is indicative of a conserved, critical role of the gene in 
the process of commitment to gametocytogenesis. Recent work also 
demonstrated the role of another ApiAP2 gene, PBANKA_103430 (termed AP2-
G2), in gametocytogenesis. In an independent work, disruption of AP2-G2 
resulted in near-complete loss of production of mature gametocytes (a few 
female gametocytes occasionally observed) and failure to transmit through 
mosquitoes (Sinha et al., 2014; data not shown). Direct growth competition 
assays between AP2-G knockout, WT P. berghei and AP2-G2 knockout revealed 
that AP2-G knockout mutants overgrew the WT and AP2-G2 knockout mutants 
indicating that AP2-G mutants completely lacked gametocytes thus offering a 
growth advantage to the asexually dividing parasites (Hughes and Billker, 
personal communication). This establishes the central role of AP2-G at the point 
of commitment to gametocytogenesis whereas AP2-G2 is probably involved 
downstream of AP2-G once the parasites are committed to form gametocytes.  
    
 
 
 
 
 
 
 
 
 
 
 
6 Gene complementation in gametocyte non-
producer mutants to restore their commitment 
to gametocytogenesis   
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6.1  Introduction 
A forward genetics whole genome sequencing-based approach to identify 
the genetic locus involved the generation of GNP mutants (Chapters 3 and 4) 
together with the targeted gene perturbation studies (Chapter 5) is generally 
sufficient to establish causality between genotype and phenotype. However for 
complete rigour it was decided to attempt complementation of the implicated 
gene to restore the WT phenotype. Plus, it was also thought that 
complementation would open the possibility to attempt to complement other 
GNP lines that have AP2-G2 defects in an attempt to ascertain if they were now 
capable of transmission.   
Genetic complementation opens opportunities to causally associate an 
implicated gene with its hypothesised function. Complementation experiments 
may serve as powerful tools in understanding the molecular basis of a variety of 
basic and applied phenomena in apicomplexan biology where most of the genes 
have hypothetical and/or unknown functions (Striepen et al., 2001; Sultan et al., 
2001; Florent et al., 2010). Also, even in the presence of the usual controls, it 
may be difficult to refute that the resulting phenotype from gene targeting 
experiments is not due to accumulation of independent genomic alterations 
during the recombination events or due to the presence of the altered 
recombinant / genomic locus per se (Janse et al., 2011).  
However, difficulty in cloning  large coding regions of  AT-rich genomes in 
order to be able to complement the full length of the knocked out gene still 
remains a major deterrent to successful complementation experiments in 
Plasmodium spp., more so when the region to be complemented extends up to 
not less than 7 kb, as in the case here with PbAP2-G. The role of a second 
independent mutant is said to be indispensable in difficult to complement genes 
(Goldberg et al., 2011).  
Amidst all the difficulties in attempting successful complementation in 
malaria parasites, especially P. berghei, the novel Gene-In Marker-Out, (the 
GIMO) approach claims to offer multiple advantages over conventional 
complementation approaches in terms of being faster, less laborious and 
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requires fewer animals (Lin and Annoura et al., 2011). Additionally, the GIMO 
method could be combined with the recently developed “recombineering” based 
high-throughput gene targeting approach (Pfander et al., 2011). 
6.2  Complementation strategies to restore  
  gametocytogenesis in the PbAP2-G   
  mutants 
As two different types of PbAP2-G mutants were created using forward 
and reverse genetic approaches independently, both generating the gametocyte 
non-producer (GNP) phenotype, restoring the full functional copy of PbAP2-G 
was attempted through at least two independent approaches. Whereas forward 
genetic experiments identified three independent natural GNP PbAP2-G mutants 
(having SNPs and indels; Chapter 3), the reverse genetics approach resulted in 
creating three knockout length variants of PbAP2-G in separate experiments 
(Chapter 6). As the two approaches resulted in a differently modified PbAP2-G 
locus, complementation strategies differed for each group of GNP mutants.  
6.2.1 Complementation strategies for natural PbAP2-
G mutants 
Chapter 3 of this thesis identified three natural GNP mutants (m7, m8 and 
m9) by forward genetic screening all these GNP mutants had a unique and 
therefore independent mutation in PbAP2-G – SNP in m7 and indels in m8 and 
m9. As these GNP mutants were negatively selected to remove the drug 
selectable markers initially in their genome, complementation was attempted 
with constructs having a full length PbAP2-G (~7 kb) flanked either by an 
upstream (PbG01_COMP-UP) or a downstream (PbG01_COMP-DOWN) copy of the 
positive-negative drug selectable marker.     
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6.2.1.1 Complementation of natural PbAP2-G GNP mutants 
with PbG01_COMP-UP 
 In order to complement all three natural PbAP2-G GNP mutants with a full 
length copy of the WT PbAP2-G, a recombineering based construct 
(PbG01_COMP-UP; Figure 6-1a) was kindly designed and gifted by Claudia 
Pfander and Oliver Billker (Wellcome Trust Sanger Institute, Cambridge, UK). 
The construct had a full length copy of the WT PbAP2-G with a positive-negative 
drug selectable marker (positioned 1.2 kb upstream of the AP2-G translation 
start site) cloned into a linear pJAZZ vector. The purified vector was double-
digested with NotI (New England BioLabs) and approximately 5 µg of the 
linearized vector was transfected into the cloned GNP m9 line (GNPm9cl1 as a 
prototype) in triplicate. The resulting transfectants (G366, G367 and G368) were 
selected by using pyrimethamine in drinking water. Transfectants were PCR-
screened for successful 5’ integration by using synthesised oligonucleotide pairs 
GW2/GU1057 as shown in the Figure 6-1(a). The expected length of the 
amplicons for each of the integration events was 1.5 kb (Table 6-1). A summary 
of all the oligonucleotide sets used as primers in the PCRs, their details, 
expected length of bands, annealing temperature (Ta) settings used and 
extension time used for various PCR reactions are shown in Table 6-1.  
Table 6-1 
 
Oligo set Details 
Expected band size with DNA (kb) Ta 
(°C) 
Ext Time 
(min) GNPm9cl1 G366-8 Water Control 
GW2/1057 5’Integration -- 1.5 -- NA 48 5 
1233/1242 Control NA NA NA 2.9 48 5 
 
Table 6-1. Basic PCR reaction settings for amplifying various regions of the PbAP2-G 
genomic locus to identify the presence of 5’integration of the recombineering based 
complementation construct (PbG01 COMP-UP) into the GNP9 genome. 
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(a) 
 
 
(b) 
 
Figure 6-1 (a). Schematic of complementation strategy used to repair the m9 mutation in the 
PbAP2-G (not-to-scale). The figure shows mutated endogenous GNP m9 & modified genetic 
locus together with the recombineering based plasmid construct which was linearized with NotI 
before transfection in triplicate into the cloned GNP m9 line. The endogenous GNP m9 locus (i) 
shows the location of the SNP in GNP m9 as a yellow bar on the PbAP2-G orf. The drug selectable 
marker (multi-coloured bar; orange=3’UTR of Pbdhfr; dark blue=pbeef1aa; violet=hdhfr; 
green=yfcu) is positioned at 1.2 kb upstream of the PbAP2-G translation start site (ii). The resulting 
transgenic mutants (G366-68) were positively selected using the drug pyrimethamine containing 
the transgenic locus (iii) with repaired m9 mutation. Also shown are the positions of the 
oligonucleotide primers (GU1057/GW2) used for examining the successful 5’ integration of the 
construct into the genomic locus. The recombinogenic potential of the drug selection cassette 
(either spontaneous or under negative selection) and the resultant transgenic locus (iv) is also 
shown in the schematic. Figure 6-1(b). Diagnostic PCR showing integration events. The PCR 
confirmed successful 5’ integration using the following primers GU1057/GW2 (5’ integration band = 
1.5 kb). Strong positive bands of desired size were observed for all the three mutants indicating the 
integration of the construct into the PbAP2-G locus thus repairing the m9 mutation.  
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The presence of a few non-specific bands in the gel picture (Figure 6-1b) 
might be due to low annealing temperature used for the PCRs. But despite the 
observation of these non-specific bands, the presence of strong integration 
bands of 1.5 kb for G366-8 and their absence in the GNP m9 and water samples 
strongly indicate the successful integration of the complementation construct 
into the desired genomic locus.  
6.2.1.1.1 Phenotypic and genotypic characterization of the 
PbG01_COMP-UP complemented natural PbAP2-G GNP 
mutants 
 
Despite the PCR-based evidence suggesting a successful 5’ integration of 
the complementation construct (PbG01_COMP-UP) into the GNP m9 PbAP2-G 
locus, there was no evidence of any gametocytes on Giemsa-stained smears and 
flow cytometry in the transfectants, G366-8. It was not possible to examine the 
3’ integration of the construct at the desired genomic locus by PCR-based 
methods because the very large region of genomic similarity between the 
construct and the target genomic locus generated a large expected product (~8 
kb) that is difficult to PCR-amplify. In the absence of confirmation of the 3’ 
integration, the precise point of integration at the 3’ end could not be 
confirmed. However, the site of an integration event at the 3’ end is important 
as this might determine the success of complementation and the restoration of 
the WT phenotype. If the site of integration is anywhere upstream to the m9 SNP 
locus, there will not be any restoration of the phenotype since the transfectants 
will still retain the m9 SNP despite a successful integration at both ends (Figure 
6-2). Conversely, if the integration happens to occur anywhere downstream to 
the m9 SNP, the restoration to the WT phenotype becomes highly likely (Figure 
6-1; see GNP m9 locus (i) and the transgenic locus (ii)). Whatever the case may 
be, there should not be any other mutations than that in question (m9 SNP) 
conferring the GNP phenotype as evident in the cloned m9 GNP line.  
 
There is a third possibility of getting a mixed population of parasites some 
having a proximal and some distal (as compared to the location of the m9 SNP) 
integration at the 3’ end. If this happens, the ultimate phenotype of the 
transfectants will most likely be that of the gametocyte non-producers, given 
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the fact that the GNP phenotype offers a growth advantage over the gametocyte 
producer phenotype. Thus, any population of the GNP type will tend to overgrow 
the gametocyte producer phenotype population and will eventually replace the 
latter, thus resulting in the pure GNP phenotype. 
 
 
 
 
 
 
 
Figure 6-2. Schematic of complementation strategy used to repair the m9 mutation (yellow 
bar) in the PbAP2-G (not-to-scale) showing mutated endogenous GNP m9 & modified 
genetic locus together with the recombineering based plasmid construct (PbG01_COMP-
UP) and the drug selectable marker (multi-coloured bar; orange=3’UTR of Pbdhfr; dark 
blue=pbeef1aa; violet=hdhfr; green=yfcu). The schematic highlights the importance of the site of 
homologous recombination event at the 3’ end. Note that in this case, the recombination event is 
shown to occur upstream of the m9 mutation and hence the resultant transgenic locus (iii) retains 
the m9 mutation and hence the GNP phenotype. This is in contrast to the 3’ homologous 
recombination event happening downstream of the m9 mutation (Figure 7.1(a)), resulting in the 
restoration of the m9 locus to the WT thus reverting the GNP phenotype to the WT phenotype 
(successful complementation).  
 
Considering all of the above possibilities, following evidence of successful 
5’ integration, the way to successfully isolate mutant parasites having the 
correct version of the 3’ integration is to clone the repaired lines first and then 
identify the correct clone by sequencing through the m9 mutation region. A 
better alternative (in terms of saving time and animals) is to first sequence the 
repaired mutants and then clone the best one from the mutants. The latter 
strategy was chosen and all three transfectants (G366-8) were sequenced. The 
region (~1000 bp) flanking the m9 SNP (around 650 bp upstream and 350 bp 
downstream to the m9 SNP) was PCR-amplified using  high fidelity Taq 
polymerase (Expand High Fidelity PCR System; Roche) and the oligonucleotide 
primers GU1084/GU1085 (Figure 6-3). As evident from Figure 6-3, the m9 SNP 
locus was restored to the WT genotype in lines G367 and G368 whereas line G366 
Drug selection cassette 
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retained the m9 GNP genotype and phenotype. A possible explanation of this 
may come from the site of recombination event happening at the 3’ end (as 
explained in section 6.2.1.1.1) suggesting that a higher frequency of the 
recombination event  downstream of the m9 locus favours restoration of the m9 
genotype and phenotype to the wild type and vice versa. The lines G367 and 
G368 were subsequently successfully cloned by the limiting dilution method 
(please see section 2.2.11 of Materials & Methods) and the clones G367cl2 and 
G368cl1 were selected for further work on complementing these lines in future. 
 
 
Figure 6-3. Multiple sequence alignment using CLC version 5.0 software. The genomic 
sequences (cropped from left and right from the original) from the PCR-amplified region 
encompassing the m9 locus from the lines G366-8 using oligonucleotide primers GU1084/GU1085 
were aligned to examine the possible site of 3’ recombination event. The black vertical box 
highlights the nucleotide base involved in the m9 T-A SNP. The WT locus had a thymine which was 
mutated to adenine in the GNP mutant m9. As evident, the lines G367 and G368 had the mutation 
corrected whereas G366 retained the mutation suggesting a higher frequency of a 3’ integration 
event downstream of the m9 SNP. In comparison, a higher frequency of a 3’ integration event 
upstream to the m9 SNP locus might have been responsible for the non-restoration of the m9 SNP 
relative to the WT genotype.   
 
6.2.1.1.2  Possible explanation for failed complementation in G367 
 and G368 
 
Despite sufficient evidence suggesting the presence of a restoration-
favourable genotype in G367 and G368, there was no evidence of successful 
complementation in terms of restoration of the GNP phenotype to the wild type 
phenotype in either of the lines. The possible reasons for a failure to 
complement were examined. A potential interruption of the AP2-G promoter 
region by the drug-selectable marker cassette (~3 kb) was suspected to be one 
of the causes.  It could also be due to altered length of the endogenous AP2-G 
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promoter rendering a conformational change in the way the DNA molecules are 
coiled around histone proteins (nucleosome phasing). It is well known that 
nucleosomal organization at the genomic level has a critical role in regulating 
gene expression in eukaryotes (Kornberg and Lorch, 1999). There is a particular 
‘phasing’ of the nucleosome in relation to the transcription start site (TSS) at 
the genomic level with an average inter-nucleosomal distance of 162 bp (Cui et 
al., 2012). Any alteration in nucleosome phasing may put the nucleosome out of 
phase in relation to the TSS and has been shown to be directly correlated with 
gene expression by either increasing or impeding the accessibility of functional 
cis-elements to RNA polymerases II or transcription factors or both (Hasan, S. 
2003, PhD thesis; Schones et al., 2008). 
 
 To verify the hypothesis that an interruption in the AP2-G promoter 
region might have contributed to failure to complement the GNP m9 line, the 
parental WT line 820 was transfected with ~5 µg of PbG01_COMP-UP DNA (Table 
6-2; Figure 6-4).   
Table 6-2 
 
Oligo set Details 
Expected band size with DNA (kb) Ta 
(°C) 
Ext Time 
(min) WT 820 G399-G400 Water Control 
GW2/1057 5’Integration -- 1.5 -- NA 48 5 
1233/1242 Control NA NA NA 2.9 48 5 
 
Table 6-2. Basic PCR reaction settings for amplifying various regions of the PbAP2-G 
genomic locus to identify the presence of 5’integration of the recombineering based 
complementation construct (PbG01 COMP-UP) into the WT line 820 genome. 
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(a) 
 
 
 
 
(b) 
 
Figure 6-4 (a) Schematic (not-to-scale) of transfection strategy used to test the role of 
PbAP2-G promoter interruption in the failure of complementation of GNP m9 line with 
PbG01_COMP-UP. The wild type line 820 (i) was transfected with the recombineering based 
plasmid construct PbG01_COMP-UP (ii) containing the drug selectable marker cassette (multi-
coloured bar; orange=3’UTR of Pbdhfr; dark blue=pbeef1aa; blue=hdhfr; green=yfcu) upstream to 
AP2-G. The resultant positively selected mutant (iii) is similar to the WT except for the presence of 
the drug selectable marker cassette sitting 1.2 kb upstream to the AP2-G TSS. The schematic 
highlights the interruption of the PbAP2-G promoter with the selection cassette. Figure 7.4(b) 
Diagnostic PCR. The PCR confirmed successful 5’ integration using the following primers 
GU1057/GW2 (5’ integration band = 1.5 kb). Strong positive bands of desired size were observed 
for both the mutants indicating the integration of the construct into the PbAP2-G locus thus 
interrupting the promoter of PbAP2-G. 
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6.2.1.1.3 Genotypic and phenotypic confirmation of G399 and G400 
 
After positive selection with oral pyrimethamine, two transfectants 
(G399-G400) were obtained; both of them were screened by PCR (Table 6-2 and 
Figure 6-4b) which was suggestive of successful 5’integration of the construct 
into the WT genome thus interrupting the promoter. Phenotypically, both G399 
and G400 had no observable gametocytes on Giemsa-stained peripheral blood 
smears and flow cytometry (Figure 6-5) and thus had the classical GNP 
phenotype, similar to that observed for the PbAP2-G knockouts (See Chapter 5). 
Although the precise length of the promoters in Plasmodium are not known, so 
as to put the position of the SM cassette in context of the probable promoter 
region, an upstream sequence length of 2 kb is conventionally used as a standard 
promoter (Mair et al., 2009; Ponzi et al., 2010). Other conditions being similar, 
the resulting GNP phenotype in G399 and G400 strongly supports the assertion 
that indeed the promoter of the AP2-G was interrupted by the SM cassette while 
attempting complementation with PbG01_COMP-UP construct.  
 
 
 
 
Figure 6-5. FACS plots showing the GFP signals (Y-axis; upper panel; male gametocytes) 
and RFP signals (Y-axis; lower panel; female gametocytes) detected in FITC and PEA 
channels, respectively in the Hoechst-positive population (X-axis) in the blood from 
uninfected, WT line 820 infected and the G400 line. The G400 line (and G399; not shown) 
showed no gametocytes on flow cytometry as compared to the WT line 820 thus suggesting that 
the G399 and G400 lines were GNP lines. 
 
Uninfected WT 820 G400 
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6.2.1.1.4  Repairing the promoter in lines G399 and G400 
 
Various attempts to repair the promoter interruption in G399 and G400 
were tried including a negative selection experiment to reduce the length of the 
interrupting SM cassette thus providing a chance (although bleak) of putting the 
nucleosomes back in phase with AP2-G TSS. The fact that the selectable marker 
cassette had two identical copies of the 3’pbdhfr/ts flanking the pbeef1αa, 
hdhfr/ts and yfcu, negative selection with 5-FC (please see section 2.1.5 of 
Materials & Methods) was attempted to recycle the selectable marker cassette 
thus leaving a footprint of only ~450 bp into the genome (Figure 6-4 (iv)). 5-FC 
was used from day0 post-passaging (Figure 6-6). Following negative selection on 
G399 and G400, the two lines obtained were labelled G399m1 and G400m1. The 
parasitemia kinetics of both G399m1 and G400m1 in Figure 6-6 suggests that 
either the majority of the pre-negative selection parasite population already had 
the selectable marker cassette recycled, possibly because the recombination 
event happened spontaneously, or there was a minimal WT contamination in 
G399 and G400 that was high enough to reflect gametocytemia in FACS (Figure 
6-5) as G399 and G400 were not cloned before proceeding for negative selection. 
The decision of proceeding with the uncloned lines was based on the FACS 
observation of a GNP phenotype and on the assumption that GNP phenotype will 
eventually overgrow the WT counterpart, if any, over time thus self-cloning the 
GNP parasites.  
 
 
 
Figure 6-6. Negative selection for lines G399 and G400 using 1.5 mg/ml 5-FC dissolved in 
drinking water. The X-axis shows days after passage of the respective lines; 5-FC was 
administered from the day of the passage in drinking water and continued till day 8. Y-axis shows 
the parasitemia as percentage of infected red blood cells. The steep rise in parasitemia in absence 
of an initial peak suggested that the majority of the starting population had already undergone 
spontaneous homologous recombination event between the two identical copies of 3’Pbdhfr/ts 
before 5-FC selection.  
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PCR analyses of the negatively selected lines G399m1 and G400m1 
suggested the latter possibility of the presence of a WT population  which  
somehow “escaped” from being overgrown by the GNP counterparts and became 
selected (over  lines with the full drug selectable marker or with the ~450 bp 
post-negative selection footprint) during negative selection (Table 6-3; Figure 6-
7). The FACS analyses showed gametocytes both in G399m1 (Figure not shown) 
and G400m1 (Figure 6-8) suggesting success in repairing the interrupted PbAP2-G 
promoter by reducing the size of the interruption. But the evidence from PCR 
analyses supported the amplification of the WT genotype instead producing the 
gametocytes. The possibility of both scenarios is intriguing – assuming the 
observation of gametocytes in flow cytometry was due to the selection and 
subsequent proliferation of the latent WT population, the absence of any 
reflection of the WT contamination in the FACS data from G399 and G400 argues 
against this assumption. This would also mean that the GNP mutants failed to 
overgrow the WT counterpart in G399 and G400 which cannot be explained. 
Thirdly, it also implies that it is possible to select for a latent gametocyte 
producing WT population even against the definite growth advantage of the 
dominant GNP population. If this was the case, then it would seem possible to 
use negative selection for selective proliferation of a complemented (WT-like) 
gametocyte producer population  against a GNP background, which would 
provide an advantageous determinant of  success of complementation (using 
negative selection) in the engineered GNP mutants. 
Table 6-3 
Oligo set DNA 
Expected band 
 size (kb) 
Ta (°C) 
Ext Time 
(Min) 
1055/1057 WT line 820 2.1 54 7 
1055/1057 G399 5.5 54 7 
1055/1057 G400 5.5 54 7 
1055/1057 G399m1 2.7 54 7 
1055/1057 G400m1 2.7 54 7 
1055/1057 Water -- 54 7 
1233/1235 Control 5.9 54 7 
 
Table 6-3. Basic PCR reaction settings for amplifying the region across selectable marker 
cassette positioned in the immediate 5’ upstream region of the PbAP2-G genomic locus in lines WT 
820, G399 and G400 and their negatively selected counterparts, G399m1 and G400m1 to identify 
the efficacy of the negative selection in terms of a reduction of the size of the promoter interruption.  
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6.2.1.1.5  Negative selection of cloned repaired lines to reduce the 
 PbAP2-G promoter interruption 
 
Because of the uncertainty of success involved in the repair (reducing the 
size) of the interruption in the PbAP2-G promoter, the cloned repaired lines 
(G367cl2 and G368cl1) were subjected to negative selection. This generated the 
lines G367cl2m1 and G368cl1m1 which when examined under Giemsa-stained 
peripheral blood smears and flow cytometry showed no evidence of 
gametocytemia and hence no evidence of successful complementation (data not 
shown). Although the negative selection successfully reduced the size of the 
interruption of the PbAP2-G promoter region, even the presence of ~450 bp of 
footprint was sufficient to prevent the expression of AP2-G and hence the 
success of  complementation  of natural GNP mutants with the PbG01_COMP-UP 
construct. 
 
 
 
Figure 6-7. Diagnostic PCR across the position of the selectable marker cassette in the 
immediate 5’ upstream region of the PbAP2-G genomic locus in lines WT 820, G399, G400 
and their negatively selected counterparts, G399m1 and G400m1 to identify the efficacy of 
the negative selection in terms of a reduction of the size of the promoter interruption. The 
lines G399 and G400 show minimal contamination of the WT band (2.1 kb) as these were still 
uncloned lines together with the band size corresponding to the full length selectable marker 
cassette (5.5 kb). The negatively selected lines G399m1 and G400m1 instead of showing a 
predominant 2.7 kb band suggesting marker recycling (thus reducing the size of the selectable 
marker interruption) showed a stronger WT band (2.1 kb) suggesting that the WT residual in G399 
and G400 selectively proliferated under negative selection in G399m1 and G400m1 rather than the 
selectable marker recycling, thus hampering the possibility of repair of the interrupted promoter in 
lines G399m1 and G400m1. 
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Figure 6-8. Flowcytometry plots showing presence of gametocytes examined in blood from 
line G400m1 (right pane) as compared to the blood from uninfected moue (left pane). The X-
axis shows the Hoechst signals in the VioBlue channel in both upper and lower panels whereas the 
vertical axis in the upper panel shows the GFP signals (male gametocytes) in the FITC channel 
and RFP signals (female gametocytes) in the PE-A channel. The presence of male and female 
gametocytes in the line G400m1 suggests the repair of the promoter and thus restored functioning 
of PbAP2-G although the reactivation of the residual WT parasites from line G400 in line G400m1 
was suspected of generating FACS-detectable gametocytemia in an apparently repaired line. 
 
6.2.1.2 Complementation of natural PbAP2-G GNP mutants 
with PbG01_COMP-DOWN 
Looking collectively at the body of evidence regarding successful 
integration of the huge recombineering-based complementation construct and 
regarding the possible interruption of the PbAP2-G promoter region with the 
PbG01_COMP-UP construct which might have hampered the success of the 
complementation attempts, it was felt essential that a new complementation 
construct be made such that the drug selectable marker cassette sits within the 
3’UTR of PbAP2-G instead of the promoter region. This new construct was again 
kindly developed and gifted to me by Oliver Billker and his group at Sanger. This 
new construct was called PbG01_COMP-DOWN and had the drug selectable 
marker cassette sitting ~2 kb downstream of the PbAP2-G stop codon (Figure 6-
9). 
Chapter 6 AP2-G complementation studies 232 
 
 
 
 
 
 
Figure 6-9. Schematic (not-to-scale) of the complementation strategy used to repair the 
naturally acquired GNP mutations in lines m9, m8 and m7. The WT endogenous locus shows 
full length PbAP2-G with relative location of the three natural GNP mutations (yellow vertical bars). 
Also shown below is the NotI digestable complementation construct (PbG01_COMP-DOWN) 
bearing the full length WT copy of PbAP2-G with a selectable marker cassette (multi-coloured 
horizontal bar; detailed at the bottom right corner of the figure; orange=3’UTR of Pbdhfr; dark 
blue=pbeef1aa; violet=hdhfr; green=yfcu) positioned approximately 2 kb downstream to the AP2-G 
stop codon. The recombinable homology regions between the endogenous locus and the construct 
are depicted as crosses. The recombined transgenic locus (a) selected using pyrimethamine as 
positive selection shows the repaired mutations in the genome together with the introduction of the 
selectable marker cassette downstream. The modified transgenic locus (b) shows the occurrence 
of possible spontaneous recombination event between two homologous copies of the 3’ Pbdhfr/ts 
resulting in elimination of the part of the cassette flanked by the two copies thus reducing the size 
of the interruption. The position of the oligonucleotides used for checking the integration of the 
construct into the genome is also shown (Table 6-4). 
 
 
Transfections were done with ~5 µg of NotI (New England BioLabs) 
linearized PbG01_COMP-DOWN constructs in triplicate into WT line 820 (G657; as 
a control to examine if the positioning of the selectable marker cassette had any 
effects on the expression of PbAP2-G) and each of the three natural de novo GNP 
lines; GNP line 9 (G654, G655 & G656), GNP line 8 (G699, G702 & G703) and GNP 
line 7 (G696, G697 & G698). The resulting transfectants were selected by using 
pyrimethamine in the drinking water. Lines G656 and G657 were subsequently 
cloned and  clones G656cl1-2, and G657cl1-3 together with  transfectant lines 
derived from GNP lines 7 and 8  PCR-screened (for successful integration of the 
complementation construct into the genome by amplifying the region spanning 
through the selectable marker cassette using  oligonucleotide primer pairs 
Drug selection cassette 
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G2243/GU2246 as shown in the Figure 6-9. The expected length of the amplicons 
for each of the integration events was 5.5 kb as compared to 2.0 kb each in the 
WT line 820 and the parental GNP lines 9, 8 and 7 (Table 6-4). A summary of all 
the oligonucleotide sets used as primers in the PCRs, their details, expected 
length of bands, annealing temperature (Ta) settings used and extension time 
used for various PCR reactions are shown in Table 6-4.  
 
Table 6-4 
 
Table 6-4. Basic PCR reaction settings for amplifying the region across the selectable 
marker cassette in the endogenous locus (WT line 820 and GNP lines) and transgenic loci 
(a) and (b) (complemented lines; Figure 6-9). The relative size of the PCR product at the desired 
locus indicates the success of integration of the construct into the targeted genomic locus. 
 
6.2.1.2.1  Genotypic and phenotypic characterization of the GNP  
  mutants complemented with PbG01_COMP-DOWN 
  
 PCR analyses through the integration site using oligonucleotide primers 
GU2243/GU2246 from the lines WT 820, natural GNPs and their corresponding 
repaired lines showed expected results. As discussed earlier, the reasons for the 
failure to complement natural GNP mutants with the upstream construct 
PbG01_COMP-UP and hence the need for the new downstream construct 
(PbG01_COMP-DOWN) were at least two-fold – first, the correction of the GNP 
mutation was dependent on the precise site for the 3’ integration of the 
complementation construct into the genome, and second, more importantly, any 
successful genotypic correction of the GNP mutation was masked by the inability 
of PbAP2-G expression stemming from the interruption of the promoter region of 
the gene by the drug selectable marker cassette built into the plasmid. The 
downstream version of the complementation construct PbG01_COMP-DOWN was 
Oligo set Details 
Expected band size with DNA (kb) 
Ta 
(°C) 
Ext 
Time 
(min) 
WT 
line 
820 
GNP Transfectants Water HP 
2243/2246 
Through the 
selectable 
marker 
2.0 2.0 5.5 -- NA 52 6 
1233/1242 Control NA NA NA NA 2.9 52 3 
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designed to solve the second problem (by maintaining the integrity of the PbAP2-
G promoter) so that any corrective homologous recombination event results in 
expression of the repaired gene copy. This possibility of non-interference of the 
expression of the locus by the complementation construct was examined by 
transfecting the construct into the WT line 820. The hypothesis being, any 
interference of expression due to the position of the SM cassette will be 
reflected in the transfectants’ GNP phenotype. If the number of gametocytes 
formed in these transfectants is optimum, it would imply that the position of the 
SM cassette is not interfering with the gene expression and thus the construct 
could be utilized to functionally repair the GNP mutation.  
 
 The PCR analyses from the three clones of line G657 revealed that the 
construct integrated into the genome as evidenced by the presence of the 5.5 kb 
band in Figure 6-10(a). There was no WT background band in all three clones, 
compared to the WT band of 2.0 kb observed for the GNP9 line (which is similar 
to the WT 820 line for the region amplified and hence used as a reference here). 
There is however the presence of a smaller less predominant ~2.7 kb band for all 
the three clones; this might be a reflection of a spontaneous homologous 
recombination event occurring between the two identical copies of the 3’UTR of 
Pbdhfr/ts present in the construct.  
 
Once confirmed that the complementation cassette had successfully 
integrated into the genome, the phenotype of the three clones was examined 
using Giemsa-stained smears and flow cytometry (Figure 6-11). G567 clones, 
except G567cl1 revealed optimal gametocyte production which suggests that 
there is no hindrance to gene expression in the presence of the SM cassette 
within the 3’UTR of PbAP2-G. The three natural GNP lines that were transfected 
with the PbG01_COMP-DOWN construct (G655cl1and G656cl1 from GNP9 & G696, 
G697 and G698 from GNP7) showed a similar genotype on PCR analyses, except 
for G696 (Figure 6-10b; G654 and G702, G703 and G704 are not shown).  
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(a) 
 
 
 
(b) 
Figure 6-10 (a-b). PCR analyses of the line WT 820 and lines WT 820, GNP9 and GNP7 
transfected with PbG01_COMP-DOWN. The region of the genome spanning the locus of the 
selectable marker cassette was amplified in each of these lines. (a) shows the corresponding PCR-
amplified bands in line WT 820, G657 cloned and G657 transmission bite-back (tbb). Band in the 
WT line 820 (2.0 kb) suggests no evidence of the selectable cassette whereas the bands in the 
transgenic line G657cl2 (820DS) and the G657cl2tbb lines (820DS-tbb) show the modified locus 
corresponding to the size of the entire cassette (5.7 kb) which strongly suggested successful 
integration and optimum gametocyte production by these lines. In figure (b), bands corresponding 
to the WT line size (2.0 kb) were observed in the GNP lines 9 and 7. The 5.7 kb bands suggesting 
successful integration could be observed for all the transgenic lines examined except G696. A 
fainter 2.7 kb band was also observed in all the transgenic lines except G696 suggesting 
spontaneous recycling of the selectable marker cassette. The transgenic lines G697 and G698 also 
show the band corresponding to the WT size as these lines were still uncloned and hence had 
some WT contamination. Overall, the evidence is highly suggestive of successful integration of the 
construct in all the transgenic lines.     
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(a)                                        (b)                                        (c) 
 
 
                             (d)                                        (e)                                        (f) 
 
 
                              (g)                                        (h)                                        (i) 
 
RFP (PE-A channel) 
 
Figure 6-11. Flow cytometry plots showing gametocytemia levels in the lines transfected 
with the complementation construct PbG01_COMP-DOWN. On the horizontal axis are the RFP 
signals (female gametocytes) as detected in the PE-A channel and on the vertical axis are the GFP 
signals (male gametocytes) as detected in the FITC channel. Quite obvious is the optimum number 
of gametocytes generated by the “complemented” WT 820 line G657cl2 (labelled 820DS; Fig 6-
11a), the functional sufficiency of which was evidenced by the number of gametocytes observed 
when the same line was transmitted through mosquitoes generating line G657cl2-tbb (labelled 
820DS-tbb; Fig 7-11b). Taken all together, this shows that the construct PbG01_COMP-DOWN is 
functionally capable of restoring the phenotype without affecting the expression of the gene, 
PbAP2-G. A sub-optimal number of gametocytes was observed in the natural GNP lines 9, 8, and 7 
when transfected with the same construct generating lines G656cl2 (labelled m9DS), G702-4 
(labelled m8DS1-3) and lines G696-9 (labelled m7DS1-3).  
 
 
The phenotypic analyses of the genotypically “repaired” lines by Giemsa-
stained peripheral blood smears and flow cytometry however showed very few 
gametocytes as compared to the WT line 820 “repaired” using the same 
construct as a control (Figure 6-11 and 6-12). Furthermore, the number of 
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gametocytes got lower and lower as these repaired GNP lines were continued to 
be grown or passaged (data not shown). This was highly suggestive of the 
possibility of the presence of a mix of two populations with differential asexual 
growth potential which could result from such a transfection – one which does 
not produce gametocytes (derived from the persistence of the parental GNP 
population as these repaired lines were not yet cloned) and the other which 
does produce gametocytes with unknown potential (derived from the 
genotypically repaired GNP population). As discussed earlier, the potential of 
the GNP population to quickly overgrow any gametocyte producer population 
and eventually replace them over time could be the main factor responsible for 
the observed sub-optimal and declining gametocyte producer phenotype.   
 
One immediate solution to rescue the second favourable type of 
population (the gametocyte producer population) from the mixed population was 
to either immediately clone the lines without further passage (to minimize the 
risk of losing the gametocyte producing population) or immediately passage the 
lines through mosquitoes and perform a bite-back experiment which will 
eventually allow only the gametocyte producers to develop inside the 
mosquitoes thus rescuing the desired population. Both strategies were 
attempted – the transfectants were re-activated from their stabilate stocks and 
grown under pyrimethamine (to keep the selection pressure on till cloning). The 
lines G656 and G657 were cloned by the limiting dilution method (generating 
lines G656cl1, G656cl2, G657cl1, G657cl2, and G657cl3) while reserving the 
originally infected mice for mosquito transmission experiments. 
 
Unfortunately, none of the “repaired” GNP lines could be rescued 
following mosquito passage signifying overgrowth of the gametocyte producer 
population by the non-producers during the reactivation and propagation of the 
“repaired” lines resulting in the total loss of gametocyte producers even before 
the attempted cloning and mosquito transmission experiments.  
 
Taken all this evidence into consideration, repeat experiments were 
planned and conducted by one of my colleagues in the lab. Basically, the 
transfections were done again (as above) but the transfectants, as soon as they 
showed parasites, were immediately cloned by limiting dilution method and also 
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passaged through mosquitoes, without waiting for genotypic confirmation. The 
mosquito passage offered a good and powerful screen in this case as there was 
no competing population (other than the desired) that could have transmitted 
through the mosquitoes. Parasites were observed in Giemsa-stained smears in 
the bite-backs which demonstrated retrospectively the presence of gametocytes 
generated by the transfectants and hence successful complementation. The 
presence of gametocytes was also observed in Giemsa-stained peripheral blood 
smears and on flow cytometry (Rachael Orr, Andy Waters’ group; personal 
communication). 
 
 
 
Figure 6-12. Giemsa-stained peripheral blood smears from mice infected with the natural 
GNP lines successfully complemented with the PbG01_COMP-DOWN construct. As 
discussed in the text, all these lines showed very few gametocytes (mostly degenerating 
gametocytes) as compared with the “complemented” WT line 820 (not shown). 
 
 
6.2.2  Complementation strategies for genetically 
 engineered PbAP2-G knockout mutants 
Chapter 5 outlined the strategies for knocking the PbAP2-G 
(PBANKA_143750) gene out which resulted in three cloned knockout length 
variants of PbAP2-G – the full length orf knockout (G401cl1), the partial 
knockout of the region of the AP2-G orf that bears the 3 mutations identified for 
the naturally selected GNP lines (G529cl2) and the DNA binding domain (DBD) 
knockout (G418cl6cl3). Complementation strategies involved in repairing these 
Gametocytes in natural GNP lines 
repaired by PBANKA_143750 
COMP_DOWN construct 
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knockouts differ from that involving the natural GNP mutants in the presence or 
absence of the positive-negative drug selectable marker cassette (SMC) in the 
complementation construct. Because the natural GNP mutants did not have the 
drug SMC in their genome, complementation of these mutants required the 
presence of drug SMC in the construct to positively select for the complemented 
parasites (using pyrimethamine) possessing the SMC and hence resistance to 
pyrimethamine. In contrast, the knockouts already possessed the drug SMC in the 
genome hence the complementation strategy in these mutants was based on 
transfecting the construct having a WT functional copy of the whole or part of 
the orf to be repaired without the drug SMC. The selection of complemented 
parasites in this case involved the use of 5-FC for targeted killing of the 
parasites possessing the drug SMC thus conferring sensitivity to 5-FC. However, it 
should be emphasized here that the drug SMC used for 5-FC mediated target 
killing must not have two identical copies of the 3’Pbdhfr/ts else, instead of 5-
FC mediated killing, use of the drug could also result in a homologous 
recombination event under drug pressure to remove the portion of the drug SMC 
flanked by identical copies of the 3’Pbdhfr/ts thus eliminating the yfcu gene 
which was responsible for conferring the sensitivity to the toxic drug 5-FC and 
hence failure of the negative selection process and ultimately failed 
complementation.  
Based on the negative selection-mediated complementation of the PbAP2-
G knockout mutants, two strategies to repair the knockout locus were used – the 
first involving a recombineering based construct possessing the full-length 
functional copy of the gene and the second involving a simple mutation-free 
PCR-product of the part of the orf that needed the repair. Whereas the first 
strategy could be used to repair all three length variant PbAP2-G knockouts, the 
second strategy could only be used to repair the partial-length PbAP2-G 
knockout and the DBD knockout. The reason why the full length PbAP2-G could 
not be repaired using the PCR-based strategy lies in the length of the gene to be 
repaired – in this case it was 7.02 kb and it is highly unlikely to obtain such a 
large PCR product of ~9 kb; 7.02 kb orf plus 1 kb homology arms on each side 
(Figure 6-13). 
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Figure 6-13. Schematic of complementation strategy used to repair the engineered 
mutations in the PbAP2-G (not-to-scale). The figure shows the WT endogenous locus (a), 
genomic loci of the three length variant AP2-G knockouts (b to d), the complementation construct 
used (e; PbG01) and the restored endogenous locus (f). The position of the selectable marker 
cassette (multi-coloured bar; orange=3’UTR of Pbdhfr; dark blue=pbeef1aa; violet=hdhfr; 
green=yfcu) is shown with each knockout variant and zoomed in for details at the bottom right 
corner. The DNA Binding Domain (DBD) is shown as a green vertical bar on the PbAP2-G orf. The 
recombineering based complementation construct which was linearized with NotI before 
transfection. The resulting transgenic mutants were negatively selected using the drug 5-FC.  
 
6.2.2.1 Complementation of the knockouts using a full length 
functional copy of PbAP2-G 
All three length variants of the PbAP2-G knockout – G401cl1 (full length 
knockout), G418cl6cl3 (DBD knockout) and G529cl2 (partial knockout) were 
subjected to repair using the PbG01 construct. 
 
 
Drug selection cassette 
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6.2.2.1.1  Complementation in full length PbAP2-G knockout G401cl1 
 
The complementation construct, called PbG01, bearing the full length 
wild type functional copy of PbAP2-G was generated using recombineering-based 
approach and kindly supplied by Oliver Billker’s Lab (Wellcome Trust Sanger 
Institute, Cambridge, UK). The construct had full length (7.02 kb) of the WT orf 
plus upstream and downstream homology arms of ~2.0 kb and ~2.5 kb, 
respectively (Figure 6-14). In the first round of transfections, approximately 3-5 
µg of NotI digested (New England BioLabs) PbG01 was transfected to G401cl1 
schizonts in triplicate and the transfectants (G424, G425 and G426) were 
negatively selected from day 1 post-transfection (Figure 6-15).  
 
 
Figure 6-14. Schematic (not-to-scale) showing the complementation strategy to repair the 
full length knockout of PbAP2-G using full length WT copy of the gene as a recombineering 
based construct. The endogenous locus for the knockout (G401cl1) had a selectable marker 
cassette (orange=3’UTR of Pbdhfr; dark blue=pbeef1aa; violet=hdhfr; green=yfcu) with only one 
copy of the 3’ Pbdhfr/ts UTR making the cassette non-recyclable and hence usable for the negative 
selection-based repair (see text). The vector (PbG01) with two NotI linearization sites is shown. 
The likely areas for homologous recombination are shown as crosses. The transfectants were 
negatively selected using the drug 5-FC in drinking water. The resultant complemented transgenic 
locus is also depicted. Also shown are the relative position of various oligonucleotide primers used 
for confirmation of integration event (Table 6-5) and the resulting repair. 
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Day post-transfection 
 
Figure 6-15. Negative selection experiment on first round of transfectants with PbG01.The 
drug 5-FC was started on the day following transfection and was replaced with fresh drug at least 
every 4
th
 day. The X-axis shows the progression of the experiment as days post-transfection and 
the y-axis shows the total parasitemia, as observed with the Giemsa-stained smears. The vertical 
red bar denotes the day when the lines were put on Sulphadiazine before being passaged to naïve 
mice. Sulphadiazine basically rescues gametocytes by selectively killing the asexuals. In this 
experiment as there were no gametocytes, the population was entirely gametocyte non-producer 
type and hence succumb to the drug. 
 
 The parasites were passaged from each of the G424 and G426 lines into 
naïve mice (thus generating lines G424m1p1, G424m1p2, G426m1p1 and 
G426m1p2, respectively; “m” here denotes negatively selected and “p” denotes 
the number of times the line was passaged) before putting the lines G424, G425 
and G426 on the drug Sulphadiazine (replacing 5-FC) on day 9 post-transfection. 
The passaged lines were put on 5-FC straightaway on the day of the passage. An 
equal amount of purified DNA (~100 ng) from each of the passaged lines was 
PCR-screened for successful integration of the complementation construct into 
the genome by amplifying  various regions within and surrounding PbAP2-G 
(Table 6-5 and Figure 6-16). A summary of all the oligonucleotide sets used as 
primers in the PCRs, their details, expected length of bands, annealing 
temperature (Ta) settings used and extension time used for various PCR 
reactions are shown in Table 6-5.   
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Table 6-5 
 
Oligo set Details 
Expected band size with DNA (kb) 
Ta 
(°C) 
Ext. 
Time 
(min) 
820 G401cl1 Transfectants Water HP 
1076/1132 
5’integration 
check for ko 
-- 2.2 -- -- NA 54 5 
53/1077 
3’integration 
check for ko 
-- 2.6 -- -- NA 54 5 
1076/1077 Through ORF 9 4.9 9 -- NA 54 8 
1070/1239 Q1 ORF 1.9 -- 1.9 -- NA 54 5 
1233/1235 Control NA NA NA NA 5.9 54 8 
1233/1242 Control NA NA NA NA 2.9 54 5 
 
Table 6-5. Basic PCR reaction settings for checking the 5’ and 3’ integration of the construct 
PbG01 into the G401cl1 genomic locus. Apart from detecting integration, amplification of a part 
of the WT orf was also attempted to show that complementation was achieved.  
 
 
 
 
 
(a) 
 
 
Figure 6-16 (a) PCR analyses of the DNA from the transgenic parasites resulting from the 
transfection of G401cl1 line with the complementation construct PbG01. The transgenic lines 
(along with the WT line 820 as a control) were first tested for the absence of the knockout genotype 
by again performing the 5’ and 3’ integration checks. All the transgenic lines except G426m1p1 
produced strong positive integration bands suggesting the persistence of the knockout genotype in 
the transfectants. 
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(b) 
Figure 6-16 (b) PCR analyses of the DNA from the transgenic parasites resulting from the 
transfection of G401cl1 line with the complementation construct PbG01. All the lines 
(especially G426m1p1) were also screened for presence of the WT orf, fully or partially, by using 
appropriate oligos (Figure 6-16b). No WT orf signals could be obtained in any of the transgenic 
lines strongly suggesting the evidence was against successful complementation.    
 
From the PCR analyses (Figure 6-16), there was no evidence of successful 
integration of the PbG01 construct into G401cl1 genome – the persistence of the 
knockout (5’ and 3’ integration positive) population in Figure 6-16(a) and 
absence of any evidence suggesting the amplification of a region of the PbAP2-G 
open reading frame from any of the transfectants indicating that 
complementation did not occur (Figure 6-16b). The genotypic findings perfectly 
matched with the continuous phenotypic examination of the lines G424m1p1-2, 
G425m1 and G426m1p1-2 by Giemsa-stained peripheral blood smear and flow 
cytometry. Both, the genotypic as well as phenotypic evidence were against any 
successful complementation of PbAP2-G in the transfected negatively selected 
lines. There were no “typical” gametocytes observed on either Giemsa-stained 
smears or FACS although some gametocyte-like parasites were noted on the 
smears very early during the course of negative selection.  
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Also, the negative selection kinetics (Figure 6-15) suggested that there 
was a parasite population that was NOT sensitive to 5-FC. This could happen in  
rather four possible ways – (a) when there are no parasites of the knockout 
genotype bearing the yfcu drug selectable marker which would imply a 
successful complementation attempt; or (b) a mutation has been acquired during 
the negative selection process which would confer resistance to 5-FC hence 
making the negative selection ineffective; the yfcu gene was sequenced from 
some of these transgenic lines and their sequence alignment with the WT yfcu 
gene did not reveal any sequence abnormality in yfcu (data not shown); or (c) 
the natural pro-GNP population selection pressure overwhelms the negative drug 
selection pressure. The latter two possibilities would naturally select for the 
GNP population (the knockouts) as they have a growth advantage over the 
gametocyte producer parasites and hence will ultimately overgrow them in time. 
The continuous rise in parasitemia during negative selection after an initial dip 
also suggests the latter possibility; (d) there is then the fourth possibility that 
the selection disadvantage offered by retaining a functional yfcu gene in the 
selection cassette could enforce the parasites to genetically rearrange in such a 
way that the selection cassette is removed from their genome, totally or 
partially. This was however, highly unlikely, as the PCR analyses in the majority 
of these transgenic lines were based on selection of at least one of the primers 
binding to the selection cassette, and yfcu in particular. Thus the presence of 
the expected sized band/s from any of these primers would imply the 
persistence of the unmutated selection cassette / yfcu in the transgenic parasite 
genomes. The presence of these bands almost every time such selection cassette 
based PCRs were performed ruled out this possibility of eliminating the cassette 
from the parasite genome. 
Based on the remote possibility of having gametocytes in the 
transfectants (as suggested by Giemsa smears as well as the negative selection 
kinetics), the transfectants were put on sulphadiazine (on day 9 post-
transfection; red vertical line in Figure 6-15) which selectively kills the asexual 
parasites leaving behind the gametocytes, if any.  The transfectant lines were 
passaged and negative selection was maintained before being put on 
sulphadiazine. As seen in the latter half of the negative selection kinetics, the 
parasitemia sharply fell to zero after exposing the parasite population to 
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sulphadiazine. This implied that by the time the transfectants were put on 
sulphadiazine, the GNP population had already overgrown the gametocyte 
producers (if there were any to start with), thus showing that there was no 
complementation at all or if it was there, it could not be rescued in time.  
Based upon the results of the first set of transfections to complement the 
full length PbAP2-G knockout line (G401cl1), a second set of repeat transfection 
experiments, in duplicate, was carried out with increased (up to double) the 
amount of PbG01 DNA used (5-10 µg per transfection) for transfection. The 
resultant transfectants, G448 and G449 were selected under 5-FC exactly as 
before (Figure 6-17, except the administration of sulphadiazine) and were 
examined by PCR analyses for integration (Table 6-6 and Figure 6-18), Giemsa-
stained smears and flow cytometry for gametocyte production and hence 
complementation. The findings were similar to that mentioned in the first 
complementation experiment – no integration event on PCR analyses and no 
gametocytes on Giemsa smears and FACS. 
 
Days post-transfection 
 
Figure 6-17. Negative selection parasitemia kinetics for the transgenic lines G448 and G449 
repaired (in the second round of transfections) by using the complementation construct 
PbG01 in the full length PbAP2-G knockout line G401cl1. In contrast to the first round of 
transfections with the same construct (Figure 6-15), the drug 5-FC was started on the day of the 
transfection and was replaced with fresh drug at least every 4
th
 day. Horizontal X-axis shows the 
progression of the experiment as days post-transfection and vertical axis shows the total 
parasitemia, as observed with the Giemsa-stained smears. Together with PCR analyses, Giemsa-
stained smears, and flowcytometry, the kinetics in these lines suggest that the negative selection 
was not successful and thus the complementation attempt. 
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Table 6-6 
Oligo set Details 
Expected band size with DNA (kb) Ext. Time 
(min) 820 G401cl1 G448-49 Water HP 
1076/1132 5’int.check for ko -- 2.2 -- -- NA 4 
53/1077 3’int.check for ko -- 2.6 -- -- NA 4 
1057/1127 5’int.check for repair 2.7 -- 2.7 -- NA 4 
1128/1287 3’int. check for repair 3.4 -- 3.4 -- NA 4 
1070/1239 Q1 ORF 1.9 -- 1.9 -- NA 4 
1182/1240 Q2 ORF 1.8 -- 1.9 -- NA 4 
1241/1242 Q3 ORF 1.9 -- 1.9 -- NA 4 
1237/1071 Q4 ORF 2.1 -- 2.1 -- NA 4 
1231/1242 Control NA NA NA NA 3.5 4 
 
Table 6-6. Basic PCR reaction settings for checking the 5’ and 3’ integration of the construct 
PbG01 into the G401cl1 genomic locus. Apart from detecting integration, amplification of four 
parts of the whole WT PbAP2-G orf was also attempted to show that the complementation was 
achieved. The annealing temperature for the above reaction was set at 54°C.  
  
 
 
(a) 
 
Figure 6-18 (a). PCR analyses of the DNA obtained from the transfectants following the 
PbG01 based complementation of the full AP2-G orf knockout line G401cl1. The 5’ and 3’ 
integration check PCRs for the knockout lines and the repaired (complemented) lines are shown. 
Both the transfectants, G448 and G449 showed evidence of the 5’ and 3’ integration bands (2.2 kb 
and 2.6 kb, respectively) in favour of the presence of the knockout genotype (quite usual at this 
stage as these were not cloned lines) but the corresponding bands in favour of the presence of a 
repaired genotype (2.7 kb and 3.4 kb, respectively) were absent in both  lines.  
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(b) 
 
Figure 6-18(b). PCR analyses of the DNA obtained from the transfectants following the 
PbG01 based complementation of the full AP2-G orf knockout line G401cl1. No WT orf bands 
corresponding to the four regions of the AP2-G orf could be observed in the knockout line G401cl1 
(expected) and in the lines G448 and G449 suggesting strongly that there has been no 
complementation of the PbAP2-G gene in the repaired full orf knockout variant. 
  
Another set of transfection-negative selection experiments was done 
to retry complementation of PbAP2-G in G401cl1 using PbG01 under enhanced 
negative selection pressure in view of the possibility of the natural GNP 
selection pressure overtaking the negative selection pressure. Thus, the 
transfectant lines G588 and G589 were generated in exactly the same way as 
before but changing the way the parasites were negatively selected. In addition 
to the usual dose of oral 5-FC, injectable 5-FC (1 mg per mouse per day, 
intraperitoneally) was supplemented to G588 and G589 infected mice 
continuously for 4 days to augment the negative selection pressure to counteract 
possible  stronger pro-GNP natural selection pressure (Figure 6-19). 
Unfortunately again, no gametocyte producing population could be observed, 
neither in smears nor in flowcytometry, again suggesting no complementation 
had occurred. 
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Days post-transfection 
 
Figure 6-19. Negative selection parasitemia kinetics for the transgenic lines G588 and G589 
repaired (in the third round of transfections) by using the complementation construct 
PbG01 in the full length PbAP2-G knockout line G401cl1. In contrast to the first two rounds of 
transfections with the same construct (Figures 6-15 and 6-17), the oral drug 5-FC was 
supplemented by injections of 5-FC (1 mg/mouse/day; intra-peritoneally) for four consecutive days 
starting from the day of transfection. The oral 5-FC was given as before. Horizontal X-axis shows 
the progression of the experiment as days post-transfection and vertical axis shows the total 
parasitemia, as observed with the Giemsa-stained smears. Together with PCR analyses, Giemsa-
stained smears, and flowcytometry, the kinetics of these lines suggest that negative selection was 
not successful for the complementation attempt.  
 
6.2.2.1.2  Complementation in PbAP2-G DNA binding domain (DBD) 
 knockout; G418cl6cl3 
 
The complementation construct, PbG01, was utilized to repair the 
mutation/s present in the DBD knock out (from Chapter 5) as well (Figure 6-20). 
NotI digested (New England BioLabs) PbG01 was transfected to G418cl6cl3 
schizonts in quadruplet. The resulting transfectants (G547, G548, G590 and 
G591) were put on negative selection using the drug 5-FC 1.5 mg/ml in drinking 
water from day 0 post-transfection. For G590 and G591, in addition to the usual 
dose of oral 5-FC, injectable 5-FC (1 mg per mouse per day, intraperitoneally) 
was supplemented continuously for 4 days to augment the negative selection 
pressure to counteract stronger pro-GNP natural selection pressure. Oral 5-FC 
mediated negative selection pressure was tightly maintained (fresh 5-FC 
supplied every four days) and the parasitemia (including gametocytemia, if any) 
was monitored daily (as described in Materials and Methods) till day 14 post-
transfection before culling the mice (Figure 6-22).  
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Diagnostic PCRs were performed on the DNA from negatively selected 
lines as per Table 6-7 and Figure 6-21. A summary of all the oligonucleotide sets 
used as primers in the PCRs, their details, expected length of bands, annealing 
temperature (Ta) settings used and extension time used for various PCR 
reactions are shown in Table 6-7.   
 
 
Figure 6-20: Schematic (not-to-scale) showing the complementation strategy to repair the 
DBD knockout of PbAP2-G using full length WT copy of the gene as a recombineering 
based construct. The endogenous locus for the DBD knockout (G418cl6cl3) had a selectable 
marker cassette (orange=3’UTR of Pbdhfr; dark blue=pbeef1aa; violet=hdhfr; green=yfcu) with only 
one copy of the 3’ Pbdhfr/ts UTR making the cassette non-recyclable and hence usable for the 
negative selection-based repair (see text). The vector (PbG01) with two NotI linearization sites is 
shown. The likely areas for homologous recombination are shown as crosses. The transfectants 
were negatively selected using the drug 5-FC in drinking water. The resultant complemented 
transgenic locus is also depicted. Also shown are the relative position of various oligonucleotide 
primers used for confirmation of integration event (Table 6-7) and the resulting repair. The inset 
(bottom right corner) shows the magnified view of the DBD along with the PCR amplification 
oligonucleotide primer pair. 
 
Table 6-7 
Oligo set Details 
Expected DNA band size  (kb) Ext. Time 
(min) 820 G418cl6cl3 G543-548 Water 
1237/1132 5’int. check for ko -- 2.2 -- -- 4 
1133/1077 3’int. check for ko -- 2.5 -- -- 4 
1237/1826 5’int. check for repair 2.0 -- 2.0 -- 4 
1128/1077 3’int. check for repair 1.6 -- 1.6 -- 4 
1237/1077 Spanning the int egration 3.1 5.0 3.1 -- 7 
1128/1826 DBD ORF 0.5 -- 0.5 -- 4 
 
Table 6-7. Basic PCR reaction settings for checking the 5’ and 3’ integration of the construct 
PbG01 into the G418cl6cl3 genomic locus. Apart from detecting integration, amplification of a 
part of the DBD WT PbAP2-G orf was also attempted to show that complementation was achieved. 
The annealing temperature for the above reaction was set at 54°C.  
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(a) 
 
 
 
 
 
 
(b) 
 
 
 
(c) 
 
Figure 6-21. PCR analyses of the DNA obtained from the transfectants following the PbG01 
based complementation of the AP2-G DBD ko line G418cl6cl3. The 5’ & 3’ integration check 
PCRs for the knockout lines are shown in (a), both integration check PCRs for the repaired lines 
are shown in (b), and PCRs spanning the integration & amplifying a part of the DBD are shown in 
(c). All transfectants showed evidence of 5’ and 3’ integration (2.2 kb & 2.5 kb, respectively) except 
the 3’ integration for ko in G545 denoting the presence of a ko genotype (usual as the lines were 
not yet cloned) but the corresponding bands denoting a repaired genotype (2.0 kb & 1.6 kb, 
respectively) were absent in all the transfectants. PCRs spanning the selectable marker cassette & 
amplifying the DBD orf (c) were also suggestive that the GNP population was still present in the 
transfectants. Further, no WT DBD orf bands could be observed in the repaired lines suggesting 
strongly that there was no complementation of the PbAP2-G DBD knockout variants. 
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       Days post-transfection 
Figure 6-22. Negative selection parasitemia kinetics for the transgenic lines G590 and G591 
repaired (in the third round of transfections) by using the complementation construct 
PbG01 in the PbAP2-G DBD knockout line G418cl6cl3. In contrast to the first two rounds of 
transfection with the same construct (Figures 6-15 and 6-17), the oral drug 5-FC was 
supplemented by injections of 5-FC (1 mg/mouse/day; intra-peritoneally) for four consecutive days 
starting from the day of transfection. The oral 5-FC was given as before. Horizontal X-axis shows 
the progression of the experiment as days post-transfection and vertical axis shows the total 
parasitemia, as observed with the Giemsa-stained smears. Together with PCR analyses (Figure 6-
21), Giemsa-stained smears, and FACS, the kinetics in these lines suggest that the negative 
selection was not successful and so was the complementation attempt.  
 
As evident from the PCR analyses (Figure 6-21a-c), there was no evidence 
of successful integration of the PbG01 construct into G418cl6cl3 genome – the 
persistence of the knockout (5’ and 3’ integration positive) genotype in Figure 6-
21 (a) and absence of any evidence suggesting the amplification of a region of 
the DBD open reading frame from any of the transfectants indicating that the 
complementation did not occur (Figure 6-21b). The genotypic findings perfectly 
matched with the phenotypic examination of G590 and G591 during negative 
selection by Giemsa-stained peripheral blood smear and flow cytometry. Both, 
the genotypic as well as the phenotypic evidence were against any successful 
complementation of the DBD knockout in the transfected negatively selected 
lines. 
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6.2.2.1.3  Complementation in PbAP2-G partial open reading frame 
 knockout; G529cl2 
 
Genetic complementation of the PbAP2-G knockout variant line (G529cl2) 
which eliminated the part of the WT gene which had three naturally acquired 
GNP mutations was attempted with the PbG01 construct (Figure 6-23). NotI 
digested (New England BioLabs) PbG01 was transfected to G529cl2 schizonts in 
duplicate. The resulting transfectants (G594 and G595) were put on negative 
selection using the drug 5-FC 1.5 mg/ml in drinking water from day 0 post-
transfection. In addition to the usual dose of oral 5-FC, injectable 5-FC (1 mg 
per mouse per day, intraperitoneally) was supplemented continuously for 4 days 
to augment the negative selection pressure to counteract any stronger pro-GNP 
natural selection pressure. Oral 5-FC mediated negative selection pressure was 
tightly maintained (fresh 5-FC supplied every four days) and the parasitemia 
(including gametocytemia, if any) was monitored daily (please see section 2.1.5  
in Materials and Methods) till day 9 post-transfection before culling the mice 
(Figure 6-24). The parasitemia kinetics under negative selection (the spurt in 
proliferation at day 2 post-transfection; Figure 6-24) suggests that the negative 
selection was not efficient in removing parasites bearing the yfcu gene. 
Together with absence of visible gametocytes in Giemsa-stained peripheral 
smears and FACS, these findings suggested a failure of complementation of the 
PbAP2-G partial orf knockout and hence PCR analyses for the integration event 
were not performed. 
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Figure 6-23. Schematic (not-to-scale) showing the complementation strategy to repair the 
partial knockout of PbAP2-G which eliminated the region of the orf (which had the three 
naturally acquired GNP mutations) using full length WT copy of the gene as a 
recombineering based construct (PbG01). The endogenous locus for the partial AP2-G 
knockout (G529cl2) had a selectable marker cassette (orange=3’UTR of Pbdhfr; dark 
blue=pbeef1aa; violet=hdhfr; green=yfcu) with only one copy of the 3’ Pbdhfr/ts UTR making the 
cassette non-recyclable and hence usable for the negative selection-based repair (see text). The 
vector (PbG01) with two NotI linearization sites is also shown. The likely areas for homologous 
recombination are shown as crosses. The transfectants were negatively selected using the drug 5-
FC in drinking water. The resultant complemented transgenic locus is also depicted.  
 
 
 
Days post-transfection 
Figure 6-24. Negative selection parasitemia kinetics for transgenic lines G594 and G595 (in 
the third round of transfections) by using the complementation construct PbG01 in the 
PbAP2-G partial orf knockout line G529cl2. In contrast to the first two rounds of transfections 
with the same construct (Figures 6-15 and 6-17), the oral drug 5-FC was supplemented by 
injections of 5-FC (1 mg/mouse/day; intra-peritoneally) for four consecutive days starting from the 
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day of transfection. The oral 5-FC was given as before. The X-axis shows the progression of the 
experiment as days post-transfection and the axis shows the total parasitemia, as observed with 
Giemsa-stained smears. Together with absence of gametocytes in Giemsa-stained smears and 
FACS, the kinetics in these lines suggests that the negative selection was not successful and so 
nor was the complementation attempt.  
 
 
6.2.2.2 Complementation of the knockouts using a mutation-
free PCR product 
Complementation using a simple PCR product is based upon the “GIMO 
approach” developed recently to recycle the drug selectable marker by 
homologous recombination (Lin et al., 2012). The “Gene In/ Marker Out” or the 
“GIMO” approach simply requires a PCR-amplified wild type copy of the gene or 
the part of the gene to be restored, including  upstream and downstream arms 
homologous to the target genome and the presence of a negative selection 
marker contained in the mutant to be complemented. Since the PbAP2-G 
knockouts had the negative selection marker in the genome, the GIMO-based 
complementation approach was used. The full-length knockout variant of PbAP2-
G (G401cl1) was not suitable for this technique as it was  difficult to obtain a 
single PCR product spanning the whole length of the gene (7.02 kb) plus a 
kilobase of homology arms on each side, thus making the  of a PCR product of ~9 
kb in sufficient amount was considered practically impossible.    
Thus the GIMO-based complementation approach was attempted only with 
the DBD knockout line (G418cl6cl3; Figure 6-25). The PCR product for the repair 
was amplified as two variants (short and long) from the WT line 820, using 
primer sets GU1389/GU1514 for the shorter product (~2 kb) and GU1416/GU1059 
for the longer product (~2.8 kb) using the HiFi Taq-polymerase (Figure 6-25).  
Approximately 5 µg each of the purified PCR products (long and short) 
were transfected to G418cl6cl3 schizonts – the short one was transfected twice 
whereas the long one was transfected four times. The resulting transfectant 
lines (G543 and G544 for short and G545, G546, G592 and G593 for long product) 
were put on negative selection using the drug 5-FC (1.5 mg/ml) in drinking water 
from day 0 post-transfection. For G592 and G593, in addition to the usual dose 
of oral 5-FC, injectable 5-FC (1 mg per mouse per day, intra-peritoneally) was 
supplemented continuously for 4 days to augment the negative selection 
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pressure to counteract any stronger pro-GNP natural selection pressure. Oral 5-
FC mediated negative selection pressure was tightly maintained (fresh 5-FC 
supplied every four days) and the parasitemia (including gametocytemia, if any) 
was monitored daily (please see section 2.1.5 in Materials and Methods) till day 
14 post-transfection before culling the mice (Figure 6-26).  
 
 
 
 
Figure 6-25. Schematic (not-to-scale) showing the PCR-based complementation strategy to 
repair the DBD knockout of PbAP2-G using long and short PCR products amplified from WT 
PbAP2-G and bearing upstream and downstream recombinable homology arms. The WT 
PbAP2-G endogenous locus is shown at the top with the DBD (green vertical bar) and the region 
around the domain which was knocked out (red transparent box). The oligonucleotide pairs used to 
amplify the long and short PCR products, GU1416/GU1059 and GU1389/GU1514, respectively are 
also indicated. The endogenous locus for the DBD knockout (G418cl6cl3) had a selectable marker 
cassette (orange=3’UTR of Pbdhfr; dark blue=pbeef1aa; violet=hdhfr; green=yfcu) with only one 
copy of the 3’ Pbdhfr/ts UTR making the cassette non-recyclable and hence usable for negative 
selection-based repair (see text). The long (2.8 kb) and short (2.0 kb) PCR products are also 
shown above the DBD knockout locus. The likely areas for homologous recombination are shown 
as crosses. The transfectants were negatively selected using the drug 5-FC in drinking water. The 
resultant complemented transgenic locus is also depicted. Also shown are the relative position of 
various oligonucleotide primers used for confirmation of an integration event (Table 6-7) and the 
resulting repair. The inset (bottom right corner) shows a magnified view of the DBD along with its 
PCR amplification oligonucleotide primer pair. 
 
 
Drug selection cassette 
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Diagnostic PCRs were performed on purified DNA from the negatively 
selected lines G543, G544, G545, and G546 as per Table 6-7 and Figure 6-25 and 
shown in Figure 6-21. A summary of all the oligonucleotide sets used as primers 
in the PCRs, their details, expected length of bands, annealing temperature (Ta) 
settings used and extension time used for various PCR reactions are shown in 
Table 6-7.   
 
Days post-transfection 
Figure 6-26. Negative selection parasitemia kinetics for the transgenic lines G592 and G593 
repaired (in the third round of transfections) by using the PCR based complementation 
products in the PbAP2-G DBD knockout line G418cl6cl3. In contrast to the usual negative 
selection of transfectants, the oral drug 5-FC was supplemented by injections of 5-FC (1 
mg/mouse/day; intra-peritoneally) for four consecutive days starting from the day of transfection. 
The oral 5-FC was given as before. Horizontal X-axis shows the progression of the experiment as 
days post-transfection and vertical axis shows the total parasitemia, as observed with the Giemsa-
stained smears. Together with absence of gametocytes in Giemsa-stained smears and FACS, the 
kinetics in these lines suggests that the negative selection was not successful and so neither was 
the complementation attempt.  
 
 
The parasitemia kinetics of lines G52 and G593 under negative selection 
(the spurt in proliferation at day2 post-transfection; Figure 6-26) suggests that 
the negative selection was not efficient in removing parasites bearing the yfcu 
gene. Together with absence of visible gametocytes in Giemsa-stained 
peripheral smears and FACS, these findings suggested a failure of 
complementation of the PbAP2-G partial orf knockout and hence PCR analyses 
for the integration event were not performed for these lines. 
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6.3  Summary and discussion 
Genetic complementation, as such, is the gold standard experiment to 
establish and prove a causal hypothesis generated during forward and reverse 
genetic manipulations. Complementing a mutated gene in Plasmodium presents 
specific problems both in terms of the relative paucity of the number of drug 
selectable markers available to perform successive genetic modification at a 
particular genetic locus and also in terms of the extreme AT-richness of the 
Plasmodium genome.  
Forward and reverse genetic studies, Chapter 3 and Chapter 5, 
respectively, identified a single gene PbAP2-G (PBANKA_143750) as the master 
regulator of the process of commitment to gametocytogenesis in P. berghei.  
PbAP2-G natural and null mutants did not produce any gametocytes and 
therefore the resultant GNP population had a significant growth advantage over 
the gametocyte producer parasites, sufficient enough to overgrow the latter in a 
mixed population. In this particular study, complementation efforts were further 
challenged by at least two more factors – first, the length of the gene to be 
complemented was ~7 kb thus giving rise to inherent problems associated with 
cloning and manipulation of such a large, and single DNA fragment; and second, 
the reversal of the GNP phenotype to a gametocyte-producer phenotype had to 
happen against a strong natural selection pressure in favour of the GNP 
parasites, posing problems in negatively selecting the transgenic complemented 
parasites. 
Despite the above mentioned deterrents to successful complementation 
of PbAP2-G null mutants, there were two distinct advantages: the natural GNP 
mutants did not have the drug selectable marker cassette as they were selected 
using a forward genetics screen and hence the need for an additional selectable 
marker or for marker recycling was not required. But at the same time, this 
generated the need of inserting a positive selection marker into the 
complementation construct to positively select for the transgenic complemented 
parasites. This drug selectable marker cassette had to be incorporated into the 
WT genome during complementation which created specific problems (discussed 
below). The second advantage was the availability of recombineering-based 
Chapter 6 AP2-G complementation studies 259 
 
vectors with relatively longer homology arms for more efficient homologous 
recombination events.  
Two types of genetic mutants were generated during the study which 
needed complementation data to prove the role of PbAP2-G in commitment to 
gametocytogenesis. The first type of mutants were generated by serial passage 
of ten isogenic wild type gametocyte producer lines (WT 820) thereby producing 
three natural GNP mutants, m9, m7 and m8. The PbG01_COMP recombineering-
based complementation construct which was used to repair the mutations was 
available in two varieties – one with the drug selectable marker cassette was 
incorporated 1.2 kb upstream to the AP2-G translational start site 
(PbG01_COMP-UP) and the other with the cassette sitting ~2 kb downstream to 
the AP2-G stop codon (PbG01_COMP-DOWN). The functional restoration of the 
GNP mutants to WT was hampered by the possible interruption of the AP2-G 
promoter while using the PbG01_COMP-UP construct. This might have 
lengthened the promoter disturbing the nucleosomal phasing and hence a 
possible hindrance in the epigenetic regulation of the AP2-G expression.  
Evidence of successful complementation (although incomplete) was seen 
using the other construct, the PbG01_COMP-DOWN. But the number of 
gametocyte producer parasites generated through successful functional 
restoration of AP2-G was quickly overgrown by the persistent remaining GNP 
parasites in the transgenic complemented line. With time and even minimal 
passage, these transgenic lines rapidly generated the GNP phenotype by out 
competing the gametocyte producer parasites even before phenotype recue 
experiments like cloning and mosquito passage were carried out. However, the 
experiments were repeated and refined with more precise and timely rescue of 
the gametocyte producer population, and functional complementation of all the 
natural GNP mutants was finaly achieved (work carried out by Rachael Orr after I 
finished my lab work, Andy Waters’ group, personal communication; data not 
shown). 
The second type of GNP mutant was engineered using reverse genetics 
techniques (gene knockout using homologous recombination). Three length 
variants of PbAP2-G knockouts were created – full orf knockout (G401cl1), 
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partial knockout of the region of the AP2-G orf that bears the 3 mutations 
identified for the naturally selected GNP lines (G529cl2) and a partial orf 
knockout eliminating the PbAP2-G DBD (G418cl6cl3). Complementation of these 
knockout variants was attempted using two approaches both using negative 
selection – full length wild type copy of the gene (recombineering-based 
construct, PbG01) which was applicable to all  three knockout variants and 
partial length wild type copy of the gene (PCR-based construct) which was 
applicable to the latter two knockout variants. None of the approaches could 
restore the phenotype in any of the engineered mutants despite multiple 
experiments using a variety of modifications. At least two possible reasons could 
be involved either singly or in combination which resulted in the failure to 
complement – ineffective negative selection which could have been due to an 
undetected mutation in the yfcu gene conferring resistance to 5-FC or site-
specific genetic rearrangements making the selectable marker cassette non-
functional, and a stronger natural phenotypic selection favouring the GNP 
population. Figure 6-27 and Table 6-8 summarise the multitude of the 
techniques used to complement the gene in the available mutants and theresults 
thereof. 
Table 6-8 
 
 
PbAP2-G mutant 
type 
Line 
Complementation constructs used 
PbG01 PCR-product 
PbG01_ 
COMP -UP 
PbG01_ 
COMP-DOWN 
Complete orf ko G401cl1 Failure Not attempted 
Not Applicable Partial orf ko G529cl2 Failure Failure 
DBD ko G418cl6cl3 Failure Failure 
Natural GNP M9, M8 & M7 Not Applicable Failure SUCCESS 
 
Table 6-8. A comprehensive summary table showing the outcomes of different types of 
complementation constructs used in the study to functionally restore a range of PbAP2-G 
null mutants thus diversifying the choice and applicability of methods. As reasoned out in the 
main text, the GIMO/PCR-based repair was not attempted for complementing the complete orf 
knockout line G401cl1 because of the obvious reasons hampering the amplification of such a long 
PCR product. Neither the recombineering-based construct bearing the full length functional copy of 
WT PbAP2-G (PbG01) nor the PCR-based long/short products could complement the gene in any 
of the three length variants of the AP2-G knockouts. In the naturally acquired GNP lines, the 
mutations were successfully repaired using the recombineering based construct bearing the full 
length functional copy of WT PbAP2-G with the drug selectable marker cassette placed 
downstream to the AP2-G stop codon (PbG01_COMP-DOWN).     
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Figure 6-27. A comprehensive schematic cartoon (not-to-scale) to summarise the range of 
experiments used in the study to complement the PbAP2-G in the three naturally acquired 
GNP mutants (top panel) and the three length knockout variants (bottom). Note: The PCR-
based complementation approach to repair the knockouts is not shown here to preserve the 
simplicity and clarity of the diagram. The WT PbAP2-G endogenous locus from the line 820 is 
shown in the centre (a). Above the WT locus are depicted the various complementation 
approaches used to repair the three natural GNP mutants (b’ through f’) and below the endogenous 
locus are shown the same for the three knockout variants (b through f). The full length positive-
negative drug selectable marker cassette (SMC) is shown at the bottom right of the figure as multi 
coloured rectangular bar (orange=3’UTR of Pbdhfr; dark blue=pbeef1aa; violet=hdhfr; green=yfcu). 
Black thick bar labelled AP2-G = open reading frame of PbAP2-G; AP2-G’ and AP2-G’’ on AP2-G 
orf = the upstream and downstream remainder of the AP2-G wherein the middle portion of the 
gene is eliminated and replaced by the SMC (Figure 6-27c); Green vertical rectangle on AP2-G orf 
= DNA binding domain; multi-coloured rectangle = SMC; yellow vertical bars on AP2-G = three 
naturally acquired PbAP2-G mutations 
 
Other possible approaches which could have used to complement the 
defect include a single crossover (SCO) homologous recombination based repair 
of the natural GNP mutants which would restore at least one functional copy of 
the wild type AP2-G, expression of the gene under its own promoter from an 
exogenous locus such as the 230p locus and a Cre-loxP based generation of 
knockout followed by recycling of the selectable marker cassette and a 
subsequent positive selection based introduction of the wild type copy of the 
gene into the endogenous locus. The SCO based approach was attempted along 
with the GFP/HA tagging of PbAP2-G thus generating a repair-tagged vector for 
complementation and tagging. The vector was not processed and transfected 
due to paucity of time and simultaneous generation of an independent tagged 
line and successful complementation of the natural GNP mutants using the 
PbG01_COMP-DOWN construct (see above). Expressing PbAP2-G from an 
exogenous locus is an attractive option but then the length of the gene along 
with its endogenous promoter and possibly 3’UTR to be cloned remains a 
possible deterrent to using such an approach.                 
It would also be interesting to study the effects of complementing an 
orthologous copy of the PbAP2-G from P. falciparum (or even trans-genera 
complementation, such as, from Theileria spp.; Huynh et al., 2004; Zou et al, 
2009) and analyse the functional restoration of the gene. Keeping in mind the 
high degree of conservation of the functional DNA-binding domains as well as 
their recognition motif within apicomplexa, a successful functional 
complementation in such a case would at least establish the proof of principle – 
the conservation of the domain and motif is functional. Because the regions out 
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with the DBD are not thought to be conserved between orthologous AP2-G, it 
would also be intriguing to see if there is any role of these regions in controlling 
the AP2-G downstream actions. That would  explain how the mutation in  GNP 
line 233 could generate the GNP phenotype and provide a possible role of 
protein-protein or other interactions by this or other  unidentified domains 
encoded by the PbAP2-G gene. 
   
  
    
 
 
 
 
 
 
 
 
 
 
 
7 Analysing protein-DNA interactions   
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7.1  Introduction 
Identification and subsequent binding of a class of proteins called 
transcription factors (TF) to their cognate cis-elements in  promoters and other 
regulatory regions in the genome comprise the initial steps in controlling the 
process of transcription of specific genes in eukaryotes (Phillips & Hoopes, 
2008). TFs work in a close orchestration with epigenetic control (alteration of 
the chromatin structure) of the DNA containing the recognition motif for these 
TFs and thus regulate the complexity of gene expression in a combinatorial 
manner (Lemon and Tjian, 2000; Zaret and Carroll, 2011). Transcription factors 
contain a DNA-binding domain (DBD) which recognizes a specific recognition 
motif (usually 6-10 base pairs long) in a sequence-specific manner (Phillips & 
Hoopes, 2008). Any changes in TFs activity and/or regulatory specificity, for 
example, a deletion of the TF encoding gene or mutations in the TF binding sites 
(TFBS), is highly likely to influence phenotypic diversity and ecological 
adaptation among the organisms affected (Bustamante et al., 2005; Wray, 2007; 
Lopez-Bigas et al., 2008; De et al., 2008). A comprehensive understanding of the 
TFs, the TFBS and their interactions is thus crucial in attributing TFs for disease 
etio-pathogenesis and phenotypic variability. 
Documenting or establishing the interaction between the DBD and its 
target DNA sequence is crucial for dissecting the downstream role of the TFs in 
terms of the specificity of action and the potential target genes for the TF. In 
vitro techniques such as Electrophoretic Mobility Shift Assay or EMSA are an ideal 
way to identify whether TFs (or their DBDs) interact with the TFBS or not 
(Elnitski et al., Genome Res 16; 2006). It has already been established that the 
Pf AP2-G DBD recognizes and subsequently binds to a specific 4-base pair core 
target sequence nnGTACnn in vitro. This target sequence is bioinformatically 
predicted to be highly conserved across orthologs of the AP2-G throughout the 
apicomplexa (Campbell et al., 2010). This predicted conservation of the core 
target sequence provides a basis of examining the interaction of the AP2-G DBD 
with the conserved DNA sequence in vitro. The aim was to identify the presence 
of a sequence-specific interaction of the DBD and the identified target sequence 
thus enabling us to predict possible downstream target genes of PbAP2-G based 
on the presence of the target motif in their 5’upstream region.     
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7.2  GST tagged DNA Binding Domain (DBD) 
To study the binding interaction between the DNA Binding Domain (DBD) 
of PbAP2-G with the cognate DNA sequence, N-terminal Glutathione S-
transferase (GST) tagged AP2 DBDs were used. GST on its own and N-terminal 
GST fused to extended ApiAP2 DNA binding domains (all cloned into pGEX-4T1) 
from P. falciparum AP2-G (PFL1085w) and P. berghei AP2-G (PBANKA_143750) 
were kindly gifted by Manuel Llinas, Bjorn Kafsack and April Williams (Princeton 
University, USA). Extended versions of the AP2-G DBDs were used for molecular 
cloning which contained the DBD along with some of flanking residues that were 
likely to be important for domain stabilization (Campbell et al., 2010). GST 
protein was used both as expression control as well as the negative control for 
assessing binding of the AP2-Gs and the cognate DNA sequence. Pf AP2-G served 
as a positive control for EMSA as it has already been shown to bind to a 
conserved DNA sequence in a sequence-specific manner (Campbell et al., 2010; 
Manuel Llinas, personal communication). The target proteins were expressed in 
Rosetta (DE3) pLys S competent cells with 0.2 mM IPTG at 25οC and batch-
purified using affinity chromatography (Glutathione HiCap Matrix slurry; Qiagen). 
The purity of protein was estimated by 10% SDS PAGE and the eluted proteins 
were quantified by spectrophotometry, absorbance at 260 nm. The eluted 
protein was concentrated and buffer exchanged using an Amicon Ultra-0.5 
Centrifugal filter; 30K device (Milipore). 
The expected size (in KDa) of GST and the two N-terminal GST-tagged 
DBDs is shown in Table 7-1. The successful induction of protein expression using 
0.2 mM fresh IPTG is shown in Figure 7-1, whereas the migration of the purified 
tagged proteins in 10% SDS-PAGE is shown in Figure 7-2. As evident from Figure 
7-2 (a & b) the amount of purified GST tagged proteins was adequate to be 
detected by SDS-PAGE for GST and Pb AP2-G. Although the amount of purified Pf 
AP2-G GST::DBD was minimal (as evident by faint bands in Figure 7-2(c)), it was 
sufficient to show the interaction with the cognate motif in EMSAs (see below). 
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Table 7-1 
 
Protein Gene id 
DBD_ext MW 
(KDa) 
Tag MW 
(KDa) 
DBD::tag 
MW (KDa) 
Pf AP2-G 
DNA binding Domain 
PFL1085w 
(PF3D7_1222600) 
14.7 26 (GST) 40.7 
Pb AP2-G 
DNA binding Domain 
PBANKA_143750 14.3 26 (GST) 40.3 
 
Table 7-1. Relative expected sizes of N-terminal GST tagged AP2-G DNA binding domains 
and GST on its own.  The size of the AP2-G DBD shown here are that of the extended versions 
i.e. DBD with few flanking residues. Both the extended AP2-G::GST proteins are ~40 KDa in size.   
 
  
Figure 7-1. A 10% SDS-PAGE image showing the separation of bands from the uninduced 
lysates and lysates after inducing the cultures with 0.2 mM fresh IPTG. The gel was stained 
with Coomassie Blue for ~40 minutes and destained overnight with freshly prepared destaining 
solution. GST = Glutathione-S-Transferase; AP2-G = N-terminal GST tagged Pb AP2-G 
(PBANKA_143750) DBD; and 1085 = N-terminal GST tagged Pf AP2-G (PF11_1085w) DBD. 
Bands of desired size are shown in red circles. 
 
 
(a) (b) 
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Figure 7-2. A 10% SDS-PAGE image showing the separation of bands from the batch-
purified eluates – three sequential eluates from 5 batches of protein purification (except in batch 
5, where only 2 sequential eluates were available). The gel was stained with Coomassie Blue for 
~40 minutes and destained overnight with a freshly prepared destaining solution. (a) GST = 
Glutathione-S-Transferase; (b) AP2-G = N-terminal GST tagged Pb AP2-G (PBANKA_143750) 
DBD; and (c) 1085w = N-terminal GST tagged Pf AP2-G (PF11_1085w) DBD. Bands of the desired 
size are shown in red rectangles. Purified proteins of the desired size were obtained from almost all 
eluates of all batches for GST and Pb AP2-G GST::DBD. Very small amount of Pf GST::AP2-G 
was obtained as evident in Figure 7-2(c). However, the amount was sufficient to perform EMSAs 
(see below). 
 
 
7.3  AP2-G DBD binds to the expected DNA 
 sequence  
7.3.1  The DBD recognizes a DNA sequence / motif: 
 experimental setup 
It has already been shown by Protein Binding Microarray (PBM) 
experiments in Plasmodium falciparum that each of the different ApiAP2 
transcription factors recognize and bind to at least one specific DNA sequence 
(motif) through their DNA binding domain/s (DBDs; Campbell et al., 2010). For 
PF11_1085w, the Pf ortholog of PBANKA_143750 (AP2-G), this target motif 
consists of GTAC as a core region and flanked by G/A, T and A, C/T on either 
side (G/A)TGTACA(C/T). Since the AP2 domains are highly conserved throughout 
the Plasmodium spp., the DBDs of the orthologous AP2 TFs were also predicted 
to bind to the same sequence across all Plasmodium spp. (Campbell et al., 
2010).  
(c) 
Lanes 1-3:      Eluates 1-3 of batch 1 
Lanes 4-6:      Eluates 1-3 of batch 2 
Lanes 7-9:      Eluates 1-3 of batch 3 
Lanes 10-12: Eluates 1-3 of batch 4 
Lanes 13-14: Eluates 1-2 of batch 5 
Chapter 7 Analysing protein-DNA interactions 269 
 
Beacuse of the DBDs of all known ApiAP2’s are predicited to be highly 
conserved across apicomplexa, the implication that the Pb AP2-G DBD should 
bind to the same motif as recognized by the Pf ortholog was utilized to assess  in 
vitro binding of the GST tagged Pb AP2 DBD to the motif sequence 
(G/A)TGTACA(C/T) by EMSA. The target recognition sequence was synthesised in 
two ways – as commercially synthesised 62-bp hypothetical oligonucleotides 
containing the core conserved recognition motif nnGTACnn flanked by an 
upstream (AATATTATAATAGTCGTAGCCATCAAT) sequence and a downstream 
(ATGGTAATATAGATTTTCGTTTATATT) sequence. The core sequence was 
modified/mutated retaining the same flanking sequences to show that the 
binding is sequence specific and that any single-base change in the core 
sequence abolishes the binding of the DBD to its cognate DNA sequence.  
To complement this experiment, a second set of oligonucleotides was also 
commercially synthesised based on discovery of real/natural sequence bearing 
the core motif sequence (GTAC) in the immediate 1 kb of the 5’ upstream region 
of the coding sequence of predicted target genes. The presence of the 
5’upstream target sequence in the following genes was tested: 2 positions in 
PBANKA_143750 (AP2-G; to explore its autoregulatory possibilities), and one 
position each in PBANKA_103430 (AP2-G2; because it is thought to be 
downstream of AP2-G), and PBANKA_081070 (SPM-1 or sub-pellicular microtubule 
protein-1; identified to be up-regulated in gametocytes by microarray analyses 
(Sinha et al., 2014; data not shown). The total length of the synthesised oligo in 
this case was ~60 bp with the target core motif in the centre of the sequence.  
In both cases, the final oligos were synthesised each as 5’-biotinylated 
(labelled) and non-biotinylated (unlabelled) forms to serve as the target binding 
sequence and as a sequence-specific competitor, respectively. The labelled 
target oligos were used at 0.001 pmol/µl (total of 0.001 pmol per 20 µl reaction 
mix) and unlabelled target competitor olgos at 0.2 pmol/µl (a 200-fold excess to 
the labelled oligo and totalling to 0.2 pmol per 20 µl reaction mix). The details 
of the typical reaction mix are shown in Materials and Methods section 2.4. 
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7.3.2  The DBD binds to the motif identified by PBM 
 analysis in a sequence-specific manner 
The binding of the GST tagged DBD from Pb and Pf AP2-G was shown as a 
positive or upward shift of the bound labelled target oligonucleotide::DBD 
complex in the EMSAs (Figures 7-3 and 7-4). Figure 7-3 (a and b) shows the EMSA 
results using a  synthesised labelled target sequence bearing the core (GTAC) 
recognition motif whereas Figure 7-4 shows the EMSA results using a naturally 
occurring P. berghei genomic sequence containing the predicted AP2-G target 
motif which was synthesised and labelled. The bound complex tends to migrate 
relatively slowly (as compared to the labelled target oligonucleotide alone) in a 
12% PAGE gel under standard operating conditions as detailed in Materials and 
Methods, Section 2.4. This upward shift in the position of the band 
corresponding to the gel lane containing labelled oligo together with the GST 
tagged DBD was compared with the position of the corresponding bands in the 
gel lanes containing labelled oligonucleotide alone. 
 
The binding of the GST tagged DBD to its predicted DNA recognition 
sequence was shown to be specific to the DBD as well as to the target sequence 
of the motif (Figures 7-3 and 7-4). This specificity was tested by conducting the 
EMSAs involving the GST tagged DBDs of Pb and Pf AP2-G and their target 
recognition motifs together with GST alone and mutated target recognition motif 
variants for AP2-G DBDs. The non-DBD protein used was GST alone. The mutated 
target recognition motif variants (Figure 7-3) included for the hypothetical 
labelled target included a poly-A variant (all 8 bases replaced with A), a GC/A 
variant (all G’s and C’s replaced with A) and a complementary base variant 
(complementary base change in the four core bases of the motif). Similarly, the 
mutated target recognition motif for the real/natural motif sequence included G 
to A and C to A base substitutions (Figure 7-4) and single nucleotide point 
mutation variants at various positions within the 4 bases included in the core 
target sequence. The mutated oligonucleotides were similar to the non-mutated 
ones outside the core recognition sequence and were synthesised, labelled and 
purified in exactly the same way as the non-mutated ones.  
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(a) 
 
 
(b) 
 
Figure 7-3. In vitro demonstration of AP2-G DBD binding to its predicted synthetic 
recognition sequence: Electrophoretic Mobility Shift Assay (EMSA) showing the recognition and 
subsequent binding of the GST tagged DBDs of Pb and Pf AP2-Gs to a hypothetical synthesised 
DNA sequence containing the predicted AP2-G DBD recognition motif in a sequence-specific 
manner. Figure 7-3 (a) shows the successful binding of the DBD to the cognate motif as a shift in 
the position of the band of the DBD::labelled oligonucleotide complex as compared to the baseline 
band position of the free labelled probe. It also shows that the binding (shift) is not affected in 
presence of a 400-fold excess of the unlabelled probe showing that the competitor effect was not 
obtained. The sequence specificity of the interaction between the DBD and the labelled probe is 
shown by absence of a shift when the labelled target sequence was changed from nGTGTACCAn 
to nATATAAAAn. Further effect of a change in the target sequence is shown in Figure 7-3 (b) 
where the labelled target sequence was modified to nAAAAAAAAn and nTGCATGCAn, re-
establishing the sequence-specificity of the interactions.  
 
Free probe 
Shift 
Free probe 
Shift 
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(a) 
 
(b) 
 
Figure 7-4. In vitro demonstration of AP2-G DBD binding to its predicted natural recognition 
sequence: Shown are the interactions between GST tagged PbAP2-G with synthesised 
oligonucleotide sequences which are found to occur naturally within the promoter region of the 
following predicted target genes for AP2-G based on the presence of occurrence of the target 
sequence GTAC within the immediate 1 kb of the promoter region of the following genes: two 
motifs in PBANKA_143750 or AP2-G (1 and 2); one motif each in PBANKA_103420 or AP2-G2 
and PBANKA_081070. The sequence-specific nature of the interaction is evident by the presence 
of band-shift (Figure 7-4 a) with the unmutated or WT probe (W) and its absence with the mutation 
variants of the probe (M; the mutated base is depicted as underlined). Successful competition of 
Free probe 
Shift 
Free probe 
Shift 
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the interaction is independently shown with addition of a 200-fold excess of the unlabelled probe. 
Figure 7-4 (b) shows a cartoon of the positional occurrence of the actual motif within the immediate 
2 kb of the promoter region with reference to the translation start site (position 0) of the respective 
coding sequence of the gene (yellow bar). The relative distance of the individual motif sites 
(coloured cross) are also shown. The sequence used for the synthesis of the original wild type 
(WT) and the mutated (Mut) probe for each site is also depicted with the core motif shown in red 
and the mutated base is underlined.   
  
 
The presence of an upward shift in the band positions involving the 
correct/complementary combination pair of the DBD and the recognition 
sequence and the absence of any noticeable shift in the mismatched pair DBD 
and recognition sequence strongly suggests that the DBDs recognize and thus 
bind to a target DNA sequence in a sequence-specific manner, that is, the DBDs 
recognize and bind to a particular 4-base sequence (GTAC, in case of AP2-G) and 
any substitution, even a SNP, in the target sequence abolishes the binding. 
 
 
7.3.3  The binding is relieved by a sequence-specific 
 competitor 
The binding (and thus the upward shift of the band) of the GST tagged 
DBD to its labelled cognate DNA sequence was non-evident in presence of excess 
unlabelled sequence-specific competitor in a dose-dependent manner. The 
competitor was the unlabelled counterpart of the target sequence 
oligonucleotide used at 200-fold excess of the labelled target sequence. The 
samples (DBD with labelled target oligonucleotide and DBD with unlabelled 
target oligonucleotide) were fractionated on a 12% PAGE gel under similar 
running conditions. The complex of the DBD with 200-fold excess of the 
unlabelled target oligonucleotide did not show a positive or upward shift in the 
gel as compared to the free labelled target probe. Together with a positive shift 
of the DBD + labelled target oligonucleotide and an absence of any shift with 
200-fold excess of unlabelled target oligonucleotide, it was highly suggestive 
that an excess of the unlabelled target oligonucleotide was preferentially 
consumed in the formation of the complex with the DBD thus leaving no DBD 
available for making a complex with the labelled target oligonucleotide and thus 
no shift was observed. For reasons not known, the ability of excess unlabelled 
target oligonucleotide to prevent the binding of the DBD to the target motif 
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could only be demonstrated for the target oligonucleotides synthesised from a 
real 5’upstream promoter region of the AP2-G bearing the recognition motif 
(Figure 7-4a).  
 
Based on the evidence of the band-shift being competed in presence of 
200-fold excess of unlabelled target competitor, the relative amount of the 
unlabelled target oligonucleotide needed to make the gel-shift disappear was 
titrated (between the range 10 and 500-fold excess to the labelled probe). It 
was observed at ~350-fold excess of the unlabelled target oligonucleotide was 
sufficient to inhibit the appearance of the gel-shift (Figure 7-5). 
 
 
 
Figure 7-5. EMSA showing dose-dependent titration of the binding competition between the 
GST tagged DBD of AP2-G with 0.01 pmol of the target labelled oligonucleotide and an 
increasing fold-excess concentration of the competitor probe i.e., unlabelled target 
oligonucleotide. The range of concentration of the competitor was 10-fold to 500-fold excess as 
compared to the labelled counterpart, based on the blocking concentration of the unlabelled 
competitor from previous experiment (see Figure 7-4(a). The end point was the concentration 
where the band-shift disappears which in this experiment was a 350-fold excess of the unlabelled 
target probe.  
 
7.4  Polyamides and competition for DNA 
 binding 
Polyamides are a class of pyrrole-imidazole (Py-Im) synthetic chemical 
compounds that can be custom-designed to bind to DNA with high affinity and 
Free probe 
Shift 
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sequence-specificity (Dervan, 2001; Dervan and Edelson, 2003). They have been 
shown to competitively recognize and subsequently bind to the cognate DNA 
sequence thus preventing the DBD from binding to the same site (Zhang et al, 
2011; Manuel Llinas, Princeton University, unpublished data). Polyamides 
targeting specific DNA sequences of AP2-G with a higher affinity and specificity 
(in targeting the cognate DNA sequence) than the natural DBD can now be 
synthesised with high yield, cost-effectiveness and versatility (Glenn Burley and 
Ishwar Singh, University of Strathclyde, personal communication). Further, 
structural modifications can be made to provide better solubility in aqueous 
media (Matt Gregory, Hope College, USA, unpublished data; Glenn Burley and 
Ishwar Singh, University of Strathclyde, personal communication) so that these 
compounds can be tested both in vitro and in vivo.  
To assess the role of these polyamides as potential competitors of the 
AP2-G DBD for the same target sequence in vitro, specific pyrrole- and 
imidazole- containing analogues of P. berghei AP2-G DBD (ISS-15) and the 
distinct AP2, P. falciparum AP2O DBD (ISS-33) were synthesised and kindly gifted 
to me by Ishwar Singh and Glenn Burley (University of Strathclyde, Glasgow). 
These polyamides had excellent binding affinity (K) and sequence specificity. 
ISS-15 was diluted to sub-nanomolar concentrations for performing competition 
assays using EMSAs. To determine the specific concentration of the polyamides 
necessary to preferentially bind to the target sequence, reflected as the point of 
disappearance of the band shift in the EMSA, a titration experiment was carried 
out with P. berghei GST::AP2-G DBD (green in Figure 7-6) and P. falciparum 
GST::AP2-G DBD (yellow in Figure 7-6) and ISS-15 concentration ranges between 
1 nM and 1000 nM and which were then refined to between 1 nM and 10 nM. As 
these polyamides are low molecular weight entities when compared to the 
actual GST tagged DBD, the binding of the polyamides to the labelled cognate 
DNA sequence does not produce a shift hence disappearance of the band shift on 
adding excess ISS-15 is the read out (Figure 7-6). ISS-33 was also tested 
separately to competitively inhibit the AP2-G DBD binding with its recognition 
motif but expectedly, it did not block the shift (data not shown). This suggests 
that the synthesised polyamides are highly sequence specific so that ISS-15 will 
only recognize the AP2-G motif and there is no cross-recognition of the AP2-G 
motif by ISS-33 (which is specific for recognition of the AP2-O motif). 
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Figure 7-6. EMSAs showing competitive interference of synthetic polyamide (ISS-15) on the 
interaction between the DBD of Pb AP2-G (green) and Pf AP2-G (yellow). The amount of ISS-
15 necessary to abolish the interaction between the AP2-G DBD and the target motif was titrated, 
the range being from 1 nM to 1000 nM (left panel). The optimum amount needed to prevent the 
interaction was less than 10 nM which was further titrated between 1 nM and 10 nM (right panel). It 
can be deduced that in vitro, 10 nM and 4-6 nM of ISS-15 sufficiently prevents almost all the 
interaction between the DBD and the target recognition motif in Pb and Pf, respectively. 
 
7.5  Summary and discussion 
Transcription factors play a very important role in controlling gene 
expression in eukaryotes. The paucity of established TFs in Plasmodium makes 
them an important candidate target for future malaria control strategies. The 
ApiAP2 class of TFs have already been proven to play important roles during 
ookinete and sporozoite stages of the Plasmodium life cycle in the invertebrate 
host. The discovery and subsequent characterization of AP2-G during this work, 
in terms of its capacity to influence multiple downstream transcriptional targets, 
through the demonstrated interactions between the DNA Binding Domain and the 
cognate target motifs indicates a critical role in controlling malaria transmission. 
AP2-G turns out to be a key regulator of the commitment of the asexual parasite 
to the sexual stage, and may be established as the master regulator of a major 
developmental switch in the life cycle of Plasmodium. 
In this chapter, through EMSAs it was successfully demonstrated in vitro 
that the GST tagged DBD of AP2-G recognizes and interacts with a conserved cis-
element sequence, nGTACn present within the promoter region of  key 
regulatory genes – seen in the EMSAs as a positive band-shift. It was also shown 
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that this interaction is highly sequence specific, as even a single base mutation 
within the GTAC sequence abolishes the interaction. The sequence-specificity of 
the interaction was again demonstrated by the fact that a 200 to 350-fold excess 
of the unlabelled recognition sequence was able to compete out with the 
interaction. Further, the use of a custom-designed synthetic polyamide (ISS-15) 
that showed preferential binding to the recognition motif, thus preventing the 
actual binding of the AP2-G DBD, established the proof of concept that such 
compounds have the potential to be explored as future transmission-blocking 
candidates particularly with the current dearth of novel therapeutic and 
protective compounds for malaria control. 
Further research questions stemming from this part of the work include 
concerns regarding the: 
 functional role of such motifs in vivo, as the mere presence of a motif 
does not guarantee a related function 
 in vivo testing through reporter constructs to check the binding of the 
DBD to the cognate DNA sequence present in the promoters/5’UTRs of 
the predicted genes 
 minimum number of bases in the recognition target motif that are 
required for efficient binding 
 nature of flanking sequences around the conserved recognition motif 
and its influence on binding 
 effect of an interruption of the promoter in terms of increased 
distance of the target motif to the ATG 
 role of the presence of one or more than one motifs in the promoter 
region 
 attempts to predict the presence of these recognition motifs in the 
promoter and/or 5’ UTRs of the critical sex-specific genes 
 presence and role (auto-regulatory) of the target motif for AP2-G 
within the 2 kb upstream region of the coding sequence of AP2-G 
itself 
 role of ISS polyamide compounds in preventing malaria transmission.  
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8  General discussion 
Despite the renewed surge in enthusiasm and optimism regarding the 
attainability of the mammoth goal of eradicating malaria globally, the current 
armamentarium of anti-malaria measures offers little in the way of novel 
strategeies. The appearance of foci of resistance to the present day frontline 
anti-malaria drugs, the Artemisinin Combination Therapy, in Thailand and the 
incipient risk of spreading the problem worldwide has generated serious 
concerns over the efficiency of malaria control and elimination (World Malaria 
Report, 2013). With no new drugs in the immediate pipeline and unconvincing 
results of Phase 3 trials of the much awaited malaria vaccine, RTS,S/AS01 
(Agnandji et al., 2012; Moorthy et al., 2013), the urgent need to discover and 
develop newer modalities of treating and preventing transmission of malaria 
cannot be overemphasized (World Malaria Report, 2013). Specifically for malaria 
elimination and eradication, the identification of compounds which are effective 
in blocking the transmission of the disease by interrupting the transition 
between asexual and sexual mode of the life cycle of Plasmodium is urgently 
required. 
  Gametocytogenesis in malaria parasites and the completion of the sexual 
cycle are critical bottlenecks in the life cycle of the parasite. This thesis was 
aimed at dissecting and understanding the hitherto unknown molecular 
mechanisms (Eksi et al., 2012; Ikadai et al., 2013) regulating the generation of 
gametocytes in P. berghei, the rodent malaria model.  
A classical forward genetics screen was used to generate the gametocyte-
less mutants. Simultaneously, ten isogenic parasite lines, all derived from the 
male (GFP) and female (RFP) fluorescent reporter parental line 820, were 
maintained in asexual propagation by repeated mechanical passage in TO mice 
for about a year. Gametocytemia was monitored each week using flow 
cytometry and the desired gametocyte non-producer (GNP) phenotype was 
finally ascertained by absence of transmission of the GNP lines through 
mosquitoes.  
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The gametocytemia declined with the number of mechanical passages in 
all the ten lines by the end of the passage period but reached zero in only three 
of the potential ten lines (GNP9, GNP7 and GNP8). Various lines have been made 
in the past to generate such GNP mutants in P. berghei and P. falciparum but 
these mutants were never subjected to an immediate high throughput whole 
genome sequencing (WGS) approach  to identify the attributable mutations in 
the genome (Micks, 1947a; Shirley et al., 1990; Janse et al, 1992; Day et al., 
1993; Alano et al., 1995). Although the rate of accumulation of spontaneous 
evolutionary mutations in Plasmodium have recently been estimated to be low 
(1.7 x 10-9 per base pair per generation) and comparable to other eukaryotes 
(Bopp et al., 2013), this study provides enough power and minimal mutational 
noise to specifically identify the causal GNP-associated mutations (if any) by 
comparative mapping of the genome sequences between the de novo GNP 
mutants and their isogenic gametocyte producer parent. Similar approaches 
have been used to identify the candidate genetic mutations associated with drug 
resistance in Plasmodium (Hunt et al., 2010; Martinelli et al., 2011; Modrzynska 
et al., 2012; Bright and Winzeler, 2013; Miotto et al., 2013; Neafsey, 2013).           
The comparative genomic sequencing study identified an ApiAP2 family 
transcription factor, PBANKA_143750, as the only gene being uniquely mutated 
in all the three de novo GNP mutants generated in this study. In addition, WGS 
of other pre-existing GNP lines K173cl1 and 233 also showed that AP2-G was 
mutated in these two lines. The ApiAP2, a family of 27 transcription factor 
proteins in Plasmodium, is the only identified specific transcription factor family 
in apicomplexans to date (Balaji et al., 2005). ApiAP2’s have already been shown 
to be involved in regulating other life-cycle stages of Plasmodium such as 
ookinetes (AP2-O; Yuda et al., 2009), sporozoites (AP2-Sp; Yuda et al., 2010) and 
liver stage sporozoites (AP2-L; Iwanaga et al., 2012). To differentiate 
PBANKA_143750 from the other three ApiAP2 members with a stage-specific 
role, the gene has been named AP2-G to indicate its role in Plasmodium 
gametocytogenesis.  
This discovery of AP2-G is quite different in terms of the implicated role 
of the gene in the life cycle of the parasite. Whereas the other three identified 
AP2’s have a role in progression of the life cycle stage of the parasite, AP2-G is 
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implicated in regulating a critical developmental switch that would determine 
the transmissibility of the parasite in nature.  
The seminal finding of this study strongly suggested AP2-G as the master 
regulator of gametocytogenesis. However, the kinetics of declining 
gametocytogenesis in the generated GNP lines in the study, particularly GNP line 
8, suggests that a cascade of genes that might need to be mutated before a line 
becomes a GNP line. If this is the case, then the findings of this study strongly 
argue that PBANKA_143750 or AP2-G is the first in a series of genes that will be 
attributed to the absolute GNP phenotype. There might be other genes or other 
mutations within the same gene involved in the cascade which then could be 
hypothesised (for now) to be present upstream to AP2-G, mutation(s) in each 
contributing to a proportional fall in the number of gametocytes generated over 
time.  
A battery of reverse genetics (gene deletion) experiments supplemented 
the observations of the classical forward genetics experiments in demonstrating 
that the AP2-G(-) mutants did not produce gametocytes and hence were not 
transmissible to  mosquitoes. The three AP2-G knockout length variants also 
proved that the region bearing the three de novo GNP mutations (which was 
upstream to the DBD) and the DBD bearing region itself were independently 
associated with absence of gametocyte production. However, it would be quite 
interesting to knockout the 264 bp region downstream to the AP2-G DBD, to 
show its functional significance in regulating gametocytogenesis as evidenced by 
the location of the mutation in the GNP line 233. However, evidence suggests 
that extra sequences both at N- and C-terminal of the DBD in addition to the 
domain itself are critical for binding to the DNA (Balaji et al., 2005; Campbell et 
al., 2010).  
It is also worth mentioning here that systematic ApiAP2 gene deletion 
experiments in P. berghei led to the concurrent but independent discovery of 
yet another ApiAP2 transcription factor, PBANKA_103430 or AP2-G2, which when 
perturbed, produced a significant marked decrease in the gametocyte 
production (but not complete abolition) with only a few female gametocytes 
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observed which obviously could not be transmitted through the mosquitoes 
(Sinha et al., 2014; data not shown).  
A high degree of conservation of the AP2-G DBD among the sexually 
reproducing apicomplexans like Plasmodium spp., Theileria spp., and Babesia 
spp., signifies the importance of the protein as a critical regulator of sexual 
differentiation. Sufficient evidence is now available to believe that AP2-G is in 
fact the master regulator of commitment to gametocytogenesis in malaria 
parasites. Some of the most crucial evidences include concurrent identification 
of a P. falciparum orthologue of AP2-G (PFL1085w) through an independent 
approach (Kafsack et al., 2014) as essential for gametocytogenesis.   
Also, direct growth competition assays between AP2-G knockout, WT P. 
berghei and AP2-G2 knockout revealed that AP2-G knockout mutants overgrew 
both the WT and AP2-G2 knockout mutants and AP2-G2 knockout mutants 
overgrew the WT indicating that AP2-G mutants completely lacked gametocytes 
thus offering a growth advantage to the asexually dividing parasites (Sinha et 
al., 2014; data not shown). This establishes the central role of AP2-G at the 
point of commitment to gametocytogenesis whereas AP2-G2 is involved 
downstream of AP2-G once the parasites are committed to form gametocytes. 
The role of AP2-G transcription factor as master regulator of the process of 
commitment to gametocytogenesis is further supported by the fact that AP2-G2 
was never associated with any of the de novo GNP lines generated in the study 
reinforcing the hypotheses that AP2-G2 lies downstream to AP2-G. Further, 
based on the observation that once committed to sexual differentiation, the 
committed merozoites are either all females or all males (Silverstrini et al., 
2000; Smith et al., 2000), it would be intriguing to know if there exists two 
flavours of AP2-G – AP2-G(m) and AP2-G(f)? Also, the answer to the question 
whether sexual stage commitment is accompanied by a concomitant sexual 
differentiation or is there a temporal gap between the two processes is of great 
interest.  
However, as the data accumulates (Kafsack et al., 2014; Sinha et al., 
2014), the regulation of the switch appears to be complex. It has been shown 
that all the AP2 transcription factors have at least one DNA binding domain 
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(DBD; conserved throughout the orthologues in apicomplexa) which recognizes 
and binds to a conserved sequence motif in a sequence-specific manner 
(Campbell et al., 2010; Painter et al., 2011). For PFL1085w, the P. falciparum 
orthologue of AP2-G, the motif, nnGTACnn, was discovered by PBMs and later 
shown to effectively bind the AP2 protein in vitro by EMSAs was also believed to 
be conserved. The present study (by using EMSAs) demonstrates that the 
nnGTACnn motif is in fact conserved for GST-tagged DBD of AP2-G identification 
and binding in vitro, and any single base substitution abrogates the binding of 
the AP2-G DBD with the cognate motif thus confirming the prediction made by 
Campbell et al (2010). The presence of the recognition motif in the upstream 
region of the AP2-G itself shows yet another level of control over transcription – 
a possible auto-regulation of AP2-G expression.  
Identification of the downstream target genes for AP2-G would be the 
next immediate experimental task although preliminary reporter-based in vivo 
experiments conducted by Katie Hughes (Andy Waters’ Lab) involving the 
promoters of some of the genes bearing the AP2-G recognition motif suggest that 
not all genes bearing the motif are under direct control of AP2-G. Though some 
of the motifs were shown to recognize and bind the GST-tagged AP2-G DBD in 
vitro using EMSAs, it might also be possible that DNA methylation and histone 
modifications at the nuclear periphery (Lopez-Rubio et al.,2009; Flueck et al., 
2010) are involved, such that the mere presence of the recognition motif does 
not guarantee a regulatory control by AP2-G, thus offering  fine tuning of gene 
expression in Plasmodium (Robertson et al., 2007; Campbell et al., 2010). 
Indeed evidence was obtained that protein-protein interactions involving the 
portion of AP2-G sequence other than the DBD might  be involved in the 
regulatory complex, as evidenced by the location of the mutation in the pre-
existing GNP line 233 (downstream to the DBD) in the final C-terminal 200aa of 
the >2300aa predicted protein.    
Gene complementation efforts to restore the WT phenotype are required 
but not mandatory to prove a causal association if forward genetic studies are 
supplemented with coherent results from the reverse genetics counterpart. But, 
to prove the causality, complementation of the de novo GNP mutants was 
successfully attempted and the surviving WT parasites from the mixed 
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transfectant (WT+GNP) population were immediately rescued through mosquito 
passage to generate a clonal WT population after the bite-back experiments.  
Complementation efforts in the study were challenged by at least two  
factors – first, the length of the gene to be complemented was ~7 kb thus giving 
rise to the inherent problems associated with cloning and manipulation of such a 
large and single DNA fragment; and second, the reversal of the GNP phenotype 
to a gametocyte-producer phenotype had to happen against a strong natural 
selection pressure in favour of the GNP parasites, posing problems in negatively 
selecting the transgenic complemented parasites. 
A proof of principle for identifying and developing AP2-G as an anti-
gametocyte agent was also established in the study by using a synthetic 
polyamide compound (ISS-15) designed by Ishwar Singh and Glenn Burley, 
University of Strathclyde, UK. Such polyamides offer molecular mimicry and 
preferentially block the DBD recognition motif thus preventing the formation of 
the transcription initiation complex (Zhang et al, 2011). ISS-15 was shown by 
EMSAs to preferentially bind to the AP2-G recognition motif and thus abolish the 
binding of the AP2-G DBD with the motif. The polyamides can be structurally 
customized to offer specificity of binding to any DNA sequence and thus can 
selectively target/inhibit the regulation of particular stage-specific transcription 
events.   
Taken together, the collective evidence strongly favours the conclusion 
that PbAP2-G has a pivotal role in the commitment of asexually dividing malaria 
parasites, causing them to developmentally switch to the sexual mode of 
reproduction and generate the sexual precursors in the mammalian host – the 
gametocytes. The fact that such a transition occurs within the mammalian host 
offers a glimpse of hope towards identification of new anti-gametocyte targets 
for vaccine/drugs based on the molecular basis of AP2-G functioning and its 
vulnerability to successful interruption, at least, in vitro. However, additional 
modes of action of AP2-G including possible protein-protein mediated actions 
and the epigenetic control of AP2-G gene expression offer possible intricacies 
and, at the same time, insight into the apparently simple molecular functioning 
of PbAP2-G and its regulation. 
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 Our current understanding of the mechanisms of transcriptional regulation 
by the ApiAP2 TFs in general offers hope for exploiting them as a new generation 
of drug targets. The areas to explore, however, include the drug candidate’s 
ability to modulate either the synthesis/stimulation of ApiAP2’s, the regulation 
of their activity by ligands or phosphorylation events, their binding to the DNA, 
the protein-protein interactions mediated by the TFs and/or at the epigenetic 
level, by stimulating  activity of transcription factors’ silencers.  
 
 Blocking TF synthesis/activation: This approach is likely to be of use only 
where it is desirable to switch on or off an entire bank of genes regulated by a 
particular TF. In such cases, it would be more effective to target the synthesis of 
the factor itself. Alternatively, the molecules/pathways involved in the 
activation of a TF could be targeted. For example, a metabolomics-based 
approach to study gametocyte non-producers in details may reveal metabolic 
signatures of commitment to sexual development and such signature molecules 
can also be explored. In many situations however, it will be preferable to 
develop ways of modulating the particular activity(ies) of the transcription 
factor, particularly when  downstream roles of the target genes remain 
unidentified. 
 
 Blocking DNA binding: Binding of the TF to specific binding site/s in the 
target DNA molecule is necessary for TF action and thus represents an obvious 
target for therapeutic drugs. Evidence from the specific role of the DBD of AP2-O 
clearly suggests that blocking of DBD-binding to the target DNA motif could be 
explored as a drug target. Further evidence generated in this research regarding 
the in vitro ability of synthetic custom-designed polyamides in blocking the 
binding of the TF DBD to the recognition motif in a sequence-specific manner is 
also supportive of the approach. The property of the TF to heterodimerize in 
order to be able to bind to the recognizable cis-element (Lindner et al., 2010) 
also could be exploited. Indeed, inhibition of E2F/DP-1 heterodimerization 
actually achieved the effect of inducing apoptosis in tumour cells by preventing 
DNA-binding of the TF which required heterodimer formation (Bandara, Girling, 
La Thangue, 1997). A potential drawback of blocking specific activity(ies) of TFs 
is the possibility of  undiscovered / unexpected redundancy in action  that 
bypasses the DBD/DNA interaction such as the presence of functional protein-
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protein interactions or epigenetics based actions and these will tend to be 
overlooked. 
  
 Blocking protein-protein interactions: Although the precise role of the 
DBD is well established as a pre-requisite for the downstream action of the TF, it 
might be possible that areas of the TF gene other than the DBD might be 
implicated in causing the altered gene expression and phenotype. In such a 
context, it is essential that the possibility of non-DBD mediated actions of the 
TF, for example, protein-protein interaction based regulation should not be 
ruled out.  
 
 Some of the other practical challenges in developing a TF-based drug 
target include the need to accumulate and sustain the proposed drug within the 
parasites, presence of multifaceted cross-talk between different transcription 
factors and their interactions with target genes across various tissues, cellular 
contexts and temporal settings, and the higher order chromatin organization of 
the TFs affecting their localization, turnover and gene targeting potential 
(Karamouzis and Papavassiliou, 2011). 
 
However, using transcription factor blockers as anti-malaria candidates 
offers certain advantages. There is no known human orthologue for the ApiAP2 
TF family so this would mean that if a transmission-blocking candidate is 
designed for intended human intake, it may have limited interference with 
human physiology and hence better compliance. Secondly, in the absence of 
mosquito bites, it would be an evolutionary advantage for the parasites to 
support and sustain the interruption in gametocytogenesis (Carter et al., 2013) 
and if such GNP changes are irreversible, then that would be a dead end for the 
parasite to escape the mammalian host. Although theoretically sound and 
convincing, a lot would depend how this GNP phenotype would behave in nature 
particularly regarding the changes in transmission dynamics and pathogenicity of 
the GNP parasites, to name a few. Importantly, the possibility of an 
undiscovered redundancy in the regulation of the gametocytogenesis switch 
cannot be ruled out at this stage, particularly when the involvement of a 
cascade of genes is hypothesized as part of the regulatory machinery.      
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Despite providing a new knowledge base about the molecular switch 
implicated in regulating gametocytogenesis in malaria parasites, the study opens 
the doors to a plethora of research questions for the malaria fraternity to 
answer and further refine knowledge on gametocytogenesis. Some of the 
research challenges are briefly mentioned below.  
The lines that did not end up as GNP but rather as low gametocyte 
producers could be fruitful in identifying the hypothesized cascade of genes (if 
any) positioned upstream to the AP2-G or any other molecular mechanisms 
responsible for the gradual lowering of gametocytemia in these lines. The 
application of mathematical modeling to predict the almost precise point in the 
gametocytemia kinetics which shows periods of significant decline of gametocyte 
numbers could be very useful to select the particular cryo-preserved stabilate 
for whole genome sequencing.  
These predictions would then help us identify the series of mutations and 
investigate whether these mutations significantly bring a change in the kinetics 
and thus reduce the proportion of gametocytes until a critical mutation affects 
AP2-G and totally stops gametocyte production or alternatively, AP2-G is 
mutated in a stochastic process thus abolishing gametocyte generation. This 
would be particularly interesting to explore in the GNP line 8 which showed a 
gradual decline of gametocytemia throughout the passage period.  
Similar observations were also recorded when a GNP line was successfully 
complemented. Unintended passages of the line prior to the mosquito 
transmission resulted in the loss of complemented parasites. It may well be 
reasoned that the complementation happened in the background of the already 
existing GNP parasites which gradually replaced the complemented counterparts 
in the absence of transmission. It would be worthwhile to show that this indeed 
happened by cloning the complemented GNP line and comparing the clones. 
Further, sequencing the AP2-G gene from other pre-existing GNP lines in the 
Andy Waters’ lab (University of Glasgow) would throw further light on the 
variety of mutations (if any) that contribute to the GNP phenotype in these 
lines. 
Chapter 8 General discussion 288 
 
What are the precise signaling cues and mechanisms that turn the 
molecular switch on is yet another area of practical potential importance. 
Although recent literature suggests that the signals are mediated via 
microvesicles and exosome-like vesicles (Mantel et al., 2013; Regev-Rudzki et al, 
2013), the precise nature and mediators of signaling are yet to be explored. In 
this context, the preserved frozen plasma from each week of the passage 
experiment could prove beneficial to decode the metabolomic signatures which 
can reveal the precise signaling mechanisms in operation at or immediately 
before the actual commitment to gametocytogenesis (delPortillo and Chitnis, 
2013). To add to the complexity of the issue, it would be interesting to know 
that if the GNP lines are exposed to mosquitoes, will the same signalling 
mechanism which was thought to be providing the sensory cues for the parasite 
to abolish the generation of gametocytes in the absence of mosquitoes, become 
recruited to produce gametocytes and if this is there, a selective advantage over 
the GNP population? This would suggest that these genetic changes may not be 
irreversible, at least for this GNP phenotype in Plasmodium.  
 
As the open reading frame of the gene does not possess any known 
functional domain other than the DBD, the functional role of the rest of the 
coding sequence remains unclear. Moreover, with the presence of a nonsense 
mutation located immediately downstream to the DBD in the pre-existing GNP 
line 233, the functional implications of the peri-DBD areas require investigation. 
Such a mutation is expected to result in a fully functional DBD which might 
indicate another level of gene expression regulation by mediation of protein-
protein and/or protein-DNA interactions involving the region of the protein 
downstream of the mutation. 
 
In addition to the rest of the open reading frame of AP2-G outside the 
DBD, the role of the un-translated regions (UTRs), particularly the 5’UTR of the 
gene, also warrant further investigation. It is worthwhile to note that when the 
5’UTR of the gene was interfered with big insertion of the drug selectable 
marker cassette (SMC) while complementing a knockout line with the 
recombineering based repair construct (Chapter 6), the expression of the gene 
was negatively affected in terms of the ability of the knock out line to 
regenerate gametocytes. It remains unclear whether the loss of expression 
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occurred due to the DBD recognition motifs getting interrupted by the SMC or 
possibly nucleosome phasing getting out of phase because of the extra length of 
DNA. Whatever the reason may be, the AP2-G promoter was interrupted and 
rendered non-functional due to the incorporation of the SMC in the 5’UTR of the 
gene.    
Further refining of the interaction between the AP2-G DBD and 
recognition motif would help answering the questions regarding uncertainty in 
the precise control of gametocytogenesis. These include, but not limited to, the 
number of motifs required for gene expression, the identification of the 
minimum number of bases required for efficient and specific binding, the 
distance between two motifs, the role of flanking sequences in binding, the 
distance of the motif relative to the ATG, the role of multiple DBDs and multiple 
recognition motifs even for a single DBD, the role of AP2-G coding sequence 
regions out with DBD, nucleosome phasing and many more. 
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Table A1: Line 1 - weekly parasitemia & gametocytemia by flow cytometry (G=Gams, 
M=Males, F=Females, A=asexuals) before discounting for control readings in uninfected mouse 
(UI). Discounted data is shown as T’ (total parasitemia), G’ (gams), M’ (males) & F’ (females) 
  
 
Discounted 
Total (%)
G M F A T' G' M' F'
1 4.14 0 0.6 0.29 0.31 3.54 4.14 14.49 7.00 7.49
2 4.52 0 0.49 0.37 0.12 4.03 4.52 10.84 8.19 2.65
3 2.96 0 0.33 0.22 0.11 2.63 2.96 11.15 7.43 3.72
4 3.34 0 0.73 0.33 0.4 2.61 3.34 21.86 9.88 11.98
5 3.74 0 0.99 0.46 0.53 2.75 3.74 26.47 12.30 14.17
6 16.14 0 0.24 0.15 0.09 15.9 16.14 1.49 0.93 0.56
7 3.33 0 0.24 0.17 0.07 3.09 3.33 7.21 5.11 2.10
8 1.67 0 0.12 0.08 0.04 1.55 1.67 7.19 4.79 2.40
9 0.72 0 0.04 0.03 0.01 0.68 0.72 5.56 4.17 1.39
10 2.44 0 0.63 0.37 0.26 1.81 2.44 25.82 15.16 10.66
11 3.26 0 0.47 0.31 0.16 2.79 3.26 14.42 9.51 4.91
12 2.96 0 0.63 0.3 0.33 2.33 2.96 21.28 10.14 11.15
13 3.01 0 0.24 0.11 0.13 2.77 3.01 7.97 3.65 4.32
14 3.22 0 0.41 0.24 0.17 2.81 3.22 12.73 7.45 5.28
15 2.88 0 0.72 0.37 0.35 2.16 2.88 25.00 12.85 12.15
16 3.81 0 0.86 0.42 0.44 2.95 3.81 22.57 11.02 11.55
17 3.7 0 0.95 0.57 0.38 2.75 3.7 25.68 15.41 10.27
18 2.58 0 0.21 0.15 0.06 2.37 2.58 8.14 5.81 2.33
19 4.94 0 0.49 0.23 0.26 4.45 4.94 9.92 4.66 5.26
20 3.28 0 0.65 0.35 0.3 2.63 3.28 19.82 10.67 9.15
21 3.04 0 0.77 0.56 0.21 2.27 3.04 25.33 18.42 6.91
22 3.97 0 0.46 0.24 0.22 3.51 3.97 11.59 6.05 5.54
23 3.81 0 0.69 0.3 0.39 3.12 3.81 18.11 7.87 10.24
24 4.7 0 0.49 0.28 0.21 4.21 4.7 10.43 5.96 4.47
25 7.09 0 0.63 0.33 0.3 6.46 7.09 8.89 4.65 4.23
26 4.73 0 0.38 0.15 0.23 4.35 4.73 8.03 3.17 4.86
27 11.06 0 0.29 0.17 0.12 10.8 11.06 2.62 1.54 1.08
28 5.92 0 0.47 0.26 0.21 5.45 5.92 7.94 4.39 3.55
29 4.2 1.31 0.28 0.17 0.11 3.92 2.89 9.69 5.88 3.81
30 7.59 0.79 0.39 0.12 0.27 7.2 6.8 5.74 1.76 3.97
31 6.25 3.62 0.27 0.09 0.18 5.98 2.63 4.32 1.44 2.88
32 8.18 3.05 0.15 0.07 0.08 8.03 5.13 1.8337 0.86 0.98
33 4.14 0.2 0.32 0.12 0.2 3.82 3.94 7.7295 2.90 4.83
34 2.68 0.19 0.07 0.02 0.05 2.61 2.49 2.6119 0.75 1.87
35 3.44 0.27 0.23 0.08 0.15 3.21 3.17 6.686 2.33 4.36
36 5.61 0.7 0.14 0.1 0.04 5.47 4.91 2.4955 1.78 0.71
37 6.42 0.34 0.29 0.08 0.21 6.13 6.08 4.5171 1.25 3.27
38 12.27 6.74 0.22 0.16 0.06 12.1 5.53 1.793 1.30 0.49
39 7.38 2.69 0.16 0.07 0.09 7.22 4.69 2.168 0.95 1.22
40 10.76 5.18 0.49 0.21 0.28 10.3 5.58 4.5539 1.95 2.60
41 20.98 1.92 0.46 0.2 0.26 20.5 19.06 2.1926 0.95 1.24
42 9.75 2.95 0.36 0.1 0.26 9.39 6.8 3.6923 1.03 2.67
43 9.81 0.32 0.31 0.16 0.15 9.5 9.49 3.16 1.63 1.53
44 9.09 1.96 0.31 0.16 0.15 8.78 7.13 3.4103 1.76 1.65
45 10.06 1.83 0.19 0.11 0.08 9.87 8.23 1.8887 1.09 0.80
46 12.26 3.65 0.19 0.11 0.08 12.1 8.61 1.5498 0.90 0.65
47 12.12 2.59 0.29 0.13 0.16 11.8 9.53 2.3927 1.07 1.32
48 7.69 1.12 0.46 0.12 0.34 7.23 6.57 5.9818 1.56 4.42
49 8.39 1.75 0.19 0.04 0.15 8.2 6.64 2.2646 0.48 1.79
50 12.28 1.76 1.02 0.81 0.21 11.3 10.52 8.3062 6.60 1.71
51 7.91 0.9 0.16 0.04 0.12 7.75 7.01 2.0228 0.51 1.52
52 9.98 1.11 0.14 0.06 0.08 9.84 8.87 1.4028 0.60 0.80
Discounted (as total %)Undicounted 
Total (%) 
Weeks
Total 
in 
control 
(%)
Discounted                 
(as % of total parasites)
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Table A2: Line 2 - weekly parasitemia & gametocytemia by flow cytometry (G=Gams, 
M=Males, F=Females, A=asexuals) before discounting for control readings in uninfected mouse 
(UI). Discounted data is shown as T’ (total parasitemia), G’ (gams), M’ (males) & F’ (females) 
 
 
Discounted 
Total (%)
G M F A T' G' M' F'
1 0.21 0.03 0.02 0.01 0.18 0.21 14.29 9.52 4.76
2 4.03 0.67 0.32 0.35 3.36 4.03 16.63 7.94 8.68
3 0.6 0.04 0.03 0.01 0.56 0.6 6.67 5.00 1.67
4 1.28 0.1 0.07 0.03 1.18 1.28 7.81 5.47 2.34
5 1.98 0.19 0.12 0.07 1.79 1.98 9.60 6.06 3.54
6 2.42 0.17 0.12 0.05 2.25 2.42 7.02 4.96 2.07
7 6.87 0.9 0.39 0.51 5.97 6.87 13.10 5.68 7.42
8 7.55 0.63 0.32 0.31 6.92 7.55 8.34 4.24 4.11
9 3.91 0.93 0.36 0.57 2.98 3.91 23.79 9.21 14.58
10 8.75 0.82 0.36 0.46 7.93 8.75 9.37 4.11 5.26
11 5.08 0.49 0.24 0.25 4.59 5.08 9.65 4.72 4.92
12 2.73 0.23 0.15 0.08 2.5 2.73 8.42 5.49 2.93
13 7.32 1.45 0.86 0.59 5.87 7.32 19.81 11.75 8.06
14 4.27 0.4 0.33 0.07 3.87 4.27 9.37 7.73 1.64
15 4.99 0.8 0.59 0.21 4.19 4.99 16.03 11.82 4.21
16 4.59 0.38 0.2 0.18 4.21 4.59 8.28 4.36 3.92
17 7.72 1.28 0.55 0.73 6.44 7.72 16.58 7.12 9.46
18 5.14 0.37 0.25 0.12 4.77 5.14 7.20 4.86 2.33
19 7.06 0.63 0.41 0.22 6.43 7.06 8.92 5.81 3.12
20 5.85 0.34 0.22 0.12 5.51 5.85 5.81 3.76 2.05
21 13.79 0.61 0.24 0.37 13.2 13.79 4.42 1.74 2.68
22 6.58 0.51 0.33 0.18 6.07 6.58 7.75 5.02 2.74
23 4.49 1.77 0.38 0.21 0.17 4.11 2.72 13.97 7.72 6.25
24 6.02 0.89 0.34 0.23 0.11 5.68 5.13 6.63 4.48 2.14
25 6.38 3.62 0.34 0.16 0.18 6.04 2.76 12.32 5.80 6.52
26 8.47 3.05 0.09 0.05 0.04 8.38 5.42 1.66 0.92 0.74
27 5.65 0.24 0.48 0.35 0.13 5.17 5.41 8.87 6.47 2.40
28 5.05 0.19 0.11 0.08 0.03 4.94 4.86 2.26 1.65 0.62
29 5.52 0.27 0.5 0.24 0.26 5.02 5.25 9.52 4.57 4.95
30 5.08 0.38 0.51 0.32 0.19 4.57 4.7 10.85 6.81 4.04
31 4.48 0.34 0.24 0.06 0.18 4.24 4.14 5.36 1.339 4.0179
32 18.12 10.04 0.51 0.21 0.3 17.6 8.08 2.81 1.159 1.6556
33 7.9 2.69 0.34 0.13 0.21 7.56 5.21 4.3 1.646 2.6582
34 9.94 5.18 0.45 0.18 0.27 9.49 4.76 4.53 1.811 2.7163
35 11.08 1.92 0.83 0.31 0.52 10.3 9.16 7.49 2.798 4.6931
36 10.26 2.95 0.23 0.06 0.17 10 7.31 2.24 0.585 1.6569
37 7.58 0.32 0.38 0.26 0.12 7.2 7.26 5.01 3.43 1.5831
38 20.38 16.99 0.46 0.13 0.33 19.9 3.39 2.26 0.638 1.6192
39 9.48 1.83 0.17 0.11 0.06 9.31 7.65 1.79 1.16 0.6329
40 13.95 3.65 0.27 0.19 0.08 13.7 10.3 1.94 1.362 0.5735
41 12.86 2.59 0.43 0.22 0.21 12.4 10.27 3.34 1.711 1.633
42 8.31 1.12 0.66 0.35 0.31 7.65 7.19 7.94 4.212 3.7304
43 7.49 1.75 0.19 0.13 0.06 7.3 5.74 2.54 1.736 0.8011
44 11.93 1.76 1.5 0.99 0.51 10.4 10.17 12.6 8.298 4.2749
45 8.1 2.92 0.1 0.06 0.04 8 5.18 1.23 0.741 0.4938
46 7.63 1.74 0.6 0.22 0.38 7.03 5.89 7.86 2.883 4.9803
47 10.61 2.33 0.25 0.13 0.12 10.4 8.28 2.36 1.225 1.131
48 6.27 0.2 0.13 0.04 0.09 6.14 6.07 2.07 0.638 1.4354
Discounted                 
(as % of total 
parasites)
Weeks
Undicounted 
Total (%) 
Total 
in 
control 
(%)
Discounted (as total %)
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Table A3: Line 3 - weekly parasitemia & gametocytemia by flow cytometry (G=Gams, 
M=Males, F=Females, A=asexuals) before discounting for control readings in uninfected mouse 
(UI). Discounted data is shown as T’ (total parasitemia), G’ (gams), M’ (males) & F’ (females) 
 
 
Discounted 
Total (%)
G M F A T' G' M' F'
1 3.15 0.29 0.19 0.1 2.86 3.15 9.21 6.03 3.17
2 9.67 0.71 0.6 0.11 8.96 9.67 7.34 6.20 1.14
3 3.44 0.42 0.28 0.14 3.02 3.44 12.21 8.14 4.07
4 4.03 0.73 0.43 0.3 3.3 4.03 18.11 10.67 7.44
5 3.58 0.62 0.27 0.35 2.96 3.58 17.32 7.54 9.78
6 1.69 0.14 0.11 0.03 1.55 1.69 8.28 6.51 1.78
7 2.9 0.21 0.14 0.07 2.69 2.9 7.24 4.83 2.41
8 4.34 0.4 0.29 0.11 3.94 4.34 9.22 6.68 2.53
9 0.92 0.06 0.04 0.02 0.86 0.92 6.52 4.35 2.17
10 0.36 0.03 0.02 0.01 0.33 0.36 8.33 5.56 2.78
11 3.65 0.34 0.24 0.1 3.31 3.65 9.32 6.58 2.74
12 2.77 0.21 0.14 0.07 2.56 2.77 7.58 5.05 2.53
13 6.73 0.48 0.2 0.28 6.25 6.73 7.13 2.97 4.16
14 2.81 0.73 0.28 0.45 2.08 2.81 25.98 9.96 16.01
15 4.07 0.38 0.21 0.17 3.69 4.07 9.34 5.16 4.18
16 3.21 0.55 0.33 0.22 2.66 3.21 17.13 10.28 6.85
17 3.02 0.36 0.19 0.17 2.66 3.02 11.92 6.29 5.63
18 1.67 0.11 0.08 0.03 1.56 1.67 6.59 4.79 1.80
19 4.15 0.49 0.26 0.23 3.66 4.15 11.81 6.27 5.54
20 3.49 0.49 0.33 0.16 3 3.49 14.04 9.46 4.58
21 5.08 0.55 0.39 0.16 4.53 5.08 10.83 7.68 3.15
22 3.48 0.53 0.31 0.22 2.95 3.48 15.23 8.91 6.32
23 4.66 0.59 0.29 0.3 4.07 4.66 12.66 6.22 6.44
24 3.33 0.45 0.17 0.28 2.88 3.33 13.51 5.11 8.41
25 3.5 0.56 0.37 0.19 2.94 3.5 16.00 10.57 5.43
26 8.79 0.39 0.17 0.22 8.4 8.79 4.44 1.93 2.50
27 7.45 0.55 0.22 0.33 6.9 7.45 7.38 2.95 4.43
28 12.69 0.37 0.18 0.19 12.32 12.69 2.92 1.42 1.50
29 6.42 0.38 0.26 0.12 6.04 6.42 5.92 4.05 1.87
30 4.98 1.77 0.19 0.09 0.1 4.79 3.21 5.92 2.80 3.12
31 7.06 0.79 0.36 0.18 0.18 6.7 6.27 5.74 2.87 2.87
32 6.4 3.62 0.08 0.05 0.03 6.32 2.78 2.88 1.80 1.08
33 5.91 3.05 0.23 0.11 0.12 5.68 2.86 3.89 1.86 2.03
34 4.42 0.24 0.25 0.14 0.11 4.17 4.18 5.66 3.17 2.49
35 8.8 0.19 0.11 0.07 0.04 8.69 8.61 1.25 0.80 0.45
36 7.97 0.37 0.22 0.14 0.08 7.75 7.6 2.76 1.76 1.00
37 8.89 0.7 0.43 0.27 0.16 8.46 8.19 4.84 3.04 1.80
38 4.76 0.34 0.1 0.07 0.03 4.66 4.42 2.10 1.47 0.63
39 15.87 6.74 0.19 0.11 0.08 15.68 9.13 1.20 0.69 0.50
40 10.61 2.08 0.33 0.19 0.14 10.28 8.53 3.11 1.79 1.32
41 14.25 5.18 0.27 0.09 0.18 13.98 9.07 1.89 0.63 1.26
42 19.04 1.92 0.34 0.13 0.21 18.7 17.12 1.79 0.68 1.10
43 14.17 2.95 0.47 0.14 0.33 13.7 11.22 3.32 0.99 2.33
44 11.11 0.32 0.3 0.19 0.11 10.81 10.79 2.70 1.71 0.99
45 24.03 16.99 0.32 0.1 0.22 23.71 7.04 1.33 0.42 0.92
46 11.41 1.83 0.33 0.23 0.1 11.08 9.58 2.89 2.02 0.88
47 14.08 3.65 0.35 0.21 0.14 13.73 10.43 2.49 1.49 0.99
48 8.81 2.59 0.23 0.17 0.06 8.58 6.22 2.61 1.93 0.68
49 6.64 1.12 0.16 0.06 0.1 6.48 5.52 2.41 0.90 1.51
50 8.58 1.75 0.14 0.05 0.09 8.44 6.83 1.63 0.58 1.05
51 11.04 0.4 0.39 0.25 0.14 10.65 10.64 3.53 2.26 1.27
52 8.48 2.92 0.18 0.12 0.06 8.3 5.56 2.12 1.42 0.71
53 10.63 1.74 0.5 0.16 0.34 10.13 8.89 4.70 1.51 3.20
Weeks
Undicounted 
Total (%) 
Total 
in 
control 
(%)
Discounted (as total %)
Discounted                 
(as % of total 
parasites)
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Table A4: Line 4 - weekly parasitemia & gametocytemia by flow cytometry (G=Gams, 
M=Males, F=Females, A=asexuals) before discounting for control readings in uninfected mouse 
(UI). Discounted data is shown as T’ (total parasitemia), G’ (gams), M’ (males) & F’ (females) 
 
 
Discounted 
Total (%)
G M F A T' G' M' F'
1 4.08 0.56 0.34 0.22 3.52 4.08 13.73 8.33 5.39
2 6.94 1.44 1.16 0.28 5.5 6.94 20.75 16.71 4.03
3 3.64 0.16 0.1 0.06 3.48 3.64 4.40 2.75 1.65
4 4.67 0.52 0.27 0.25 4.15 4.67 11.13 5.78 5.35
5 2.18 0.49 0.25 0.24 1.69 2.18 22.48 11.47 11.01
6 4.24 0.48 0.33 0.15 3.76 4.24 11.32 7.78 3.54
7 5.05 0.44 0.24 0.2 4.61 5.05 8.71 4.75 3.96
8 4.72 0.42 0.28 0.14 4.3 4.72 8.90 5.93 2.97
9 0.48 0.03 0.02 0.01 0.45 0.48 6.25 4.17 2.08
10 0.89 0.03 0.02 0.01 0.86 0.89 3.37 2.25 1.12
11 0.99 0.04 0.03 0.01 0.95 0.99 4.04 3.03 1.01
12 2.67 0.19 0.14 0.05 2.48 2.67 7.12 5.24 1.87
13 3.99 0.27 0.16 0.11 3.72 3.99 6.77 4.01 2.76
14 4.08 0.49 0.23 0.26 3.59 4.08 12.01 5.64 6.37
15 4.25 0.2 0.1 0.1 4.05 4.25 4.71 2.35 2.35
16 3.58 0.46 0.33 0.13 3.12 3.58 12.85 9.22 3.63
17 2.95 0.37 0.19 0.18 2.58 2.95 12.54 6.44 6.10
18 3.06 0.46 0.29 0.17 2.6 3.06 15.03 9.48 5.56
19 3.91 0.71 0.42 0.29 3.2 3.91 18.16 10.74 7.42
20 3.4 0.27 0.2 0.07 3.13 3.4 7.94 5.88 2.06
21 3.57 0.57 0.42 0.15 3 3.57 15.97 11.76 4.20
22 2.43 0.29 0.21 0.08 2.14 2.43 11.93 8.64 3.29
23 4.85 0.54 0.25 0.29 4.31 4.85 11.13 5.15 5.98
24 8.94 0.57 0.27 0.3 8.37 8.94 6.38 3.02 3.36
25 4.07 0.24 0.09 0.15 3.83 4.07 5.90 2.21 3.69
26 5.46 0.18 0.11 0.07 5.28 5.46 3.30 2.01 1.28
27 4.09 1.31 0.38 0.22 0.16 3.71 2.78 13.67 7.91 5.76
28 3.93 0.79 0.47 0.21 0.26 3.46 3.14 14.97 6.69 8.28
29 4.67 3.62 0.2 0.11 0.09 4.47 1.05 19.05 10.48 8.57
30 8.21 3.05 0.26 0.09 0.17 7.95 5.16 5.04 1.74 3.29
31 3.42 0.24 0.25 0.17 0.08 3.17 3.18 7.86 5.35 2.34
32 3.38 0.19 0.15 0.04 0.11 3.23 3.19 4.44 1.18 3.25
33 4.29 0.74 0.2 0.09 0.11 4.09 3.55 4.66 2.10 2.56
34 6.02 0.7 0.36 0.25 0.11 5.66 5.32 5.98 4.15 1.83
35 4.01 0.34 0.33 0.12 0.21 3.68 3.67 8.23 2.99 5.24
36 18.73 10.04 0.54 0.23 0.31 18.19 8.69 2.88 1.23 1.66
37 11.27 2.08 0.22 0.1 0.12 11.05 9.19 1.95 0.89 1.06
38 10.26 5.18 0.33 0.12 0.21 9.93 5.08 3.22 1.17 2.05
39 12.68 1.92 0.2 0.04 0.16 12.48 10.76 1.58 0.32 1.26
40 8.52 2.95 0.44 0.15 0.29 8.08 5.57 5.16 1.76 3.40
41 8.83 0.32 0.65 0.35 0.3 8.18 8.51 7.36 3.96 3.40
42 8.63 1.96 0.35 0.26 0.09 8.28 6.67 4.06 3.01 1.04
43 9.46 1.83 0.36 0.28 0.08 9.1 7.63 3.81 2.96 0.85
44 19.43 3.65 0.33 0.18 0.15 19.1 15.78 1.70 0.93 0.77
45 14.5 2.59 0.71 0.34 0.37 13.79 11.91 4.90 2.34 2.55
46 7.34 1.12 0.48 0.25 0.23 6.86 6.22 6.54 3.41 3.13
47 7.77 1.75 0.19 0.13 0.06 7.58 6.02 2.45 1.67 0.77
48 11.63 1.76 1.38 0.89 0.49 10.25 9.87 11.87 7.65 4.21
49 9.57 0.9 0.2 0.05 0.15 9.37 8.67 2.09 0.52 1.57
50 10.95 1.74 0.33 0.12 0.21 10.62 9.21 3.01 1.10 1.92
51 12.65 2.33 0.33 0.18 0.15 12.32 10.32 2.61 1.42 1.19
52 7.52 0.2 0.2 0.06 0.14 7.32 7.32 2.66 0.80 1.86
Weeks
Undicounted 
Total (%) 
Total 
in 
control 
Discounted (as total %)
Discounted                 
(as % of total parasites)
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Table A5: Line 5 - weekly parasitemia & gametocytemia by flow cytometry (G=Gams, 
M=Males, F=Females, A=asexuals) before discounting for control readings in uninfected mouse 
(UI). Discounted data is shown as T’ (total parasitemia), G’ (gams), M’ (males) & F’ (females) 
 
 
Discounted 
Total (%)
G M F A T' G' M' F'
1 4.02 0.45 0.32 0.13 3.57 4.02 11.19 7.96 3.23
2 5.06 0.43 0.32 0.11 4.63 5.06 8.50 6.32 2.17
3 2.47 0.18 0.11 0.07 2.29 2.47 7.29 4.45 2.83
4 2.44 0.14 0.09 0.05 2.3 2.44 5.74 3.69 2.05
5 3.74 0.75 0.35 0.4 2.99 3.74 20.05 9.36 10.70
6 1.72 0.11 0.08 0.03 1.61 1.72 6.40 4.65 1.74
7 3.06 0.28 0.21 0.07 2.78 3.06 9.15 6.86 2.29
8 2.19 0.13 0.1 0.03 2.06 2.19 5.94 4.57 1.37
9 3.16 0.38 0.29 0.09 2.78 3.16 12.03 9.18 2.85
10 1.2 0.09 0.07 0.02 1.11 1.2 7.50 5.83 1.67
11 0.68 0.06 0.04 0.02 0.62 0.68 8.82 5.88 2.94
12 3.22 0.28 0.21 0.07 2.94 3.22 8.70 6.52 2.17
13 3.44 0.63 0.3 0.33 2.81 3.44 18.31 8.72 9.59
14 3.68 0.59 0.34 0.25 3.09 3.68 16.03 9.24 6.79
15 3.49 0.68 0.46 0.22 2.81 3.49 19.48 13.18 6.30
16 4.81 0.76 0.53 0.23 4.05 4.81 15.80 11.02 4.78
17 5 1.03 0.5 0.53 3.97 5 20.60 10.00 10.60
18 4.44 0.85 0.49 0.36 3.59 4.44 19.14 11.04 8.11
19 5.25 0.55 0.26 0.29 4.7 5.25 10.48 4.95 5.52
20 3.18 0.68 0.47 0.21 2.5 3.18 21.38 14.78 6.60
21 4.9 0.85 0.63 0.22 4.05 4.9 17.35 12.86 4.49
22 6.78 0.81 0.38 0.43 5.97 6.78 11.95 5.60 6.34
23 4.85 0.28 0.16 0.12 4.57 4.85 5.77 3.30 2.47
24 12.77 0.67 0.35 0.32 12.1 12.77 5.25 2.74 2.51
25 8.6 0.23 0.12 0.11 8.37 8.6 2.67 1.40 1.28
26 13.19 1.31 1.09 0.61 0.48 12.1 11.88 9.18 5.13 4.04
27 5.21 0.6 0.33 0.14 0.19 4.88 4.61 7.16 3.04 4.12
28 7.19 3.62 0.16 0.09 0.07 7.03 3.57 4.48 2.52 1.96
29 6.35 3.05 0.12 0.06 0.06 6.23 3.3 3.64 1.82 1.82
30 6.26 0.24 0.47 0.27 0.2 5.79 6.02 7.81 4.49 3.32
31 4.07 0.19 0.13 0.03 0.1 3.94 3.88 3.35 0.77 2.58
32 6.23 0.37 0.15 0.11 0.04 6.08 5.86 2.56 1.88 0.64
33 6.72 0.7 0.41 0.24 0.17 6.31 6.02 6.10 3.57 2.53
34 6.05 0.34 0.32 0.16 0.16 5.73 5.71 5.29 2.64 2.64
35 18.02 10.04 0.32 0.11 0.21 17.7 7.98 1.78 0.61 1.17
36 10.38 2.08 0.32 0.2 0.12 10.06 8.3 3.08 1.93 1.16
37 12.11 3.64 0.2 0.11 0.09 11.91 8.47 1.65 0.91 0.74
38 12.5 1.92 0.34 0.11 0.23 12.16 10.58 2.72 0.88 1.84
39 16.37 2.95 0.52 0.22 0.3 15.85 13.42 3.18 1.34 1.83
40 11.59 0.32 0.27 0.12 0.15 11.32 11.27 2.33 1.04 1.29
41 26.24 16.99 0.3 0.12 0.18 25.94 9.25 1.14 0.46 0.69
42 9.89 2.77 0.41 0.21 0.2 9.48 7.12 4.15 2.12 2.02
43 11.37 3.65 0.37 0.25 0.12 11 7.72 3.25 2.20 1.06
44 11.73 2.59 0.25 0.16 0.09 11.48 9.14 2.13 1.36 0.77
45 7.65 1.12 0.27 0.1 0.17 7.38 6.53 3.53 1.31 2.22
46 7.91 1.75 0.1 0.06 0.04 7.81 6.16 1.26 0.76 0.51
47 12.44 0.4 0.26 0.14 0.12 12.18 12.04 2.09 1.13 0.96
48 8.95 2.92 0.21 0.1 0.11 8.74 6.03 2.35 1.12 1.23
49 10.47 1.74 0.4 0.16 0.24 10.07 8.73 3.82 1.53 2.29
50 13.03 2.33 0.32 0.19 0.13 12.71 10.7 2.46 1.46 1.00
51 11.29 0.2 0.27 0.08 0.19 11.02 11.09 2.39 0.71 1.68
Weeks
Undicounted 
Total (%) 
Total 
in 
control 
Discounted (as total %)
Discounted                 
(as % of total 
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Table A6: Line 6 - weekly parasitemia & gametocytemia by flow cytometry (G=Gams, 
M=Males, F=Females, A=asexuals) before discounting for control readings in uninfected mouse 
(UI). Discounted data is shown as T’ (total parasitemia), G’ (gams), M’ (males) & F’ (females) 
 
 
Discounted 
Total (%)
G M F A T' G' M' F'
1 3.85 0.41 0.23 0.18 3.44 3.85 10.65 5.97 4.68
2 2.46 0.25 0.2 0.05 2.21 2.46 10.16 8.13 2.03
3 2.65 0.16 0.1 0.06 2.49 2.65 6.04 3.77 2.26
4 3.05 0.37 0.24 0.13 2.68 3.05 12.13 7.87 4.26
5 2.71 0.39 0.18 0.21 2.32 2.71 14.39 6.64 7.75
6 0.34 0.03 0.02 0.01 0.31 0.34 8.82 5.88 2.94
7 2.4 0.17 0.12 0.05 2.23 2.4 7.08 5.00 2.08
8 2.91 0.14 0.1 0.04 2.77 2.91 4.81 3.44 1.37
9 1.83 0.05 0.03 0.02 1.78 1.83 2.73 1.64 1.09
10 2.84 0.11 0.08 0.03 2.73 2.84 3.87 2.82 1.06
11 0.42 0.02 0.01 0.01 0.4 0.42 4.76 2.38 2.38
12 1.32 0.06 0.04 0.02 1.26 1.32 4.55 3.03 1.52
13 1.95 0.22 0.14 0.08 1.73 1.95 11.28 7.18 4.10
14 3.68 0.78 0.46 0.32 2.9 3.68 21.20 12.50 8.70
15 6.08 0.94 0.39 0.55 5.14 6.08 15.46 6.41 9.05
16 4.31 0.67 0.24 0.43 3.64 4.31 15.55 5.57 9.98
17 5.19 1.13 0.54 0.59 4.06 5.19 21.77 10.40 11.37
18 3.79 0.86 0.53 0.33 2.93 3.79 22.69 13.98 8.71
19 4.48 0.37 0.27 0.1 4.11 4.48 8.26 6.03 2.23
20 4.78 0.51 0.34 0.17 4.27 4.78 10.67 7.11 3.56
21 2.96 0.19 0.11 0.08 2.77 2.96 6.42 3.72 2.70
22 3.7 0.6 0.42 0.18 3.1 3.7 16.22 11.35 4.86
23 3.92 0.62 0.36 0.26 3.3 3.92 15.82 9.18 6.63
24 3.37 1.23 0.6 0.63 2.14 3.37 36.50 17.80 18.69
25 5.71 0.55 0.36 0.19 5.16 5.71 9.63 6.30 3.33
26 8.19 0.53 0.27 0.26 7.66 8.19 6.47 3.30 3.17
27 10.55 0.71 0.29 0.42 9.84 10.55 6.73 2.75 3.98
28 11.84 0.2 0.1 0.1 11.64 11.84 1.69 0.84 0.84
29 5.47 0.33 0.19 0.14 5.14 5.47 6.03 3.47 2.56
30 5.17 1.77 0.26 0.18 0.08 4.91 3.4 7.65 5.29 2.35
31 7.27 0.79 0.34 0.13 0.21 6.93 6.48 5.25 2.01 3.24
32 5.46 3.62 0.26 0.09 0.17 5.2 1.84 14.13 4.89 9.24
33 7.14 3.05 0.28 0.1 0.18 6.86 4.09 6.85 2.44 4.40
34 5.89 0.2 0.46 0.15 0.31 5.43 5.69 8.08 2.64 5.45
35 4.34 0.19 0.13 0.04 0.09 4.21 4.15 3.13 0.96 2.17
36 4.76 0.27 0.31 0.09 0.22 4.45 4.49 6.90 2.00 4.62
37 6.66 0.7 0.22 0.14 0.08 6.44 5.96 3.30 2.10 1.20
38 6.99 0.34 0.39 0.11 0.28 6.6 6.65 5.58 1.57 4.01
39 14.9 6.74 0.31 0.23 0.08 14.59 8.16 2.08 1.54 0.54
40 8.85 2.08 0.22 0.13 0.09 8.63 6.77 2.49 1.47 1.02
41 9.12 3.64 0.12 0.08 0.04 9 5.48 1.32 0.88 0.44
42 10.76 1.92 0.22 0.07 0.15 10.54 8.84 2.04 0.65 1.39
43 15.56 2.95 0.18 0.07 0.11 15.38 12.61 1.16 0.45 0.71
44 11.71 0.32 0.44 0.21 0.23 11.27 11.39 3.76 1.79 1.96
45 26.63 16.99 0.48 0.18 0.3 26.15 9.64 1.80 0.68 1.13
46 9.21 1.83 0.26 0.2 0.06 8.95 7.38 2.82 2.17 0.65
47 14.95 3.65 0.28 0.15 0.13 14.67 11.3 1.87 1.00 0.87
48 12.37 2.59 0.32 0.2 0.12 12.05 9.78 2.59 1.62 0.97
49 7.78 1.12 0.33 0.13 0.2 7.45 6.66 4.24 1.67 2.57
50 17.8 0.63 0.25 0.09 0.16 17.55 17.17 1.40 0.51 0.90
51 8.33 0.4 0.5 0.26 0.24 7.83 7.93 6.00 3.12 2.88
52 8.18 0.31 0.25 0.09 0.16 7.93 7.87 3.06 1.10 1.96
53 12.17 1.74 0.44 0.17 0.27 11.73 10.43 3.62 1.40 2.22
Weeks
Undicounted 
Total (%) 
Total in 
control 
(%)
Discounted (as total %)
Discounted                 
(as % of total 
parasites)
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Table A7: Line 7 - weekly parasitemia & gametocytemia by flow cytometry (G=Gams, 
M=Males, F=Females, A=asexuals) before discounting for control readings in uninfected mouse 
(UI). Discounted data is shown as T’ (total parasitemia), G’ (gams), M’ (males) & F’ (females) 
 
 
 
  
Discounted 
Total (%)
G M F A T' G' M' F'
1 4.63 0.43 0.23 0.2 4.2 4.63 9.29 4.97 4.32
2 1.92 0.16 0.14 0.02 1.76 1.92 8.33 7.29 1.04
3 1.01 0.08 0.05 0.03 0.93 1.01 7.92 4.95 2.97
4 7.51 0.88 0.4 0.48 6.63 7.51 11.72 5.33 6.39
5 4.2 0.19 0.14 0.05 4.01 4.2 4.52 3.33 1.19
6 3.81 0.3 0.2 0.1 3.51 3.81 7.87 5.25 2.62
7 2.49 0.11 0.08 0.03 2.38 2.49 4.42 3.21 1.20
8 3.96 0.5 0.23 0.27 3.46 3.96 12.63 5.81 6.82
9 0.13 0 0 0 0.13 0.13 0.00 0.00 0.00
10 4.71 0.35 0.19 0.16 4.36 4.71 7.43 4.03 3.40
11 5.07 0.33 0.24 0.09 4.74 5.07 6.51 4.73 1.78
12 6.01 0.46 0.31 0.15 5.55 6.01 7.65 5.16 2.50
13 5.79 1.33 0.68 0.65 4.46 5.79 22.97 11.74 11.23
14 9.17 1.05 0.47 0.58 8.12 9.17 11.45 5.13 6.32
15 6.86 0.66 0.28 0.38 6.2 6.86 9.62 4.08 5.54
16 3.64 0.24 0.17 0.07 3.4 3.64 6.59 4.67 1.92
17 7.72 0.73 0.35 0.38 6.99 7.72 9.46 4.53 4.92
18 6.94 0.95 0.48 0.47 5.99 6.94 13.69 6.92 6.77
19 3.27 0.25 0.17 0.08 3.02 3.27 7.65 5.20 2.45
20 4.4 0.37 0.27 0.1 4.03 4.4 8.41 6.14 2.27
21 6.74 0.65 0.44 0.21 6.09 6.74 9.64 6.53 3.12
22 5.85 0.78 0.31 0.47 5.07 5.85 13.33 5.30 8.03
23 5.16 0.58 0.4 0.18 4.58 5.16 11.24 7.75 3.49
24 10.26 0.43 0.21 0.22 9.83 10.26 4.19 2.05 2.14
25 6.41 0.09 0.02 0.07 6.32 6.41 1.40 0.31 1.09
26 13.92 8.72 0.03 0.01 0.02 13.89 5.2 0.58 0.19 0.38
27 11.04 1.7 0 0 0 11.04 9.34 0.00 0.00 0.00
28 6.64 1.77 0 0 0 6.64 4.87 0.00 0.00 0.00
29 6.87 0.79 0 0 0 6.87 6.08 0.00 0.00 0.00
30 11.57 3.62 0 0 0 11.57 7.95 0.00 0.00 0.00
31 14.78 3.05 0 0 0 14.78 11.73 0.00 0.00 0.00
32 4.46 0.24 0 0 0 4.46 4.22 0.00 0.00 0.00
33 9.56 0.23 0 0 0 9.56 9.33 0.00 0.00 0.00
34 18.74 0.74 0 0 0 18.74 18 0.00 0.00 0.00
Weeks
Undicounted 
Total (%) 
Total 
in 
control 
(%)
Discounted (as total %)
Discounted                 
(as % of total 
parasites)
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Table A8: Line 8 - weekly parasitemia & gametocytemia by flow cytometry (G=Gams, 
M=Males, F=Females, A=asexuals) before discounting for control readings in uninfected mouse 
(UI). Discounted data is shown as T’ (total parasitemia), G’ (gams), M’ (males) & F’ (females) 
 
 
Discounted 
Total (%)
G M F A T' G' M' F'
1 5.55 0.43 0.28 0.15 5.12 5.55 7.75 5.05 2.70
2 3.02 0.2 0.15 0.05 2.82 3.02 6.62 4.97 1.66
3 2.75 0.19 0.12 0.07 2.56 2.75 6.91 4.36 2.55
4 3.66 0.6 0.28 0.32 3.06 3.66 16.39 7.65 8.74
5 2.88 0.75 0.32 0.43 2.13 2.88 26.04 11.11 14.93
6 2.39 0.13 0.1 0.03 2.26 2.39 5.44 4.18 1.26
7 3.81 0.34 0.2 0.14 3.47 3.81 8.92 5.25 3.67
8 3.54 0.18 0.13 0.05 3.36 3.54 5.08 3.67 1.41
9 1.96 0.13 0.09 0.04 1.83 1.96 6.63 4.59 2.04
10 1.86 0.13 0.1 0.03 1.73 1.86 6.99 5.38 1.61
11 0.8 0.03 0.02 0.01 0.77 0.8 3.75 2.50 1.25
12 2.9 0.2 0.13 0.07 2.7 2.9 6.90 4.48 2.41
13 5.39 0.55 0.22 0.33 4.84 5.39 10.20 4.08 6.12
14 5.34 0.58 0.37 0.21 4.76 5.34 10.86 6.93 3.93
15 4.55 0.8 0.33 0.47 3.75 4.55 17.58 7.25 10.33
16 5.02 0.82 0.53 0.29 4.2 5.02 16.33 10.56 5.78
17 3.81 0.3 0.16 0.14 3.51 3.81 7.87 4.20 3.67
18 8.72 0.52 0.24 0.28 8.2 8.72 5.96 2.75 3.21
19 3.67 0.27 0.2 0.07 3.4 3.67 7.36 5.45 1.91
20 6.09 0.68 0.4 0.28 5.41 6.09 11.17 6.57 4.60
21 14.53 1.04 0.5 0.54 13.49 14.53 7.16 3.44 3.72
22 15.01 0.57 0.26 0.31 14.44 15.01 3.80 1.73 2.07
23 7.72 0.46 0.23 0.23 7.26 7.72 5.96 2.98 2.98
24 9.57 0.57 0.26 0.31 9 9.57 5.96 2.72 3.24
25 8.59 0.33 0.13 0.2 8.26 8.59 3.84 1.51 2.33
26 13.11 0.44 0.25 0.19 12.67 13.11 3.36 1.91 1.45
27 8.54 0.36 0.21 0.15 8.18 8.54 4.22 2.46 1.76
28 6.23 1.77 0.34 0.15 0.19 5.89 4.46 7.62 3.36 4.26
29 6.71 0.79 0.43 0.16 0.27 6.28 5.92 7.26 2.70 4.56
30 5.9 3.62 0.29 0.13 0.16 5.61 2.28 12.72 5.70 7.02
31 5.4 3.05 0.11 0.05 0.06 5.29 2.35 4.68 2.13 2.55
32 4.96 0.24 0.25 0.19 0.06 4.71 4.72 5.30 4.03 1.27
33 3.38 0.19 0.08 0.06 0.02 3.3 3.19 2.51 1.88 0.63
34 4.74 0.27 0.37 0.14 0.23 4.37 4.47 8.28 3.13 5.15
35 7.34 0.7 0.36 0.27 0.09 6.98 6.64 5.42 4.07 1.36
36 4.37 0.34 0.18 0.11 0.07 4.19 4.03 4.47 2.73 1.74
37 22 10.04 0.29 0.26 0.03 21.71 11.96 2.42 2.17 0.25
38 8.74 2.69 0.13 0.05 0.08 8.61 6.05 1.49 0.57 0.92
39 10.43 5.18 0.32 0.11 0.21 10.11 5.25 3.07 1.05 2.01
40 9.94 1.92 0.26 0.07 0.19 9.68 8.02 2.62 0.70 1.91
41 9.45 2.95 0.27 0.11 0.16 9.18 6.5 2.86 1.16 1.69
42 8.2 0.32 0.19 0.1 0.09 8.01 7.88 2.32 1.22 1.10
43 31.94 16.99 0.64 0.34 0.3 31.3 14.95 2.00 1.06 0.94
44 8.64 1.83 0.18 0.11 0.07 8.46 6.81 2.08 1.27 0.81
45 11.48 3.65 0.18 0.08 0.1 11.3 7.83 1.57 0.70 0.87
46 10.96 2.59 0.17 0.09 0.08 10.79 8.37 1.55 0.82 0.73
47 4.28 0.43 0.05 0.01 0.04 4.23 3.85 1.17 0.23 0.93
48 6.83 0.85 0.05 0.03 0.02 6.78 5.98 0.73 0.44 0.29
49 5.12 0.71 0 0 0 5.12 4.41 0.00 0.00 0.00
50 9.57 0.3 0 0 0 9.57 9.27 0.00 0.00 0.00
51 13.73 1.74 0 0 0 13.73 11.99 0.00 0.00 0.00
52 10.75 1.77 0 0 0 10.75 8.98 0.00 0.00 0.00
53 7.24 0.17 0 0 0 7.24 7.07 0.00 0.00 0.00
Weeks
Undicounted 
Total (%) 
Total 
in 
control 
(%)
Discounted (as total %)
Discounted                 
(as % of total 
parasites)
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Table A9: Line 9 - weekly parasitemia & gametocytemia by flow cytometry (G=Gams, 
M=Males, F=Females, A=asexuals) before discounting for control readings in uninfected mouse 
(UI). Discounted data is shown as T’ (total parasitemia), G’ (gams), M’ (males) & F’ (females) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discounted 
Total (%)
G M F A T' G' M' F'
1 4.49 0.43 0.24 0.19 4.06 4.49 9.58 5.35 4.23
2 0.9 0.06 0.05 0.01 0.84 0.9 6.67 5.56 1.11
3 0.97 0.05 0.03 0.02 0.92 0.97 5.15 3.09 2.06
4 2.14 0.12 0.08 0.04 2.02 2.14 5.61 3.74 1.87
5 3.45 0.74 0.36 0.38 2.71 3.45 21.45 10.43 11.01
6 3.86 0.44 0.31 0.13 3.42 3.86 11.40 8.03 3.37
7 3.82 0.47 0.32 0.15 3.35 3.82 12.30 8.38 3.93
8 3.58 0.22 0.15 0.07 3.36 3.58 6.15 4.19 1.96
9 0.91 0.03 0.02 0.01 0.88 0.91 3.30 2.20 1.10
10 3.32 0.52 0.3 0.22 2.8 3.32 15.66 9.04 6.63
11 2.55 0.45 0.17 0.28 2.1 2.55 17.65 6.67 10.98
12 3.06 0.17 0.11 0.06 2.89 3.06 5.56 3.59 1.96
13 4.42 0.23 0.13 0.1 4.19 4.42 5.20 2.94 2.26
14 3.89 0.22 0.1 0.12 3.67 3.89 5.66 2.57 3.08
15 2.8 0.1 0.07 0.03 2.7 2.8 3.57 2.50 1.07
16 2.34 0.02 0.01 0.01 2.32 2.34 0.85 0.43 0.43
17 3.25 0.03 0.02 0.01 3.22 3.25 0.92 0.62 0.31
18 3.78 0.67 0 0 0 3.78 3.11 0.00 0.00 0.00
19 3.33 0.09 0 0 0 3.33 3.24 0.00 0.00 0.00
20 5.05 0.11 0 0 0 5.05 4.94 0.00 0.00 0.00
21 5.11 0.22 0 0 0 5.11 4.89 0.00 0.00 0.00
Weeks
Undicounted 
Total (%) 
Total in 
control 
(%)
Discounted (as total %)
Discounted                 
(as % of total parasites)
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Table A10: Line 10 - weekly parasitemia & gametocytemia by flow cytometry (G=Gams, 
M=Males, F=Females, A=asexuals) before discounting for control readings in uninfected mouse 
(UI). Discounted data is shown as T’ (total parasitemia), G’ (gams), M’ (males) & F’ (females) 
 
 
 
Discounted 
Total (%)
G M F A T' G' M' F'
1 5.83 0.41 0.17 0.24 5.42 5.83 7.03 2.92 4.12
2 2.7 0.18 0.14 0.04 2.52 2.7 6.67 5.19 1.48
3 2.81 0.15 0.11 0.04 2.66 2.81 5.34 3.91 1.42
4 6.62 0.77 0.48 0.29 5.85 6.62 11.63 7.25 4.38
5 7.44 0.8 0.38 0.42 6.64 7.44 10.75 5.11 5.65
6 5.4 0.43 0.26 0.17 4.97 5.4 7.96 4.81 3.15
7 2.09 0.11 0.07 0.04 1.98 2.09 5.26 3.35 1.91
8 3.38 0.22 0.15 0.07 3.16 3.38 6.51 4.44 2.07
9 1.06 0.04 0.03 0.01 1.02 1.06 3.77 2.83 0.94
10 3.77 0.2 0.13 0.07 3.57 3.77 5.31 3.45 1.86
11 0.21 0.01 0.01 0 0.2 0.21 4.76 4.76 0.00
12 4.73 0.63 0.27 0.36 4.1 4.73 13.32 5.71 7.61
13 3.12 0.33 0.22 0.11 2.79 3.12 10.58 7.05 3.53
14 7.03 0.29 0.15 0.14 6.74 7.03 4.13 2.13 1.99
15 7.46 0.15 0.08 0.07 7.31 7.46 2.01 1.07 0.94
16 4.69 0.53 0.3 0.23 4.16 4.69 11.30 6.40 4.90
17 5.31 0.46 0.22 0.24 4.85 5.31 8.66 4.14 4.52
18 4.31 0.3 0.22 0.08 4.01 4.31 6.96 5.10 1.86
19 5.87 0.76 0.44 0.32 5.11 5.87 12.95 7.50 5.45
20 7.08 0.57 0.26 0.31 6.51 7.08 8.05 3.67 4.38
21 5.47 0.52 0.4 0.12 4.95 5.47 9.51 7.31 2.19
22 4.47 0.74 0.55 0.19 3.73 4.47 16.55 12.30 4.25
23 6.25 0.51 0.21 0.3 5.74 6.25 8.16 3.36 4.80
24 8.77 1.61 0.9 0.71 7.16 8.77 18.36 10.26 8.10
25 6.18 0.61 0.4 0.21 5.57 6.18 9.87 6.47 3.40
26 10.47 0.68 0.33 0.35 9.79 10.47 6.49 3.15 3.34
27 8.57 0.51 0.19 0.32 8.06 8.57 5.95 2.22 3.73
28 12.69 0.45 0.28 0.17 12.24 12.69 3.55 2.21 1.34
29 8.84 0.26 0.11 0.15 8.58 8.84 2.94 1.24 1.70
30 6.16 1.77 0.21 0.09 0.12 5.95 4.39 4.78 2.05 2.73
31 7.28 0.89 0.15 0.08 0.07 7.13 6.39 2.35 1.25 1.10
32 7.15 3.62 0.12 0.07 0.05 7.03 3.53 3.40 1.98 1.42
33 14.56 3.05 0.07 0.04 0.03 14.49 11.51 0.61 0.35 0.26
34 4.57 1.75 0.12 0.07 0.05 4.45 2.82 4.26 2.48 1.77
35 4.92 0.23 0.04 0.03 0.01 4.88 4.69 0.85 0.64 0.21
36 5.33 0.27 0.13 0.07 0.06 5.2 5.06 2.57 1.38 1.19
37 10.56 0.7 0.59 0.5 0.09 9.97 9.86 5.98 5.07 0.91
38 10.65 0.34 0.66 0.51 0.15 9.99 10.31 6.20 4.79 1.41
39 15.79 10.04 0.23 0.08 0.15 15.56 5.75 1.46 0.51 0.95
40 12.91 2.69 0.31 0.15 0.16 12.6 10.22 2.40 1.16 1.24
41 9.16 5.18 0.25 0.06 0.19 8.91 3.98 2.73 0.66 2.07
42 8.74 1.92 0.27 0.11 0.16 8.47 6.82 3.09 1.26 1.83
43 8.46 2.95 0.28 0.07 0.21 8.18 5.51 3.31 0.83 2.48
44 9.55 0.32 0.19 0.07 0.12 9.36 9.23 1.99 0.73 1.26
45 7.35 1.96 0.16 0.1 0.06 7.19 5.39 2.18 1.36 0.82
46 7.53 2.77 0.21 0.08 0.13 7.32 4.76 2.79 1.06 1.73
47 10.79 3.65 0.17 0.08 0.09 10.62 7.14 1.58 0.74 0.83
48 10.17 2.59 0.26 0.14 0.12 9.91 7.58 2.56 1.38 1.18
49 6.23 1.12 0.27 0.09 0.18 5.96 5.11 4.33 1.44 2.89
50 6.26 1.75 0.08 0.02 0.06 6.18 4.51 1.28 0.32 0.96
51 9.56 1.76 0.75 0.52 0.23 8.81 7.8 7.85 5.44 2.41
52 9.57 2.92 0.16 0.08 0.08 9.41 6.65 1.67 0.84 0.84
53 7.69 1.11 0.24 0.11 0.13 7.45 6.58 3.12 1.43 1.69
Weeks
Undicounted 
Total (%) 
Total in 
control 
(%)
Discounted (as total %)
Discounted                 
(as % of total parasites)
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Table A11 – Details of mutated gene products temporarily considered under reduced 
ranking priority and hence not included in the analysis 
 
 
REF STR LINE TYPE CHR GENE ID PRODUCT 
COMMON IN ALL GNPs 
ANKA 233 SNP 2 PBANKA_020060 Pb-fam-1 protein" 
ANKA M7 SNP 2 PBANKA_020060 Pb-fam-1 protein" 
ANKA M9 SNP 2 PBANKA_020060 Pb-fam-1 protein" 
COMMON IN 233, M7 AND M9 
ANKA M7 INDEL 3 PBANKA_030330 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 3 PBANKA_030330 
conserved Plasmodium protein, 
unknown function" 
ANKA 233 SNP - 1 5 PBANKA_050025 
tryptophan-rich antigen, putative, 
pseudogene" 
ANKA M7 SNP - 3 5 PBANKA_050025 
tryptophan-rich antigen, putative, 
pseudogene" 
ANKA M9 SNP - 2 5 PBANKA_050025 
tryptophan-rich antigen, putative, 
pseudogene" 
COMMON IN M7 AND M9 
820 M7 INDEL 11 PBANKA_114510 
conserved Plasmodium protein, 
unknown function" 
820 M9 INDEL 11 PBANKA_114510 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 2 PBANKA_021270 zinc finger protein, putative" 
ANKA M9 INDEL 2 PBANKA_021270 zinc finger protein, putative" 
ANKA M7 SNP - 4 2 PBANKA_020090 
conserved rodent malaria protein, 
unknown 
ANKA M9 SNP 2 PBANKA_020090 
conserved rodent malaria protein, 
unknown 
ANKA M7 INDEL 12 PBANKA_122610 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL - 2 12 PBANKA_122610 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 13 PBANKA_131030 
conserved Plasmodium protein, 
unknown function, 
ANKA M9 INDEL 13 PBANKA_131030 
conserved Plasmodium protein, 
unknown function, 
ANKA M7 SNP 14 PBANKA_146500 PYST-C2 homologue, putative" 
ANKA M9 SNP 14 PBANKA_146500 PYST-C2 homologue, putative" 
ANKA 234 SNP 14 PBANKA_146500 PYST-C2 homologue, putative" 
ANKA M7 INDEL 1 PBANKA_011180 adapter-related protein, putative" 
ANKA M9 INDEL 1 PBANKA_011180 adapter-related protein, putative" 
ANKA M7 INDEL 2 PBANKA_020700 calcium-transporting ATPase, putative" 
ANKA M9 INDEL 2 PBANKA_020700 calcium-transporting ATPase, putative" 
ANKA M7 INDEL 2 PBANKA_020710 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 2 PBANKA_020710 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 2 PBANKA_021270 zinc finger protein, putative" 
ANKA M9 INDEL 2 PBANKA_021270 zinc finger protein, putative" 
ANKA M7 INDEL 3 PBANKA_030330 
conserved Plasmodium protein, 
unknown function" 
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REF STR LINE TYPE CHR GENE ID PRODUCT 
ANKA M9 INDEL 3 PBANKA_030330 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 3 PBANKA_030400 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 3 PBANKA_030400 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL - 1 12 PBANKA_122610 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL - 2 12 PBANKA_122610 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 13 PBANKA_131030 
conserved Plasmodium protein, 
unknown function, 
ANKA M9 INDEL 13 PBANKA_131030 
conserved Plasmodium protein, 
unknown function, 
COMMON IN M7 AND M9 
ANKA 233 SNP - 2 5 PBANKA_050020 BIR protein" 
ANKA M7 SNP 5 PBANKA_050020 BIR protein" 
ANKA 233 SNP - 3 B PBANKA_000440 BIR protein, fragment" 
ANKA M7 SNP  B PBANKA_000440 BIR protein, fragment" 
COMMON IN 233 AND M9 
820 233 SNP - 3 5 PBANKA_050070 Pb-fam-1 protein 
820 M9 SNP - 2 5 PBANKA_050070 Pb-fam-1 protein 
ANKA 233 SNP - 2 B PBANKA_000550 
Plasmodium exported protein, 
unknown function" 
ANKA M9 SNP - 2 B PBANKA_000550 
Plasmodium exported protein, 
unknown function" 
ANKA 233 INDEL 3 PBANKA_030240 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 3 PBANKA_030240 
conserved Plasmodium protein, 
unknown function" 
ANKA 234 INDEL 3 PBANKA_030240 
conserved Plasmodium protein, 
unknown function" 
ANKA 233 INDEL 3 PBANKA_030250 hexose transporter" 
ANKA M9 INDEL 3 PBANKA_030250 hexose transporter" 
ANKA 234 INDEL 3 PBANKA_030250 hexose transporter" 
ANKA 233 
SNP - 1 
INDEL - 1 
7 PBANKA_072260 
Plasmodium exported protein, 
unknown function" 
ANKA M9 SNP - 2 7 PBANKA_072260 
Plasmodium exported protein, 
unknown function" 
ANKA 233 SNP 9 PBANKA_090090 reticulocyte binding protein, putative, 
ANKA M9 SNP 9 PBANKA_090090 reticulocyte binding protein, putative, 
ANKA 820 INDEL 9 PBANKA_090090 reticulocyte binding protein, putative, 
ANKA 233 SNP - 2 10 PBANKA_100060 erythrocyte membrane antigen 1" 
ANKA M9 SNP - 2 10 PBANKA_100060 erythrocyte membrane antigen 1" 
ANKA 233 INDEL 11 PBANKA_113040 proteasome subunit, putative" 
ANKA M9 INDEL 11 PBANKA_113040 proteasome subunit, putative" 
ANKA 233 SNP  14 PBANKA_140030 BIR protein" 
ANKA M9 SNP  14 PBANKA_140030 BIR protein" 
ANKA 233 INDEL 14 PBANKA_144600 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 14 PBANKA_144600 
conserved Plasmodium protein, 
unknown function" 
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820 233 SNP 1 PBANKA_011220 myosin-like protein, putative" 
820 233 SNP 3 PBANKA_031340 
conserved Plasmodium protein, 
unknown function" 
820 233 SNP 4 PBANKA_041130 
conserved Plasmodium protein, 
unknown function" 
820 233 SNP 5 PBANKA_051540 
conserved Plasmodium protein, 
unknown function" 
820 233 SNP 6 PBANKA_061220 
conserved Plasmodium protein, 
unknown function" 
820 233 SNP - 2 9 PBANKA_090230 
conserved Plasmodium protein, 
unknown function, 
820 233 SNP - 2 9 PBANKA_090240 
conserved Plasmodium protein, 
unknown function, 
820 233 INDEL 11 PBANKA_112960 
conserved Plasmodium protein, 
unknown function" 
820 233 INDEL 12 PBANKA_121660 
conserved Plasmodium protein, 
unknown function" 
820 233 INDEL 12 PBANKA_121680 
conserved Plasmodium protein, 
unknown function" 
820 233 SNP 12 PBANKA_124630 BIR protein" 
820 233 SNP 14 PBANKA_143540 
conserved Plasmodium protein, 
unknown function" 
820 233 SNP 14 PBANKA_144010 
conserved Plasmodium protein, 
unknown function" 
820 233 INDEL -2 14 PBANKA_145320 
conserved Plasmodium protein, 
unknown function" 
820 233 SNP 14 PBANKA_146520 BIR protein" 
820 233 SNP - 2 B PBANKA_000200 BIR protein" 
820 233 SNP - 4 B PBANKA_000320 BIR protein" 
ANKA 233 SNP - 5 2 PBANKA_021570 BIR protein" 
ANKA 233 SNP 2 PBANKA_021540 
Plasmodium exported protein, 
unknown function" 
ANKA 233 SNP 4 PBANKA_040060 BIR protein" 
ANKA 233 SNP 6 PBANKA_062390 BIR protein" 
      
ANKA 233 SNP 6 PBANKA_062300 
Plasmodium exported protein, 
unknown function" 
ANKA 233 SNP 7 PBANKA_070010 BIR protein" 
ANKA 233 SNP 7 PBANKA_070050 Pb-fam-1 protein" 
ANKA 233 SNP 9 PBANKA_090010 
conserved rodent malaria protein, 
unknown 
ANKA 233 INDEL 10 PBANKA_102650 
conserved Plasmodium protein, 
unknown function" 
ANKA 233 SNP 10 PBANKA_104050 BIR protein, pseudogene" 
ANKA 233 SNP 14 PBANKA_143540 
conserved Plasmodium protein, 
unknown function" 
ANKA 233 SNP 14 PBANKA_145310 
sphingomyelin phosphodiesterase, 
putative" 
ANKA 233 INDEL 14 PBANKA_145320 
conserved Plasmodium protein, 
unknown function" 
ANKA 233 SNP - 3 B PBANKA_000100 BIR protein" 
ANKA 233 SNP B PBANKA_000300 BIR protein, fragment" 
ANKA 233 SNP - 2 B PBANKA_000340 BIR protein" 
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ANKA 233 SNP -2   PBANKA_000300 BIR protein, fragment" 
ANKA 233 SNP - 3   PBANKA_000310 BIR protein" 
ANKA 233 SNP   PBANKA_000360 BIR protein" 
ANKA 233 SNP - 5   PBANKA_000400 
Plasmodium exported protein, 
unknown function" 
ANKA 233 SNP - 3   PBANKA_000440 BIR protein, fragment" 
ANKA 233 SNP - 7 2 PBANKA_021580 
Plasmodium exported protein, 
unknown function" 
ANKA 233 SNP - 2 2 PBANKA_021590 BIR protein, pseudogene" 
ANKA 233 INDEL 3 PBANKA_030110 
conserved Plasmodium protein, 
unknown function" 
ANKA 233 INDEL 3 PBANKA_030120 
ERCC1 nucleotide excision repair 
protein, 
ANKA 233 INDEL - 2 3 PBANKA_031570 
conserved Plasmodium protein, 
unknown function" 
ANKA 233 SNP 4 PBANKA_040030 
Plasmodium exported protein, 
unknown function" 
ANKA 233 SNP 6 PBANKA_062300 
Plasmodium exported protein, 
unknown function" 
ANKA 233 SNP - 2 6 PBANKA_062390 BIR protein" 
ANKA 233 SNP - 2 7 PBANKA_070010 BIR protein" 
ANKA 233 SNP 7 PBANKA_072270 BIR protein, pseudogene" 
ANKA 233 INDEL 8 PBANKA_083360 
conserved Plasmodium protein, 
unknown function" 
ANKA 233 SNP 9 PBANKA_090010 
conserved rodent malaria protein, 
unknown 
ANKA 233 INDEL 10 PBANKA_102650 
conserved Plasmodium protein, 
unknown function" 
ANKA 233 INDEL 12 PBANKA_121680 
conserved Plasmodium protein, 
unknown function" 
ANKA 233 SNP 12 PBANKA_124620 
Plasmodium exported protein, 
unknown function" 
ANKA 233 SNP 13 PBANKA_130050 tubulin, putative" 
ANKA 233 INDEL 13 PBANKA_132220 
conserved Plasmodium protein, 
unknown function" 
ANKA 233 INDEL 13 PBANKA_132230 
conserved Plasmodium protein, 
unknown function" 
ANKA 233 INDEL 13 PBANKA_133720 SFT2-like protein, putative" 
ANKA 233 INDEL 13 PBANKA_136510 
conserved Plasmodium protein, 
unknown function" 
ANKA 233 INDEL 14 PBANKA_141440 exportin-T, putative" 
ANKA 233 INDEL 14 PBANKA_141450 protein kinase, putative" 
ANKA 233 INDEL 14 PBANKA_142810 asparagine-rich antigen, putative" 
ANKA 233 SNP 14 PBANKA_143540 
conserved Plasmodium protein, 
unknown function" 
ANKA 233 INDEL 14 PBANKA_145060 
conserved Plasmodium protein, 
unknown function" 
ANKA 233 SNP 14 PBANKA_145310 
sphingomyelin phosphodiesterase, 
putative" 
ANKA 233 INDEL 14 PBANKA_145320 
conserved Plasmodium protein, 
unknown function" 
M7 ALONE 
820 M7 INDEL 2 PBANKA_021270 zinc finger protein, putative" 
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820 M7 INDEL 7 PBANKA_070510 
conserved Plasmodium protein, 
unknown function" 
820 M7 INDEL 8 PBANKA_082260 
conserved Plasmodium protein, 
unknown function" 
820 M7 INDEL 9 PBANKA_091000 
conserved Plasmodium protein, 
unknown function" 
820 M7 INDEL 10 PBANKA_100690 
conserved Plasmodium protein, 
unknown function" 
820 M7 INDEL 10 PBANKA_101970 
conserved Plasmodium protein, 
unknown function" 
820 M7 INDEL 10 PBANKA_102330 
conserved Plasmodium protein, 
unknown function" 
820 M7 INDEL 12 PBANKA_124580 
conserved Plasmodium protein, 
unknown function" 
820 M7 INDEL 13 PBANKA_131420 
conserved Plasmodium protein, 
unknown function" 
820 M7 INDEL 14 PBANKA_141260 
telomerase reverse transcriptase, 
putative, 
820 M7 INDEL 14 PBANKA_141270 
telomerase reverse transcriptase, 
putative, 
820 M7 INDEL 14 PBANKA_145190 
conserved Plasmodium protein, 
unknown function" 
820 M7 INDEL 11 PBANKA_112690 protein kinase, putative" 
ANKA M7 INDEL 3 PBANKA_031120 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 5 PBANKA_051310 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 7 PBANKA_070310 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 8 PBANKA_080270 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 8 PBANKA_082300 ubiquitin-like protein, putative" 
ANKA M7 INDEL 10 PBANKA_100690 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 10 PBANKA_102330 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 SNP 12 PBANKA_120060 
Plasmodium exported protein, 
unknown function" 
ANKA M7 INDEL 12 PBANKA_122590 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 12 PBANKA_123350 RNA-binding protein, putative" 
ANKA M7 INDEL 12 PBANKA_124580 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 14 PBANKA_141810 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 SNP 14 PBANKA_145190 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 SNP -4 B PBANKA_000260 BIR protein" 
ANKA M7 INDEL 3 PBANKA_031120 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 4 PBANKA_040290 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 4 PBANKA_040300 60S ribosomal protein L44, putative" 
ANKA M7 INDEL 5 PBANKA_051310 
conserved Plasmodium protein, 
unknown function" 
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ANKA M7 INDEL 7 PBANKA_070310 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 8 PBANKA_080270 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 8 PBANKA_082300 ubiquitin-like protein, putative" 
ANKA M7 INDEL 9 PBANKA_092830 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 9 PBANKA_093020 DNA mismatch repair protein, putative" 
ANKA M7 INDEL 10 PBANKA_100690 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 10 PBANKA_101730 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 10 PBANKA_101740 selenoprotein, putative" 
ANKA M7 INDEL 10 PBANKA_102660 GTP-binding protein, putative" 
ANKA M7 INDEL 10 PBANKA_102670 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 11 PBANKA_110030 BIR protein, pseudogene" 
ANKA M7 INDEL 11 PBANKA_110590 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 11 PBANKA_110600 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 11 PBANKA_113760 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 11 PBANKA_114230 rhoptry protein, putative" 
ANKA M7 INDEL 12 PBANKA_122590 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 12 PBANKA_123450 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 12 PBANKA_123460 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 12 PBANKA_123780 multidrug resistance protein, putative" 
ANKA M7 INDEL 12 PBANKA_123790 
mitochondrial processing peptidase 
alpha 
ANKA M7 INDEL 12 PBANKA_124360 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 13 PBANKA_130310 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 13 PBANKA_130320 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 13 PBANKA_133830 60S ribosomal protein L6, putative" 
ANKA M7 INDEL 13 PBANKA_134880 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 14 PBANKA_141810 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 14 PBANKA_143830 
phospholipid-transporting ATPase, 
putative" 
ANKA M7 INDEL 14 PBANKA_143840 
conserved Plasmodium protein, 
unknown function" 
ANKA M7 INDEL 14 PBANKA_144650 asparagine-rich protein, putative" 
ANKA M7 INDEL 14 PBANKA_145180 
conserved Plasmodium protein, 
unknown function" 
      
M9 ALONE 
820 M9 SNP - 2 B PBANKA_001030 BIR protein" 
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820 M9 SNP  7 PBANKA_072270 BIR protein, pseudogene" 
820 M9 INDEL 10 PBANKA_101430 
conserved Plasmodium protein, 
unknown function" 
820 M9 INDEL 13 PBANKA_131020 
conserved Plasmodium protein, 
unknown function, 
820 M9 INDEL 13 PBANKA_131030 
conserved Plasmodium protein, 
unknown function, 
820 M9 INDEL -2 13 PBANKA_133980 
conserved Plasmodium protein, 
unknown function" 
820 M9 SNP 11 PBANKA_110050 Pb-fam-1 protein" 
ANKA M9 SNP 2 PBANKA_021560 
Plasmodium exported protein, 
unknown function" 
ANKA M9 SNP 4 PBANKA_040030 
Plasmodium exported protein, 
unknown function" 
ANKA M9 SNP 5 PBANKA_050040 BIR protein, fragment" 
ANKA M9 INDEL 7 PBANKA_070300 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 7 PBANKA_070580 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 7 PBANKA_070960 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 7 PBANKA_071350 
asparagine-rich antigen, putative, 
fragment" 
ANKA M9 SNP - 2 7 PBANKA_072260 
Plasmodium exported protein, 
unknown function" 
ANKA M9 INDEL 8 PBANKA_080020 Pb-fam-1 protein, pseudogene" 
ANKA M9 INDEL 8 PBANKA_083290 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 SNP 9 PBANKA_090020 BIR protein" 
ANKA M9 INDEL 10 PBANKA_101270 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 12 PBANKA_124130 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 13 PBANKA_131310 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 SNP 13 PBANKA_134050 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 13 PBANKA_136470 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 SNP 14 PBANKA_146540 
Plasmodium exported protein, 
unknown function" 
ANKA M9 INDEL 1 PBANKA_010840 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 1 PBANKA_010850 
mitochondrial ribosomal protein L19 
precursor, 
ANKA M9 INDEL 1 PBANKA_011250 organic anion transporter, putative" 
ANKA M9 SNP 2 PBANKA_020030 BIR protein" 
ANKA M9 SNP - 2 3 PBANKA_031640 BIR protein, pseudogene" 
ANKA M9 INDEL 4 PBANKA_040030 
Plasmodium exported protein, 
unknown function" 
ANKA M9 INDEL 4 PBANKA_040940 protein kinase, putative" 
      
ANKA M9 INDEL 4 PBANKA_040950 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 5 PBANKA_051170 topoisomerase, putative" 
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ANKA M9 INDEL 5 PBANKA_051180 centrin-3, putative" 
ANKA M9 INDEL 6 PBANKA_062350 Pb-fam-1 protein" 
ANKA M9 INDEL 7 PBANKA_070580 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 7 PBANKA_070590 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 7 PBANKA_071350 
asparagine-rich antigen, putative, 
fragment" 
ANKA M9 INDEL 7 PBANKA_072040 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 7 PBANKA_072230 
Plasmodium exported protein, 
unknown function" 
ANKA M9 SNP - 2 7 PBANKA_072240 BIR protein" 
ANKA M9 INDEL 8 PBANKA_083280 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 8 PBANKA_083290 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 9 PBANKA_091800 60S ribosomal protein, putative" 
ANKA M9 INDEL 9 PBANKA_093630 syntaxin, putative" 
ANKA M9 INDEL 9 PBANKA_093640 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 10 PBANKA_101260 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 10 PBANKA_101270 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 10 PBANKA_101900 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 10 PBANKA_101910 
DNA-directed DNA polymerase, 
putative" 
ANKA M9 INDEL 10 PBANKA_102250 surface protein, putative" 
ANKA M9 INDEL 11 PBANKA_110650 rhomboid protease, putative" 
ANKA M9 INDEL 11 PBANKA_110660 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 11 PBANKA_111520 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 11 PBANKA_111530 metabolite/drug transporter, putative" 
ANKA M9 INDEL 11 PBANKA_111990 DNAJ protein, putative" 
ANKA M9 INDEL 11 PBANKA_112460 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 12 PBANKA_120350 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 12 PBANKA_120360 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 12 PBANKA_120890 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 12 PBANKA_122400 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 12 PBANKA_124130 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 13 PBANKA_130990 leucine aminopeptidase, putative" 
ANKA M9 INDEL 13 PBANKA_131310 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 13 PBANKA_131980 
serine hydroxymethyltransferase, 
putative" 
ANKA M9 INDEL 13 PBANKA_131990 SNARE protein, putative" 
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ANKA M9 INDEL 13 PBANKA_136470 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 14 PBANKA_141010 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL - 2 14 PBANKA_142270 fe-superoxide dismutase, putative" 
ANKA M9 INDEL - 2 14 PBANKA_142280 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 14 PBANKA_144420 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 INDEL 14 PBANKA_144440 
conserved Plasmodium protein, 
unknown function" 
ANKA M9 SNP 14 PBANKA_146610 BIR protein" 
M8 ALONE 
820 M8 SNP 2 PBANKA_020065 Pb-fam-1 protein" 
820 M8 SNP 2 PBANKA_020080 
Plasmodium exported protein, 
unknown function" 
820 M8 SNP 2 PBANKA_020090 
conserved rodent malaria protein, 
unknown 
820 M8 SNP 2 PBANKA_021460 
Plasmodium exported protein, 
unknown function, 
820 M8 SNP 3 PBANKA_030060 
Plasmodium exported protein, 
unknown function" 
820 M8 SNP 4 PBANKA_040080 Pb-fam-1 protein, pseudogene" 
820 M8 SNP 5 PBANKA_050010 Pb-fam-1 protein" 
820 M8 SNP 6 PBANKA_060630 
conserved Plasmodium protein, 
unknown function" 
820 M8 SNP 6 PBANKA_062080 
conserved Plasmodium protein, 
unknown function" 
820 M8 SNP 6 PBANKA_062360 BIR protein" 
820 M8 SNP 7 PBANKA_072230 
Plasmodium exported protein, 
unknown function" 
820 M8 SNP 12 PBANKA_124710 
Plasmodium exported protein, 
unknown function" 
820 M8 SNP 8 PBANKA_082080 
conserved Plasmodium protein, 
unknown function" 
820 M8 SNP 8 PBANKA_083700 BIR protein" 
820 M8 SNP 8 PBNAKA_083685 BIR protein, pseudogene" 
820 M8 SNP 9 PBANKA_090020 BIR protein" 
820 M8 SNP 9 PBANKA_090030 BIR protein" 
820 M8 SNP 9 PBANKA_092770 
conserved Plasmodium protein, 
unknown function" 
820 M8 SNP 9 PBANKA_093590 
conserved Plasmodium protein, 
unknown function" 
820 M8 SNP 10 PBANKA_010010 Pb-fam-1 protein" 
820 M8 SNP 10 PBANKA_100040 Pb-fam-1 protein" 
820 M8 SNP 6 PBANKA_060010 BIR protein" 
820 M8 SNP 11 PBANKA_110090 Pb-fam-1 protein" 
820 M8 SNP 11 PBANKA_110130 
conserved rodent malaria protein, 
unknown 
820 M8 SNP 11 PBANKA_111840 
conserved Plasmodium protein, 
unknown function" 
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820 M8 SNP 11 PBANKA_114670 BIR protein" 
820 M8 SNP 12 PBANKA_120710 
Plasmodium exported protein, 
unknown function" 
820 M8 SNP 12 PBANKA_122300 
conserved Plasmodium protein, 
unknown function" 
820 M8 SNP 12 PBANKA_124670 BIR protein" 
820 M8 SNP 13 PBANKA_134050 
conserved Plasmodium protein, 
unknown function" 
820 M8 SNP 14 PBANKA_146580 BIR protein" 
820 M8 SNP B PBANKA_000130 BIR protein, fragment" 
820 M8 SNP B PBANKA_000180 
Plasmodium exported protein, 
unknown function" 
820 M8 SNP B PBANKA_000380 BIR protein" 
820 M8 SNP B PBANKA_000390 BIR protein" 
820 M8 SNP B PBANKA_000470 BIR protein, pseudogene" 
820 M8 SNP B PBANKA_000540 BIR protein" 
820 M8 SNP 2 PBANKA_020030 BIR protein" 
820 M8 SNP 9 PBANKA_090070 BIR protein" 
ANKA M8 SNP 1 PBANKA_010010 Pb-fam-1 protein" -  
ANKA M8 SNP 1 PBANKA_010580 conserved Plasmodium protein 
ANKA M8 SNP 1 PBANKA_010990 conserved Plasmodium protein 
ANKA M8 SNP 1 PBANKA_011260 Pb-fam protein 
ANKA M8 SNP 2 PBANKA_020050 BIR protein 
ANKA M8 SNP 2 PBANKA_020060 Pb-fam-1 protein" -  
ANKA M8 SNP 2 PBANKA_021000 conserved Plasmodium protein 
ANKA M8 SNP 2 PBANKA_021490 Pb-fam-1 protein" -  
ANKA M8 SNP 3 PBANKA_030030 BIR protein" -  
ANKA M8 SNP 3 PBANKA_030400 conserved Plasmodium protein 
ANKA M8 SNP 3 PBANKA_031620 conserved rodent malaria protein 
ANKA M8 SNP 4 PBANKA_040070 Pb-fam-1 protein 
ANKA M8 SNP 4 PBANKA_040080 Pb-fam-1 protein 
ANKA M8 SNP 4 PBANKA_040400 conserved Plasmodium protein 
ANKA M8 SNP 4 PBANKA_041560 conserved Plasmodium protein 
ANKA M8 SNP 5 PBANKA_050010 Pb-fam-1 protein"  
ANKA M8 SNP 5 PBANKA_050030 conserved rodent malaria protein 
ANKA M8 SNP 5 PBANKA_051020 conserved Plasmodium protein 
ANKA M8 SNP 6 PBANKA_060020 BIR protein" -  
ANKA M8 SNP 6 PBANKA_060370 conserved Plasmodium protein 
ANKA M8 SNP 6 PBANKA_061260 conserved Plasmodium protein 
ANKA M8 SNP 6 PBANKA_062360 BIR protein" -  
ANKA M8 SNP 6 PBANKA_062380 BIR protein 
ANKA M8 SNP 7 PBANKA_070440 conserved Plasmodium protein 
ANKA M8 SNP 7 PBANKA_070580 conserved Plasmodium protein 
ANKA M8 SNP 7 PBANKA_070760 conserved Plasmodium protein 
ANKA M8 SNP 7 PBANKA_070960 conserved Plasmodium protein 
ANKA M8 SNP 7 PBANKA_071070 conserved Plasmodium protein 
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ANKA M8 SNP 7 PBANKA_071180 conserved Plasmodium protein 
ANKA M8 SNP 7 PBANKA_071950 conserved Plasmodium protein 
ANKA M8 SNP 7 PBANKA_072010 conserved Plasmodium protein 
ANKA M8 SNP 7 PBANKA_072200 conserved Plasmodium protein 
ANKA M8 SNP 7 PBANKA_072220 BIR protein 
ANKA M8 SNP 8 PBANKA_080010 BIR protein" -  
ANKA M8 SNP 8 PBANKA_080020 Pb-fam-1 protein 
ANKA M8 SNP 8 PBANKA_080200 conserved Plasmodium protein 
ANKA M8 SNP 8 PBANKA_081550 conserved Plasmodium protein 
ANKA M8 SNP 8 PBANKA_082080 conserved Plasmodium protein 
ANKA M8 SNP 8 PBANKA_082260 conserved Plasmodium protein 
ANKA M8 SNP 8 PBANKA_082280 conserved Plasmodium protein 
ANKA M8 SNP 8 PBANKA_083150 conserved Plasmodium protein 
ANKA M8 SNP 8 PBNAKA_083685 BIR protein 
ANKA M8 SNP 9 PBANKA_090010 conserved rodent malaria protein 
ANKA M8 SNP 9 PBANKA_090030 BIR protein" -  
ANKA M8 SNP 9 PBANKA_092770 conserved Plasmodium protein 
ANKA M8 SNP 9 PBANKA_094400 BIR protein" -  
ANKA M8 SNP 10 PBANKA_100690 conserved Plasmodium protein 
ANKA M8 SNP 10 PBANKA_101990 conserved Plasmodium protein 
ANKA M8 SNP 10 PBANKA_102330 conserved Plasmodium protein 
ANKA M8 SNP 10 PBANKA_103600 conserved Plasmodium protein 
ANKA M8 SNP 11 PBANKA_110070 Pb-fam-1 protein" -  
ANKA M8 SNP 11 PBANKA_110075 Pb-fam-1 protein" -  
ANKA M8 SNP 11 PBANKA_110210 conserved Plasmodium protein 
ANKA M8 SNP 11 PBANKA_110230 conserved Plasmodium protein 
ANKA M8 SNP 11 PBANKA_111820 conserved Plasmodium protein 
ANKA M8 SNP 11 PBANKA_113900 conserved Plasmodium protein 
ANKA M8 SNP 11 PBANKA_114030 conserved Plasmodium protein 
ANKA M8 SNP 12 PBANKA_122460 conserved Plasmodium protein 
ANKA M8 SNP 12 PBANKA_122610 conserved Plasmodium protein 
ANKA M8 SNP 12 PBANKA_124030 conserved Plasmodium protein 
ANKA M8 SNP 12 PBANKA_124510 conserved Plasmodium protein 
ANKA M8 SNP 12 PBANKA_124680 BIR protein" -  
ANKA M8 SNP 13 PBANKA_130030 Pb-fam-1 protein 
ANKA M8 SNP 13 PBANKA_131410 conserved Plasmodium protein 
ANKA M8 SNP 13 PBANKA_131420 conserved Plasmodium protein 
ANKA M8 SNP 13 PBANKA_132010 conserved Plasmodium protein 
ANKA M8 SNP 13 PBANKA_132730 conserved Plasmodium protein 
ANKA M8 SNP 13 PBANKA_136120 conserved Plasmodium protein 
ANKA M8 SNP 13 PBANKA_136565 Pb-fam-1 protein 
ANKA M8 SNP 14 PBANKA_142460 conserved Plasmodium protein 
ANKA M8 SNP 14 PBANKA_144490 conserved Plasmodium protein 
ANKA M8 SNP 14 PBANKA_144660 conserved Plasmodium protein 
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ANKA M8 SNP 14 PBANKA_146580 BIR protein" -  
ANKA M8 SNP 14 PBANKA_146590 BIR protein" -  
ANKA M8 SNP B PBANKA_000170 BIR protein" -  
ANKA M8 SNP B PBANKA_000200 BIR protein" -  
ANKA M8 SNP B PBANKA_000210 Pb-fam protein 
ANKA M8 SNP B PBANKA_000250 BIR protein" -  
ANKA M8 SNP B PBANKA_000290 BIR protein" -  
ANKA M8 SNP B PBANKA_000370 conserved rodent malaria protein 
ANKA M8 SNP B PBANKA_000410 BIR protein 
ANKA M8 SNP B PBANKA_000490 conserved rodent malaria protein 
ANKA M8 SNP B PBANKA_000580 BIR protein" -  
 
 
Shade codes to the table: 
 
Light Grey: Mutations exclusively involving UTRs 
Dark Grey: Important mutations but also in the parent lines.. 
 
Text codes to the table: 
 
Ref Str: reference strain 
Chr: Chromosome number 
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Table A12 – A comprehensive list of selected prioritised mutations grouped according to their co-occurrence in the studied GNP lines 
 
REF STR LINE TYPE CHR GENE ID POS R BASE M BASE AA CHANGE PRODUCT 
COMMON IN ALL GNPs 
820 233 SNP 14 PBANKA_143750 1371537 C T R2263STOP Transcription factor with AP2 domains 
820 M7 INDEL 14 PBANKA_143750 1369916 AA A FSHIFT Transcription factor with AP2 domains 
820 M9 SNP 14 PBANKA_143750 1367390 T A Y880STOP Transcription factor with AP2 domains 
ANKA M8 INDEL 14 PBANKA_143750 1369436 TA A FSHIFT Transcription factor with AP2 domains 
ANKA 233 SNP 14 PBANKA_143750 1372335 C T R2263STOP Transcription factor with AP2 domains 
ANKA M7 INDEL 14 PBANKA_143750 1370714 AA A FSHIFT Transcription factor with AP2 domains 
ANKA M9 SNP 14 PBANKA_143750 1368188 T A Y880STOP Transcription factor with AP2 domains 
ANKA K173 INDEL 14 PBANKA_143750 1369423 CATATA CATA FSHIFT Transcription factor with AP2 domains 
ANKA K173 INDEL 9 PBANKA_093910 1446117 t tT 829US transcription factor with AP2 domain(s), 
ANKA K173 INDEL 9 PBANKA_093910 1446332 
aatatatatat
atatatatata
tatatat 
aATatatatatata
tatatatatatatat
at 614US transcription factor with AP2 domain(s), 
ANKA 233 INDEL 9 PBANKA_093910 1446814 t tGT 132US transcription factor with AP2 domain(s), 
ANKA M7 INDEL 9 PBANKA_093910 1446814 t tGT 132US transcription factor with AP2 domain(s), 
ANKA M9 INDEL  9 PBANKA_093910 1446814 t tGT 132US transcription factor with AP2 domain(s), 
ANKA M9 INDEL  9 PBANKA_093910 1446501 
catatatatat
atatatat 
catatatatatatat
at 442US transcription factor with AP2 domain(s), 
ANKA 234 INDEL 9 PBANKA_093910 1446814 ta tTTa 132US transcription factor with AP2 domain(s), 
ANKA 820 INDEL 9 PBANKA_093910 1446813 tt tTGt 131US transcription factor with AP2 domain(s), 
COMMON IN M7 AND M9 
820 M7 INDEL 12 PBANKA_123350 1259303 TG TTG FSHIFT RNA binding protein, putative 
20 M9 INDEL 12 PBANKA_123350 1259303 TGTT TTGTT,T FSHIFT RNA binding protein, putative 
ANKA M7 SNP 14 PBANKA_146500 2408385 T A S672T PYST-C2 homologue, putative" 
ANKA M9 SNP 14 PBANKA_146500 2408385 T A S672T PYST-C2 homologue, putative" 
820 M8 SNP 14 PBANKA_146500     PYST-C2 homologue, putative" 
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ANKA 234 SNP 14 PBANKA_146500 2408385 T A S672T PYST-C2 homologue, putative" 
ANKA M7 INDEL 8 PBANKA_082560 986910 
 
ctttttttttttt 
cTTTTTTTtt
tttttttttt,c
TTTTTTTTt
ttttttttttt 346DS splicing factor 3a, putative" 
ANKA M9 INDEL 8 PBANKA_082560 986922 t tTTTTTTT 358DS splicing factor 3a, putative" 
ANKA 234 INDEL 8 PBANKA_082560 986910 ctttttttttttt 
cTTTTTTTT
tttttttttttt,
cTTTTTTttt
ttttttttt,cT
TTTTTTtttt
tttttttt   splicing factor 3a, putative" 
COMMON IN 233 AND K173 
ANKA 233 SNP 1 PBANKA_011210 453650 T C F1823S transcription factor with AP2 domain(s), 
ANKA K173 SNP 1 PBANKA_011210 453650 T C F1823S transcription factor with AP2 domain(s), 
ANKA 234 SNP 1 PBANKA_011210 453650 T C F1823S transcription factor with AP2 domain(s), 
ANKA 233 SNP 5 PBANKA_051920 701552 G A G131D CCAT-binding transcription factor-like protein, 
ANKA 234 SNP 5 PBANKA_051920 701552 G A G131D CCAT-binding transcription factor-like protein, 
ANKA 233 SNP 12 PBANKA_122210 819068 T G Y489D regulator of chromosome condensation  
          
ANKA 234 SNP 12 PBANKA_122210 819068 T G Y489D regulator of chromosome condensation protein, 
ANKA 233 SNP 14 PBANKA_141570 591556 G A M2487I transcription factor with AP2 domain(s), 
ANKA K173 SNP  14 PBANKA_141570 591556 G A M2487I transcription factor with AP2 domain(s), 
ANKA K173 SNP 14 PBANKA_141570 586073 G T A660S transcription factor with AP2 domain(s), 
ANKA 234 SNP 14 PBANKA_141570 591556 G A M2487I transcription factor with AP2 domain(s), 
233 ALONE 
820 233 SNP 10 PBANKA_102190 836265 T A V40E RNA polymerase subunit, putative" 
820 233 INDEL 11 PBANKA_110870 314827 ACG AACG FSHIFT chromosome condensation protein putative 
ANKA 233 INDEL 8 PBANKA_080330 176812 t tT FSHIFT RNA helicase, putative" 
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ANKA 233 INDEL 11 PBANKA_112110 766876 tg tTg FSHIFT radical SAM protein, putative" 
ANKA 233 dsSNP  1 PBANKA_011210 ? ? ? ? transcription factor with AP2 domain(s), 
ANKA 234 dsSNP  1 PBANKA_011210 ? ? ? ? transcription factor with AP2 domain(s), 
ANKA 233 INDEL 3 PBANKA_031580 545510 ttat tTAtat 884US Ribosome associated memb. protein RAMP4, 
ANKA 233 INDEL 14 PBANKA_145050 1909733 atgt aTtgt 545US RNA-processing protein, putative" 
820 M7 INDEL 2 PBANKA_020950 333828 AG AAG FSHIFT ATP dependent RNA helicase, putative" 
M7 ALONE 
820 M7 INDEL 7 PBANKA_071830 617574 T TT FSHIFT DNA replication licensing factor, putative" 
ANKA M7 INDEL 7 PBANKA_071830 621042 t Tt FSHIFT DNA replication licensing factor, putative" 
ANKA M7 INDEL 12 PBANKA_123350 1264140 tg tTg FSHIFT RNA-binding protein, putative" 
ANKA M7 INDEL 8 PBANKA_080800 389107 
catatatatat
atatatatata
tatatatatat
atatatatata
ta 
catatatatatatat
atatatatatatata
tatatatatatata 115DS cdc2-related protein kinase 4" 
M9 ALONE 
820 M9 INDEL 6 PBANKA_061010 388494 A AA FSHIFT lysine-specific histone demethylase 1, putative" 
ANKA M9 INDEL 8 PBANKA_081930 759012 ata a 454DS eukaryotic translation initiation factor 3 
ANKA M9 INDEL 11 PBANKA_112450 889515 
catatatatat
atatatatata
tatatatatat
atatat 
catatatatatatat
atatatatatatata
tatatat 174DS poly(A) polymerase PAP, putative" 
ANKA M9 INDEL 12 PBANKA_120900 321486 agt aTAgt 210DS eukaryotic translation initiation factor 2, 
M8 ALONE 
ANKA M8 SNP 1 PBANKA_010030 NA NA NA NA phospholipase 
ANKA M8 SNP 1 PBANKA_010040 NA NA NA NA rhoptry protein 
ANKA M8 SNP 2 PBANKA_021520 NA NA NA NA reticulocyte-binding protein 
ANKA M8 SNP 2 PBANKA_021530 NA NA NA NA reticulocyte-binding protein 
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820 M8 SNP 3 PBANKA_030600 NA NA NA NA 6-cysteine protein" 
820 M8 SNP 3 PBANKA_031270 NA NA NA NA DEAD/DEAH helicase, putative 
ANKA M8 SNP 3 PBANKA_031660 NA NA NA NA reticulocyte-binding protein 
820 M8 SNP 3 PBANKA_031660 NA NA NA NA reticulocyte-binding protein, putative" 
ANKA M8 SNP 4 PBANKA_041600 NA NA NA NA RhopH3 
820 M8 SNP 4 PBANKA_041600 NA NA NA NA RhopH3 
ANKA M8 SNP 5 PBANKA_050100 NA NA NA NA reticulocyte binding protein 
820 M8 SNP 5 PBANKA_050100 NA NA NA NA reticulocyte binding protein 
ANKA M8 SNP 5 PBANKA_051900 NA NA NA NA S-antigen 
ANKA M8 SNP 6 PBANKA_060240 NA NA NA NA transporter 
ANKA M8 SNP 6 PBANKA_060950 NA NA NA NA kinesin-related protein 
ANKA M8 SNP 6 PBANKA_061030 NA NA NA NA polyubiquitin 
ANKA M8 SNP 7 PBANKA_070100 NA NA NA NA tryptophan-rich antigen 
ANKA M8 SNP 7 PBANKA_071350 NA NA NA NA asparagine-rich antigen 
ANKA M8 SNP 7 PBANKA_071370 NA NA NA NA GTPase 
ANKA M8 SNP 8 PBANKA_080320 NA NA NA NA inositol phosphatase 
ANKA M8 SNP 8 PBANKA_081060 NA NA NA NA exoribonuclease 
ANKA M8 SNP 8 PBANKA_081490 NA NA NA NA arginyl-tRNA synthetase 
820 M8 SNP 8 PBANKA_081700 NA NA NA NA Sugar transporter,putative 
ANKA M8 SNP 8 PBANKA_082600 NA NA NA NA methyltransferase 
ANKA M8 SNP 8 PBANKA_083330 NA NA NA NA zinc finger protein 
ANKA M8 SNP 9 PBANKA_090080 NA NA NA NA reticulocyte binding protein 
ANKA M8 SNP 9 PBANKA_090090 NA NA NA NA reticulocyte binding protein 
ANKA M8 SNP 9 PBANKA_090130 NA NA NA NA merozoite adhesive erythrocytic binding protein 
820 M8 SNP 9 PBANKA_090130 NA NA NA NA merozoite adhesive erythrocytic binding protein   
ANKA M8 SNP 10 PBANKA_100010 NA NA NA NA reticulocyte binding protein 
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ANKA M8 SNP 10 PBANKA_102410 NA NA NA NA ATP-dependent RNA helicase 
ANKA M8 SNP 10 PBANKA_102800 NA NA NA NA ubiquitin C-terminal hydrolase 
ANKA M8 SNP 10 PBANKA_102820 NA NA NA NA protein kinase 
ANKA M8 SNP 10 PBANKA_103640 NA NA NA NA BOP1-like protein 
820 M8 SNP 10 PBANKA_103640 NA NA NA NA BOP1-like protein 
ANKA M8 SNP 11 PBANKA_110810 NA NA NA NA guanidine nucleotide exchange factor 
ANKA M8 SNP 11 PBANKA_110870 NA NA NA NA chromosome condensation protein 
ANKA M8 SNP 11 PBANKA_111660 NA NA NA NA alpha adaptin-like protein 
ANKA M8 SNP 11 PBANKA_112350 NA NA NA NA SNF2 helicase 
ANKA M8 SNP 11 PBANKA_113330 NA NA NA NA elongation factor 1 alpha 
ANKA M8 SNP 11 PBANKA_113340 NA NA NA NA elongation factor 1 alpha 
ANKA M8 SNP 12 PBANKA_120620 NA NA NA NA histone deacetylase 
ANKA M8 SNP 12 PBANKA_122850 NA NA NA NA ubiquitin-like protease 1 homolog 
ANKA M8 SNP 12 PBANKA_124020 NA NA NA NA G-protein coupled receptor 
ANKA M8 SNP 13 PBANKA_130650 NA NA NA NA TRAP-like protein 
820 M8 SNP 13 PBANKA_131570 NA NA NA NA rhoptry neck protein 2 
ANKA M8 SNP 13 PBANKA_133970 NA NA NA NA DEAD box helicase 
ANKA M8 SNP 14 PBANKA_143290 NA NA NA NA GTP-binding protein 
ANKA M8 SNP 14 PBANKA_143400 NA NA NA NA phosphate translocator 
ANKA M8 SNP 14 PBANKA_143820 NA NA NA NA DNA GyrAse a-subunit 
ANKA M8 SNP 14 PBANKA_144820 NA NA NA NA asparagine/aspartate rich protein 
ANKA M8 SNP bin PBANKA_000160 NA NA NA NA reticulocyte binding protein 
ANKA M8 SNP bin PBANKA_000220 NA NA NA NA reticulocyte binding protein 
ANKA M8 SNP bin PBANKA_000280 NA NA NA NA reticulocyte binding protein 
ANKA M8 SNP bin PBANKA_000450 NA NA NA NA reticulocyte-binding protein 
ANKA M8 SNP bin PBANKA_000510 NA NA NA NA reticulocyte binding protein 
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820 M8 SNP bin PBANKA_000220 NA NA NA NA reticulocyte binding protein 
820 M8 SNP bin PBANKA_000280 NA NA NA NA reticulocyte binding protein 
820 M8 SNP bin PBANKA_000450 NA NA NA NA reticulocyte binding protein 
820 M8 SNP bin PBANKA_000510 NA NA NA NA reticulocyte binding protein 
 
 
Colour codes to the table: 
 
Green: Mutations of prime importance 
Orange: Other potentially relevant mutations 
Grey: Mutations exclusively involving UTRs 
Dark orange: Important mutations but also in the parent lines.. 
 
Text codes to the table: 
 
Ref Str: reference strain 
Chr: Chromosome number 
Pos: position of the mutation (base number) 
R base: base in the reference genome 
M base: base in the mutant 
AA change: Amino acid change 
US: upstream 
DS: downstream 
FSHIFT: frameshift 
NOSHIFT: No frameshift 
dsSNP: synonymous SNP 
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Table A13: Summary of all the oligonucleotides used in the study (fonts shaded in grey indicate the restriction enzyme recognition sites) 
 
NAME SEQUENCE 
Tm 
(°C) 
RESTRICTION 
SITE 
DESCRIPTION 
GU0274 GGGaagcttGTCTGTACATAAGTGAATATAC 64.2 HindIII Forward primer, flanking pb000676.02.0 upstream 
GU0275 CCCgggcccCAATGGTGTGCAAATAAG 69.5 ApaI Reverse primer, flanking pb000676.02.0 upstream 
GU0276 GGGgatatcGCTGAGTGGAGCACATTGC 69.5 EcoRV 
Forward primer, flanking pb000676.02.0 
downstream 
GU0277 CCCgaattcCCGAACGTAACAATACAAATTCCC 68.2 EcoRI 
Reverse primer, flanking pb000676.02.0 
downstream 
GU0287 CATTTCCCATATTACAATTTTAGC 54.2   Forward Primer; checking the integration of SMC 
GU0288 GAAAATACCCAAAGCGATAG 53.2   Reverse Primer; checking the integration of SMC 
GU0587 GTGAACAAATAAAAGATAAAAG 43.8   230p 5'int forward 
GU0588 GTCCAACTATTTATGAATC 42.7   pbdhfr 3'UTR reverse 
GU0589 GAAGTAGTGTGTAGCGTATTC 50.4   3'UTR pb48/45 forward 
GU0590 GGATTCAAATCAATATTGCATC  48.1   230p 3'int reverse 
GU0980 GGGaagcttGTATTCCTTCTCTTTTTTTATGAAGGATACAAAATCGC 58.2 HindIII Forward HA1 PBANKA141570 ko 
GU0981 CCCgggcccCCACAATATGATTAATATTAATTTGTTATAGGGCGTGAATG 58.1 ApaI Reverse HA1 PBANKA141570 ko 
GU0982 CCCgggcccCCCACGGTTATTCATTTTTTATTTTCCACAATATG 57.4 ApaI Reverse HA1 (mix) PBANKA141570 ko 
GU0983 GGGctcgagGCATATATAAGCCAGATGGAAATGTAATCTACCTCAAAAAAAC 60.1 XhoI Forward HA2 (mix) PBANKA141570 ko 
GU0984 GGGctcgagCTACCTCAAAAAAACTTAACTTTTTCATTTTTTGG 55.5 XhoI Forward HA2 PBANKA141570 ko 
GU0985 CCCgaattcCAAGTTTAAAAGATGTCCTAAATAGCTATGTTAAATCCG 57.8 EcoRI Reverse HA2 PBANKA141570 ko 
GU0986 GGGaagcttGTTAGCTTTATTTTTTCATGATTGTAATGTATAATGCC 56.3 HindIII Forward for complementation of PBANKA141570 
GU0987 GGGaagcttGCACAATATCATATCTACAGTTGTGTGCGTTTTATAGG 60 HindIII Forward HA1 PBANKA091860 ko 
GU0988 CCCgggcccGAAAAACTATAGCATTTGTAAAGAAGCAAACAAATTATATCC 57.8 ApaI Reverse HA1 PBANKA091860 ko 
GU0989 GGGctcgagGTATTGAAAAATATATTAACACATTTAGCTATTATTATGAGGC 56.1 XhoI Forward HA2 PBANKA091860 ko 
GU0990 CCCgaattcCATTGAAAATTATTAAAAATTATGTTTTCCCTTTCCTATGC 57.1 EcoRI Reverse HA2 PBANKA091860 ko 
GU1004 CGTTTTTTTGACGCTTTAATTTCGTATTTGACGTTTATTG 60   5' Int check Api2 141570 ko 
GU1005 GTTTTTAATTTGTTCTTCCAAGTGTGCGTCTACAG 61   3' Int check Api2 141570 ko 
GU1006 GCATACTTATATAATTTCTGCATTGCATATATGCCTC 60   5' Int check Kinase 091860 ko 
GU1007 CACACATAAATATATGTATATAAAAAAAGGGGGGTGTATGC 62   3' Int check Kinase 091860 ko 
GU1008 GGTGAAGTAATAAAAGCATATATATTTTGCAATCATCC 59   Forward for complementation of PBANKA091860 
GU1009 GGGgggcccGTATTCCTTCTCTTTTTTTATGAAGGATACAAAATCGC 58.2 ApaI Forward HA1 PBANKA141570 ko 
GU1010 CCCccgcggCCACAATATGATTAATATTAATTTGTTATAGGGCGTGAATG 58.1 SacII Reverse HA1 PBANKA141570 ko 
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GU1011 CCCccgcggCCCACGGTTATTCATTTTTTATTTTCCACAATATG 57.4 SacII Reverse HA1 (mix) PBANKA141570 ko 
GU1012 GGGccgcggCCAATCCTAAGGAATATAAAAATTCTACACAAATTGAG 59 SacII EXT FW GFP Tag PBANKA_141570  
GU1013 CCCggatccCATTTCCATCTGGCTTATATATGCAGTATTATTCG 60 BamHI EXT REV GFP Tag PBANKA_141570  
GU1014 CATACAATtctagaTTATCGAAAATGAGGTCACTATTAATAATC 61 XbaI INT FW GFP Tag PBANKA_141570  
GU1015 CCTCATTTTCGATAAtctagaATTGTATGTTTATTTTTTTCAT 59 XbaI INT REV GFP Tag PBANKA_141570  
GU1016 GGGccgcggGAAGAATTTTTACATACTGGACAAATTAATCAACTAC 58 SacII EXT FW GFP Tag PBANKA_091860  
GU1017 CCCggatccTTTTTTTTGATTAACTTTACTAACTCCTAAAATTTTTTTAAAAAAAG 57 BamHI EXT REV GFP Tag PBANKA_091860  
GU1018 GCCCTAAGCAATATCtctagaTATAATAATAAAAAAAATGC 60 XbaI INT FW GFP Tag PBANKA_091860  
GU1019 TTTTTTTATTATTATAtctagaGATATTGCTTAGGGCAGAAG 60 XbaI INT REV GFP Tag PBANKA_091860  
GU1028 GTGAAGTTCAAATATGTGAAAAAACAATAAATGAATTTAGC 59  FW outside 230p in 820 
GU1029 GTGACTTCTAGTGGAATCGCTACCATAAGTATC 62  RE outside 230p in 820 
GU1030 ATGAGTAGATCTTCTAAGAACGTCATCAAGG 59   FW RFP in 820 
GU1031 CAAGAACAAGTGGTGTCTACCTTCAGTACG 62   RE RFP in 820 
GU1032 GTGAGCAAGGGCGAGGAGCTG 60   FW eGFP in 820 (mid) 
GU1033 CTCGGCATGGACGAGCTGTACAAG 61   FW eGFP in 820 (end) 
GU1034 CAGCAGGACCATGTGATCGCG 58   RE eGFP in 820 
GU1054 GGGaagcttGGTGCAAATATATATGTATTTATTCATATATATACAC 60.6 HindIII Forward HA1 PBANKA143750 ko 
GU1055 CCCgggcccGTTTATTACAAATACTTCTAAATCAATATCACTAC 60.1 ApaI Reverse HA1 PBANKA143750 ko 
GU1056 CCCgggcccGTTTTGAATATCAGAGATCATTTTTTGTTTATTAC 60.1 ApaI Reverse HA1 (mix) PBANKA143750 ko 
GU1057 GGGaagcttGTTATCTATTTTACTTCTAAAAACATGTATATATTTAATTTG 60.7 HindIII Forward for complementation PBANKA143750 ko 
GU1058 GGGctcgagCGCCAATTATTATTGCATATAATAATAATAATAATAAC 59.7 XhoI Forward HA2 PBANKA143750 ko 
GU1059 CCCgaattcGTCACAATATGTATAAAAACGTTAATAATTTCTAAAATTG  61.2 EcoRI Reverse HA2 PBANKA143750 ko 
GU1060 GGGctcgagGAGTGTAGTAGCGAATAATAATCGCC 61.6 XhoI Forward HA2 (mix) PBANKA143750 ko 
GU1061 GGGaagcttCTTTTACATTTTTCCTATATTTCTATTTCAATTGG 60.1 HindIII Forward HA1 PBANKA011210 ko 
GU1062 CCCgggcccGTAACAATTATCAATCATATATACACATATAGAAAAAAC 61 ApaI Reverse HA1 PBANKA011210 ko 
GU1063 CCCgggcccCAATTTTCCGATTTAGAATATTTATCCATTTTAGC 61.3 ApaI Reverse HA1 (mix) PBANKA011210 ko 
GU1064 GGGgggcccCCTCAAATTATATGTGTATTAAATATCCAATAAAGG 61.5 ApaI Forward for complementation PBANKA011210 ko 
GU1065 GGGctcgagGAATATAATCATAATATTAACTATTTATTTGCAATGTTTG 60.2 XhoI Forward HA2 PBANKA011210 ko 
GU1066 CCCgaattcGGATAAAGTTATTTATATTAATAATAATAACGATTTTAGTG  60.4 EcoRI Reverse HA2 PBANKA011210 ko 
GU1067 GGGctcgagGTAGAATCGAAAGATGAATGATAAAATAAAAG 59.2 XhoI Forward HA2 (mix) PBANKA011210 ko 
GU1068 CGCCCTATAACAAATTAATATTAATCATATTGTGG 62.4   ORF PBANKA_141570 FW 
GU1069 CCAAAAAATGAAAAAGTTAAGTTTTTTTGAGGTAG  61.3   ORF PBANKA_141570 RE 
GU1070 GTAGTGATATTGATTTAGAAGTATTTGTAATAAAC 60.1   ORF PBANKA_143750 FW 
GU1071 GTTATTATTATTATTATTATATGCAATAATAATTGGCG 59.7   ORF PBANKA_143750 RE 
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GU1072 GTTTTTTCTATATGTGTATATATGATTGATAATTGTTAC 61   ORF PBANKA_011210 FW 
GU1073 CAAACATTGCAAATAAATAGTTAATATTATGATTATATTC 60.2   ORF PBANKA_011210 RE 
GU1074 GTTTGCTTCTTTACAAATGCTATAGTTTTTC 60.2   ORF PBANKA_091860 FW 
GU1075 GCCTCATAATAATAGCTAAATGTGTTAATATATTTTTCAATAC 63.7   ORF PBANKA_091860 RE 
GU1076 CATATTTAAAGCTATGATAAGTAGAGTAAGCAAC 62.2   5’ INT CHECK PBANKA_143750  
GU1077 GTCTTGCTTGTTCAGGTAAAATAATATAAAATGG 62.2   3’ INT CHECK PBANKA_143750  
GU1078 GAACATTAAATTCGGGGGTTAAAGAAAATTTG 61.8   5’ INT CHECK PBANKA_011210  
GU1079 CATATTAATGACCGGATCAGATTACTATTTTAAATC 62.6   3’ INT CHECK PBANKA_011210  
GU1080 GGGgaattcGGGAAATAATAGTGACAGTAATATTTGTAATAATAC 61.5 EcoRI FW SXO HA PBANKA_141570 
GU1081 CCCctcgagGATATTTATTATATTTAACATTTTGGGTATTTATATTATCATC 60.9 XhoI RE SXO HA PBANKA_141570  
GU1082 GGGgaattcGAAACGAATGGTTGTTGTTCATGTCAAAC 62.4 EcoRI FW SXO HAPBANKA_ 011210  
GU1083 CCCctcgagGAATCATATCTTTTTTTTCTTTTACACCTTCC 60.5 XhoI RE SXO HA PBANKA_011210  
GU1084 GGGgaattcGTAGCAATTATGATTTAAAAATCAATAACGAACATAG 61.7 EcoRI FW SXO HA PBANKA_143750 
GU1085 CCCctcgagCGGAAATATGCTATAATAATAATTATTATTACAATAATTC 60.2 XhoI RE SXO HA PBANKA_143750  
GU1086 GAAATAAATAT tccggaGAAAAGTT TACATAATAACAATGATC 63.3 Kpn2I INT FW SXO HA PBANKA_143750  
GU1087 GTAAACTTTTCtccggaATATTTATTTCATTTGCACATATTAATG 65.8 Kpn2I INT REV SXO HA PBANKA_143750  
GU1125 CCCccgcggCTGTTGAGACATTTGGTATAGTTGTTTTC 61 SacII Reverse for HA1'' PBANKA_141570 
GU1126 GGGctcgagGATACAAAAAATGGATTACGTAATACAAAAAATATGG 61.7 XhoI Forward for HA2'' PBANKA_141570 
GU1127 CCCgggcccCAGTCGAATTAACATCCATCAATTGAC 60.4 apaI Reverse for HA1'' PBANKA_143750 
GU1128 GGGctcgagCATATAAAGAGCGTCGCTATAACAAGAAAC 62.7 XhoI Forward for HA2'' PBANKA_143750 
GU1129 CCCgggcccCGGTTGTATATTTTCAGAATATTCATTATAGTTTG 61.3 apaI Reverse for HA1'' PBANKA_011210 
GU1130 GGGctcgagCAACCATTTTAAAAATAATAATTTAGAGATGAATGATAAC 61.2 XhoI Forward for HA2'' PBANKA_011210 
GU1139 TTYAGGGTTYAGGGTTYAGGGTTYAGGGTTYAGGGTTYAGGGTTYAGGG 76.5   Telomere probe for CHEF gels 
GU1168 GGGccgcggCCAAAAAATGTTGTTATAGAAAATAGTACTCAAATTAC 61.9 SacII PBANKA_143750 GFP tag EXT FW 
GU1169 CCCggatccCGCTACTACACTCATCATGTAGCACGCTG 68.1 BamHI PBANKA_143750 GFP tag EXT RE 
GU1170 GCCCAAGGGAtctagaTGAGTAATAATTT AGAAAATAGTTTAG 65 XbaI PBANKA_143750 GFP tag INT FW 
GU1171 CTAAATTATTACTCAtctagaTCCCTTGGGCAAATGGATTAGTG 67.3 XbaI PBANKA_143750 GFP tag INT RE 
GU1172 GGGccgcggCATTTAATGGATTTCCAAAATATACAAATATAAATAATGG 61.2 SacII PBANKA_011210 GFP tag EXT FW 
GU1173 CCCggatccCATCTTTCGATTCTACTTTATTTCTATAATCGAAAATGG 64.2 BamHI PBANKA_011210 GFP tag EXT RE 
GU1182 GGGctcgagCGATGAAGGTAATAAAAGTAGAAATATAAAAAACAAC 61.7 XhoI PBANKA_143750 SXO Complementation EXT FW 
GU1183 CCCgatatcTTATTATTCGCTACTACACTCATCATGTAG 61.3 EcoRV PBANKA_143750 SXO Complementation EXT RE 
GU1184 GACAAAAATATATTAACAAATAAAGCtccggaCATAGACAATC 61.7 Kpn2I PBANKA_143750 SXO Complementation INT FW 
GU1185 TTAATTCATTTTGATTGTCTATGtccggaGCTTTATTTG 59.5 Kpn2I PBANKA_143750 SXO Complementation INT RE 
GU1186 CCCgatatcGTCTTGCTTGTTCAGGTAAAATAATATAAAATGG 62.2 EcoRV PBANKA_143750 SXO Comp EXT_RE with homoUTR 
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GU1187 CCCgatatcGATCCGCATATCGAAATGATGCTATC  61.6 EcoRV PBANKA_143750 SXO Comp EXT_RE with exoUTR 
GU1231 GGGtctagaCGATGAAGGTAATAAAAGTAGAAATATAAAAAACAAC 59.5 XbaI PBANKA_143750 SXO pL31 Comp. EXT FW (NEW) 
GU1232 CCCggatccTTATTATTCGCTACTACACTCATCATGTAG 62.2 BamHI PBANKA_143750 SXO pL31 Comp. EXT RE (NEW) 
GU1233 GACAAAAATATATTAACAAATAAAGCggccggccCATAGACAATC 60.2 FseI PBANKA_143750 SXO pL31 Comp INT FW (NEW) 
GU1234 TTAATTCATTTTGATTGTCTATGggccggccGCTTTATTTG 61.3 FseI PBANKA_143750 SXO pL31 Comp INT RE (NEW) 
GU1235 CCCggatccGTCTTGCTTGTTCAGGTAAAATAATATAAAATGG 61.3 BamHI 
PBANKA_143750 SXO pL31 Comp EXT RE with 
homoUTR (NEW) 
GU1236 GAAAGTCTGATGAATTTTATAAAAATGAGGG 60.4   
Sequencing oligo for m8/K173 mutation in 820 
PBANKA_143750 
GU1237 CTCCTGTCGACACAAATAATGATAATTATG 61   
Sequencing oligo for m7 mutation in 820 
PBANKA_143750 
GU1238 GGAAAGATTCAACGAGAGGACATTG 59.8   
Sequencing oligo for 233 mutation in 820 
PBANKA_143750 
GU1239 CTGGTTTGTTACTAATCCAATATGTCC 61.3   Q1R - Rev for Q1 amplification PBANKA_143750 
GU1240 CATTATTTGTCCCATCATTATTTCCTATTATATC 61   Q2R - Rev for Q2 amplification PBANKA_143750 
GU1241 GATTATAAAATAGGCTATATTAATGACGAAAATG 59.8   Q3F - FW for Q3 amplification PBANKA_143750 
GU1242 GCCCACCATTTTCTGTATTTTTAAAATTTTCTTC 62.2   Q3R - Rev for Q3 amplification PBANKA_143750 
GU1287 GTATAATGTAATGTAACGAAAACATAAGTTATTTTAAC 60.8   
3' Int check sense oligo for PBANKA_143750 
Repair/ko 
GU1315 CCTCTATGAAGGTCAAGGGAG 59.8   PBANKA_052270 (Alpha-tubulin II) RE RTPCR oligo 
GU1317 CAGGTGGGCATTCAAAAGCTATTAC 61.3   PBANKA_030610 (P230) RE RTPCR oligo (5' set) 
GU1319 CCCTGAAATGCGGAATTTTAAAAGCTG 61.9   PBANKA_030610 (P230) RE RTPCR oligo (3' set) 
GU1322 CTTTCCCGACGTCGTTCCG 61   PBANKA_135970 (P47) Sense RTPCR oligo 
GU1325 CTGAGTATATAAAAATATATTTAACAAAAGTGAGC 60.1   PBANKA_051490 (P28) Sense RTPCR oligo 
GU1327 CTTCAATTATACTATTGTTCATTTGGCTCTTC 61.8   PBANKA_051500 (P25) Sense RTPCR oligo 
GU1338 GGGccgcggCGATTGATAATTCCTGCAGCCC 60.3 SacII Pbeef1aa sense in pL0035 with SacII site 
GU1385 GGGgcggccgcCGATGAAGGTAATAAAAGTAGAAATATAAAAAACAAC 59.5 NotI 
PBANKA_143750 SXO pL31 CompEXT 
FW_CORRECTED 
GU1386 CCCtctagaTTCGCTACTACACTCATCATGTAGC 61.3 XbaI PBANKA_143750 SXO pL31 Comp EXT RECORRECTED 
GU1387 GACAAAAATATATTAACAAATAAAGCaagcttCATAGACAATC 61.7 HindIII 
PBANKA_143750 SXO pL31 Compl INT FW 
CORRECTED 
GU1388 TTAATTCATTTTGATTGTCTATGaagcttGCTTTATTTG 59.5 HindIII PBANKA_143750 SXO pL31 Comp INT RE CORRECTED 
GU1411 GCTTAATATATCTTCATAAAACATATTATTATTATGGC 60.8   PBANKA_143750 REV oligo for promoter repair 
GU1412 GGGaagcttGGGAAAATGCGATGTGGAAATAGTTG 61.6 HindIII PBANKA_143750 part orf with mutations ko FW HA1 
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GU1413 CCCccgcggGCATATTTAATTCATTTTGATTGTCTATGGC 60.2 SacII PBANKA_143750 part orf with mutations ko RE HA1 
GU1414 GGGctcgagGAAAATAATTATTGTGTTAAAGACATTTCCGAC 60.8 XhoI PBANKA_143750 part orf with mutations ko FW HA2 
GU1415 CCCgaattcCTGCCTTTCAAACCCTTTTCTGG 60.6 EcoRI PBANKA_143750 part orf with mutations ko RE HA2 
GU1416 GGGaagcttGAAAATATGAATAATGAAGAAAATTTTAAAAATACAGAAAATG 60.9 HindIII PBANKA_143750 part orf with DBD ko FW HA1 
GU1417 CCCccgcggCATATTAAAACGTGAATGATTTGTGGGG 60.7 SacII PBANKA_143750 part orf with DBD ko RE HA1 
GU1446 AATATTATAATAGTCGTAGCCATCAATGTGTACACATGGTAATATAGATTTTCGTTTATATT 69.4   Target motif (PBANKA_143750/PFL1085w) for EMSA 
GU1447 AATATTATAATAGTCGTAGCCATCAATAAAAAAAAATGGTAATATAGATTTTCGTTTATATT 66.8   No motif (negative control) for EMSA 
GU1448 AATATTATAATAGTCGTAGCCATCAATATATAAAAATGGTAATATAGATTTTCGTTTATATT 66.8   Mutated motif (neg. control; G/C replaced with A)  
GU1449 AATATTATAATAGTCGTAGCCATCAATTGCATGCAATGGTAATATAGATTTTCGTTTATATT 69.4   
Another ApiAP2 motif (negative control; 
PBANKA_132980/PF14_0633) for EMSA 
GU1497 GAAAACAATAATTCTGAAAATATTATTTCTACACATC 60.6   PBANKA_143750 SXO complementation FW 
GU1498 GAAAATGGAAAATTGCTATGTCCATTCAAG 61.3   PBANKA_143750 SXO complementation RE 
GU1516 CATATATACATATACCATTTTTATTCTATTGGGTC 61.3   PBANKA_143750 5' repair FW (NS & SM removal 
GU1517 CCCAAAAAGCAAAGAAGACATTTATTTGG 61   PBANKA_143750 5' repair RE (NS and SM removal) 
GU1625 AATATTATAATAGTCGTAGCCATCAATGTGTACACATGGTAATATAGATTTTCGTTTATATT 69.4   Target motif (PBANKA_143750/PFL1085w) for EMSA 
GU1626 AATATTATAATAGTCGTAGCCATCAATAAAAAAAAATGGTAATATAGATTTTCGTTTATATT 66.8   No motif (negative control) for EMSA 
GU1627 AATATTATAATAGTCGTAGCCATCAATATATAAAAATGGTAATATAGATTTTCGTTTATATT 66.8   Mutated motif (neg. control; G/C replaced with A  
GU1628 AATATTATAATAGTCGTAGCCATCAATTGCATGCAATGGTAATATAGATTTTCGTTTATATT 69.4   
Another ApiAP2 motif (negative control; 
PBANKA_132980/PF14_0633) for EMSA 
GU1822 AATATAAACGAAAATCTATATTACCATGTGTACACATTGATGGCTACGACTATTATAATATT 69.4   REVERSE Target motif (PBANKA_143750/PFL1085w) 
GU1823 AATATAAACGAAAATCTATATTACCATTTTTTTTTATTGATGGCTACGACTATTATAATATT 66.8   REVERSE No motif (negative control) for EMSA 
GU1824 AATATAAACGAAAATCTATATTACCATTTTTATATATTGATGGCTACGACTATTATAATATT 66.8   
REVERSE Mutated motif (neg control; G/C replaced 
with A  
GU1825 AATATAAACGAAAATCTATATTACCATTGCATGCAATTGATGGCTACGACTATTATAATATT 69.4    
GU1885 CGCTAAAAAGAATTAAGGAACGCTTTC 60.2   5'IC FW SXO RepTag (from genome) AP2-G  
GU1886 CAACTCCAGTGAAAAGTTCTTCTCC 61.3   5'IC RE SXO RepTag (from GFP) AP2-G 
GU1887 GGGccgcggCACTTTGTACTAACACAAATTCCTATATTTTTC 60.8 SacII FW PROMOTER+ORF AP2-G PBANKA_143750 
GU1888 CCCaagcttGTTGTTGTTAGTGGCACTCGTATTTTC 61.9 HindIII RE PROMOTER+ORF AP2-G PBANKA_143750 
GU2068 TATGTTAAACATTGGCAAATTTATAGTACACCCTAATAGTATCATTCCTATTGCATCATT     PBANKA_143750 UP1F 
GU2069 TATGTTAAACATTGGCAAATTTATAGTAAACCCTAATAGTATCATTCCTATTGCATCATT     PBANKA_143750 UP1F MUT1 
GU2070 TATGTTAAACATTGGCAAATTTATAAAAAAACCTAATAGTATCATTCCTATTGCATCATT     PBANKA_143750 UP1F MUT2 
GU2071 TAATATACTGTATGTATATATGCATGCGTACTTATGCATTATAAATTGTCTACACAATTT     PBANKA_143750 UP2F 
GU2072 TAATATACTGTATGTATATATGCATGCATACTTATGCATTATAAATTGTCTACACAATTT     PBANKA_143750 UP2F MUT1 F 
GU2073 TAATATACTGTATGTATATATGCATAAAAAATTATGCATTATAAATTGTCTACACAATTT     PBANKA_143750 UP2F MUT2 F 
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GU2074 ATATTTTAATCTGGTTCCTTTTTCTGCGTACTTATCCAGAATGAATGTTTTAATTCATTT     PBANKA_103430F 
GU2075 ATATTTTAATCTGGTTCCTTTTTCTGCATACTTATCCAGAATGAATGTTTTAATTCATTT     PBANKA_103430F MUT1F  
GU2076 ATATTTTAATCTGGTTCCTTTTTCTAAAAAATTATCCAGAATGAATGTTTTAATTCATTT     PBANKA_103430F MUT2F  
GU2077 TCATTTGATCAATTTCTACAACGTGAGTACGCGCTATCAAAAATGTAAAAAAGATTTTTA     PBANKA_106086F 
GU2078 TCATTTGATCAATTTCTACAACGTGAATACGCGCTATCAAAAATGTAAAAAAGATTTTTA     PBANKA_106086F MUT1F  
GU2079 TCATTTGATCAATTTCTACAACGTAAAAAAAAGCTATCAAAAATGTAAAAAAGATTTTTA     PBANKA_106086F MUT2F  
GU2080 GAAAAAATAATAATAAAGTATAAATGTGTACATCATAGTTTTATTCTAAATTCATTCCTG     PBANKA_141480F 
GU2081 GAAAAAATAATAATAAAGTATAAATGTATACATCATAGTTTTATTCTAAATTCATTCCTG     PBANKA_141480F MUT1F  
GU2082 GAAAAAATAATAATAAAGTATAAATAAAAAAATCATAGTTTTATTCTAAATTCATTCCTG     PBANKA_141480F MUT2F  
GU2083 TTTCTTGTTTAGTGTTATAATAACGTGTACACACAACACATAAAAAATGCGCACCTATAT     PBANKA_081070F 
GU2084 TTTCTTGTTTAGTGTTATAATAACGTGTAAACACAACACATAAAAAATGCGCACCTATAT     PBANKA_081070F MUT1F  
GU2085 TTTCTTGTTTAGTGTTATAATAACAAAAAAAAACAACACATAAAAAATGCGCACCTATAT     PBANKA_081070F MUT2F  
GU2225 ATGGCTAACGCAAAAGCAAAGCC 60.6   HSP70 orf FW PBANKA_071190 
GU2226 TTAATCAACTTCTTCAACAGTTGGTCC 60.4   HSP70 orf RE PBANKA_071190 
GU2227 GGATTTTTGGAATTCTTGTTGAACCAC 60.4   HSP70 orf RE (middle) PBANKA_071190 
GU2242 TTTGTGGTGCACTTCATTGC 55.2   QCR1 for 143750_COMP_DOWN 
GU2243 GTATATTATTTATGGTAAAATGTCGGTG 57.8   QCR2 for 143750_COMP_DOWN 
GU2244 CATACTAGCCATTTTATGTG 51.1   GW1 for 143750_COMP_DOWN 
GU2245 CTTTGGTGACAGATACTAC 52.4   GW2 for 143750_COMP_DOWN 
GU2246 CACATTGAATTAATAAATGTGTGTGG 56.9   Genomic integration check 143750_COMP_DOWN 
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A14 – List of chemicals and reagents used 
 
 
1. LB (Luria Bertani) culture medium/agar: 
 
1.0% peptone     5.0  (gram per 500 ml) 
0.5% yeast extract   2.5 
1.0% NaCl    5.0 
 
Bring the components in solution and autoclave for 15 minutes at 120C. To enrich the 
medium, the amount of Tryptone and Yeast Extract can be doubled. For preparing LB 
agar, add 1.5% agar prior to autoclaving. 
 
 
2. SOB culture medium: 
 
2.0% peptone    10.0  (gram per 500 ml) 
0.5% yeast extract   2.5 
10 mM NaCl    0.29 
2.5 mM KCl    0.09 
10 mM MgCl2.6H2O   1.02 
10 mM MgSO4.7H2O   1.23 
 
Bring the components in solution and autoclave 15 minutes at 120C. One can choose to 
make 100 X stock solutions of NaCl, KCl, MgCl2, and MgSO4. 
 
 
3. SOC culture medium: 
 
SOB culture medium plus 20 mM glucose. 
 
After autoclaving and cooling down of the SOB medium, add a filter-sterile solution of 
glucose to a final concentration of 20 mM. 
 
 
4. Denaturing buffer: 
 
0.5 M NaOH                                   10.0       (gram per 500 ml)      
1.5 M NaCl 43.8      
 
 
5. 20 X SSC stock solution: 
 
3.0 M NaCl                                  175.3      (gram per 500 ml)      
0.3 M Na3citrate.2H2O   88.2 
 
Bring the components in solution and autoclave 15 minutes at 120C. 
 
6. TNE buffer: 
 
10 mM Tris pH 8.0 
5 mM EDTA pH 8.0 
100 mM NaCl 
 
Combine 1 ml of 1 M Tris (pH 8.0) with 1 ml of 0.5 M EDTA (pH 8.0) and 10 ml of 1 M 
NaCl. Add demineralised water up to 100 ml. If required, autoclave for 15 minutes at 
120C.   
 
7. 10 X TAE electrophoresis buffer: 
 
400 mM Tris    387.6 (gram per 8 litre) 
Acetic acid    - 
10 mM EDTA    - 
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Dissolve Tris in  3 litres of demineralised water; add 160 ml of 0.5 M EDTA (pH 8.0) and 
91.5 ml of a 100% acetic acid solution. Adjust the volume up to 8 litres with 
demineralised water. 
 
 
8. 5 X TBE electrophoresis buffer: 
 
445 mM Tris    540  (gram per 10 litre) 
445 mM Boric acid   275 
10 mM EDTA    - 
 
Dissolve Tris and Boric acid in  3 litres of demineralised water, add 200 ml of 0.5 M 
EDTA (pH 8.0) and adjust the volume up to 10 litres with demineralised water. 
 
9. TE: 
 
10 mM Tris-Cl, pH 8.0 
1 mM EDTA, pH 8.0 
 
Combine 10 ml 1 M Tris-Cl, pH 8.0, with 2 ml of 0.5 M EDTA, pH 8.0. Add demineralised 
water up to 1 litre and autoclave for 15 minutes at 120C. 
 
 
10. Parasite lysis buffer for RNA extraction: 
 
10 mM Tris-Cl, pH 8.0 
0.4 M NaCl 
1% SDS (v/v) 
 
 
11. Hepes buffer: 
 
10 mM Hepes, pH 7.5 
 
Prepare the buffer with DEPC treated water and autoclave for 15 minutes at 120C. 
 
 
12. 10 X RNA Gel Running Buffer: 
 
0.2 M MOPS 
50 mM NaAc 
10 mM EDTA 
 
Dissolve and autoclave for 15 minutes at 120C. 
 
 
13. RNA denaturing buffer: 
 
50% (v/v) Formamide 
2.2 M Formaldehyde 
1 X Running buffer 
 
Combine 500 l demineralised Formamide with 179 l of 37% formaldehyde solution (12.3 
M) and 100 l 10 X running buffer. Add demineralised water up to 1 ml.  
 
 
14. RNA loading buffer (5X): 
 
 30% (w/v) Ficoll 
 1 mM EDTA, pH 8.0 
 0.25% (w/v) Bromo Phenol Blue (runs with  0.5 Kb) 
 0.25% (w/v) Xylene Cyanol FF (runs with  4 Kb) 
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15. 5 X dATP-mix: 
 
5 X React buffer 2 (Gibco BRL) or Sure/Cut buffer L or M (Roche) 
2.5 mM dCTP 
2.5 mM dGTP 
2.5 mM dTTP 
 
Combine 50 l of 10 X React buffer 2 (or Sure/Cut buffer L or M) with 2.5 l of each 
nucleotide (100 mM solutions). Add demineralised water up to 100 l. Make 5 l aliquots 
and store at –20C 
 
 
16. Denhardt's solution (100 X): 
 
2% (w/v) Ficoll 
2% (w/v) polyvinylpyrrolidone 
2% (w/v) BSA 
 
Dissolve the components in demineralised water. Make 50 ml aliquots in Falcon tubes and 
store at –20C. Filter sterilisation is an option but not necessary. 
 
 
17. Hybridisation buffer: 
 
6 X SSC 
5 X Denhardt's 
0.5% (v/v) SDS 
0.1% (v/v) disodium pyrophosphate 
15 g/ml tRNA 
 
For 100 ml: take about 50 ml of demineralised water and add 30 ml of 20 X SSC, 5 ml of 
100 X Denhardt's solution, 5 ml of a 10% (w/v) SDS solution, 1 ml of a 10% (w/v) disodium 
pyrophosphate solution, and 150 l of a 10 mg/ml tRNA solution. Add demineralised 
water up to 100 ml. Before use, place at 60C. 
 
18. PBS (phosphate buffered saline) normal:  
 
The 10x stock is the commercial available PBS from Roche (Cat. nr: 1666 789). 
Components of the 10x PBS: 0.01 M KH2 PO4, 1.37 M NaCl, and 0.027 M KCl, pH 7.0 
Working solution: 
- Dilute the stock 10 x with demineralised water 
- Adjust the pH to 7.2 with 1 M HCl solution  
- Autoclave for 20 minutes 
 
19. PBS (phosphate buffered saline) ‘rich’: 
 
20mM Hepes, 20 mM Glucose, 4mM NaHCO3, 0.1% BSA 
Working solution: 
- Dilute the stock PBS solution 10 times (see above) and add the above mentioned 
components 
- Adjust the pH to 7.25 with 5 M NaOH 
- Sterilise the solution by passing it through a 0.2 μm filter 
- Store the solution at 4ºC 
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20. Giemsa-solution and staining buffer: 
 
For dilution of the stock Giemsa solution (Merck Cat. nr. 1.09204.0500) we use the 
Sörensen staining buffer. 
Sörensen staining buffer: 
- KH2 PO4    2,541 g per 5 liter 
- Na2 HPO4 .2 H2O 0  5507 g per 5 liter 
- Adjust the pH to 7.2 with NaOH 
We use a 12 % Giemsa-buffer solution for staining slides for a period of 10 minutes. 
 
21. Complete culture medium: RPMI1640 pH 7.3 containing 25% foetal calf serum: 
 
Culture medium: RPMI1640, with L-glutamine and 25 mM HEPES, without NaHCO3 
(Invitrogen).  
Preparation of medium: 
- Dissolve 15,89 g powder of RPMI1640 medium in 1l demineralised water. Add 
powder slowly under continuous stirring. 
- Add 0.85 g NaHCO3  
- Add 50.000 I.U. Neomycin (stock-solution of 10.000 I.U./ml; Gibco) 
- Sterilise by filtration through a 0,2 μm sieve (see below) 
- Store at -20°C in 100-200 ml bottles 
- Immediately prior to use, add foetal calf serum (FCS) to a final concentration of 
25% (v/v) to give complete culture medium. 
 
Sterilisation of culture medium 
- Fill reservoir with medium and close lid 
- Connect reservoir to N2-gas bottle and to the filter container which is placed in 
the flow hood 
- Open gas bottle (0.5 bar) 
- At the same time open the small tap on the filter container until the air has 
escaped. 
- Open the other tap and collect the medium 
 
Sterilisation of the filter container 
- Remove the upper part of the filter container by removing the three screws 
- Place the Metricel membrane (0.2 µm) with the shiny side downwards on the 
metal sieve. The blue side of the metal sieve should be facing upwards 
- Place the polypropylene sieve on the Metricel membrane 
- Place the glassfiber filter on top and close the filter container  
- Autoclave for 20 min. Taps and in-and outlets covered with aluminium foil. 
 
Filters 
1. Metricel Membrane filter G/A-8; 0.2 µm, 142 mm 
2. Polypropylene filter, 127 mm 
3. Glassfiber filter A/E, 127 mm 
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22. Ookinete culture medium: RPMI1640 pH 8.0 containing 10% fetal calf serum: 
 
- RPMI1640 medium prepared and stored as complete culture medium (see above) 
- The pH is adjusted to 8.2 with 1N NaOH prior to sterilisation 
- Immediately prior to use, foetal calf serum (FCS) is added at a final 
concentration of 10% (v/v) to give ookinete culture medium with a pH of about 
8.0. 
 
23. Nycodenz stock solution: 
 
Nycodenz powder (Lucron Bioproduct BV) is obtained from Life Technologies. Store at 
room temperature. Dissolve 138g Nycodenz-powder in 500 ml Buffered Medium (see 
below) (density 1.15g/ml at 20ºC). Autoclave for 20min at 120ºC and store at 4ºC 
 
Buffered medium:  
5mmol/l Tris/HCl  605.7 mg/l, pH 7.5  
3mmol/l KCl    223.7 mg/l 
0.3 mmol/l Ca Na 2EDTA  112.3 mg/l 
 
24. Erythrocyte-lysis buffer:   
 
10x stock-solution:  
1.5M NH4Cl  80.23 g/l  
0.1M KHCO3  10.012 g/l  
0.01M EDTA  3.72 g/l 
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